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A wide array of intracellular signaling events in eukaryotic cells, including metabolism, 
growth, division, differentiation, motility, organelle trafficking, membrane transport, 
muscle contraction, immunity, learning and memory, are mediated by protein 
phosphorylation.
1
 The diversity of processes regulated by this post-
translationalmodification is reflected by the large number of protein kinases (about 600) 
encoded by the human genome.
2
 Protein kinases are related by their conserved 
homologous kinase domains; a catalytic core that consists of 250 – 350 residues.
3
 The site 
of phosphate transfer is located between a N-terminal lobe composed of a β-sheet and a 
1 
12 
single α-helix (the “C-helix”) and a larger C-terminal lobe consisting of α-helices, 
connected by a linker referred to as the hinge region (Figure 1A). Within the conserved, 
narrow and hydrophobic ATP-binding pocket, the adenine ring of ATP makes a number of 
hydrophobic contacts in the ATP-binding cleft and forms at least one hydrogen bond with 
the backbone of the hinge region.
4
 The triphosphate group of ATP points out of the 
adenosine pocket towards the hydrophilic medium. When the substrate (peptide, lipid or 
carbohydrate) binds to its kinase, a set of conserved residues within the kinase catalytic 
domain catalyses the transfer of the terminal γ-phosphate of ATP to the hydroxyl oxygen 
of Ser, Thr or Tyr residue of the substrate. Phosphorylation may result in significant 
changes in either structural features or function of the target protein (Figure 1B).  
 
Figure 1. A) In general, protein kinases consist of a N-terminal (blue) and a C-terminal lobe (green, yellow, 
orange). The crystal structure of cyclin-dependent kinase 2 (CDK2) (Protein Data Bank (PDB) ID: 1QMZ) shows the 
representative fold. ATP is modeled bound in the cleft (red ball and stick model). B) The general catalytic cycle for 
substrate phosphorylation by a kinase.   
 
The kinase superfamily consists of four major families, namely AGC, Ca
2+
/calmodulin-
dependent protein kinases (CaMK), CMGC and tyrosine kinases (TK), and four minor 
families, namely casein kinase 1 (CK1), STE, receptor guanylate cyclase (RGC) and TK-like 
(TKL) kinase.
5
   
The AGC group of kinases comprises more than 60 members including the cyclic-
nucleotide-dependent family protein kinases A (PKA) and G (PKG), the protein kinase C 
(PKC) family, the β-andrenergic receptor kinase (βARK) family, the ribosomal S6 kinase 
family, and other close relatives. In general, this group of kinases tends to be basic amino 
acid-directed enzymes by phosphorylating at Ser/Thr residues, which are near Arg and Lys. 
The AGC kinases participate in a variety of well-known signaling processes. They mediate 
cyclic AMP signaling, the response to insulin, protection against apoptosis, diacylglycerol 






















The CaMK group protein kinases are Ser/Thr protein kinases. Almost all are activated by 
Ca
2+
/calmodulin binding to a small domain located near the COOH-terminal to the 
catalytic domain. CaMKs are particularly abundant in the brain and the nervous system, 
where they are involved in synaptic development and plasticity, gene transcription, 
muscle contraction and learning and memory processes by targeting various factors 
including structural proteins, ion channels and protein pumps.
8, 9,10
  
CMCG is a major category of Ser/Thr kinases. Mostly, CMCG members phosphorylate 
substrates at proline-rich sites. This group includes the protein kinases cyclin-dependent 
kinase (CDK), mitogen-activated protein kinase (MAPK), glycogen synthase kinase (GSK3), 
CDC-like kinase (CLK). These kinases are known for controlling the cell cycle, activity of 
human tumor suppressors and cell-fate decisions.
11,12
 
The protein tyrosine kinase family phosphorylates, in contrast to the families described 
above, on Tyr residues. Family members play a role in mitogenesis, differentiation and 
development, angiogenesis, cell cycle control, growth control, cell survival and apoptosis, 
transcriptional regulation, and glucose uptake.
13
  
TKL kinases are a diverse group of Ser/Thr protein kinases with sequence similarity to TK, 
but lacking TK-specific motifs.
1
 These kinases are involved in programmed cell death, 
growth and immune system.
14
  
CK1 represents an unique group within the superfamily of Ser/Thr kinases. They have 




Members of the STE kinase family include the homologues of yeast sterile 7, sterile 11 and 
sterile 20 kinases. This group of kinases prefers to phosphorylate serine and threonine 
residues with an arginine residue N-terminal to the phosphorylation site. They form the 
MAPK cascade and transduce signals from the cell surface to the nucleus.
17
   
The kinases of the RGC family contain an active guanylate cyclase domain, which 
generates the cGMP second messenger. This second messenger is a key signaling molecule 
that in turn modulates the activity of cGMP dependent kinases, ion channels, and 
phosphodiesterases. They also contain a catalytically inactive kinase domain, which 
appears to have a regulatory domain.
18
 RGCs have attracted considerable interest due to 




Kinases as drug targets 
 
Since protein kinases are key components of most signal transduction networks, this 
makes them therapeutically relevant drug targets and interesting to explore their 
biological roles and functions in detail. A few kinases together with their inhibitors 
relevant to studies described in this thesis are highlighted below.  
 
14 
PKB/AKT1 and FLT3 
 
AKT, also known as protein kinase B (PKB), is an intracellular anti-apoptotic 
serine/threonine kinase belonging to the AGC family of kinases. Three isoforms of AKT are 
known to exist, namely AKT1, AKT2 and AKT3. These isoforms exhibit about 90% sequence 
identity in the kinase domain and 97-100% sequence identity in the ATP-binding site.
20
 
PKB/AKT is a key component of the PI3K-AKT-mTor kinase pathway, which is responsible 
for cell proliferation, survival, cell growth, apoptosis and metabolism.
21
  
Full activation of PKB is a multi-step process that uses the PI3K signaling pathway. First, 
extracellular ligands (hormones and growth factors) bind to receptor tyrosine kinase 
(RTK), which in turn forms homo-oligomers.
22
 In response, phosphatidylinositol-3 kinase 
(PI3K) is activated through binding to phosphotyrosine residues in the receptor and 
phosphorylates in turn phophoinositides (PI) to generate phosphatidylinositol 3,4,5 
triphosphate (PIP3). PIP3 organizes PKB/AKT, PDK1 and Ser473-kinase on the plasma 
membrane, where PKB/AKT becomes phosphorylated and activated. Then, the activated 




Figure 2. Schematic representation of PKB activation.  
 
PKB/AKT is recognized as an important therapeutic target for the treatment of human 
cancers, such as breast, ovarian, prostate and pancreatic cancers,
26
 as well as diabetes.
27
 
In addition, one of the three PKB/AKT isomers has been identified as a potential target to 
prevent intracellular growth of Salmonella typhymurium and Mycobacterium tuberculosis. 
Kuijl et al. have shown that inhibition of PKB/AKT1 resulted in less infection, which makes 
it a potential antibiotic drug target.
28
 However, the major bottleneck is to find selective 
PKB/AKT1 inhibitors, since elimination of both AKT1 and AKT2 is lethal whereas genetic 




















Studies have revealed that the PKA inhibitor H-89 (1, Figure 3) has a higher selectivity 
towards AKT1 then AKT2, which makes this compound an interesting lead compound. 
Many analogues of H-89 have been synthesized, however a nanomolar inhibitor needs still 
to be developed.   
 
Figure 3. Structures of lead compounds 1 (PKB/AKT1) and 2 (FLT3).
 
Within many synthesized analogues of H-89, one interesting compound that was 
identified comprises naphthalene analogue 2 (Figure 3). This bulky aromatic compound 
showed hardly any PKB/AKT1 inhibition, but inhibited another interesting kinase named 
FMS-like tyrosine kinase 3 (FLT3) with an IC50 of 1.01 µM. FLT3 is a type III receptor 
tyrosine kinase and consists of five immunoglobulin-like domains in the extracellular 
region, a juxtamembrane domain, a tyrosine kinase domain separated by a kinase insert 
domain and a C-terminal domain in the intracellular region.
29
  This kinase is expressed on 
the surface of normal hematopoietic stem/progenitor cells and plays a well-established 
role in normal growth, survival and differentiation of hematopoietic precursor cells. Like 
other RTKs, upon binding of FLT3 ligand (FL), which is expressed by bone marrow stroma 
cells, the FLT3 receptor dimerizes at the plasma membrane (Figure 2).
30
 This leads to 
autophosphorylation and activation of multitude downstream effector signaling cascades, 
including Ras/Mek, PI3K/AKT/mTor, and STAT-5 pathways. All these pathways play 
important roles in the promotion of cell cycle progression, inhibition of apoptosis, and 
activation of differentation. FLT3 is an important key regulator in multiple hematopoietic 
pathways, and mutated FLT3 causes altered mechanisms of cellular proliferation and 
apoptosis that promote cell survival thereby conferring a substantial growth advantage to 
leukemic stem and progenitor cells. FLT3 mutations are mostly found in patients with 




 and acute lymphoblastic 
leukemia (ALL).
36,37
 Potent and selective FLT3 inhibitors may form the starting point for 
therapeutics for these diseases. 
 
Bruton’s tyrosine kinase (BTK) 
 
Another tyrosine kinase that plays a major role in the pathogenesis of hematological 
malignancies, such as chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma 
(MCL), and autoimmune diseases as well is Bruton’s tyrosine kinase (BTK).
38
 BTK is a 
member of the Tec tyrosine kinase family and is expressed in most hematopoietic cells 
16 
such as B-cells, mast cells and microphages, except in T-cells and plasma cells. It is 
predominantly situated in the cytosol and has several conserved domains from the N-
terminus: pleckstrin homology (PH), Tec homology (TH), Src homology 2 and 3 (SH2 and 
SH3) and a carboxyl-terminal regulatory and catalytic region that contains the tyrosine 
kinase (TK) or SH1 domains.
39
 BTK functions downstream of multiple receptors including 
growth factors, B-cell antigen, chemokine and innate immune receptors. BTK initiates a 
diverse range of cellular processes, such as cell proliferation, survival, differentiation, 
motility, angiogenesis, cytokine production and antigen presentation.
40
  
From the many pathways, the B-cell receptor (BCR) signaling pathway is crucial for the 
pathogenesis of many B-cell malignancies. BCR plays a fundamental role in B-cell 
proliferation, differentiation and function including production of antibodies.
41
 It serves as 
an antigen receptor, which consists of a surface transmembrane immunoglobulin (Ig) 
receptor associated with the Ig-alpha (CD79a) and Ig-beta (CD79b) heterodimers.
42
 In 
normal B-cells, antigen binding to the receptor leads to receptor aggregation and recruits 
other kinases such spleen tyrosine kinase (SYK) and LYN kinases. These in turn, 
phosphorylate the receptor’s cytoplasmic tyrosine-based activation motifs (ITAMs) on the 
cytoplasmic Ig domains of the receptor. ITAM phosphorylation sets off a cascade of 
downstream events including activation of downstream kinases, adaptor molecules, and 
generation of second messengers. SYK propagates the signal by activation of PI3K, which 
stimulates the production of PIP3. Once an adequate amount of PIP3 is produced, BTK is 
mobilized to the plasma membrane. At this site, BTK is activated by phosphorylation at the 
Y551 site by the Src family kinases, especially LYN and FYN. BTK amplifies the signal via 
phosphorylation of phopholipase gamma C2 (PLCγ2), mobilization of calcium secondary 
messengers, PKC, and finally activation of MAP kinase pathways, nuclear factor of 
activated T cells (NFAT) and nuclear factor κB (NFκB). These signals regulate patterns of 
gene expression necessary for B cell survival and proliferation (Figure 4).
40, 42
 




















Among the many kinases involved in BCR signaling, BTK is a unique therapeutic target for 
treatment of B-cell malignancies. This is due to the fact that BTK inhibition leads to 
inhibition of NFκB DNA binding, reduction of integrin-mediated cell adhesion and 
migration, limitation of cell production of chemokines and, ultimately, apoptosis. The first-
in-class BTK-inhibitor ibrutinib (Imbruvica®, PCI-32765, 3, Figure 5) has recently been 
approved for the treatment of Waldenström’s macroglobulinemia (WM), MCL and CLL by 
the FDA.
43,44,45,46
 Apart from its clinical efficacy, ibrutinib is of interest because of its 
mechanism of action. Ibrutinib irreversibly blocks BTK activity through covalent 
modification of Cys481 within the enzyme ATP-binding pocket following conjugate 
addition of the cysteine thiol to the acrylamide moiety in 3 (Figure 5), an event that 
prevents phosphorylation of Tyr223, an essential step for BTK activation.
47
 Even though 
the action of this drug has been studied in detail for BTK, it would also be interesting to 
investigate whether this drug has other cellular targets. This will give insight into the 











Figure 5. Covalent binding of ibrutinib (3) to Cys481 in the active site of BTK. 
 
Dasatinib as inhibitor for Bcr-Abl 
 
Chronic myeloid leukemia (CML) is a hematological malignancy, which is defined to be 
Philadelphia chromosome/Bcr-Abl positive. In 1960, the Philadelphia chromosome was 
first discovered in cell cultures from CML patients.
48
 A Philadelphia chromosome is a 
truncated version of chromosome 22 produced by a reciprocal translocation between the 
Abl gene on chromosome 9 and the breakpoint cluster region (BCR) on chromosome 22, 
which leads to the formation of the novel Bcr Abelson tyrosine kinase (Bcr-Abl) fusion 
gene. This fusion kinase possesses the tyrosine kinase activity of Abl, which is 
constitutively active in the cytosol. As a result, the downstream signaling pathways are 
dysregulated and proliferation and survival of leukemic cells are increased.
49
  
BCR is a serine/threonine kinase with several interactions domains for proteins such as 



































































































between the nucleus and cytoplasm. It is involved in many processes such as regulation of 
cell growth and survival, oxidative stress reaction, response to DNA damage and 
regulation of actin dynamics and cell migration. Specific breakpoints in the chromosomal 
translocation lead to distinct forms of Bcr-Abl protein: p185 Bcr-Abl, p210 Bcr-Abl and 
P230 Bcr-Abl. Each type is found in different types of leukemia; the p210 form is 
associatied with CML, whereas p230 and p185 are associated with neutrophilic leukemia 
and acute lympoblastic leukemia, respectively.
50
  
Up to now, there are three generation of BCR-Abl inhibitors approved by the FDA. One of 
the many inhibitors is dasatinib (4), which is a dual-specificity Abl- and Src-family kinases 
inhibitor having a substituted thiazole-carboxamide (Figure 6). However, the molecule is 
not selective for Bcr-Abl and Src, since it has been successively reported that this 
compound also inhibits other TKs.
48 
This information provides a rationale for investigating 
it in other hematologic malignancies, such as CLL. 
 
Figure 6. Structure of dasatinib (4).  
 
Finally, it should be mentioned that kinase inhibitors are important not just for the 
treatment of diseases, but also as reagents for gaining understanding about the 
physiological roles of protein kinases and additional targets that cause side effects or 
synergy. In these cases, the use of chemo-proteomic tools, also known as activity-based 
probes (ABPs), for performing activity-based protein profiling (ABPP) comes to a rescue. 
These chemical tools need to bind or have affinity for the target(s) of interest and contain 
a reporter group, such as the fluorescent group Bodipy-FL or biotin for detection, 
quantification, and/or enrichment/identification of labeled proteins. In cases where 
enzyme activities in living cells or organisms are subject of study, the use of reporter 
groups with a small, latent chemical handle (alkyne, azide or norbornene) may be a 
solution, because bulky reporter groups may hamper cell permeability feature of an ABP. 
Since the inhibitors (H-89, ibrutinib and dasatinib) that are discussed above bind 
(non)covalently to their specific subset (or family) of catalytically related enzymes, these 
compounds are interesting candidates to turn into an affinity- or activity-based probe. This 
will provide more insight into the additional drug targets and mechanism of the various 




Aim and outline of this thesis 
 
The central role of protein kinases in many signal transduction pathways has generated 
intense interest in targeting these enzymes for a wide range of diseases. This thesis 
focuses on both the development of more potent kinase inhibitors and the development 
of ABPs to study the roles of kinases, inhibitor selectivity profile and the additional targets 
of known kinase inhibitors. 
In Chapter 2, an overview will be provided about three kinase profiling methods that are 
published in literature, namely activity-based protein profiling, photoaffinity protein 
profiling and affinity-based protein profiling. The fundaments of these profiling methods 
will be explained in detail. 
More potent inhibitors towards FLT3 are needed to treat certain types of leukemia. 
Chapter 3 describes the design and synthesis of 102 isoquinolinesulfonamide compounds, 
which share the same core as H-89 (1). The variations between these related compounds 
were created by substitution of the phenyl bromide with bulky (hetereo)aromatic groups 
at the ortho, meta or para phenyl site under Suzuki coupling conditions.  
The biological activities of these 102 compounds together with 137 structurally related 
isoquinolinesulfonamides were evaluated in Chapter 4. IC50 and Ki values towards the 
kinases PKA, AKT1, AKT2 and FLT3 are given. Based on these findings, structure-activity 
relationships (SAR) are discussed and the most active and selective inhibitors shown.  
In the second part of the thesis, three ways to label kinases are outlined. In Chapter 5 the 
synthesis of two direct (Bodipy-FL and Bodipy-TMR) and three two-step labeling ibrutinib-
based probes (azide, alkyne and norbornene) are discussed. These probes are used to 
label BTK and act as activity-based probes, since they bind covalently to BTK after a 
nucleophilic attack of the thiol-group in the active site of BTK. Furthermore, labeling of 
BTK in Ramos cells and lysate is visualized on SDS-PAGE gel. 
Chapter 6 focuses on the synthesis of photoaffinity-based probes for PKB/AKT1 and PKA. 
These core of the probes are based on the PKA inhibitor H-89 (1) and they also contain a 
diazerine group as the photoaffinity group, which bind covalently to its target after 
exposure to UV. In addition, these probes also contain an azide ligation handle, which is 
useful for visualization and/or enrichment of proteins. Labeling of recombinant PKA and 
AKT1 kinases and competition assays will be shown. 
A third way to label kinases is by affinity-based protein profiling, which is discussed in 
Chapter 7. The synthesis of an affinity-based probe based on dasatinib, which is 
immobilized on NHS-activated beads, will be discussed. Furthermore, information about 
the targets of this probe will be provided by Western blot analysis.  
Finally, Chapter 8 provides a summary of the results gained in this thesis and projects 
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The protein kinase family is one of the largest protein superfamilies in eukaryotic 
genomes. Due to their central role in cell signaling, physiology and pathophysiology, there 
is need for biomarker discovery or development of selective kinase agonists or antagonists 
as therapeutics. To be able to develop more potent kinase inhibitors or to identify and 
assign function to the whole kinome completely, it is essential to determine the substrates 
of each individual protein kinase, to define how signaling pathways operate and to 
determine the (off)targets of kinase inhibitors. For this reason, there is interest in the 
development and application of chemical biology tools that allow the global analysis of the 
2 
24 
protein expression and activity in complex biological samples. Three major strategies used 
for profiling of small molecule-protein interactions are: affinity-based protein profiling, 
activity-based protein profiling (ABPP), and photoaffinity labeling. Affinity-based probes 
(AfBP) are bi-functional small molecules that create a reversible interaction with the target 
proteins and are linked to either a sorting function or directly to a solid phase. After 
binding, non-binding proteins are washed away, and the bound proteins are analyzed with 
an analytical technique (e.g. LC-MS/MS) after elution (Figure 1A).
1,2
  
Figure 1. Schematic workflow for affinity pull down (A), activity-based protein profiling (B) and photoaffinity 
based profiling (C). 
 
In ABPP the probe design consists of three general elements, namely a reactive group (the 
“warhead”), a recognition site and a chemical tag. The reactive group, which is an 
electrophilic group, binds and covalently modifies nucleophilic amino acids in the active 
sites of a single enzyme or a broad range of enzymes from a particular protein class (or 
classes). Due to the covalent and irreversible nature of this interaction, it enables 
subsequent sample processing steps employing other parts of the probe such as detection 
or sorting functions. The structure of the recognition site is in most cases based on the 
structure of the natural substrate of the target(s) or a known inhibitor (Figure 1B).
3
 Finally, 
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accomplishes an equilibrium-driven affinity binding to target proteins, 2) the photo-
reactivity function binds covalently to the active site of the target protein through photo-




Various techniques are available to visualize the probe-labeled proteins, such as 
fluorescence scanning of SDS-PAGE gels, fluorescence microscopy, fluorescence assisted 
cell sorting (FACS), and positron emission tomography (PET). Furthermore, labeling can 
also be used for enrichment of the sample for subsequent analysis by MS/MS or NMR 
techniques. For the visualization and/or isolation of the labeled enzymes, numerous 
reporter tags have been used. Commonly used reporter tags include fluorescent tags (e.g. 
BODIPY and cyanine dyes (Cy2, Cy3 and Cy5)) and affinity tags such as biotin.
1,3,5,6
  Even 
though the vast majority of chemical proteomics studies have been conducted on lysate 
samples, it is preferably to probe intracellular proteins in intact cells with membrane-
permeable probes. Since only a minority of probes has been reported to be cell permeable 
and in some cases the bulkiness of the reporter group hampers recognition by the target 
enzymes, reporter tags in probes are replaced by markedly smaller bio-orthogonal ligation 
handles to overcome these problems. This strategy uses a two-step labeling method to 
label proteins in a chemoselective manner. Ligation handles that are frequently used are 
azide, alkyne and norbornene. Azides and alkynes can be used to perform a copper(I)-
catalyzed Huisgen 1,3-dipolar cycloaddition (“click” reaction). Azides can also be used for 
Staudinger ligation. Norbornenes are used for an inverse-electron demand Diels-Alder 
reaction. All these ligation methods can be performed in the same biological sample in a 
chemoselective way (Figure 2).
7,8,9,10 
Figure 2. Schematic representation of three different bioorthogonal ligation methods: copper(I)-catalyzed click 



























Affinity-based protein profiling 
 
A powerful technique for the identification of the intracellular targets of small molecules 
and substrates is affinity chromatography. This methodology uses affinity-based probes, 
which contain a molecule of interest that can be immobilized on a solid support, to enrich 
ligand-binding proteins from cell lysates. This technique is attractive for determining the 
specificity of protein kinase inhibitors. For these studies, a known protein kinase inhibitor 
is immobilized on a solid support.
11
 A number of notable examples of the application of 
this methodology are described below. 
  
The first example that uses affinity chromatography to study the intracellular targets of a 
protein kinase inhibitor was performed with an analog of the CDK-family inhibitor 
purvalanol B (Figure 3, 1 en 2).
12
 Based on the crystal structure of CDK2-purvalanol, a 
linker could be attached to the carboxylic acid of the 6-anilino substituent of the inhibitor 
without interfering with its interaction with the kinase.
13
 This site was used to link 
purvalonal B to an agarose matrix through a polyethylene glycol linker (2). As a negative 
control, an inactive N6-methylated purvalanol (3) was synthesized and immobilized on 
agarose (4) (Figure 3). The immobilized purvalanol 2 was used to affinity purify interacting 
proteins from starfish oocytes, diverse mammalian tissues and protozoan parasites. The 
bound proteins were eluted, resolved by SDS-PAGE and analyzed by Western blotting or 
microsequencing. As a result, immobilized purvalanol 2 targets next to CDK1, CDK2, CDK5 
also ERK1, ERK2, calcium/calmodulin-dependent protein kinase II (CamKII), p70 S6 kinase 
(S6K) and casein kinase 1 (CK1). The only non-protein kinase identified is the enzyme 
biliverdin reductase. In vitro assays have been performed to validate the interaction of 
purvalanol B (1) with ERK1, ERK2, CamKII, S6K and CK1. It should be noted that soluble 
purvalanol B (1) was less potent for ERK1, ERK2, CamKII, S6K and CK1 than CDK1, CDK2 
and CDK5. 
 Figure 3. Structures of Purvalanol B (1), immobilized purvalanol 2, the N6-methylated negative control 3 and its 
immobilized analogue 4. M = agarose matrix.  
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Following a similar concept for the identification of protein kinase inhibitor targets in 
order to predict side effects and novel medical uses, Rix et al.
14
 have immobilized three 
BCR-ABL tyrosine kinase inhibitors that are used in the current frontline therapy in chronic 
myeloid leukemia (CML): imatinib (5), nilotinib (6) and dasatinib (7) (Figure 4). These three 
drugs (5-6) were converted into their coupleable analogues 8-10, respectively, before 
being immobilized on NHS-activated Sepharose 4 Fast Flow beads via their amino 
functionalities to yield immobilized imatinib, nilotinib and dasatinib 11-13 (Figure 4). Since 
the acetylated analogues 14-16, which are mimicking the immobilized compounds, did not 
display significantly altered activities, it was assumed that the immobilized drugs would 
act the same as their soluble analogue. Lysates of K562 and CML primary cells were 
subjected to affinity chromatography with immobilized drugs (11-13), and matrix-bound 
proteins were identified by liquid chromatography electrospray ionization tandem mass 
spectrometry (LC-ESI-MS/MS) and/or western blot analysis after being resolved by SDS-
PAGE. According to mass spectrometry analysis, imatinib has 11, nilotinib has 14 and 
dasatinib 38 targets. Among the most prominent targets of dasatinib were the TEC family 
kinases TEC and BTK, next to BCR-ABL. Since imatinib and nilotinb displayed much more 
specific target profiles compared with dasatinib, the latter is thus more likely to have a 
more pronounced impact on multiple biologic processes.   
Figure 4. Structures of BCR-ABL inhibitors imatinib (5), nilotinib (6) and Dasatinib (7), their coupleable analogues 
(8-10), their immobilized analogues (11-13) (on NHS-activated Sepharose 4 Fast Flow beads) and their acetylated 
positive controls 14-16. M = sepharose matrix 
 
Other BCR-ABL inhibitors, INNO-406 (17)
15
 and bosutinib (18)
16
 were converted into 
coupleable precursors (19 and 20, respectively) prior to immobilization on sepharose 
beads (21 and 22, respectively) and were used to enrich for interacting proteins in human 
CML K562 cells (Figure 5). INNO-406 is known to inhibit BCR-ABL and LYN efficiently, but 
28 
this study additonally identified several novel kinases targets including ZAK, the receptor 
tyrosine kinases DDR1 and DDR2, and various ephrin receptor kinases (predominantly 
EPHA2, EPHA5 and EPHA8). Found interaction partners of bosutinib were BCR-ABL, SRC 
kinases LYN and YES, CSK, BTK, GAK, EPHB4 and PTK2.  
 
Figure 5. Structures of BCR-ABL inhibitors INNO-406 (17) and bosutinib (18), their coupleable analogues 19  and 
20 and their immobilized analogues 21 and 22 (on NHS-activated Sepharose 4 Fast Flow beads). M = sepharose 
matrix. 
 
Recently, Sewald et al. developed an affinity probe in order to understand new links of 
Janus Kinase (JAK) family members with other signaling pathways, because the JAK 
signaling pathways play a key role in many cellular processes, and was recently associated 
with neuronal disorders.
17
 The developed probe 24 is an aminopyrimidine derivative 
based on the known JAK inhibitor 23 (Figure 6), which is known to have high affinity 
towards all JAK isoforms. To design a probe to address all JAK isoforms, the acetanilide 
moiety in inhibitor 23 was substituted for an alcohol group and an additional methyl ester 
group, leading to probe 24. Probe 24 was immobilized on NHS-activated sepharose beads 
through covalent linkage using the primary amine group, and pull down experiments were 
performed using the acute monocytic leukemia cell line MV4-11. The eluted target 
proteins were digested with trypsin into peptide fragments and analyzed by LC-MS/MS. By 
this method 133 kinases were identified with probe 24, and these included the JAK 
isoforms JAK1, JAK2 and Tyk2. Next to the JAK kinases, a large number of other kinases 
related to signaling pathways, including MAPK1, MAPK3, MAPK8, MAPK9, MAPK14, 
MAP4K4, MKNK1 and PI3K, were identified. Due to the broad kinase coverage of probe 24, 
it can be applied for the selectivity profiling of kinase inhibitors for the identified 133 
kinases.  
29 
Figure 6. Structures of JAK inhibitor 23 and affinity based probe 24. M = matrix (sepharose bead).  
 
Other studies have also focused on the broadband-isolation of protein kinases combined 
with quantitative mass spectrometry. Herein, a mixed inhibitor affinity matrix, termed 
Kinobeads, that carry a collection of >100 ATP-competitive kinase inhibitors including 
chemical scaffolds, research tool compounds, drug candidates in development, as well as 
approved drugs, is used to map kinases from complex biological samples and to assess the 
selectivity profiles of kinase inhibitor drugs. For example, Bantscheff and colleagues 
applied this methodology to three drugs targeting the oncogenic BCR-ABL kinase, which 
induces CML.
18
 The immobilized compounds were first incubated with lysates of HeLa or 
K562 CML cells to allow protein binding, which was followed by separation of the beads 
from the lysate. The bound proteins were eluted, digested with trypsin, and identified by 
MS. The kinobeads matrix specifically captures roughly 200 protein kinases (two-thirds of 
the expressed kinome) from any given cell type. This data set works as a control sample 
(Figure 7a).  
Figure 7. Schematic workflow of proteomic drug target profiling by a kinobead competition assay. 
 
To quantitatively profiling the targets of the three BCR-ABL drugs, namely bosutinib, 
imatinib and dasatinib, these drugs were added to K562 cell lysates and the lysates were 
subsequently subjected to kinobeads. When the drug in the lysate has bound to its target 
and thus has blocked the ATP-binding site, a reduced amount of the free target has been 






















other proteins has been unaffected. The kinobead-bound material was subjected for 
quantification by MS. The selectivity drug profile can be determined by comparing this 
labeling profile with the control profile (Figure 7b). As a result, for imatinib 13 proteins 
exhibited >50% binding reduction on kinobeads. These proteins include ABL, BCR-ABL, the 
ABL family kinase ARG and two novel target candidates DDR1 and NQO2. Dasatinib and 
bosutinib labeled more targets than imatinib (39 and 53 proteins respectively), including 
BCR-ABL, ARG and DDR1, BTK, EphB4, focal adhesion kinase (FAK), FER, MER and Syk. 
Thus, the combination of a mixed-affinity matrix with quantitative MS provides a 
convenient tool to map a drug’s direct and indirect targets in a single set of experiments.  
 
Activity-based protein profiling 
 
Many ABPs have been developed for numerous enzyme classes up to now, including 
serine hydrolases, cysteine proteases, metallohydrolases, phosphatases, glycosidases, 
deubiquitylating enzymes, penicillin-binding proteins, palmitoyl transferases, various 
oxidoreductates and for kinases as well. A characteristic feature of ABPP probes is that 
they contain a selectivity function capable of covalently reacting with the active site of 
target enzymes driven by the catalytic mechanism of the enzyme. However, kinases 
catalyze phosphate transfer from ATP to their substrate by a direct transfer mechanism 
that does not involve covalent enzyme intermediates. Thus, the kinase active site does not 
contain conserved nucleophilic residues for catalysis. In these cases, electrophilic ABPs 
that react with native or engineered noncatalytic nucleophilic residues must be used. 
Based on sequence comparisons, it is known that almost all protein kinases have at least 
one conserved lysine residue within their active sites that represents a possible 
modification site for an appropriate probe. These lysine residues are situated close to β- 
and γ-phophates of bound ATP, suggesting that the positively charged ε-amino groups of 
these lysines provide electrostatic interactions with the phosphate backbone. Therefore, it 
has been reasoned that kinase ABPP probes based on ATP might take advantage of the 
conserved lysine.
19
 In an approach by Patricelli and colleagues, ABPs were used with a 
biotinylated acyl group positioned at the terminal phosphate of ATP (25) or ADP (26) to 
provide broad proteome coverage (Figure 8A).
20
 These acyl phosphates have appropriate 
reactivity with amines and are stable in aqueous solution. Upon addition of the acyl 
phosphate probes to cell lysates, a stable amide bond with the biotin tag has been formed 
and an ATP or ADP has been released by a reaction between the active-site lysine(s) and 
the activated acyl phosphate (Figure 8B). Subsequently, the biotinylated kinases were 
subjected to proteolytic digestion with trypsin. The labeled peptides were purified on 
steptavidin-agarose beads prior to analysis by LC-MS/MS to determine the identity of the 
labeled protein as well as the site of labeling. The acyl phosphate probes were shown to 
selectively label at least 75% (~ 400) of human kinases in cell lysates. This method is thus 
31 
able to profile the functional state of many kinases in native proteomes in a parallel 
manner. 
 
Figure 8. A) Structures of ATP-Biotin probe 25 and ADP-Biotin probe 26. B) Mechanism of labeling of ATP-biotin 
probe 25 with target lysine.  
 
Another ATP containing ABP has been developed and used for enrichment and 
identification of kinases and other ATP-binding proteins from complex protein mixtures, 
namely the isotope-coded ATP ABPP probes (ICAPs) 27 and 28 (Figure 9).
21 
The differences 
between this probe and the ATP probe 25 are that this probe contains a desthiobiotin as 
the tag instead of biotin and a linker with isotopes. Since chemical isotopic labeling 
methods like dimethyl labeling are prone to additional experimental errors due to late 
stage incorporation of the isotopes during sample preparation, the isotopes are already 
incorporated into the ATP-probe. Two different probes have been developed, one 
containing a heavy linker (containing six deuterons, 27) and the other containing a light 
linker (containing six hydrogens, 28). 
Figure 9. Structures of isotope-coded ATP probes (ICAP). 
32 
By using two different ATP probes, two protein labeling profiles of two different samples 
can be compared. The general procedure with the use of ICAP is as follows: 1) ATP-binding 
proteins from a sample representing one experimental state are obtained with the 
isotopically light form ATP probe 28, whereas the ATP-binding proteins from a sample 
representing another experimental state are labeled with the isotopically heavy form ATP 
probe 27. 2) The two protein samples are mixed and digested with trypsin, and the 
resulting light/heavy isotope-coded desthiobiotin-labeled proteins are enriched with 
streptavidin agarose beads. 3) The purified peptides are analyzed by LC-MS/MS. 
Quantification results can be obtained by comparing the MS peak intensity ratios of the 
light and heavy forms of desthiobiotin-modified peptide pairs (Figure 10).  
Figure 10. General strategy for quantitative ATP-ABPP using ICAP.  
 
A disadvantage of the ATP-containing probes is that they also label other non-kinase 
proteins, since ATP is a substrate not only for kinases, but for other ATP-binding proteins 
as well. Therefore, many studies have focused on the development of kinase-selective 
ABPP to overcome this problem by using probes based on covalent kinase inhibitors. 
Wortmannin, which is a metabolite of the fungus Penicillium funiculosum, irreversibly 
inhibits phosphoinositide-3-kinases (PI3Ks) and the PI3K-related kinases (PIKK) families by 
covalent modification of a lysine in the active site. This lysine is conserved in the different 
Protein sample A Protein sample B
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33 
PI3K and PIKK family members. Therefore, wortmannin is a promising starting point for 
development of a new ABPP probe. Yee et al. have synthesized and characterized three 
ABPs based on wortmannin. These probes are linked via a water-soluble polyethylene 
glycol linker to biotin (29), or to the fluorescent tags BODIPY (30) and TMR (31) (Figure 
10).
22
 This study revealed that all the three wortmannin probes inactivated members of 
the PI3K and PIKK families in cellular lysates through covalent linkage with the conserved 
active-site lysine. Biotin-wortmannin (29) was used to isolate sensitive kinases from 
nuclear extracts. After incubation with streptavidin-sepharose, three members of the PIKK 
family, namely ATM, ATR and DNA PKcs were isolated. The fluorescent wortmannin 
probes 30 and 31 were used for quantification of kinase activity and determination of 
expression pattern. Of note, BODIPY-wortmannin is cell-permeable, whereas TMR-
wortmannin and biotin-wortmannin are only useful for lysates. Since the activity of some 
proteins may vary under different cellular conditions and in a manner that can only be 
detected in the context of a cell, BODIPY-wortmannin is a potential tool for examining the 
biological activity of wortmannin-sensitive kinases within their native environment.  
Figure 10. Structures of covalent kinase inhibitor based probes: biotin-wortmannin (29), BODIPY-wortmannin 
(30) and TMR-wortmannin (31).  
 
Another ATP analogue, namely 5’-fluorosulfonylbenzoyl 5’-adenosine (32, FSBA) (Figure 
11), which is used to study the mechanism of action of wortmannin, has been used as a 
general ABP for the protein kinase family.
23
 FSBA covalently modifies most protein kinases 
34 
by binding irreversibly to the ε-amino group of a conserved ATP pocket lysine. This 
reagent is structurally similar to ATP, but the phosphoryl groups of ATP are replaced by a 
fluorosulfonylbenzoyl moiety. To profile protein kinases, biotin-tagged FSBA ABPs have 
been designed and synthesized.
24
 Biotin groups were introduced by modifying the free 
hydroxyl groups of the ribose ring of FSBA, which resulted in the three different FSBA-
biotin probes 33-35, whereof probe 35 carries two biotin tags (Figure 11). Biotin-tagged 
ABPs allow visualization of labeled proteins after Western blotting and can also be used as 
handle for protein isolation by streptavidin-coated beads. Ratcliffe et al. have proven that 
FSBA and its biotin-tagged probes can be used to screen and validate ATP competitive 
kinases inhibitors using LC/MS or Western blot techniques. 
Figure 11. Structures of FSBA (32) and its biotin-labeled ABPs 33-35.  
 
Taunton et al. have developed irreversible selective Src-family kinase probes by 
modification of FSBA (32).
25
 The Src active site contains at least two potentially 
nucleophilic side chains Lys295 and Cys277. It is known that Lys295 reacts with millimolar 
concentration of FSBA. The second nucleophile in the Src active site, Cys277, is situated 
proximal to both Lys295 and the γ-phophate of ATP. Since this cysteine is poorly 
conserved, it is an attractive target for selective covalent inhibition. Only nine human 
kinases contain an equivalent cysteine, including Src, Yes, FGFR1-4, LIMK1 and TNK1. To 
improve the selectivity of FSBA for the Src-family kinases, two hybrid nucleosides (36 and 
37) which borrowing structural elements from FSBA and the Src-family inhibitor PP1 (38) 
35 
(Figure 12), have been developed. Since the p-tolyl substituent in PP1 exploits a 
hydrophobic pocket found in all Src-family kinases, this group has been introduced in 
FSBA. For monitoring of covalent binding to proteins using copper-catalyzed click 
chemistry, a propargyl ether has been included as bioorthogonal tag. These modifications 
gave ABPs 36 and 37. Of note, compound 37 contains a vinylsulfone as the electrophilic 
trap instead of the fluorosulfonylbenzoyl group. The two probes were compared for their 
selectivity and their reactivity. Both the probes were able to capture multiple Src-family 
kinases in intact cells, along with robust competition by kinases inhibitors including the 
clinical Bcr-Abl inhibitor ponatinib. The fluorsulfonylbenzoyl probe 36 reacts with the 
conserved lysine and shows little discrimination among related kinases. However, the 5’-
vinylsulfonate 37 reacts with the poorly conserved cysteine.  
Figure 12. Structures of two alkyne containing Src-family kinase ABPs based on FSBA (32) and PP1 (38): 5’-
fluorosulfonylbenzoyl probe 36 and 5’-vinylsulfonate 37.  
 
Other cysteine protein kinases have been targeted by covalent kinase inhibitors as well. 
The targeted active site cysteines offer a potential selectivity filter, since these residues 
are not uniformly conserved across the kinome. Thus far, irreversible inhibitors have been 
developed for some protein kinases, including oncogenic drug targets like the epidermal 
growth factor receptor (EGFR) and Bruton’s tyrosine kinase (BTK), for which the 
corresponding irreversible inhibitors afatinib and ibrutinib have shown to treat non-small 
cell lung cancer and chronic lymphocytic leukemia (CLL), respectively. Recently, ABPP 
combined with quantitative MS was used to perform global and in-depth analysis of 
proteins targeted by the covalent EGFR inhibitor PF-6271184 (39) and BTK inhibitor 
ibrutinib (40) (Figure 13). Both the inhibitors 39 and 40 use Michael receptors (αβ-
unsaturated amide) for covalent binding with the nucleophilic active-site cysteines in the 
ATP-binding pockets. To use these inhibitors as ABPs, an alkyne group was installed as the 
ligation handle to yield probes 41 and 42 (Figure 13).
26
 Rhodamine azide was used as their 
ligation partner for visualization of targeted enzymes and off targets in A431 and Ramos 
cells, which possess high levels of the primary inhibitor targets EGFR and BTK, respectively. 
SDS-PAGE and in-gel fluorescence scanning revealed that the probes 41 and 42 were able 
36 
to probe their corresponding on-targets EGFR and BTK, and to detect off-targets. To 
identify all the targets of these probes, ABPP was combined with MS. Consistent with 
other studies, EGFR and ERB2 were identified as specific targets for both the probes. 
However, BTK was primarily labeled by the ibrutinib-probe 41. Most of the off-targets 
identified contain the active-site cysteine residue except for MLTK. Non-kinase targets 
were found as well, including FAM213A and DUS2L for probes 41 and 42, respectively.  
Figure 13. Structures of cysteine kinase inhibitors PF-6274484 (39) and ibrutinib (40) and their corresponding 
alkynylated ABPs 41 and 42.  
 
More ibrutinib-based ABPs have been developed both direct and two-step bioorthogonal 
probes. Both Honigberg et al.
27
 and Turetsky et al.
28
 used a Bodipy-FL containing ibrutinib 
probe (43 or 44, respectively, Figure 14A). Both studies have proven that the direct 
Bodipy-FL ibrutinib probes were able to label BTK in several BTK-positive tumor cell lines. 
Recently, Liu et al. developed two fluorescent ibrutinib probes (BodipyFL-like 45 and 
Bodipy-TMR 46) and three two-step bioorthogonal probes (alkyne 47, azide 48 and 
norbornene 49) to compare the direct and two-step labeling ABPP methodologies in 
labeling of BTK using Ramos cells and lysates (Figure 14A).
29
 The ligation partners of the 
alkyne 47, the azide 48 and norbornene 49 were azido Bodipy-FL 50, alkyne Bodipy-FL 51 
and tetrazine Bodipy-FL 52, respectively (Figure 14B). Cu(I)-catalyzed azide-alkyne [2+3] 
cycloaddition reactions were performed for the ligation of the bioorthogonal ABPP pairs 
47/50 and 48/51, and an inverse-electron demand Diels-Alder reaction was performed for 
the ligation of 49/52. All the five probes (45 – 49) were able to label BTK in in vitro and in 
situ experiments. Direct imaging using Bodipy-ibrutinib 45 and 46 appears most effective 
37 
and with less background labeling in in situ experiments than the two-step bioorthogonal 
analogues. A more detailed discussion will be given in Chapter 5 of this thesis.  
 
Figure 14. Structures of ibrutinib-based direct and two-step bioorthogonal ABPs and ligation reagents. A)  
Compounds 43 – 46 are fluorescent probes and compounds 47 – 49 are two-step labeling probes. B) 




Since not every kinase possesses a conserved and reactive active-site residue for targeting 
by ABPs, a photochemical group can be used to form a covalent bond between the probe 
and the kinase. Under UV-exposure conditions, the photoreactive group forms a reactive 
38 
intermediate that rapidly reacts and binds to the nearest molecule, which ideally will be 
the target protein. Probes contain in general three functionalities: an affinity unit (small 
molecule of interest), a photoreactive moiety and an identification/reporter tag. The 
affinity unit is responsible for reversible binding to the target kinase, the photoreactive 
moiety allows permanent attachment to its target and the identification tag is necessary 
for the detection and isolation of probe-protein complexes. The main photoreactive 
moieties used for photoaffinity labeling are phenylazides, phenyldiazerines and 
benzophenones, where under irradiation condition a nitrene, a carbene and a diradical, 




Figure 15. The major photoaffinity groups: phenylazide, phenyldiazerine and benzophenone.  
 
Phenylazides are frequently used as photoaffinity moiety, since they are easily to 
synthesize and are commercially available. However, damage to biological molecules can 
be caused by the use of the shorter wavelengths required to excite the phenylazide 
probes. In addition, the formed nitrene intermediates after expelling molecular nitrogen 
(N2) decrease photoaffinity yields compared with carbenes, which might be due to that 
nitrenes are less reactive than carbenes. Rearrangement of nitrenes can also form 
benzazirines and dehydroazepines/ketenimines as undesired side products. To prevent 
the formation of ketenimines, substituted arylazides such as tetrafluorophenylazides have 
been developed. 
Benzophenones are activated by a long wavelength (350-360 nm), which lowers the risk of 
damaging biomolecules, and thereby a reactive triplet diradical is formed upon UV 
irradiation. However, the drawbacks of benzophenones are: 1) it is relatively bulky, which 
can affect the interaction between the affinity pharmocophore and the target protein, 2) 
the steric hindrance can lead to increased nonspecific labeling and capture, 3) a longer 
irradiation period is required which can lead to increased nonspecific labeling.  
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Aryldiazerines are the most commonly used photoaffinity group, since they are highly 
resistant towards a number of factors such as temperature, nucleophiles, acidic and basic 
conditions as well as oxidizing and reducing agents. In addition, the photolabile diazerine 
group absorb most efficiently at a wavelength of 350-380 nm, at which hardly no 
significant cell damage would occur. Upon irradiation of diazirine, molecular nitrogen is 
expelled and a singlet carbene is formed. This intermediate is extremely reactive and has a 
short half life, which leads to fast insertion reactions and less discrimination between 
reaction sites.  
Other functionalities that have been used for photoaffinity labeling include diazo groups, 
diazocarbonyls, enones, sulfur radicals, halogenated substrates, nitrobenzenes, diazonium 
salts and alkyl derivatives of azides and diazirines. In the following part, some examples of 
photoaffinity labeling of kinases using both direct and two-step bioorthogonal probes 
containing one of the above mentioned photoreactive moieties will be discussed.  
 
Also in the case of photoaffinity labeling, adenine-based probes have been developed. 
Biotinylated adenine-benzophenone conjugates 53 and 54 (Figure 16) were synthesized to 
label selectively Lck kinase, which belongs to the Src-family and plays roles in thymocyte 
differentiation and T-cell activation.
31
 These two probes were incubated with six 
commercially available kinases, PKA, GSK3, CK1, Src, Fyn and Lck. Upon irradiaton at 350 
nm, the biotinylated proteins were blotted onto PVDF membrane and visualized after 
treatment of anti-biotin horseradish peroxidase-conjugated antibody. The S-configured 
probe 53 showed to label Lck only and the R-configured probe 54 does not label any of the 
kinases. This proves that a simple configuration change leads to a drastic change in 
selectivity and activity of the probe. Based on these findings, five other adenine-
benzophenone conjugates were developed to gain insights into the relative importance 
between target-binding affinity and conformational flexibility of the probe for labeling of 
LCK kinase. In this study the central Gly residue has been replaced by five other D-amino 
acids, namely proline (55), serine (56), piperidine (57), glutamic acid (58) and γ-
aminobutyric acid (GABA, 59) (Figure 16).
32
 This study showed that binding-affinity did not 
predict photolabeling efficiency of the LCK probes. However, conformational flexibility 
showed to have correlation with labeling efficiency, since compound 59, which has the 
most flexibility around benzophenone, showed to have the highest labeling efficiency. The 
proline containing probe 55 did not label Lck, because of the conformational constraint on 
the backbone.  
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Figure 16. Structure of the biotinylated adenine-benzophenone probes for labeling of LCK 53 – 59. 
 
The use of known reversible kinase inhibitors as the affinity moiety has been done by 
many studies. Sewald and co-workers have developed the direct photoaffinity probe 61 by 
using H-9 (60), which is an isoquinolinesulfonamide of the H-series, as the reversible  
inhibitor (affinity moiety), a benzophenone as the photoreactive group and the isomeric 
mixture of 5- and 6-carboxyfluorescein as the reporter tag (Figure 17).
33
 This study has 
shown that this isoquinolinesulfonamide benzophenone probe was able to label and 
visualize four purified proteins, namely hexokinase, creatine kinase, 3PGA phosphokinase 
and cAMP-dependent protein kinase A. However, a very low binding tendency for the 
probe has been seen for 3PGA phosphokinase.  
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Figure 17. Structures of isoquinolinesulfonamide kinase inhibitors H9 (60) and H-89 (62) and their corresponding 
photoaffinity labeling probes 61 and 63 – 64, respectively.  
 
Another group also has developed photoaffinity labeling probes based on an 
isoquinolinesulfonamide of the H-series, namely H-89 (62, Figure 17), which is known for 
its inhibition towards PKA and other kinases including AKT1 and AKT2. In this case, the 
two-step bioorthogonal probes 63 and 64 are developed and contain a 
trifluoromethylphenyldiazerine, which is a more stable version of the original 
phenyldiazerine, as the photoaffinity reactive group and an azide group that functions as 
the ligation handle (Figure 17).
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 Both the probes showed inhibition activity against PKA 
and AKT1, and for AKT2 and AKT3 in a much lower extent. To prove that these probes 
were able to be used as photoaffinity labeling probes, both the probes 63 and 64 were 
incubated with recombinant PKA and AKT1, followed by photo-crosslinking at 350 nm and 
a final click reaction with an alkyne-modified Cy5 reporter for in-gel analysis. Probe 63 
labels both kinases with a higher affinity than probe 64, which can be explained by the fact 
that probe 63 is structurally more similar to the lead compound H-89 (62) than probe 64. 
This study will be discussed in more detail in Chapter 6.  
Since most kinase inhibitors target the highly conserved ATP-binding site of kinases, they 
tend to inhibit multiple cellular targets. To better understand the cellular selectivity of 
anti-kinase drugs and to anticipate potential side effects of these drugs, known reversible 
kinase drugs were converted into a photoaffinity labeling probe.
35
 An example is the dual 
Src/Abl inhibitor dasatinib, which is used for the treatment of imatinib-resistant CML. 
Related method to profile the off-targets of dasatinib has already been performed using 
immobilized dasatinib on sepharose beads (7), which is discussed above. However, 
disadvantages of this method are: 1) the heavy reliance on a small number of bead-
immobilized kinase baits, which affects the accessibility of some target kinases, and leads 
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to missed targets, 2) due to non-covalent inhibition between the immobilized probe and 
the kinases, relatively mild wash conditions must be applied, which often leads to 
accumulation of false positives, as well as exclusion of weaker kinase-drug interaction. 
Therefore, alkynylated dasatinib-photoreactive labeling probes, which bind covalently to 
its target have been used to profile the off-targets of dasatinib. Yao and co-workers
36
 have 
designed and synthesized two-step bioorthogonal alkynylated-dasatinib probes, one 
contains an aliphatic diazirine moiety (65) and the other a benzophenone (66) as the 
photoreactive group. For protein profiling and pull-down/target identification, the small 
terminal alkyne handle was ligated to rhodamine-N3 (67) or biotin-N3 (68), respectively 
(Figure 18). First, to prove that these probes can be used to profile the targets of 
dasatinib, docking experiments and in vitro kinase assays were performed to determine 
the binding site and IC50 values respectively. As a result, both the probes were able to 
inhibit c-Src/c-Abl kinase domains in the same range as dasatinib, however only the 
aliphatic diazirine probe 65 was much more cell-permeable than the benzophenone probe 
66. Therefore, further protein profiling experiments were performed using the cell-
permeable diazirine probe 65 only. This aliphatic diazirine probe (65) was capable of 
proteome-wide profiling of potential cellular targets of Dasatinib. Results obtained from 
different proteomic setups (cell lysates, live cells and immobilized affinity matrix) were 
compared and it has been found that under similar experimental settings, the 
photoaffinity probe (65) was able to identify more putative kinase targets over 
immobilized dasatinib affinity matrix. In addition to Abl and Src family tyrosine kinase, six 
serine/threonine kinases were identified by pull-down/immunoblotting experiments as 
new targets, namely PCTK3, STK25, eIF-2A, PIM3, PKA Cα and PKN2. 
 
Figure 18. Structures of two-step bioorthogonal phofoaffinity-group containing dasatinib-probes 65 and 66. 
Rhodamine-N3 (67) and biotin-N3 served as the ligation reagents for visualization and pull-down of targets, 
respectively. 
 
Instead of labeling one particular kinase or kinase family, in some cases large scale labeling 
of kinases are preferable. For the labeling of kinases in broad-scale, many studies have 
already done this by using bead affinity-driven techniques as mentioned above. To 
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overcome the disadvantages of the bead affinity-driven approach, biological samples may 
be profiled in solution by soluble, multitargeted small molecule probes. To allow labeling 
of the ATP-binding sites of as much as possible kinases, a few studies has used the 
reversible ATP mimetic kinase inhibitor staurosporine, which is known for inhibiting at 
least 253 kinases, as the affinity group.
37, 38
 An example is the biotinylated staurosporine-
arylazide 69 developed by Fisher et al. (Figure 19). The staurosporine probe 69 were 
incubated with human liver cancer cell line HepG2 whole cell lysates prior to irradiation at 
312 nm. Streptavidin coated magnetic beads was used to isolate the covalently cross-
linked protein-probe complexes. According to the LC-MS/MS results 101 kinase and 144 
non-kinases were labeled. Among these identified kinases, the majority are members of 
the serine/threonine kinase family.  






Three methods of chemical profiling are applied for the labeling and identification of 
kinases. Each method has its own advantages and disadvantages. Thus, dependent on the 
purpose of the study and under which conditions the experiments need to be performed, 
one of these methods will suit the best for the experiment and kinase(s) of interest. Even 
though many studies have already been done up to now, much more experiments need to 
be done in the future. Not every kinase or kinase subset can be labeled and not every 
function of the many kinases are determined yet due to the complexity of the kinome and 
the low abundance of most kinases. Therefore, there is need for the development of more 
selective and active probes, which in turn can be analyzed using highly sensitive and 
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Hematopoietic cells express specific receptors, which are activated by a variety of 
cytokines leading to cell proliferation, differentiation and survival. FMS (Feline 
McDonough Sarcoma)-like tyrosine kinase 3 (FLT3) ligand is one of the cytokines 
that regulates the hematopoietic system and the corresponding FLT3 receptor is 
expressed on both stem cells and progenitors.
1
 FLT3 belongs to the receptor 
tyrosine kinase (RTK) family (subclass III) and is 993 amino acids in length. FLT3 is 
composed of five immunoglobulin-like extracellular domains, a transmembrane 
domain, a juxtamembrane domain and two intracellular tyrosine-kinase domains 
3 
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(TKDs) linked by a kinase-insert domain. Non-stimulated FLT3 receptors are present 
as monomers in the plasma membrane. After stimulation with FLT3 ligand, 
membrane-bound FLT3 receptors quickly change conformation and form 
homodimers. Activated, homodimerized FLT3 receptors trigger the 
phosphatidylinositol 3-kinase (PI3K) and RAS/RAF pathways, thereby stimulate 
downstream proteins such as 3-phosphoinositide-dependent protein kinase 1 
(PDK1) and protein kinase B (PKB/AKT), which ultimately leads to increased cell 
proliferation and inhibition of apoptosis.
2
  
Despite the many checks and balances that are in place to regulate hematopoiesis, 
mutations of regulatory genes including FLT3 can disrupt hematopoiesis and 
promote leukemogenesis. FLT3 mutations occur in several hematopoietic 
malignancies, and may result in FLT3-ligand independent tyrosine kinase activation 
of the FLT3 receptor,
3
 as first described Nakao et al.
4
 The most common form of 
FLT3 mutation comprises internal tandem duplication (ITD) in exons 14 and 15, 
which occurs in 15-35% of patients suffering from acute myeloid leukemia (AML)
5,6,7
 
and 5-10% of patients with myelodysplasia (MDS).
8,9 
The second most common type 
of FLT3 mutation concerns missense point mutations in exon 20 of the TKD. TKD 
mutations occur in patients suffering from AML (5-10%), MDS (2-5%) and acute 
lymphoblastic leukemia (ALL) (1-3%).
10,11
 Thus, the wild-type and mutant FLT3 
receptors are appealing drug targets for inhibition. Several small molecule 
inhibitors of tyrosine kinase such as the indolocarbazole derivatives lestaurtinib and 
midostaurin, which inhibit both the wild-type and mutant FLT3 next to a small 
spectrum of other tyrosine kinases, were studied in early phase clinical trials.
12
  
At the basis of the work described in this chapter is the discovery of the 
isoquinolines 2 and 3 (Figure 1) as a new structural class of FLT3 kinase inhibitors. 
Compounds 2 and 3 are analogues of the known PKA inhibitor H-89 (1) and were 
identified from a focused library of H-89 analogues, which were assessed on their 
PKB/AKT1 inhibitory properties. 
Figure 1. Lead compounds 1 (H-89), 2 and 3. 
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In this screen, the in vitro activity of the compounds against PKB/AKT1 was 
determined together with the translocation activity of the AKT-regulated forkhead 
transcription factor, FOXO3a, into the nucleus. The latter is a way to measure the 
cellular activity of an inhibitor, since nuclear translocation of FOXO3a is correlated 
to inactivation of the AKT pathway. Apart from the identification of 2 as the most 
potent PKB/AKT1 inhibitor of the compounds tested (Figure 1), a set of compounds 
was discovered that showed hardly any PKB/AKT1 inhibition, but a high 
translocation activity of FOXO3a into the nucleus. In subsequent studies, it was 
found that these compounds, exemplified by 3, inhibit FLT3, which is upstream of 
AKT1 in the same pathway. Therefore, a higher FOXO3a translocation into the 
nucleus has been observed without inhibition of PKB/AKT1. The most potent 
inhibitor of this set of compounds proved to be isoquinolinesulfonamide 3 (Figure 
1), with an IC50 against FLT3 of 1.01 µM. To obtain insight in the specificity of this 
compound, the activities of compound 2 and 3 towards a panel of 111 human 
kinases were determined using the Kinomescan
TM
 assay, which was performed by 
the company LeadHunter discovery services.
13
 Briefly, the Kinomescan assay is 
conducted as follows. Purified recombinant kinases (111 in total) tagged with DNA 
for qPCR detection are incubated with 10 µM of test compound (here: 2 or 3) for 1 
hour. Subsequently the mixture of kinases and test compound is transferred to an 
immobilized ligand that binds to the panel of kinases. Compounds that bind the 
kinase active site will prevent kinase binding to the immobilized ligand. As a result, 
the amount of kinase captured on the solid support will be reduced (Figure 2A and 
C). Compounds that do not bind the kinase have no effect on the amount of kinase 
captured on the solid support (Figure 2B). Potential inhibitors are identified by 
measuring the amount of kinase captured in test versus control samples by 
quantitative qPCR. 
 
Figure 2. General outline of the KinomescanTM kinase assay applied to identify off targets of compounds 




















Table 1. Kinase activity relative to control sample (%) after inhibition by compounds 2 and 3 (10 µM). a 
Kinase 2 3  Kinase 2 3 Kinase 2 3 
ABL1 87 79  FLT1 78 70 PDPK1 56 67 
ACVR1B 28 83  FLT3 28 1.6 PIK3C2B 100 94 
ADCK3 15 87  GSK3B 100 100 PIK3CA 96 76 
AKT1 1.3 46  HIPK2 100 75 PIK3CG 100 100 
AKT2 24 94  IGF1R 75 100 PIK4CB 100 100 
AKT3 4.3 40  IKK-alpha 100 100 PIM1 84 74 
ALK 78 36  IKK-beta 87 97 PIM2 100 72 
AMPK-α2 60 60  INSR 95 97 PIM3 85 60 
AURKA 100 96  JAK2 91 70 PIP5K1A 17 52 
AURKB 28 77  JAK3 82 75 PKAC-alpha 1.6 19 
AXL 64 54  JNK1 93 73 PLK1 100 100 
BMPR2 100 100  JNK2 100 76 PLK3 100 97 
BRAF 67 96  JNK3 80 100 PLK4 70 76 
BTK 52 100  KIT 66 55 PRKCD 5 40 
CDK11 4.3 64  LKB1 100 100 PRKCE 67 26 
CDK2 93 78  MAP3K4 11 96 PRKCH 2.8 16 
CDK3 97 58  MAPKAPK2 60 59 PRKCI 30 77 
CDK7 5.6 54  MARK3 15 41 PRKCQ 12 100 
CDK9 100 95  MEK1 60 93 RAF1 38 68 
CHEK1 46 87  MEK2 54 88 RET 71 51 
CLK2 45 92  MET 89 93 RIOK2 67 90 
CSF1R 47 69  MKNK1 59 100 ROCK2 0.6 5 
CSNK1D 3.4 6.6  MKNK2 24 85 RSK2 71 78 
CSNK1G2 66 100  MLCK 73 32 SGK3 63 74 
CSNK1G3 97 96  MLK1 93 90 SNARK 10 39 
DCAMKL1 80 100  MST2 51 92 SRC 69 78 
DYRK1A 70 75  MTOR 97 67 SRPK3 93 63 
DYRK1B 54 74  MUSK 0.2 62 TAOK1 10 84 
EGFR 29 91  MYO3A 87 100 TGFBR1 34 48 
EPHA2 48 84  p38-alpha 95 86 TIE2 18 91 
ERBB2 38 100  p38-beta 40 93 TRKA 85 83 
ERBB4 87 97  PAK1 59 77 TSSK1B 88 61 
ERK1 77 100  PAK2 63 69 TYK2 100 100 
ERN1 80 77  PAK4 72 91 ULK2 42 81 
FAK 83 75  PCTK1 1.1 74 VEGFR2 59 98 
FGFR2 33 54  PDGFRA 84 96 YANK3 56 68 
FGFR3 25 68  PDGFRB 16 5.4 ZAP70 100 100 
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The results for binding interactions are reported as relative activity percentage, 
where lower numbers indicate stronger hits in the matrix (Table 1). Compound 3 
proved 18 times more activity towards FLT3 than compound 2 and near 30 times 
more specific for FLT3 over PKB/AKT1. Since compound 3 also has affinity for other 
kinases including ROCK2, PDGFRB and CSNK1D, more active and specific FLT3 
inhibitors would be desirable. With the purpose to discover such entities, a set of 
isoquinolinesulfonamide compounds were designed based on compound 3. 
This chapter describes the synthesis of a focused FLT3 inhibitor library, the core 
structures of which are given in Figure 3. The naphthalene moiety in 3 is either 
modified or substituted for by thiophene or pyrrole moieties. Since the FLT3 
inhibitor library consists of compound 3 and H-89 (1) analogues, more potent 
















Figure 3. Target structures of the isoquinolinesulfonamide library described here and based on the 
scaffold of lead compound 3. The naphthalene in 3 was modified (A – C) or substituted for thiophene or 











The focused isoquinoline library is synthesized in a similar way as compound 22, the 
synthesis of which is depicted in scheme 1. The synthesis of compound 22 
commenced with a Horner-Wadsworth-Emmons (HWE) reaction between 
commercially available diethyl cyanomethylphosphonate 12 and o-
bromobenzaldehyde 13 to obtain the corresponding E-isomer cinnamonitrile 14 in 
77% yield after column purification and recrystallization. Subsequently, E-isomer 14 
was used in the four-step-one-pot trans-imination procedure according to Brussee 
et al.
14
 This sequence started with reduction of nitrile 14 using DiBAlH to form imine 
15. The latter was reacted with amine 17, which was obtained by conversion of 
isoquinoline sulfonic amine 16 into the corresponding isoquinoline sulfonic 
chloride, which was in turn reacted with ethylenediamine. Next, the resulting 
secondary imine was reduced by NaBH4 and the crude isoquinolinesulfonamide 18 
was protected with a Boc-group to yield pure E-isoquinolinesulfonamide 19. A 
Suzuki reaction (Pd(PPh3)4, K2CO3) was used to couple aryl bromide 19 with aryl 
boronic acid 20 to form the Boc-protected isoquinolinesulfonamide 21. Removal of 
the Boc protective group, and final HPLC purification, furnished 
isoquinolinesulfonamide 22 in 13% yield. The yields of the complete library are 
given in Table 2 and in the experimental section. 
 
Scheme 1. Exemplified synthesis of bulky arylated isoquinolinesulfonamides. Reagents and conditions: a) 
NaH, 13, 0 °C, THF, 77%; b) DiBAlH, -78 °C, Et2O/DCM 1:1 v/v; c) i) SOCl2, reflux, DMF; ii) 
ethylenediamine, DCM, 0 °C, 69%; d) i) MeOH, -100 °C; ii) 17, MeOH, RT; iv) NaBH4, -10 °C – RT; e) Boc2O, 
TEA, DCM, 0 °C. 48%; f) 20, K2CO3, Pd(PPh3)4, DMF, 90 °C; g) TFA, DCM, H2O, 13%. 
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Table 2. Yields (%) of the Suzuki cross coupling reaction. 
R =  yield (%)  yield (%)  yield (%) 
 
22 12.7 56 10.1 90 6.4 
 
23 14.3 57 11.6 91 9.6 
 
24 18.2 58 13.6 92 6.4 
 
25 16.1 59 12.9 93 6.5 
 
26 5.3 60 6.6 94 1.5 
 
27 5.5 61 9.3 95 2.6 
 
28 15.1 62 7.2 96 8.0 
 
29 17.9 63 17.0 97 9.9 
 
30 26.8 64 13.8 98 15.3 
 
31 24.6 65 15.3 99 13.7 
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32 24.3 66 12.3 100 13.3 
 
33 28.5 67 17.1 101 14.6 
 





35 15.6 69 10.2 103 7.3 
 
 














39 22.1 73 16.0 107 15.1 
 




41 24.8 75 14.9 109 21.1 
 
42 23.4 76 13.0 110 18.5 
 
43 12.9 77 16.5 111 12.6 
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44 24.4 78 16.9 112 21.2 
 
45 38.9 79 12.8 113 20.9 
 
46 35.5 80 31.9 114 71.1 
 
47 50.2 81 34.2 115 43.9 
 
48 32.1 82 23.4 116 34.4 
 





50 26.1 84 27.6 118 40.7 
 
51 12.0 85 13.9 119 26.6 
 
52 78.4 86 40.6 120 67.8 
 
53 15.8 87 10.4 121 22.3 
 
54 26.5 88 18.4 122 26.0 
 




In this chapter the synthesis of 102 new analogues of lead compound 3 is 
described. The library was assembled in a parallel synthesis fashion using 34 
heterocyclic aromatic boronic acids and three isoquinolinesulfonamide-modified 
aryl bromides using Suzuki cross-coupling methodology. The biological evaluation of 
the 102 compounds as inhibitors of the four kinases, PKA, AKT1, AKT2 and FLT3 is 
described in Chapter 4. 
 
 
General: Tetrahydrofuran (THF) was distilled over LiAlH4 before use. Acetonitrile (ACN), dichloromethane (DCM), 
N,N-dimethylformamide (DMF), methanol (MeOH) and trifluoroacetic acid (TFA) were of peptide synthesis grade, 
purchased at Biosolve, and used as received. All general chemicals (Fluka, Acros, Merck, Aldrich, Sigma) were 
used as received. Traces of water were removed from reagents used in reactions that require anhydrous 
conditions by coevaporation with toluene. Solvents that were used in reactions were stored over 4Å molecular 
sieves, except methanol and acetonitrile, which were stored over 3Å molecular sieves. Molecular sieves were 
flame dried before use. Unless noted otherwise all reactions were performed under an argon atmosphere. 
Column chromatography was performed on Silicycle Silia-P Flash Silica Gel, with a particle size of 40 – 63 µm. The 
eluents toluene and ethyl acetate were distilled prior to use. TLC analysis was conducted on Merck aluminium 
sheets (Silica gel 60 F254). Compounds were visualized by UV absorption (254 nm), by spraying with a solution of 
(NH4)6Mo7O24·4H2O (25 g/L) and (NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% sulphuric acid, a solution of KMnO4 (20 g/L) 
and K2CO3 (10 g/L) in water, or ninhydrin (0.75 g/L) and acetic acid (12.5 mL/L) in ethanol, where appropriate, 
followed by charring at ca. 150°C. 1H- and 13C-NMR spectra were recorded on a Bruker DMX-400 (400 MHz) or a 
Bruker DMX-600 (600 MHz) spectrometer. Chemical shifts are given in ppm (δ) relative to tetramethylsilane (1H-
NMR) or CDCl3 (
13C-NMR) as internal standard. Mass spectra were recorded on a PE/Sciex API 165 instrument 
equipped with an Electrospray Interface (ESI) (Perkin-Elmer). High-resolution MS (HRMS) spectra were recorded 
with a Finnigan LTQ-FT (Thermo Electron). IR spectra were recorded on a Shimadzu FTIR-8300 and absorptions 
are given in cm-1. Optical rotations [α]D
23 were recorded on a Propol automatic polarimeter at room temperature. 
LC-MS analysis was performed on a Jasco HPLC system with a Phenomenex Gemini 3 µm C18 50 x 4.6 mm 
column (detection simultaneously at 214 and 254 nm), coupled to a PE Sciex API 165 mass spectrometer with ESI. 
HPLC gradients were 10 → 90%, 0 → 50% or 10 → 50% ACN in 0.1% TFA/H2O. Chiral HPLC analysis was 
performed on a Spectroflow 757 system (ABI Analytical Kratos Division, detection at 254 nm) equipped with a 
Chiralcel OD column (150 x 4.6 mm). The compounds were purified on a Gilson HPLC system coupled to a 
Phenomenex Gemini 5 µm 250 x 10 mm column and a GX281 fraction collector. The used gradients were either 0 
→ 30% or 10 → 40% ACN in 0.1% TFA/water, depending on the lipophilicity of the product. Appropriate fractions 




Diethyl cyanomethylphosphonate (35.43 g, 200 mmol) was slowly added to an ice-cold solution of NaH (1.1 eq., 
8.80 g, 220 mmol, 60% mineral oil) in DMF (900 mL) and the mixture was allowed to stir for 30 min. Hereafter, a 
solution of 2-bromobenzaldehyde 13 (1.1 eq., 40.70 g, 220 mmol) in DMF (100 mL) was dropwise added. The 
reaction was allowed to warm to RT and stirred overnight before being quenched with freshly prepared sat. aq. 
Na2HSO3 (800 mL). The mixture was diluted with H2O (800 mL) and Et2O (800 mL) and the layers were separated.  
The aqueous phase was extracted with Et2O (3 x 600 mL) and the combined organic phases were washed with 
sat. aq. NaHCO3 and brine, dried over MgSO4, filtered and concentrated in vacuo. The resulting residue was 
purified by crystallization from EtOAc/PE (9/1, v/v) to provide ortho-14 as a white solid (yield: 32.0 g, 154.0 
mmol, 77%). 1H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 16.4 Hz, 1H), 7.58 (dd, J1 = 1.2 Hz, J2 = 8.4 Hz, 1H), 7.50 (dd, J1 
= 1.6 Hz, J2 = 8.0 Hz, 1H), 7.34 (t, J = 6.8 Hz, 1H), 7.26 (td, J1 = 1.6 Hz, J2 = 8.0 Hz, 1H), 5.84 (d, J = 16.4 Hz, 1H). 
13C 
NMR (101 MHz, CDCl3) δ 148.45, 133.19, 132.95, 131.87, 127.66, 126.70, 124.38, 117.35, 98.73. 
 
(E)-3-(3-bromophenyl)acrylonitrile: meta-14 
The same procedure as described for ortho-14 was applied for the preparation of meta-14. The resulting residue 
was purified by crystallization from EtOAc/PE (9/1, v/v) to provide ortho-14 as a white solid (yield: 33.8 g, 162.6 
mmol, 81.3%). 1H NMR (400 MHz, CDCl3) δ 7.57 – 7.53 (m, 2H), 7.37 (d, J = 8.0 Hz, 1H), 7.32 – 7.26 (m, 2H), 5.88 




The same procedure as described for ortho-14 was applied for the preparation of para-14. The title compound 
was afforded by crystallization from EtOAc/PE (9/1, v/v) as a white solid (yield: 25.4 g, 122.0 mmol, 61%). 1H 
NMR (400 MHz, CDCl3) δ 7.51 (d, J = 8.8 Hz, 2H), 7.33 – 7.29 (m, 3H), 5.89 (d, J = 16.8 Hz, 1H). 
13C NMR (101 MHz, 
CDCl3) δ 149.89, 132.12, 132.03, 128.52, 125.26, 117.67, 96.84. 
 
N-(2-aminoethyl)isoquinoline-5-sulfonamide 17 
Isoquinoline-5-sulfonic acid 16 (20.92 g, 100 mmol) was treated with thionylchloride (13 eq., 91.5 mL, 1300 
mmol) and a catalytic amount of DMF for 2 h at reflux. The reaction mixture was concentrated and the residue 
was thoroughly washed with DCM before being resuspended in H2O (300 mL) at 0 °C. NaHCO3 (1 eq., 8.42 g, 
100.2 mmol) was added portion-wise. Next, the mixture was extracted with DCM (3x 500 mL) and dried over 
MgSO4. The filtrate was dropwise added to a cooled solution of ethylenediamine (5 eq., 33.4 mL, 500 mL) in DCM 
(250 mL) and the reaction mixture was allowed to warm to RT and stirred for 1 h. The mixture was then 
evaporated partially before being washed with brine (50 mL). The aqueous layer was extracted with DCM (10 x 
50 mL) and the combined organic layers were washed with brine (50 mL), dried over MgSO4, filtered and 
concentrated. The title compound was obtained as a thick yellowish oil (yield: 17.3 g, 69 mmol, 69%) and was 
used without further purification. 1H NMR (400 MHz, CDCl3, Me4Si) δ 9.36 (1H, s, CHar), 8.67 (1H, d, J = 8.4 Hz, 
CHar), 8.47 – 8.43 (2H, m, 2 x CHar), 8.21 (1H, d, J = 11.2 Hz, CHar), 7.71, (1H, t, J = 10.0 Hz, CHar), 3.45 (3H, bs, NH2 
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and NH), 3.00 (2H, t, J = 5.2 Hz, CH2), 2.76 (2H, t, J = 6.0 Hz, CH2). 
13C NMR (101 MHz, CDCl3) δ 153.26, 145.06, 
133.46, 133.19, 131.23, 129.01, 125.91, 117.22, 45.12, 40.76. 
 
Tert-butyl (E)-(3-(4-bromophenyl)allyl)(2-(isoquinoline-5-sulfonamido)ethyl)carbamate: ortho-19                                                                                                                                                                                                                                                                                                                                                                                                                               
A solution of nitrile ortho-4 (11.18 g, 53.72 mmol) in anhydrous Et2O (250 mL) was cooled to -78 °C before 
dropwise addition of DiBAL-H (2 eq., 100 mL, 100 mmol, 1M solution in hexanes) and the reaction mixture was 
allowed to warm to 0 °C and was stirred for 2 h, after which TLC analysis showed complete consumption of 
starting material. Next, the mixture was cooled to -100 °C followed by rapid addition of MeOH (100 mL). After 5 
min a solution of isoquinoline amine 17 (2 eq., 25.18 g, 100 mmol) in MeOH (100 mL) was dropwise added and 
the reaction mixture was allowed to stir at RT overnight. Hereafter, the reaction was cooled to -10 °C and NaBH4 
(2 eq., 3.78 g, 100 mmol) was added and the mixture was allowed to stir at RT for 4 h. The reaction mixture was 
diluted with 0.5M aq. NaOH (250 mL) and the layers were separated. The aqueous layer was extracted with DCM 
(3 x 250 mL) and the combined organic phases were washed with H2O (3 x 250 mL) and brine before being dried, 
filtered and evaporated. The crude product was subjected to the next step without further purification. 
To the ice-cooled solution of crude product in THF (250 mL) Boc2O (2.5 eq., 27.28 g, 125 mmol) was added and 
the reaction was allowed to warm to RT and was stirred overnight. The reaction mixture was diluted with H2O 
(250 mL) and EtOAc (250 mL) were added before being separated. The aqueous phase was extracted with EtOAc 
(3x 250 mL). The combined organic layers were washed with sat. aq. NaHCO3 (2x 250 mL) and brine, dried over 
MgSO4, filtered and concentrated in vacuo. The title compound was obtained after purification by silica gel 
column chromatography (0.5 – 3% MeOH/DCM) as a white solid (yield: 14.0 g, 25.6 mmol, 47.6%). 1H NMR (400 
MHz, CDCl3) δ 9.30 (s, 1H), 8.59 (d, J = 6.0 Hz, 1H), 8.44 (d, J = 6.0 Hz, 1H), 8.40 (d, J = 7.2 Hz, 1H), 8.11 (d, J = 8.0 
Hz, 1H), 7.60 (t, J = 8.0 Hz, 1H), 7.50 (d, J = 7.6 Hz, 1H), 7.38 (d, J = 7.6 Hz, 1H), 7.23 (br s, 1H), 7.09 (t, J = 7.2 Hz, 
1H), 6.67 (d, J = 14.8 Hz, 1H), 5.97 – 5.90 (m, 1H), 3.89 (d, J = 6.0 Hz, 2H), 3.37 (s, 2H), 3.17 – 3.13 (m, 2H), 1.43 (s, 
9H). 13C NMR (101 MHz, CDCl3) δ 152.98, 144.68, 136.09, 134.32, 133.22, 132.87, 132.64, 131.01, 130.58, 128.84, 
128.81, 127.88, 127.37, 126.96, 125.71, 123.23, 117.21, 80.49, 50.17, 46.54, 42.42, 28.16. 
 
Tert-butyl (E)-(3-(3-bromophenyl)allyl)(2-(isoquinoline-5-sulfonamido)ethyl)carbamate: meta-19  
An identical method was used as for the synthesis of ortho-19 except that compound meta-4 (12.48 g, 60 mmol) 
was used as starting material and the amounts of the other materials were adjusted accordingly. The title 
compound was obtained after purification by silica gel column chromatography (25 – 50% EtOAc/PE) as a white 
solid (yield: 13.4 g, 24.6 mmol, 41.0%). 1H NMR (400 MHz, CDCl3) δ 9.29 (s, 1H), 8.57 (d, J = 6.0 Hz, 1H), 8.42 (d, J 
= 6.0 Hz, 1H), 8.36 (d, J = 7.2 Hz, 1H), 8.14 (d, J = 8.4 Hz, 1H), 7.59 (t, J = 7.6 Hz, 1H), 7.42 (s, 1H), 7.33 – 7.31 (m, 
2H), 7.21 – 7.17 (m, 2H), 6.29 (d, J = 16.4 Hz, 1H), 6.04 – 6.00 (m, 1H), 3.87 (d, J = 5.2 Hz, 2H), 3.33 (s, 2H), 3.10 (s, 
2H), 1.42 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 152.87, 144.53, 138.35, 134.25, 133.21, 132.78, 130.94, 130.28, 
129.90, 128.89, 128.75, 126.46, 125.67, 124.86, 122.46, 117.18, 80.33, 50.09, 46.39, 42.16, 28.09. 
 
Tert-butyl (E)-(3-(2-bromophenyl)allyl)(2-(isoquinoline-5-sulfonamido)ethyl)carbamate: para-19  
An identical method was used as for the synthesis of ortho-19 except that compound para-4 (10.40 g, 50 mmol) 
was used as starting material and the amounts of the other materials were adjusted accordingly. The title 
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compound was obtained after purification by silica gel column chromatography (0.1 – 2% MeOH/DCM) as a 
white solid (yield: 14.9 g, 27.4 mmol, 54.7%). 1H NMR (400 MHz, CDCl3) δ 9.32 (s, 1H), 8.59 (d, J = 6.4 Hz, 1H), 
8.44 (d, J = 6.0 Hz, 1H), 8.36 (d, J = 7.2 Hz, 1H), 8.14 (d, J = 8.0 Hz, 1H), 7.59 (t, J = 7.6 Hz, 1H), 7.38 (s, 2H), 7.15 (d, 
J = 7.6 Hz, 2H), 6.77 (br s, 1H), 6.30 (d, J = 16.0 Hz, 1H), 6.06 – 5.99 (m, 1H), 3.87 (d, J = 5.2 Hz, 2H), 3.35 (s, 2H), 
3.12 (s, 2H), 1.42 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 152.93, 144.54, 135.13, 134.33, 133.23, 132.82, 131.43, 
131.00, 128.80, 127.70, 125.72, 121.23, 117.25, 80.38, 50.16, 46.45, 42.11, 29.41, 28.12. 
 
General procedure for the Suzuki coupling: 
Stock solutions of ortho-19 (1M in DCM), K2CO3 (2M in H2O) and Pd(PPh3)4 (0.017M in DCM) were thoroughly 
degassed in a sonication bath for 15 minutes. K2CO3 (2.5 eq., 0.14 g, 1.0 mmol, 0.5 mL stock), ortho-19 (0.22 g, 
0.4 mmol, 0.4 mL stock) and Pd(PPh3)4 (0.05 eq., 0.02 g, 0.02 mmol, 1.2 mL stock) were added to arylbromide 20 
(1.5 eq., 0.11 g, 0.6 mmol) and the resulting mixture was stirred at 90 °C overnight. The mixture was filtered over 
a short plug of silica and eluted with DCM/MeOH (4x column volume, 1:1, v/v). The eluent was evaporated and 
the residue was subjected to the next step without further purification.  
The residue was dissolved in DCM (2.5 mL) and TFA (2.5 ML) and the reaction mixture was stirred for 1 hr. before 
being evaporated and coevaporated with toluene thrice. The resulting residue was purified by RP-HPLC gradient. 
 
(E)-N-(2-((3-(2-(4-methylnaphthalen-1-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 22 
Prepared according to the general procedure. Yield: 25.8 mg, 50.8 µmol, 12.7%. 1H NMR (400 MHz, CD3OD) δ 
9.42 (s, 1H), 8.64 (d, J = 6.0 Hz, 1H), 8.51 (d, J = 6.4 Hz, 1H), 8.44 (dd, J1 = 8.4 Hz, J2 = 12.0 Hz, 2H), 8.00 (d, J = 16.0 
Hz, 1H), 7.85 (t, J = 7.6 Hz, 1H), 7.78 (d, J = 7.2 Hz, 1H), 7.51 – 7.43 (m, 3H), 7.40 – 7.34 (m, 3H), 7.28 (d, J = 7.2 Hz, 
1H), 7.21 (d, J = 7.2 Hz, 1H), 6.39 (d, J = 15.6 Hz, 1H), 6.17 – 6.09 (m, 1H), 3.56 – 3.43 (m, 2H), 2.94 – 2.86 (m, 2H), 
2.68 (s, 3H). 13C NMR (101 MHz, CD3OD) δ 154.27, 144.73, 141.51, 138.86, 137.85, 136.04, 135.54, 135.44, 
135.23, 135.15, 133.96, 133.60, 132.67, 132.69, 130.71, 129.76, 129.19, 128.17, 127.85, 127.66, 127.16, 126.94, 
126.89, 126.74, 125.48, 119.76, 119.10, 50.08, 46.96, 39.69, 19.52. HRMS: calculated for C31H29N3O2S [M+H]
+: 
508.20532; found: 508.20508. 
 
(E)-N-(2-((3-(2-(4-methoxynaphthalen-1-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 23 
Prepared according to the general procedure. Yield: 30.0 mg, 57.2 µmol, 14.3%. 1H NMR (400 MHz, CD3OD) δ 
9.47 (s, 1H), 8.64 (d, J = 6.0 Hz, 1H), 8.54 (d, J = 6.0 Hz, 1H), 8.45 (dd, J1 = 8.4 Hz, J2 = 16.4 Hz, 2H), 8.20 (d, J = 9.2 
Hz, 1H), 7.86 (t, J = 8.0 Hz, 1H), 7.76 (d, J = 7.2 Hz, 1H), 7.49 – 7.43 (m, 2H), 7.39 – 7.32 (m, 2H), 7.29 – 7.22 (m, 
3H), 6.97 (d, J = 7.6 Hz, 1H), 6.42 (d, J = 16.0 Hz, 1H), 6.16 – 6.08 (m, 1H), 4.02 (s, 3H), 3.57 – 3.44 (m, 2H), 2.88 – 
2.77 (m, 4H). 13C NMR (101 MHz, CD3OD) δ 156.59, 154.02, 144.18, 141.37, 139.07, 136.31, 135.53, 135.38, 
135.29, 134.40, 132.83, 132.56, 131.59, 129.77, 129.08, 128.70, 128.02, 127.70, 126.85, 126.15, 123.23, 119.61, 
104.49, 56.10, 50.07, 46.88, 39.66. HRMS: calculated for C31H29N3O3S [M+H]
+: 524.20024; found: 524.20000. 
 
(E)-N-(2-((3-(2-(6-methoxynaphthalen-2-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 24 
Prepared according to the general procedure. Yield: 38.1 mg, 72.8 µmol, 18.2%. 1H NMR (400 MHz, CD3OD) δ 
9.39 (s, 1H), 8.60 – 8.55 (m, 2H), 8.38 (dd, J1 = 7.2 Hz, J2 = 23.6 Hz, 2H), 7.78 (t, J = 8.0 Hz, 2H), 7.73 – 7.71 (m, 1H), 
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7.68 – 7.66 (m, 1H), 7.63 (s, 1H), 7.41 – 7.33 (m, 4H), 7.22 (s, 1H), 7.09 (dd, J1 = 2.4 Hz, J2 = 8.8 Hz, 1H), 6.79 (d, J = 
16.0 Hz, 1H), 6.22 – 6.15 (m, 1H), 3.89 (s, 3H), 3.68 (d, J = 7.2 Hz, 2H), 3.08 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 
159.43, 153.78, 143.85, 142.95, 139.24, 136.94, 135.44, 135.18, 134.88, 132.83, 131.54, 130.53, 130.03, 129.32, 
128.70, 128.00, 127.87, 127.51, 120.27, 119.97, 119.47, 106.63, 55.80, 50.41, 47.33, 39.93. HRMS: calculated for 
C31H29N3O3S [M+H]
+: 524.20024; found: 524.19987. 
 
(E)-N-(2-((3-(2-(6-ethoxynaphthalen-2-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 25 
Prepared according to the general procedure. Yield: 34.6 mg, 64.4 µmol, 16.1%. 1H NMR (400 MHz, CD3OD) δ 
9.33 (s, 1H), 8.58 (s, 1H), 8.50 (d, J = 6.0 Hz, 1H), 8.38 (d, J = 7.2 Hz, 1H), 8.32 – 8.30 (m, 1H), 7.77 – 7.67 (m, 4H), 
7.62 (s, 1H), 7.38 – 7.28 (m, 4H), 7.19 (s, 1H), 7.09 (d, J = 8.8 Hz, 1H), 6.79 (d, J = 15.6 Hz, 1H), 6.22 – 6.14 (m, 1H), 
4.11 (q, J = 6.8 Hz, 2H), 3.68 (d, J = 7.2 Hz, 2H), 3.08 (s, 4H), 1.43 (t, J = 6.8 Hz, 3H). 13C NMR (101 MHz, CD3OD) δ 
158.66, 154.16, 144.70, 142.95, 139.23, 136.84, 135.28, 135.20, 135.00, 134.86, 132.55, 131.54, 130.51, 129.97, 
129.78, 129.28, 128.69, 127.83, 127.72, 127.51, 120.55, 119.94, 119.08, 107.36, 64.55, 50.40, 47.33, 39.91, 
15.12. HRMS: calculated for C32H31N3O3S [M+H]
+: 538.21589; found: 538.21569. 
 
(E)-N-(2-((3-(2-(6-(benzyloxy)naphthalen-2-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 26 
Prepared according to the general procedure. Yield: 12.7 mg, 21.2 µmol, 5.3%. 1H NMR (400 MHz, CD3OD) δ 9.50 
(s, 1H), 8.64 (s, 2H), 8.45 (t, J = 8.0 Hz, 2H), 7.88 (d, J = 8.4 Hz, 1H), 7.81 (t, J = 7.6 Hz, 1H), 7.69 – 7.64 (m, 3H), 
7.39 – 7.35 (m, 3H), 7.29 (d, J = 8.8 Hz, 1H), 7.22 – 7.19 (m, 3H), 7.14 (t, J = 7.2 Hz, 2H), 7.04 (t, J = 6.8 Hz, 1H), 
6.80 (d, J = 15.6 Hz, 1H), 6.21 – 6.13 (m, 1H), 4.41 (s, 2H), 3.66 (d, J = 7.2 Hz, 2H), 3.05 (s, 4H). 13C NMR (101 MHz, 
CD3OD) δ 154.30, 153.37, 143.04, 142.81, 142.75, 139.45, 135.91, 135.80, 135.71, 135.55, 134.87, 134.21, 
133.21, 131.63, 130.13, 130.06, 129.80, 129.39, 129.17, 129.05, 128.62, 128.41, 127.43, 126.57, 124.48, 119.77, 
119.66, 119.53, 50.36, 47.32, 39.92, 31.42. HRMS: calculated for C37H33N3O3S [M+H]




Prepared according to the general procedure. Yield: 12.0 mg, 22.0 µmol, 5.5%. 1H NMR (400 MHz, CD3OD) δ 9.50 
(s, 1H), 8.67 (s, 1H), 8.60 – 8.58 (m, 1H), 8.53 (d, J = 8.0 Hz, 1H), 8.49 (s, 1H), 8.42 (d, J = 7.2 Hz, 1H), 8.01 (d, J = 
8.4 Hz, 2H), 7.93 – 7.89 (m, 2H), 7.60 – 7.55 (m, 2H), 7.43 – 7.27 (m, 7H), 3.35 – 3.34 (m, 2H), 3.67 (dd, J1 = 5.2 Hz, 
J2 = 18.4 Hz, 4H). 
13C NMR (101 MHz, CD3OD) δ 153.33, 142.67, 139.21, 138.39, 137.03, 136.01, 135.80, 135.67, 
135.49, 133.28, 132.99, 132.81, 131.60, 130.07, 129.71, 128.52, 128.17, 127.24, 127.11, 127.02, 126.39, 120.36, 
49.75, 46.62, 39.47. HRMS: calculated for C34H29N3O2S [M+H]
+: 544.20532; found: 544.20506. 
 
(E)-N-(2-((3-(2-(9H-fluoren-2-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 28 
Prepared according to the general procedure. Yield: 32.1 mg, 60.4 µmol, 15.1%. 1H NMR (400 MHz, CD3OD) δ 
9.41 (s, 1H), 8.56 (s, 2H), 8.42 (d, J = 7.2 Hz, 1H), 8.35 (d, J = 8.0 Hz, 1H), 7.82 – 7.74 (m, 3H), 7.68 – 7.66 (m, 1H), 
7.49 (d, J = 7.2 Hz, 1H), 7.43 (s, 1H), 7.38 – 7.33 (m, 4H), 7.27 (t, J = 7.2 Hz, 2H), 6.82 (d, J = 15.6 Hz, 1H), 6.22 – 
6.15 (m, 1H), 3.87 (s, 2H), 3.71 (d, J = 7.2 Hz, 2H), 3.16 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 153.46, 144.71, 
143.18, 143.14, 142.34, 142.16, 140.33, 139.24, 135.63, 135.54, 135.44, 134.78, 133.01, 131.39, 130.49, 129.77, 
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129.67, 128.70, 128.20, 128.02, 127.92, 127.49, 127.37, 126.09, 120.80, 120.57, 119.88, 119.76, 50.40, 47.37, 
39.91, 37.65. HRMS: calculated for C33H29N3O2S [M+H]
+: 532.20532; found: 532.20521. 
 
(E)-N-(2-((3-(2-(phenanthren-9-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 29 
Prepared according to the general procedure. Yield: 38.9 mg, 71.6 µmol, 17.9%. 1H NMR (400 MHz, CD3OD) δ 
9.44 (s, 1H), 8.68 (t, J = 12.4 Hz, 2H), 8.60 (d, J = 5.6 Hz, 1H), 8.51 (d, J = 6.0 Hz, 1H), 8.41 (d, J = 8.4 Hz, 1H), 8.35 
(d, J = 7.2 Hz, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.81 – 7.78 (m, 2H), 7.62 – 7.40 (m, 7H), 7.35 – 7.30 (m, 2H), 6.42 (d, J = 
16 Hz, 1H), 6.18 – 6.11 (m, 1H), 3.49 – 3.37 (m, 2H), 2.81 – 2.69 (m, 4H). 13C NMR (101 MHz, CD3OD) δ 153.68, 
143.60, 141.06, 138.59, 138.07, 136.12, 135.52, 135.26, 132.88, 132.69, 132.05, 131.66, 131.32, 130.53, 129.86, 
129.72, 129.41, 129.07, 128.14, 128.11, 128.08, 127.94, 127.85, 126.86, 124.08, 123.59, 120.14, 119.54, 49.88, 
46.76, 39.52. HRMS: calculated for C34H29N3O2S [M+H]
+: 544.20532; found: 544.20519. 
 
(E)-N-(2-((3-(2-(dibenzo[b,d]furan-4-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 30 
Prepared according to the general procedure. Yield: 57.2 mg, 107.2 µmol, 26.8%. 1H NMR (400 MHz, CD3OD) δ 
9.41 (s, 1H), 8.61 – 8.59 (m, 1H), 8.52 (d, J = 6.4 Hz, 1H), 8.39 – 8.37 (m, 2H), 7.97 (dd, J1 = 7.6 Hz, J2 = 18.4 Hz, 
2H), 7.80 (d, J = 7.6 Hz, 1H), 7.76 (d, J = 9.2 Hz, 1H), 7.47 – 7.38 (m, 5H), 7.34 – 7.30 (m, 2H), 7.24 (t, J = 7.2 Hz, 
1H), 6.63 (d, J = 16.0 Hz, 1H), 6.25 – 6.17 (m, 1H), 3.58 (d, J = 7.2 Hz, 2H), 2.88 (dd, J1 = 4.4 Hz, J2 = 11.2 Hz, 4H). 
13C NMR (101 MHz, CD3OD) δ 157.34, 154.76, 153.71, 143.72, 138.65, 137.25, 135.60, 135.45, 135.24, 132.82, 
131.99, 130.50, 129.86, 129.76, 129.53, 128.54, 128.06, 127.16, 126.05, 125.52, 125.28, 124.24, 124.12, 121.93, 
121.36, 120.23, 119.48, 112.49, 50.14, 46.91, 39.72. HRMS: calculated for C32H27N3O3S [M+H]




Prepared according to the general procedure. Yield: 55.7 mg, 98.4 µmol, 24.6%. 1H NMR (400 MHz, CD3OD) δ 
9.64 (s, 1H), 8.76 – 8.71 (m, 2H), 8.58 – 8.55 (m, 2H), 7.96 (t, J = 7.6 Hz, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.48 – 7.42 
(m, 2H), 7.25 (d, J = 8.4 Hz, 1H), 7.20 – 7.05 (m, 5H), 7.01 – 6.97 (m, 1H), 6.65 (d, J = 15.6 Hz, 1H), 6.59 (d, J = 8.0 
Hz, 1H), 6.25 – 6.18 (m, 1H), 3.63 – 3.57 (m, 2H), 3.01 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 153.36, 152.56, 
150.62, 140.93, 138.91, 138.05, 136.82, 136.11, 135.82, 135.48, 133.85, 131.78, 131.57, 131.12, 129.72, 129.39, 
129.09, 129.00, 127.81, 127.74, 126.70, 126.10, 125.72, 122.54, 121.90, 120.87, 120.17, 118.94, 50.26, 47.11, 
39.90. HRMS: calculated for C32H27N3O3S2 [M+H]
+: 566.15666; found: 566.15650. 
 
(E)-N-(2-((3-(2-(2,3-dihydrobenzofuran-5-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 32 
Prepared according to the general procedure. Yield: 47.2 mg, 97.2 µmol, 24.3%. 1H NMR (400 MHz, CD3OD) δ 
9.66 (s, 1H), 8.83 (d, J = 6.4 Hz, 1H), 8.69 (d, J = 6.0 Hz, 1H), 8.58 (dd, J1 = 7.2 Hz, J2 = 27.2 Hz, 2H), 7.95 (t, J = 8.0 
Hz, 1H), 7.62 (d, J = 8.4, 1H), 7.35 – 7.29 (m, 2H), 7.24 – 7.22 (m, 1H), 7.10 (s, 1H), 6.95 (d, J = 8.4 Hz, 1H), 6.80 (d, 
J = 15.6 Hz, 1H), 6.73 (d, J = 8.0 Hz, 1H), 6.21 – 6.13 (m, 1H), 4.54 (t, J = 8.8 Hz, 2H), 3.74 (d, J = 7.2 Hz, 2H), 3.22 – 
3.14 (m, 6H). 13C NMR (101 MHz, CD3OD) δ 160.92, 151.89, 143.01, 139.61, 139.31, 137.33, 136.26, 136.03, 
134.69, 134.17, 133.98, 131.39, 130.60, 130.34, 129.68, 129.43, 128.73, 128.29, 127.37, 127.32, 121.44, 119.55, 
62 
109.70, 72.45, 50.52, 45.59, 40.01, 30.47. HRMS: calculated for C28H27N3O3S [M+H]





Prepared according to the general procedure. Yield: 58.8 mg, 114.0 µmol, 28.5%. 1H NMR (400 MHz, CD3OD) δ 
9.61 (s, 1H), 8.79 (d, J = 6.4 Hz, 1H), 8.68 (d, J = 6.0 Hz, 1H), 8.56 (dd, J1 = 7.2 Hz, J2 = 33.2 Hz, 2H), 7.92 (t, J = 7.6 
Hz, 1H), 7.62 – 7.59 (m, 1H), 7.32 (t, J = 4.4 Hz, 2H), 7.23 – 7.21 (m, 1H), 6.97 (d, J = 8.0 Hz, 1H), 6.83 (s, 1H), 6.81 
– 6.75 (m, 2H), 6.21 – 6.13 (m, 1H), 4.16 – 4.12 (m, 4H), 3.75 (d, J = 7.2 Hz, 2H), 3.16 (dd, J1 = 4.4 Hz, J2 = 12.0 Hz, 
4H), 2.15 – 2.10 (m, 2H). 13C NMR (101 MHz, CD3OD) δ 152.25, 152.14, 152.10, 141.85, 140.21, 139.15, 137.07, 
137.03, 136.13, 135.90, 134.66, 133.94, 131.14, 130.34, 129.73, 129.22, 128.68, 127.50, 125.85, 123.94, 122.59, 





Prepared according to the general procedure. Yield: 34.5 mg, 65.2 µmol, 16.3%. 1H NMR (400 MHz, CD3OD) δ 
9.66 (s, 1H), 8.83 (d, J = 6.4 Hz, 1H), 8.70 (d, J = 5.6 Hz, 1H), 8.59 (dd, J1 = 7.2 Hz, J2 = 26.8 Hz, 2H), 7.96 (t, J = 8.0 
Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.38 – 7.32 (m, 2H), 7.29 – 7.28 (m, 1H), 7.26 (d, J = 8.4 Hz, 2H), 7.15 (d, J = 8.8 
Hz, 2H), 6.82 (d, J = 16.0 Hz, 1H), 6.23 – 6.15 (m, 1H), 3.87 (t, J = 4.4 Hz, 4H), 3.75 (d, J = 7.2 Hz, 2H), 3.26 (t, J = 4.4 
Hz, 4H), 3.18 – 3.15 (m, 4H). 13C NMR (101 MHz, CD3OD) δ 152.06, 150.36, 142.36, 139.89, 139.34, 137.24, 
136.24, 136.04, 134.85, 134.71, 134.12, 131.78, 131.27, 130.40, 129.80, 129.37, 128.50, 127.57, 121.34, 119.83, 
117.45, 67.48, 51.38, 47.49, 40.05. HRMS: calculated for C30H32N4O3S [M+H]
+: 529.22679; found: 529.22658. 
 
(E)-N-(2-((3-(4''-ethoxy-[1,1':4',1''-terphenyl]-2-yl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 35 
Prepared according to the general procedure. Yield: 35.2 mg, 62.4 µmol, 15.6%. 1H NMR (400 MHz, (CD3)2SO) δ 
9.47 (s, 1H), 8.70 (d, J = 5.6 Hz, 1H), 8.44 – 8.42 (m, 2H), 8.36 (d, J = 7.2 Hz, 1H), 7.81 (t, J = 7.6 Hz, 1H), 7.69 (d, J = 
8.0 Hz, 2H), 7.64 (d, J = 8.0 Hz, 3H), 7.44 – 7.42 (m, 2H), 7.37 (d, J = 8.0 Hz, 3H), 7.03 (d, J = 8.8 Hz, 2H), 6.74 (d, J = 
15.6 Hz, 1H), 6.25 – 6.18 (m, 1H), 4.07 (q, J = 6.8 Hz,  2H), 3.71 (d, J = 6.4 Hz, 2H), 3.06 (d, J = 31.6 Hz, 4H), 1.35 (t, 
J = 6.8 Hz, 3H). 13C NMR (101 MHz, (CD3)2SO) δ 158.34, 153.43, 144.70, 140.23, 138.76, 138.13, 135.78, 133.87, 
133.77, 133.31, 132.75, 131.73, 130.31, 130.08, 128.74, 128.60, 127.69, 126.39, 126.01, 120.75, 117.08, 114.92, 
63.12, 49.30, 45.29, 14.67. HRMS: calculated for C34H33N3O3S [M+H]
+: 564.23154; found: 564.23131. 
 
(E)-N-(2-((3-(3'-(benzyloxy)-[1,1'-biphenyl]-2-yl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 36 
Prepared according to the general procedure. Yield: 24.2 mg, 44.0 µmol, 11.0%. 1H NMR (400 MHz, CD3OD) δ 
9.52 (s, 1H), 8.67 (s, 1H), 8.50 (dd, J1 = 7.2 Hz, J2 = 22.0 Hz, 2H), 7.87 (t, J = 7.6 Hz, 1H), 7.65 – 7.63 (m, 1H), 7.37 – 
7.32 (m, 2H), 7.29 – 7.17 (m, 6H), 7.13 – 7.10 (m, 1H), 7.04 (d, J = 7.6 Hz, 1H), 6.85 (d, J = 15.6 Hz, 1H), 6.74 (s, 
1H), 6.67 (d, J = 7.6 Hz, 1H), 6.19 – 6.12 (m, 1H), 3.94 (s, 2H), 3.72 (d, J = 7.2 Hz, 2H), 3.10 (s, 4H). 13C NMR (101 
MHz, CD3OD) δ 156.09, 153.36, 142.94, 142.76, 142.54, 140.97, 139.45, 136.02, 135.74, 135.61, 134.60, 133.27, 
63 
131.28, 129.99, 129.69, 129.24, 128.58, 128.47, 127.28, 126.79, 122.10, 119.54, 117.28, 50.44, 47.37, 39.99, 
36.42. HRMS: calculated for C33H31N3O3S [M+H]
+: 550.21589; found: 550.21576. 
 
(E)-N-(2-((3-(2-(pyridin-3-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 37 
Prepared according to the general procedure. Yield: 32.4 mg, 72.8 µmol, 18.2%. 1H NMR (400 MHz, CD3OD) δ 
9.62 (s, 1H), 8.84 – 8.76 (m, 3H), 8.68 (s, 1H), 8.61 – 8.52 (m, 2H), 8.48 – 8.46 (m, 1H), 8.06 – 8.04 (m, 1H), 7.96 – 
7.91 (m, 1H), 7.74 – 7.73 (m, 1H), 7.54 – 7.41 (m, 3H), 6.77 – 6.73 (m, 1H), 6.33 – 6.26 (m, 1H), 3.86 – 3.75 (m, 
2H), 3.21 – 3.14 (m, 4H). 13C NMR (101 MHz, CD3OD) δ 152.33, 146.81, 144.38, 142.92, 140.88, 140.51, 137.01, 
136.75, 136.13, 135.87, 135.57, 135.45, 133.91, 131.53, 131.12, 130.41, 129.16, 128.39, 127.84, 123.37, 121.04, 
50.79, 47.67, 40.06. HRMS: calculated for C25H24N4O2S [M+H]
+: 445.16927; found: 445.16911. 
 
(E)-N-(2-((3-(2-(pyridin-4-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 38 
Prepared according to the general procedure. Yield: 48.7 mg, 109.6 µmol, 27.4%. 1H NMR (400 MHz, CD3OD) δ 
9.55 (s, 1H), 8.87 (d, J = 5.2 Hz, 2H), 8.69 (s, 2H), 8.54 (dd, J1 = 7.2 Hz, J2 = 21.6 Hz, 2H), 8.01 (d, J = 6.0 Hz, 2H), 
7.91 (t, J = 7.6 Hz, 1H), 7.78 (d, J = 7.6 Hz, 1H), 7.64 – 7.50 (m, 3H), 6.82 (d, J = 15.6 Hz, 1H), 6.38 – 6.31 (m, 1H), 
3.83 (d, J = 6.8 Hz, 2H), 3.19 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 158.81, 153.15, 143.17, 142.34, 137.12, 136.65, 
136.25, 135.84, 135.60, 135.37, 133.38, 131.90, 131.16, 130.47, 128.92, 128.69, 128.61, 123.71, 120.24, 50.01, 
47.76, 40.03. HRMS: calculated for C25H24N4O2S [M+H]
+: 445.16927; found: 445.16914 . 
 
(E)-N-(2-((3-(2-(6-methoxypyridin-3-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 39 
Prepared according to the general procedure. Yield: 42.0 mg, 88.4 µmol, 22.1%. 1H NMR (400 MHz, CD3OD) δ 
9.57 (s, 1H), 8.75 – 8.68 (m, 2H), 8.54 (dd, J1 = 7.2 Hz, J2 = 28.4 Hz, 2H), 8.04 (s, 1H), 7.91 (t, J = 8.0 Hz, 1H), 7.67 – 
7.65 (m, 2H), 7.40 – 7.38 (m, 2H), 7.29 – 7.27 (m, 1H), 6.89 (d, J = 8.8 Hz, 1H), 6.77 (d, J = 15.6 Hz, 1H), 6.27 – 6.20 
(m, 1H), 3.93 (s, 3H), 3.78 (d, J = 7.2 Hz, 2H), 3.21 – 3.15 (m, 4H). 13C NMR (101 MHz, CD3OD) δ 164.84, 152.64, 
147.69, 145.61, 141.91, 141.27, 138.60, 138.33, 136.61, 135.95, 135.79, 135.17, 133.66, 131.37, 130.78, 130.44, 
130.01, 129.29, 128.90, 127.79, 120.98, 111.25, 54.38, 50.470, 47.52, 40.04. HRMS: calculated for C26H26N4O3S 
[M+H]+: 475.17984; found: 475.17944. 
 
(E)-N-(2-((3-(2-(2-fluoropyridin-4-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 40 
Prepared according to the general procedure. Yield: 46.1 mg, 99.6 µmol, 24.9%. 1H NMR (400 MHz, CD3OD) δ 
9.54 (s, 1H), 8.71 – 8.67 (m, 2H), 8.52 (dd, J1 = 7.2 Hz, J2 = 25.6 Hz, 2H), 8.24 (d, J = 4.8 Hz, 1H), 7.90 (t, J = 7.6 Hz, 
1H), 7.71 (d, J = 7.2 Hz, 1H), 7.49 – 7.43 (m, 2H), 7.35 – 7.33 (m, 1H), 7.27 (d, J = 4.8 Hz, 1H), 7.04 (s, 1H), 6.77 (d, J 
= 15.6 Hz, 1H), 6.32 – 6.25 (m, 1H), 3.80 (d, J = 7.2 Hz, 2H), 3.18 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 166.27, 
163.90, 156.07, 155.98, 152.90, 148.43, 148.28, 141.85, 138.54, 137.39, 136.34, 135.85, 135.69, 134.73, 133.48, 
130.80, 130.56, 130.47, 130.15, 128.72, 128.01, 124.19, 122.11, 120.43, 111.93, 111.16, 50.25, 47.63, 40.05. 
HRMS: calculated for C25H23FN4O2S [M+H]






Prepared according to the general procedure. Yield: 44.2 mg, 99.2 µmol, 24.8%. 1H NMR (400 MHz, CD3OD) δ 
9.59 (s, 1H), 9.16 (s, 1H), 8.78 – 8.74 (m, 3H), 8.69 – 8.67 (m, 1H), 8.55 (dd, J1 = 7.2 Hz, J2 = 26.4 Hz, 2H), 7.93 (t, J 
= 7.6 Hz, 1H), 7.75 – 7.73 (m, 1H), 7.51 – 7.46 (m, 2H), 7.38 – 7.36 (m, 1H), 7.76 (d, J = 15.6 Hz, 1H), 6.33 – 6.26 
(m, 1H), 3.81 (d, J = 7.2 Hz, 2H), 3.19 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 158.19, 158.03, 152.57, 141.10, 
137.16, 136.72, 135.99, 135.85, 125.51, 134.76, 133.72, 131.51, 130.61, 130.43, 130.33, 128.97, 128.16, 122.64, 
120.78, 50.22, 47.59, 40.08. HRMS: calculated for C24H23N5O2S [M+H]
+: 446.16452; found: 446.16414. 
 
(E)-N-(2-((3-(2-(2-methoxypyrimidin-5-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 42 
Prepared according to the general procedure. Yield: 44.5 mg, 93.6 µmol, 23.4%. 1H NMR (400 MHz, CD3OD) δ 
9.59 (s, 1H), 8.74 (d, J = 6.0 Hz, 1H), 8.69 – 8.67 (m, 1H), 8.58 (d, J =7.2 Hz, 1H), 8.53 – 8.51 (m, 3H), 7.92 (t, J = 7.6 
Hz, 1H), 7.71 – 7.69 (m, 1H), 7.46 – 7.43 (m, 2H), 7.33 – 7.31 (m, 1H), 6.78 (d, J = 15.6 Hz, 1H), 6.32 – 6.24 (m, 1H), 
4.02 (s, 3H), 3.81 (d, J = 6.8 Hz, 2H), 3.19 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 165.87, 160.56, 152.58, 141.14, 
137.49, 136.70, 135.98, 135.78, 135.52, 134.92, 133.70, 131.43, 130.42, 130.24, 130.06, 129.13, 128.96, 128.01, 
122.08, 120.77, 55.68, 50.26, 47.57, 40.07. HRMS: calculated for C25H25N5O3S [M+H]




Prepared according to the general procedure. Yield: 27.3 mg, 51.6 µmol, 12.9%. 1H NMR (400 MHz, CD3OD) δ 
9.66 (s, 1H), 8.79 (d, J = 6.0 Hz, 1H), 8.72 (s, 1H), 8.59 (dd, J1 = 2.8 Hz, J2 = 10.4 Hz, 2H), 8.22 – 8.20 (m, 1H), 7.97 
(t, J = 8.0 Hz, 1H), 7.89 – 7.87 (m, 1H), 7.83 – 7.81 (m, 1H), 7.54 – 7.49 (m, 2H), 7.43 – 7.41 (m, 1H), 7.32 – 7.28 
(m, 1H), 6.72 (d, J = 15.6 Hz, 1H),  6.39 – 6.31 (m, 1H), 3.87 – 3.77 (m, 2H), 3.54 (s, 4H), 3.23 – 3.21 (m, 4H), 3.17 
(s, 4H). 13C NMR (101 MHz, CD3OD) δ 156.11, 152.38, 148.33, 140.59, 140.31, 136.99, 136.16, 135.88, 134.79, 
133.93, 131.07, 130.78, 130.73, 129.91, 129.18, 128.02, 122.39, 121.08, 117.80, 66.90, 49.98, 47.60, 40.03. 
HRMS: calculated for C29H31N5O3S [M+H]
+: 530.22204; found: 530.22178. 
 
(E)-N-(2-((3-(2-(quinolin-2-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 44 
Prepared according to the general procedure. Yield: 48.3 mg, 97.6 µmol, 24.4%. 1H NMR (400 MHz, CD3OD) δ 
9.65 (s, 1H), 9.16 (s, 1H), 8.94 (s, 1H), 8.77 (d, J = 6.4 Hz, 1H), 8.68 – 8.66 (m, 1H), 8.57 – 8.54 (m, 2H), 8.27 (dd, J1 
= 8.0 Hz, J2 = 16.0 Hz, 2H), 8.05 (t, J = 8.0 Hz, 1H), 7.96 – 7.86 (m, 2H), 7.79 – 7.77 (m, 1H), 7.58 – 7.54 (m, 3H), 
6.83 (d, J = 15.6 Hz, 1H),  6.39 – 6.32 (m, 1H), 3.80 (d, J = 7.2 Hz, 2H), 3.17 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 
151.97, 148.09, 145.26, 140.82, 139.85, 137.26, 136.98, 136.22, 136.04, 135.90, 135.75, 135.59, 134.94, 134.07, 
131.79, 130.86, 130.77, 130.41, 130.33, 130.05, 129.35, 128.31, 123.54, 123.17, 121.29, 50.48, 47.59, 40.00. 
HRMS: calculated for C29H26N4O2S [M+H]
+: 495.18492; found: 495.18463. 
 
(E)-N-(2-((3-(2-(6-fluoropyridin-3-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 45 
Prepared according to the general procedure. Yield: 72.0 mg, 155.6 µmol, 38.9%. 1H NMR (400 MHz, CD3OD) δ 
9.67 (s, 1H), 8.84 (d, J = 6.8 Hz, 1H), 8.69 (d, J = 6.4 Hz, 1H), 8.60 (dd, J1 = 7.2 Hz, J2 = 28.0 Hz, 2H), 8.10 (s, 1H), 
7.97 (t, J = 8.0 Hz, 1H), 7.71 (td, J1 = 2.0 Hz, J2 = 8.0 Hz, 1H), 7.69 – 7.67 (m, 1H), 7.44 – 7.39 (m, 2H), 7.30 – 7.28 
65 
(m, 1H), 7.13 (dd, J1 = 2.0 Hz, J2 = 8.4 Hz, 1H), 6.73 (d, J = 16.0 Hz, 1H), 6.30 – 6.22 (m, 1H), 3.79 (d, J = 7.2 Hz, 2H), 
3.22 – 3.18 (m, 4H). 13C NMR (101 MHz, CD3OD) δ 165.41, 163.03, 151.81, 148.58, 148.44, 144.33, 144.25, 
139.51, 137.70, 137.35, 136.24, 135.98, 135.69, 135.25, 134.16, 131.39, 130.28, 130.05, 129.84, 129.44, 127.88, 





Prepared according to the general procedure. Yield: 70.6 mg, 142.0 µmol, 35.5%. 1H NMR (400 MHz, CD3OD) δ 
9.53 (s, 1H), 8.69 (d, J = 6.4 Hz, 1H), 8.65 – 8.63 (m, 1H), 8.48 (dd, J1 = 7.6 Hz, J2 = 18.0 Hz, 2H), 7.98 (s, 1H), 7.86 
(t, J = 7.6 Hz, 1H), 7.75 (d, J = 8.4 Hz, 1H), 7.72 – 7.68 (m, 1H), 7.41 – 7.33 (m, 4H), 7.05 (dd, J1 = 1.2 Hz, J2 = 8.4 Hz, 
1H), 6.78 (d, J = 16.0 Hz, 1H), 6.26 – 6.18 (m, 1H), 4.03 (s, 3H), 3.71 (d, J = 7.2 Hz, 2H), 3.16 – 3.10 (m, 4H). 13C 
NMR (101 MHz, CD3OD) δ 152.69, 142.91, 141.50, 141.28, 140.64, 138.70, 136.43, 135.86, 135.69, 134.86, 
133.66, 133.53, 131.55, 130.39, 129.00, 128.78, 127.38, 124.39, 124.22, 121.79, 120.54, 120.28, 110.99, 50.41, 
47.43, 39.84, 35.65. HRMS: calculated for C28H27N5O2S [M+H]
+: 498.19582; found: 498.19532. 
 
(E)-N-(2-((3-([1,1':3',1''-terphenyl]-2-yl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 47 
Prepared according to the general procedure. Yield: 104.3 mg, 200.8 µmol, 50.2%. 1H NMR (400 MHz, CD3OD) δ 
9.38 (s, 1H), 8.60 (d, J = 6.4 Hz, 1H), 8.52 (d, J = 6.4 Hz, 1H), 8.41 (d, J = 7.2 Hz, 1H), 8.52 (d, J = 8.0 Hz, 1H), 7.77 (t, 
J = 7.6 Hz, 1H), 7.69 – 7.65 (m, 1H), 7.60 – 7.53 (m, 3H), 7.49 – 7.45 (m, 2H), 7.41 – 7.36 (m, 2H), 7.34 – 7.30 (m, 
3H), 7.26 – 7.23 (m, 1H), 7.21 – 7.18 (m, 1H), 6.79 (d, J = 16.0 Hz, 1H), 6.23 – 6.15 (m, 1H), 3.71 (d, J = 7.2 Hz, 2H), 
3.03 – 2.96 (m, 4H). 13C NMR (101 MHz, CD3OD) δ 154.08, 144.50, 142.70, 142.40, 141.92, 139.15, 135.34, 
135.29, 135.14, 134.78, 132.65, 131.30, 130.57, 129.95, 129.91, 129.84, 129.70, 129.25, 128.50, 128.13, 127.99, 
127.84, 127.53, 127.07, 120.17, 119.19, 50.33, 47.18, 39.86. HRMS: calculated for C32H29N3O2S [M+H]
+: 
520.20532; found: 520.20510. 
 
(E)-N-(2-((3-(2-(1H-pyrazol-4-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 48 
Prepared according to the general procedure. Yield: 55.7 mg, 128.4 µmol, 32.1%. 1H NMR (400 MHz, CD3OD) δ 
9.63 (s, 1H), 8.81 (d, J = 6.4 Hz, 1H), 8.71 (s, 1H), 8.64 (d, J = 7.2 Hz, 1H), 8.54 (d, J = 8.4 Hz, 1H), 7.95 (t, J = 8.0 Hz, 
1H), 7.76 (s, 1H), 7.61 (d, J = 7.2 Hz, 1H), 7.46 – 7.29 (m, 3H), 7.04 (d, J = 16.0 Hz, 1H), 6.29 – 6.18 (m, 1H), 3.84 (d, 
J = 7.2 Hz, 2H), 3.20 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 152.41, 140.71, 139.04, 139.92, 136.10, 135.96, 134.96, 
133.92, 133.28, 131.032, 129.93, 129.13, 128.36, 127.80, 120.54, 50.60, 47.62, 40.12. HRMS: calculated for 
C23H23N5O2S [M+H]
+: 434.16452; found: 434.16395. 
 
(E)-N-(2-((3-(2-(thiophen-2-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 49 
Prepared according to the general procedure. Yield: 62.2 mg, 138.4 µmol, 34.6%. 1H NMR (400 MHz, CD3OD) δ 
9.52 (s, 1H), 8.11 (d, J = 6.4 Hz, 1H), 8.67 (s, 1H), 8.55 (d, J = 7.2 Hz, 1H), 8.45 (d, J = 8.4 Hz, 1H), 7.87 (t, J = 8.0 Hz, 
1H), 7.64 – 7.60 (m, 1H), 7.44 (dd, J1 = 1.2 Hz, J2 = 5.2 Hz, 1H), 7.43 – 7.38 (m, 1H), 7.37 – 7.32 (m, 2H), 7.11 – 7.09 
(m, 1H), 7.04 – 7.00 (m, 2H), 3.80 (d, J = 7.2 Hz, 2H), 3.21 – 3.15 (m, 4H). 13C NMR (101 MHz, CD3OD) δ 152.89, 
142.60, 141.67, 138.80, 136.31, 135.82, 135.73, 135.40, 134.97, 133.46, 131.72, 130.45, 129.77, 129.28, 129.00, 
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128.68, 128.54, 128.02, 127.28, 120.82, 50.48, 47.53, 40.05. HRMS: calculated for C24H23N3O2S2 [M+H]
+: 
450.13044; found: 450.12986. 
  
(E)-N-(2-((3-(2-(benzo[b]thiophen-2-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 50 
Prepared according to the general procedure. Yield: 52.2 mg, 104.4 µmol, 26.1%. 1H NMR (400 MHz, CD3OD) δ 
9.55 (s, 1H), 8.73 (d, J = 6.4 Hz, 1H), 8.65 – 8.63 (m, 1H), 8.54 (d, J = 7.2 Hz, 1H), 8.46 (d, J = 8.4 Hz, 1H), 7.88 – 
7.76 (m, 3H), 7.68 (dd, J1 = 6.0 Hz, J2 = 8.0 Hz, 1H), 7.50 – 7.48 (m, 1H), 7.42 – 7.38 (m, 2H), 7.37 – 7.28 (m, 2H), 
7.25 (s, 1H), 7.07 (d, J = 15.6 Hz, 1H),  6.29 – 6.21 (m, 1H), 3.79 (d, J = 7.2 Hz, 2H), 3.16 (s, 4H). 13C NMR (101 MHz, 
CD3OD) δ 152.53, 142.84, 141.56, 141.10, 138.51, 136.62, 135.93, 135.80, 134.88, 133.67, 131.92, 130.41, 
129.91, 129.81, 128.89, 128.05, 125.70, 125.67, 125.61, 124.85, 122.94, 121.22, 120.73, 50.37, 47.51, 39.99. 
HRMS: calculated for C28H25N3O2S2 [M+H]
+: 500.14610; found: 500.14576. 
 
(E)-N-(2-((3-(2-(1H-indol-2-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 51 
Prepared according to the general procedure. Yield: 23.2 mg, 48.0 µmol, 12.0%. 1H NMR (400 MHz, CD3OD) δ 
9.50 (s, 1H), 8.65 (q, J = 7.6 Hz, 2H), 8.52 (dd, J1 = 1.2 Hz, J2 = 7.6 Hz, 1H), 8.44 (d, J = 8.0 Hz, 1H), 7.84 (t, J = 7.6 Hz, 
1H), 7.67 (dd, J1 = 1.2 Hz, J2 = 7.2 Hz, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.45 – 7.37 (m, 3H), 7.10 (td, J1 = 0.8 Hz, J2 = 6.8 
Hz, 1H), 7.00 (td, J1 = 1.2 Hz, J2 = 8.0 Hz, 1H), 6.26 – 6.18 (m, 1H), 3.81 (d, J = 6.8 Hz, 2H), 3.15 (s, 4H). 
13C NMR 
(101 MHz, CD3OD) δ 153.16, 142.36, 139.35, 138.43, 137.31, 136.15, 135.78, 135.65, 135.41, 134.10, 133.37, 
130.63, 130.53, 130.01, 129.79, 129.04, 128.55, 128.08, 122.87, 121.19, 120.53, 120.33, 120.18, 112.13, 50.47, 
47.43, 39.98. HRMS: calculated for C28H26N4O2S [M+H]
+: 483.18492; found: 483.18449. 
 
(E)-N-(2-((3-(2-(quinoxalin-6-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 52 
Prepared according to the general procedure. Yield: 155.4 mg, 313.6 µmol, 78.4%. 1H NMR (400 MHz, CD3OD) δ 
9.46 (s, 1H), 8.83 (s, 2H), 8.61 (s, 2H), 8.47 (d, J = 7.2 Hz, 1H), 8.40 (d, J = 8.4 Hz, 1H), 8.09 (d, J = 8.8 Hz, 1H), 7.92 
(s, 1H), 7.84 – 7.76 (m, 2H), 7.71 – 7.69 (m, 1H), 7.47 – 7.39 (m, 3H), 6.77 (d, J = 15.6 Hz, 1H), 6.30 – 6.23 (m, 1H), 
3.76 (d, J = 7.2 Hz, 2H), 3.17 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 152.99, 146.95, 146.61, 143.92, 143.32, 142.91, 
142.20, 140.70, 138.40, 136.09, 135.69, 135.51, 135.03, 133.50, 133.23, 131.35, 130.42, 130.34, 130.02, 129.71, 
128.51, 127.97, 121.37, 120.17, 50.29, 47.49, 39.98. HRMS: calculated for C28H25N5O2S [M+H]




Prepared according to the general procedure. Yield: 31.6 mg, 63.2 µmol, 15.8%. 1H NMR (400 MHz, CD3OD) δ 
9.52 (s, 1H), 8.66 (s, 2H), 8.61 (s, 2H), 8.52 (d, J = 7.2 Hz, 1H), 8.47 (d, J = 8.0 Hz, 1H), 7.86 (t, J = 7.6 Hz, 1H), 7.70 
(d, J = 7.2 Hz, 1H), 7.58 (d, J = 7.6 Hz, 1H), 7.47 – 7.40 (m, 2H), 7.35 (dd, J1 = 4.4 Hz, J2 = 8.8 Hz, 1H), 7.20 – 7.16 
(m, 2H), 6.88 (td, J1 = 2.4 Hz, J2 = 9.2 Hz, 1H), 6.47 (s, 1H), 6.28 – 6.21 (m, 1H), 3.84 (d, J = 6.8 Hz, 2H), 3.19 – 3.14 
(m, 4H). 13C NMR (101 MHz, CD3OD) δ 160.36, 158.04, 153.49, 143.02, 139.33, 139.19, 135.89, 135.73, 135.53, 
135.45, 135.00, 133.78, 133.17, 130.62, 130.30, 130.26, 129.87, 129.32, 128.38, 128.12, 120.53, 112.97, 111.08, 
110.81, 105.68, 105.44, 104.87, 104.82, 50.45, 47.49, 39.98. HRMS: calculated for C28H25FN4O2S [M+H]
+: 
501.17550; found: 501.17528. 
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(E)-N-(2-((3-(2-(2-(trifluoromethyl)pyridin-4-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 54 
Prepared according to the general procedure. Yield: 54.3 mg, 106.0 µmol, 26.5%. 1H NMR (400 MHz, CD3OD) δ 
9.54 (s, 1H), 8.78 (d, J = 3.6 Hz, 1H), 8.68 – 8.66 (m, 2H), 8.54 (d, J = 4.4 Hz, 1H), 8.50 (d, J = 5.2 Hz, 1H), 7.90 (t, J = 
5.2 Hz, 1H), 7.79 (s, 1H), 7.76 (d, J = 5.6 Hz, 1H), 7.64 (d, J = 3.6 Hz, 1H), 7.55 – 7.49 (m, 2H), 7.41 (d, J = 4.8 Hz, 
1H), 6.32 – 6.27 (m, 1H), 3.80 (d, J = 4.8 Hz, 2H), 3.32 – 3.31 (m, 4H). 13C NMR (101 MHz, CD3OD) δ 153.45, 
152,18, 151.19, 149.14 (q, J = 23.23 Hz), 142.94, 138.52, 137.43, 135.91, 135.75, 135.59, 134.89, 133,25, 131.07, 
130.80, 130.38, 129.20, 128.42, 128.15, 123.20 (q, J = 171.7 Hz), 122.55, 122.51, 119.99, 50.22, 47,65, 40.08. 
HRMS: calculated for C26H23F3N4O2S [M+H]
+: 513.15666; found: 513.15631. 
 
(E)-N-(2-((3-(2-(imidazo[1,2-a]pyridin-7-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 55 
Prepared according to the general procedure. Yield: 120.7 mg, 249.6 µmol, 62.4%. 1H NMR (400 MHz, CD3OD) δ 
9.54 (s, 1H), 8.82 (s, 1H), 8.68 – 8.65 (m, 2H), 8.50 (d, J = 5.2 Hz, 1H), 8.26 (s, 1H), 8.05 (s, 1H), 8.50 (d, J = 6.4 Hz, 
1H), 7.94 (d, J = 6.0 Hz, 1H), 7.91 (t, J = 2.4 Hz, 1H), 7.78 (d, J = 5.2 Hz, 1H), 7.56 – 7.49 (m, 2H), 7.45 (d, J = 0.8 Hz, 
1H), 6.84 (d, J = 10.8 Hz, 1H), 6.35 – 6.30 (m, 1H), 3.80 (d, J = 4.4 Hz, 2H), 3.18 – 3.14 (m, 4H). 13C NMR (101 MHz, 
CD3OD) δ 153.28, 142.55, 140.61, 137.31, 136.97, 136.11, 136.02, 135.82, 135.72, 135.54, 133.30, 132.01, 
131.66, 130.72, 130.58, 130.28, 129.50, 128.52, 128.07, 124.14, 122.64, 120.11, 117.13, 112.88, 50.04, 47.66, 
40.00. HRMS: calculated for C27H25N5O2S [M+H]
+: 484.18017; found: 484.17998. 
 
(E)-N-(2-((3-(3-(4-methylnaphthalen-1-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 56 
Prepared according to the general procedure. Yield: 20.5 mg, 40.4 µmol, 10.1%. 1H NMR (400 MHz, CD3OD) δ 
9.50 (s, 1H), 8.67 (s, 2H), 8.54 (d, J = 7.6 Hz, 1H), 8.44 (d, J = 8.0 Hz, 1H), 8.07 (d, J = 8.4 Hz, 1H), 7.86 (t, J = 8.0 Hz, 
1H), 7.78 (d, J = 8.4 Hz, 1H), 7.54 – 7.46 (m, 4H), 7.42 – 7.36 (m, 3H), 7.26 (d, J = 7.2 Hz, 1H), 6.93 (d, J = 16.0 Hz, 
1H), 6.36 – 6.28 (m, 1H), 3.85 (d, J = 7.2, 2H), 3.18 (s, 4H), 2.71 (s, 3H). 13C NMR (101 MHz, CD3OD) δ 153.23, 
142.98, 140.04, 139.91, 139.32, 137.19, 136.90, 136.05, 135.72, 135.66, 135.25, 134.18, 133.31, 132.86, 131.67, 
129.83, 129.49, 128.58, 127.55, 127.19, 127.04, 126.76, 125.48, 120.13, 119.48, 50.78, 47.52, 39.88, 19.59. 
HRMS: calculated for C31H29N3O2S [M+H]
+: 508.20532; found: 508.20510. 
 
(E)-N-(2-((3-(3-(4-methoxynaphthalen-1-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 57 
Prepared according to the general procedure. Yield: 24.3 mg, 46.4 µmol, 11.6%. 1H NMR (400 MHz, CD3OD) δ 
9.54 (s, 1H), 8.73 (d, J = 6.0 Hz, 1H), 8.68 (s, 1H), 8.57 (d, J = 7.6 Hz, 1H), 8.47 (d, J = 8.4 Hz, 1H), 8.28 (d, J = 8.4 Hz, 
1H), 7.88 (t, J = 8.0 Hz, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.52 – 7.37 (m, 6H), 7.30 (d, J = 8.0 Hz, 1H), 6.95 – 6.90 (m, 
2H), 6.36 – 6.28 (m, 1H), 4.03 (s, 3H), 3.85 (d, J = 6.8 Hz, 2H), 3.18 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 156.45, 
152.85, 142.84, 141.67, 140.12, 136.90, 136.43, 135.88, 135.80, 133.63, 133.22, 131.78, 130.51, 129.84, 129.71, 
128.77, 128.11, 127.57, 127.00, 126.54, 126.34, 126.09, 123.25, 120.53, 119.38, 104.51, 56.08, 50.49, 47.52, 
40.13. HRMS: calculated for C31H29N3O3S [M+H]
+: 524.20024; found: 524.19998. 
 
(E)-N-(2-((3-(3-(6-methoxynaphthalen-2-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 58 
Prepared according to the general procedure. Yield: 28.5 mg, 54.4 µmol, 13.6%. 1H NMR (400 MHz, CD3OD) δ 
9.48 (s, 1H), 8.69 (d, J = 6.0 Hz, 1H), 8.64 (s, 1H), 8.54 (d, J = 7.6 Hz, 1H), 8.41 (d, J = 8.4 Hz, 1H), 7.97 (s, 1H), 7.85 
68 
– 7.76 (m, 4H), 7.71 – 7.63 (m, 2H), 7.46 – 7.43 (m, 2H), 7.21 (s, 1H), 7.12 (dd, J1 = 2.4 Hz, J2 = 8.8 Hz, 1H), 6.92 (d, 
J = 16.0 Hz, 1H), 6.39 – 6.32 (m, 1H), 3.89 (s, 3H), 3.86 (d, J = 7.2 Hz, 2H), 3.19 (s, 4H). 13C NMR (101 MHz, CD3OD) 
δ 159.38, 152.98, 142.94, 142.08, 140.14, 137.40, 136.84, 136.21, 135.76, 135.67, 135.47, 133.39, 130.70, 
130.54, 130.39, 128.56, 126.64, 126.50, 120.21, 119.38, 106.56, 55.77, 50.49, 47.50, 40.12. HRMS: calculated for 
C31H29N3O3S [M+H]
+: 524.20024; found: 524.19998. 
 
(E)-N-(2-((3-(3-(6-ethoxynaphthalen-2-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 59 
Prepared according to the general procedure. Yield: 27.7 mg, 51.6 µmol, 12.9%. 1H NMR (400 MHz, CD3OD) δ 
9.53 (s, 1H), 8.71 – 8.67 (m, 2H), 8.58 (d, J = 7.6 Hz, 1H), 8.49 (d, J = 8.0 Hz, 1H), 8.02 (s, 1H), 7.90 (t, J = 7.6 Hz, 
1H), 7.85 – 7.81 (m, 3H), 7.74 – 7.69 (m, 2H), 7.50 – 7.47 (m, 2H), 7.24 (s, 1H), 7.15 (dd, J1 = 2.4 Hz, J2 = 8.8 Hz, 
1H), 6.97 (d, J = 16.0 Hz, 1H), 6.42 – 6.35 (m, 1H), 4.17 (q, J = 6.8 Hz, 2H), 3.89 (d, J = 3.2 Hz, 2H), 3.14 (s, 4H), 1.46 
(t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CD3OD) δ 158.71, 153.28, 143.14, 142.53, 140.29, 137.43, 136.87, 136.11, 
135.80, 135.72, 135.59, 133.39, 130.69, 130.58, 130.44, 128.67, 128.54, 126.69, 126.58, 126.52, 120.53, 120.15, 
119.34, 107.35, 64.59, 50.54, 47.56, 40.17, 15.14. HRMS: calculated for C32H31N3O3S [M+H]




Prepared according to the general procedure. Yield: 15.8 mg, 26.4 µmol, 6.6%. 1H NMR (400 MHz, CD3OD) δ 9.47 
(s, 1H), 8.65 (s, 2H), 8.53 (d, J = 7.2 Hz, 2H), 8.43 (d, J = 8.4 Hz, 1H), 8.01 (s, 1H), 7.86 – 7.80 (m, 4H), 7.72 – 7.67 
(m, 2H), 7.50 – 7.47 (m, 4H), 7.39 (t, J = 6.8 Hz, 2H), 7.33 – 7.30 (m, 2H), 7.22 (dd, J1 = 2.4 Hz, J2 = 9.2 Hz, 1H), 6.95 
(d, J = 15.6 Hz, 1H), 6.41 – 6.33 (m, 1H), 5.19 (s, 2H), 3.87 (d, J = 7.2 Hz, 2H), 3.19 (s, 4H). 13C NMR (101 MHz, 
CD3OD) δ 158.46, 153.55, 143.21, 143.03, 140.23, 138.54, 137.43, 137.05, 135.78, 135.64, 135.59, 135.45, 
133.13, 130.82, 130.72, 130.43, 129.54, 128.95, 128.68, 128.65, 128.61, 128.29, 126.70, 126.55, 120.53, 119.37, 
108.14, 71.09, 50.51, 47.55, 40.14. HRMS: calculated for C37H33N3O3S [M+H]
+: 600.23154; found: 600.23139. 
 
(E)-N-(2-((3-(3-(anthracen-9-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 61 
Prepared according to the general procedure. Yield: 20.2 mg, 37.2 µmol, 9.3%. 1H NMR (400 MHz, CD3OD) δ 9.40 
(s, 1H), 8.63 (d, J = 6.0 Hz, 1H), 8.57 (d, J = 6.0 Hz, 1H), 8.52 (s, 1H), 8.48 (d, J = 7.6 Hz, 1H), 8.37 (d, J = 8.0 Hz, 1H), 
8.05 (d, J = 8.4 Hz, 2H), 7.79 (t, J = 8.0 Hz, 1H), 7.66 (d, J = 7.6 Hz, 1H), 7.60 (t, J = 7.2 Hz, 1H), 7.54 (d, J = 8.8 Hz, 
2H), 7.48 (s, 1H), 7.43 (t, J = 7.2 Hz, 2H), 7.33 – 7.29 (m, 3H), 6.94 (d, J = 16.0 Hz, 1H), 6.36 – 6.28 (m, 1H), 3.83 (d, 
J = 7.2 Hz, 2H), 3.15 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 153.87, 143.98, 140.75, 139.85, 137.33, 137.19, 135.44, 
132.85, 132.75, 131.34, 130.61, 130.10, 129.54, 128.10, 128.00, 127.29, 126.61, 126.20, 119.76, 119.44, 50.42, 
47.52, 40.09. HRMS: calculated for C34H29N3O2S [M+H]
+: 544.20532; found: 544.20504. 
 
(E)-N-(2-((3-(3-(9H-fluoren-2-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 62 
Prepared according to the general procedure. Yield: 15.3 mg, 28.8 µmol, 7.2%. 1H NMR (400 MHz, CD3OD) δ 9.37 
(s, 1H), 8.62 (d, J = 6.0 Hz, 1H), 8.55 (d, J = 6.0 Hz, 1H), 8.48 (d, J = 7.2 Hz, 1H), 8.36 (d, J = 8.0 Hz, 1H), 7.84 – 7.77 
(m, 4H), 7.72 (s, 1H), 7.61 – 7.59 (m, 2H), 7.53 (d, J = 7.6 Hz, 2H), 7.44 – 7.43 (m, 2H), 7.35 (t, J = 7.2 Hz, 1H), 7.28 
(d, J = 7.2 Hz, 1H), 6.92 (d, J = 15.6 Hz, 1H), 6.39 – 6.31 (m, 1H), 3.90 (s, 2H), 3.86 (d, J = 7.2 Hz, 2H), 3.18 (s, 4H). 
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13C NMR (101 MHz, CD3OD) δ 154.14, 145.33, 144.79, 144.57, 143.32, 142.47, 142.43, 140.49, 140.18, 137.35, 
135.37, 135.32, 135.16, 132.67, 130.62, 130.36, 128.58, 127.95, 127.91, 127.83, 126.90, 126.65, 126.56, 126.07, 





Prepared according to the general procedure. Yield: 37.0 mg, 68.0 µmol, 17.0%. 1H NMR (400 MHz, CD3OD) δ 
9.30 (s, 1H), 8.78 – 8.76 (m, 1H), 8.73 – 8.70 (m, 1H), 8.59 (d, J = 6.0 Hz, 2H), 8.50 (d, J = 6.0 Hz, 1H), 8.42 (d, J = 
7.6 Hz, 1H), 8.27 (d, J = 8.0 Hz, 1H), 7.86 – 7.84 (m, 1H), 7.80 – 7.69 (m, 2H), 7.65 – 7.34 (m, 9H), 6.88 (d, J = 16 Hz, 
1H), 6.34 – 6.27 (m, 1H), 3.80 (d, J = 6.8 Hz, 2H), 3.14 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 154.28, 145.00, 
142.60, 139.83, 139.40, 137.02, 135.23, 135.18, 134.90, 132.78, 132.47, 132.06, 131.95, 131.49, 131.26, 130.57, 
129.90, 129.73, 129.50, 128.48, 128.01, 127.90, 127.72, 127.63, 127.52, 127.00, 124.12, 123.59, 119.66, 118.98, 
50.40, 47.47, 40.06, 31.11. HRMS: calculated for C34H29N3O2S [M+H]
+: 544.20532; found: 544.20519. 
 
(E)-N-(2-((3-(3-(dibenzo[b,d]furan-4-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 64 
Prepared according to the general procedure. Yield: 29.5 mg, 55.2 µmol, 13.8%. 1H NMR (400 MHz, CD3OD) δ 
9.32 (s, 1H), 8.59 (s, 1H), 8.53 (s, 1H), 8.45 (d, J = 7.2 Hz, 1H), 8.30 (d, J = 8.0 Hz, 1H), 8.02 – 7.96 (m, 2H), 7.82 – 
7.80 (m, 1H), 7.74 (t, J = 7.6 Hz, 1H), 7.61 – 7.56 (m, 2H), 7.50 – 7.40 (m, 5H), 7.35 (t, J = 7.2 Hz, 1H), 6.93 (d, J = 
16.0 Hz, 1H), 6.39 – 6.32 (m, 1H), 3.85 (d, J = 7.2 Hz, 2H), 3.18 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 157.36, 
154.41, 154.16, 144.72, 140.01, 138.21, 137.79, 135.31, 135.26, 135.04, 132.56, 130.20, 130.15, 128.53, 128.34, 
127.84, 127.74, 127.15, 126.37, 126.18, 125.23, 124.63, 124.14, 121.82, 121.11, 119.56, 112.58, 50.45, 47.49, 
40.08. HRMS: calculated for C32H27N3O3S [M+H]
+: 534.18459; found: 534.18438. 
 
(E)-N-(2-((3-(3-(phenoxathiin-4-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 65 
Prepared according to the general procedure. Yield: 34.6 mg, 61.2 µmol, 15.3%. 1H NMR (400 MHz, CD3OD) δ 
9.32 (s, 1H), 8.59 (s, 1H), 8.52 – 8.51 (m, 1H), 8.44 (d, J = 7.2 Hz, 1H), 8.31 (d, J = 8.0 Hz, 1H), 7.74 (d, J = 7.6 Hz, 
1H), 7.55 (s, 1H), 7.48 – 7.43 (m, 3H), 7.18 – 7.09 (m, 5H), 7.07 – 7.02 (m, 1H), 6.96 (d, J = 30.4 Hz, 1H), 6.78 (d, J = 
8.0 Hz, 1H), 6.35 – 6.28 (m, 1H), 3.85 (d, J = 6.8 Hz, 2H), 3.17 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 154.29, 153.79, 
150.41, 144.95, 139.96, 138.94, 136.78, 135.26, 135.23, 134.95, 132.51, 132.40, 131.05, 130.84, 130.59, 130.35, 
129.69, 129.13, 127.88, 127.68, 127.47, 127.00, 126.06, 125.78, 123.09, 122.34, 119.45, 119.02, 118.47, 50.43, 
47.49, 40.07. HRMS: calculated for C32H27N3O3S2 [M+H]
+: 566.15666; found: 566.15641. 
 
(E)-N-(2-((3-(3-(2,3-dihydrobenzofuran-5-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 66 
Prepared according to the general procedure. Yield: 23.9 mg, 49.2 µmol, 12.3%. 1H NMR (400 MHz, CD3OD) δ 
9.40 (s, 1H), 8.63 (d, J = 6.0 Hz, 1H), 8.58 (d, J = 5.6 Hz, 1H), 8.49 (d, J = 7.2 Hz, 1H), 8.39 (d, J = 8.4 Hz, 1H), 7.81 (t, 
J = 8.0 Hz, 1H), 7.61 (s, 1H), 7.50 – 7.49 (m, 1H), 7.45 (s, 1H), 7.38 (d, J = 4.8 Hz, 2H), 7.33 (dd, J1 = 1.6 Hz, J2 = 8.4 
Hz, 1H), 6.89 (d, J = 16.0 Hz, 1H), 6.78 (d, J = 8.0 Hz, 1H), 6.36 – 6.29 (m, 1H), 4.56 (t, J = 8.8 Hz, 2H), 3.85 (d, J = 
7.2 Hz, 2H), 3.23 (t, J = 8.8 Hz, 2H), 3.18 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 161.35, 153.79, 143.77, 143.21, 
140.47, 137.23, 135.53, 135.48, 134.52, 132.93, 130.60, 130.22, 129.32, 128.17, 128.11, 127.87, 126.23, 125.92, 
70 
124.66, 119.57, 119.18, 110.28, 72.52, 50.50, 47.50, 40.11, 30.51. HRMS: calculated for C28H27N3O3S [M+H]
+: 




Prepared according to the general procedure. Yield: 35.3 mg, 68.4 µmol, 17.1%. 1H NMR (400 MHz, CD3OD) δ 
9.47 (s, 1H), 8.65 (s, 2H), 8.53 (d, J = 7.2 Hz, 1H), 8.42 (d, J = 8.4 Hz, 1H), 7.84 (t, J = 7.6 Hz, 1H), 7.60 (s, 1H), 7.51 – 
7.47 (m, 1H), 7.39 – 7.36 (m, 2H), 7.21 – 7.16 (m, 2H), 7.01 (d, J = 8.0 Hz, 1H), 6.88 (d, J = 15.6 1H), 6.36 – 6.29 (m, 
1H), 4.18 (q, J = 5.2 Hz, 4H), 3.85 (d, J = 7.2 Hz, 2H), 3.19 (s, 4H), 2.19 – 2.13 (m, 2H). 13C NMR (101 MHz, CD3OD) δ 
152.95, 152.68, 152.49, 142.02, 141.38, 140.06, 137.32, 136.56, 135.93, 135.80, 133.63, 130.31, 128.86, 128.16, 
126.49, 126.24, 123.10, 122.89, 121.07, 120.68, 119.41, 71.97, 50.48, 47.50, 40.13, 33.22. HRMS: calculated for 
C29H29N3O4S [M+H]
+: 516.19515; found: 516.19490. 
 
(E)-N-(2-((3-(4'-morpholino-[1,1'-biphenyl]-3-yl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 68 
Prepared according to the general procedure. Yield: 36.2 mg, 68.4 µmol, 17.1%. 1H NMR (400 MHz, CD3OD) δ 
9.49 (s, 1H), 8.68 (t, J = 6.0 Hz, 2H), 8.55 (d, J = 6.4 Hz, 1H), 8.43 (d, J = 8.0 Hz, 1H), 7.89 (t, J = 8.0 Hz, 1H), 7.63 (s, 
1H), 7.55 – 7.50 (m, 3H), 7.39 – 7.38 (m, 2H), 7.07 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 16.0 Hz, 2H), 6.37 – 6.29 (m, 1H), 
3.86 – 3.83 (m, 6H), 3.21 – 3.19 (m, 8H). 13C NMR (101 MHz, CD3OD) δ 152.47, 150.86, 142.36, 140.89, 140.16, 
137.33, 136.78, 136.02, 135.87, 134.58, 133.77, 130.32, 129.01, 128.75, 127.92, 126.14, 126.01, 120.87, 119.32, 
117.82, 67.54, 51.18, 50.50, 47.50, 40.13. HRMS: calculated for C30H32N4O3S [M+H]




Prepared according to the general procedure. Yield: 23.0 mg, 40.8 µmol, 10.2%. 1H NMR (400 MHz, CD3OD) δ 
9.49 (s, 1H), 8.66 (s, 2H), 8.55 (dd, J1 = 1.2 Hz, J2 = 7.6 Hz, 1H), 8.45 (d, J = 8.0 Hz, 1H), 7.87 (t, J = 7.6 Hz, 1H), 7.74 
(s, 1H), 7.69 – 7.59 (m, 5H), 7.59 – 7.56 (m, 2H), 7.48 – 7.43 (m, 2H), 7.00 – 6.92 (m, 3H), 6.40 – 6.33 (m, 1H), 4.06 
(q, J = 6.8 Hz,  2H), 3.87 (d, J = 7.2 Hz, 2H), 3.19 (s, 4H), 1.40 (t, J = 6.8 Hz, 3H). 13C NMR (101 MHz, CD3OD) δ 
160.17, 153.10, 142.62, 142.20, 141.38, 140.18, 139.97, 137.42, 136.25, 135.84, 135.76, 134.01, 133.47, 130.56, 
130.41, 128.86, 128.64, 128.32, 127.93, 126.68, 126.44, 120.31, 119.41, 115.91, 64.55, 50.52, 47.55, 40.15, 
15.18. HRMS: calculated for C34H33N3O3S [M+H]
+: 564.23154; found: 564.23135. 
 
(E)-N-(2-((3-(3'-(benzyloxy)-[1,1'-biphenyl]-3-yl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 70 
Prepared according to the general procedure. Yield: 19.6 mg, 35.6 µmol, 8.9%. 1H NMR (400 MHz, CD3OD) δ 9.44 
(s, 1H), 8.63 (q, J = 6.0, 2H), 8.52 (d, J = 7.2 Hz, 1H), 8.42 (d, J = 8.4 Hz, 1H), 7.83 (t, J = 7.6 Hz, 1H), 7.67 (s, 1H), 
7.56 – 7.54 (m, 1H), 7.45 – 7.43 (m, 4H), 7.36 (td, J1 = 0.8 Hz, J2 = 6.8 Hz, 3H), 7.31 – 7.28 (m, 1H), 7.23 – 7.19 (m, 
2H), 7.00 (dd, J1 = 2.0 Hz, J2 = 7.6 Hz, 1H), 6.92 (d, J = 16.0 Hz, 1H), 6.38 – 6.31 (m, 1H), 5.13 (s, 2H), 3.87 (d, J = 6.8 
Hz, 2H), 3.18 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 160.69, 153.79, 148.30, 143.74, 143.41, 142.92, 140.10, 
138.86, 137.36, 135.55, 135.48, 132.97, 131.00, 130.61, 130.35, 129.92, 129.51, 128.90, 128.62, 128.21, 126.69, 
71 
126.65, 120.70, 119.58, 119.44, 114.96, 114.84, 71.07, 50.46, 47.50, 40.12. HRMS: calculated for C33H31N3O3S 
[M+H]+: 550.21589; found: 550.21565. 
 
(E)-N-(2-((3-(3-(pyridin-3-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 71 
Prepared according to the general procedure. Yield: 27.7 mg, 62.4 µmol, 15.6%. 1H NMR (400 MHz, CD3OD) δ 
9.47 (s, 1H), 9.07 (s, 1H), 8.75 (d, J = 5.6 Hz, 1H), 8.66 – 8.62 (m, 3H), 8.54 (dd, J1 = 1.2 Hz, J2 = 7.6 Hz, 1H), 8.45 (d, 
J = 8.0 Hz, 1H), 7.95 (dd, J1 = 5.6 Hz, J2 = 8.0 Hz, 1H), 7.89 – 7.84 (m, 2H), 7.71 (d, J = 7.6 Hz, 1H), 7.62 (d, J = 8.0 Hz, 
1H), 7.55 (t, J = 7.6 Hz, 1H), 6.95 (d, J = 16.0 Hz, 1H), 6.48 – 6.40 (m, 1H), 3.89 (d, J = 6.8 Hz, 2H), 3.24 – 3.21 (m, 
4H). 13C NMR (101 MHz, CD3OD) δ 153.50, 144.05, 143.61, 143.5, 142.39, 140.35, 139.09, 138.25, 136.85, 135.84, 
135.63, 135.54, 133.12, 131.07, 130.55, 128.87, 128.65, 128.32, 127.60, 126.90, 120.77, 119.86, 50.35, 47.63, 
40.13. HRMS: calculated for C25H24N4O2S [M+H]
+: 445.16927; found: 445.16911. 
 
(E)-N-(2-((3-(3-(pyridin-4-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 72 
Prepared according to the general procedure. Yield: 34.0 mg, 76.4 µmol, 19.1%. 1H NMR (400 MHz, CD3OD) δ 
9.46 (s, 1H), 8.84 (d, J = 6.8 Hz, 2H), 8.64 (q, J = 6.4 Hz, 2H), 8.53 (dd, J1 = 1.2 Hz, J2 = 7.6 Hz, 1H), 8.45 (d, J = 8.0 
Hz, 1H), 8.30 (d, J = 6.8 Hz, 2H), 8.01 (s, 1H), 7.89 – 7.85 (m, 2H), 7.73 (d, J = 8.0 Hz, 1H), 7.61 (t, J = 7.6 Hz, 1H), 
6.98 (d, J = 15.6 Hz, 1H), 6.52 – 6.44 (m, 1H), 3.91 (d, J = 7.2 Hz, 2H), 3.25 – 3.20 (m, 4H). 13C NMR (101 MHz, 
CD3OD) δ 157.53, 153.65, 144.21, 143.48, 138.75, 138.51, 136.98, 135.70, 135.58, 135.51, 133.04, 131.28, 
130.76, 130.59, 129.14, 129.00, 128.23, 127.47, 125.32, 121.29, 119..72, 50.31, 47.67, 40.13. HRMS: calculated 
for C25H24N4O2S [M+H]
+: 445.16927; found: 445.16904 . 
 
(E)-N-(2-((3-(3-(6-methoxypyridin-3-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 73 
Prepared according to the general procedure. Yield: 30.4 mg, 64.0 µmol, 16.0%. 1H NMR (400 MHz, CD3OD) δ 
9.62 (s, 1H), 8.80 (d, J = 6.4 Hz, 1H), 8.69 (d, J = 8.0 Hz, 1H), 8.62 (dd, J1 = 1.2 Hz, J2 = 7.6 Hz, 1H), 8.54 (d, J = 8.4 
Hz, 1H), 8.38 (d, J = 2.8 Hz, 1H), 7.99 – 7.92 (m, 2H), 7.65 (s, 1H), 7.54 – 7.52 (m, 1H), 7.48 – 7.42 (m, 2H), 6.94 – 
6.90 (m, 2H), 6.41 – 6.33 (m, 1H), 3.96 (s, 3H), 3.88 (d, J = 7.2 Hz, 2H), 3.22 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 
165.06, 152.34, 145.32, 140.53, 139.79, 139.53, 139.24, 137.66, 136.96, 136.10, 135.94, 133.93, 131.16, 130.59, 
130.43, 129.16, 128.06, 126.95, 136.16, 121.03, 119.81, 111.70, 54.51, 50.46, 47.57, 40.15. HRMS: calculated for 
C26H26N4O3S [M+H]
+: 475.17984; found: 475.17964. 
 
(E)-N-(2-((3-(3-(2-fluoropyridin-4-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 74 
Prepared according to the general procedure. Yield: 30.5 mg, 66.0 µmol, 16.5%. 1H NMR (400 MHz, CD3OD) δ 
9.63 (s, 1H), 8.80 (d, J = 6.4, 1H), 8.70 (d, J = 6.0, 1H), 8.63 (dd, J1 = 1.2 Hz, J2 = 7.6 Hz, 1H), 8.55 (d, J = 8.0 Hz, 1H), 
8.25 (d, J = 5.2, 1H), 7.95 (t, J = 8.0 Hz, 1H), 7.83 (s, 1H), 7.70 (d, J = 7.6 Hz, 1H), 7.61 – 7.60 (m, 2H), 7.52 (t, J = 
7.6, 1H), 7.36 (s, 1H), 6.95 (d, J = 16.0 Hz, 1H), 6.46 – 6.38 (m, 1H), 3.90 (d, J = 7.2 Hz, 2H), 3.23 (s, 4H). 13C NMR 
(101 MHz, CD3OD) δ 167.07, 164.70, 155.57, 155.48, 152.43, 148.98, 1548.83, 140.71, 139.26, 138.59, 138.01, 
136.91, 136.09, 135.94, 133.91, 130.87, 130.47, 129.18, 128.51, 126.72, 120.90, 120.86, 120.52, 108.24, 107.87, 
50.40, 47.63, 40.17. HRMS: calculated for C25H23FN4O2S [M+H]




Prepared according to the general procedure. Yield: 26.6 mg, 59.6 µmol, 14.9%. 1H NMR (400 MHz, CD3OD) δ 
9.62 (s, 1H), 9.15 (s, 1H), 9.07 (s, 2H), 8.79 (d, J = 6.4 Hz, 1H), 8.70 (d, J = 6.0 Hz, 1H), 8.63 (d, J = 7.2 Hz, 1H), 8.55 
(d, J = 8.0 Hz, 1H), 7.95 (t, J = 8.4 Hz, 1H), 7.80 (s, 1H), 7.67 (d, J = 7.6 Hz, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.54 (t, J = 
7.6 Hz, 1H), 6.96 (d, J = 16.0 Hz, 1H), 6.47 – 6.39 (m, 1H), 3.90 (d, J = 7.2 Hz, 2H), 3.23 (s, 4H). 13C NMR (101 MHz, 
CD3OD) δ 158.08, 156.14, 152.48, 140.79, 139.27, 138.17, 136.87, 136.08, 135.93, 135.85, 135.62, 133.88, 
131.03, 130.48, 129.10, 128.53, 128.47, 126.63, 120.93, 120.56, 50.40, 47.64, 40.18. HRMS: calculated for 
C24H23N5O2S [M+H]
+: 446.16452; found: 446.16416. 
 
(E)-N-(2-((3-(3-(2-methoxypyrimidin-5-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 76 
Prepared according to the general procedure. Yield: 24.7 mg, 52.0 µmol, 13.0%. 1H NMR (400 MHz, CD3OD) δ 
9.56 (s, 1H), 8.82 (s, 2H), 8.73 (d, J = 6.4 Hz, 1H), 8.68 (d, J = 6.4 Hz, 1H), 8.59 (d, J = 7.2 Hz, 1H), 8.51 (d, J = 8.4 Hz, 
1H), 7.92 (t, J = 8.0 Hz, 1H), 7.70 (s, 1H), 7.58 (d, J = 7.2 Hz, 1H), 7.52 – 7.47 (m, 2H), 6.94 (d, J = 16.0 Hz, 1H), 6.43 
– 6.35 (m, 1H), 4.05 (s, 3H), 3.89 (d, J = 7.2 Hz, 2H), 3.22 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 166.19, 158.60, 
152.90, 141.79, 139.49, 137.97, 136.42, 136.04, 135.90, 135.79, 133.58, 130.86, 130.51, 129.32, 128.77, 127.97, 





Prepared according to the general procedure. Yield: 35.0 mg, 66.0 µmol, 16.5%. 1H NMR (400 MHz, CD3OD) δ 
9.63 (s, 1H), 8.79 (d, J = 6.4 Hz, 1H), 8.70 (d, J = 6.4 Hz, 1H), 8.62 (dd, J1 = 0.8 Hz, J2 = 7.2 Hz, 1H), 8.56 (d, J = 8.4 
Hz, 1H), 8.18 (dd, J1 = 2.0 Hz, J2 = 6.0 Hz, 1H), 8.00 – 7.94 (m, 2H), 7.71 (s, 1H), 7.59 – 7.54 (m, 3H), 7.31 (dd, J1 = 
6.0 Hz, J2 = 7.6 Hz, 1H), 6.95 (d, J = 16.0 Hz, 1H), 6.46 – 6.38 (m, 1H), 3.89 (d, J = 7.2 Hz, 2H), 3.54 (t, J = 4.4 Hz, 
4H), 3.25 – 3.23 (m, 8H). 13C NMR (101 MHz, CD3OD) δ 156.46, 152.50, 147.01, 140.86, 140.02, 138.99, 138.92, 
138.13, 136.87, 136.07, 135.90, 133.87, 131.22, 131.05, 130.48, 129.11, 129.08, 128.44, 127.42, 120.92, 120.76, 
118.32, 66.85, 50.35, 50.25, 47.03, 40.15. HRMS: calculated for C29H31N5O3S [M+H]




Prepared according to the general procedure. Yield: 33.4 mg, 67.6 µmol, 16.9%. 1H NMR (400 MHz, CD3OD) δ 
9.55 (s, 1H), 9.41 (s, 1H), 9.11 (s, 1H), 8.73 (d, J = 6.4 Hz, 1H), 8.66 (d, J = 6.4 Hz, 1H), 8.58 (dd, J1 = 1.2 Hz, J2 = 7.6 
Hz, 1H), 8.49 (d, J = 8.4 Hz, 1H), 8.25 – 8.19 (m, 2H), 8.02 (td, J1 = 1.2 Hz, J2 = 6.8 Hz, 1H), 7.95 – 7.78 (m, 4H), 7.61 
– 7.55 (m, 2H), 6.97 (d, J = 15.6 Hz, 1H), 6.50 – 6.43 (m, 1H), 3.91 (d, J = 7.2 Hz, 2H), 3.24 (s, 4H). 13C NMR (101 
MHz, CD3OD) δ 152.73, 148.30, 146.84, 141.68, 141.45, 139.16, 138.26, 137.04, 136.54, 135.92, 135.77, 135.45, 
134.38, 133.61, 131.08, 130.51, 130.44, 130.32, 130.18, 129.92, 128.84, 128.77, 127.02, 124.07, 120.73, 120.59, 
5038, 47.63, 40.15. HRMS: calculated for C29H26N4O2S [M+H]






Prepared according to the general procedure. Yield: 23.7 mg, 51.2 µmol, 12.8%. 1H NMR (400 MHz, CD3OD) δ 
9.58 (s, 1H), 8.75 (d, J = 6.4 Hz, 1H), 8.69 (d, J = 6.0 Hz, 1H), 8.60 (dd, J1 = 1.2 Hz, J2 = 7.6 Hz, 1H), 8.52 (d, J = 8.4 
Hz, 1H), 8.45 (d, J = 2.4 Hz, 1H), 8.22 – 8.17 (m, 1H), 7.93 (t, J = 8.4 Hz, 1H), 7.71 (s, 1H), 7.60 – 7.47 (m, 3H), 7.16 
(dd, J1 = 2.8 Hz, J2 = 8.8 Hz, 1H), 6.94 (d, J = 15.6 Hz, 1H), 6.43 – 6.38 (m, 1H), 3.89 (d, J = 7.2 Hz, 2H), 3.21 (s, 4H). 
13C NMR (101 MHz, CD3OD) δ 165.77, 163.38, 152.77, 146.56, 146.42, 141.81, 141.72, 139.58, 138.39, 137.82, 
136.57, 136.04, 136.00, 135.96, 133.68, 130.75, 130.51, 128.88, 128.49, 127.66, 126.62, 120.64, 120.13, 110.91, 
110.54, 50.44, 47.61, 40.16. HRMS: calculated for C25H23FN4O2S [M+H]
+: 463.15985; found: 463.15945. 
 
(E)-N-(2-((3-(3-(1-methyl-1H-indazol-6-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 80 
Prepared according to the general procedure. Yield: 63.4 mg, 127.6 µmol, 31.9%. 1H NMR (400 MHz, CD3OD) δ 
9.56 (s, 1H), 8.77 (d, J = 6.8 Hz, 1H), 8.65 (d, J = 6.4 Hz, 1H), 8.59 (d, J = 7.2 Hz, 1H), 8.47 (d, J = 8.0 Hz, 1H), 7.96 (s, 
1H), 7.88 (t, J = 8.0 Hz, 1H), 7.76 (s, 1H), 7.74 (s, 1H),  7.67 (s, 1H), 7.63 – 7.61 (m, 1H), 7.45 – 7.42 (m, 2H), 7.38 
(dd, J1 = 1.2 Hz, J2 = 8.4 Hz, 1H), 6.92 (d, J = 16.0 Hz, 1H), 6.41 – 6.34 (m, 1H), 4.05 (s, 3H), 3.87 (d, J = 7.2 Hz, 2H), 
3.22 (m, 4H). 13C NMR (101 MHz, CD3OD) δ 152.30, 143.05, 141.81, 140.77, 140.63, 139.93, 137.44, 136.89, 
136.03, 135.88, 133.85, 133.58, 130.38, 130.34, 129.01, 127.12, 126.93, 124.47, 122.45, 121.80, 120.96, 119.63, 
108.27, 50.49, 47.54, 40.14, 35.58. HRMS: calculated for C28H27N5O2S [M+H]
+: 498.19582; found: 498.19539. 
 
(E)-N-(2-((3-([1,1':3',1''-terphenyl]-3-yl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 81 
Prepared according to the general procedure. Yield: 71.1 mg, 136.8 µmol, 34.2%. 1H NMR (400 MHz, (CD3)2SO) δ 
9.48 (s, 1H), 8.71 (d, J = 6.4 Hz, 1H), 8.45 – 8.43 (m, 2H), 8.39 (d, J = 7.2 Hz, 1H), 7.90 (s, 1H), 7.85 – 7.81 (m, 2H), 
7.75 (d, J = 8.4 Hz, 2H), 7.70 (d, J = 7.2 Hz, 1H), 7.66 (d, J = 7.6 Hz, 1H), 7.57 (d, J = 7.6 Hz, 1H), 7.52 – 7.46 (m, 4H), 
7.40 – 7.36 (m, 1H), 6.87 (d, J = 16.0 Hz, 1H), 6.42 – 6.35 (m, 1H), 3.78 (d, J = 6.4 Hz, 2H), 3.13 – 3.07 (m, 4H). 13C 
NMR (101 MHz, (CD3)2SO) δ 153.49, 144.67, 141.13, 140.80, 140.66, 140.21, 136.94, 136.33, 133.97, 133.93, 
133.87, 133.04, 130.50, 129.77, 129.08, 128.85, 127.76, 127.24, 127.05, 126.60, 126.23, 126.03, 125.85, 125.33, 
125.30, 120.21, 117.27, 48.45, 45.48, 38.77, 38.69. HRMS: calculated for C32H29N3O2S [M+H]




Prepared according to the general procedure. Yield: 40.6 mg, 93.6 µmol, 23.4%. 1H NMR (400 MHz, CD3OD) δ 
9.56 (s, 1H), 8.75 (d, J = 6.4 Hz, 1H), 8.67 (d, J = 6.4 Hz, 1H), 8.60 (dd, J1 = 1.2 Hz, J2 = 7.6 Hz, 1H), 8.49 (d, J = 8.4 
Hz, 1H), 7.99 (s, 2H), 7.91 (t, J = 8.4 Hz, 1H), 7.65 (s, 1H), 7.52 (d, J = 7.2 Hz, 1H), 7.37 – 7.30 (m, 2H), 6.87 (d, J = 
15.6 Hz, 1H), 6.37 – 6.29 (m, 1H), 3.86 (d, J = 6.8 Hz, 2H), 3.21 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 152.66, 
141.26, 140.08, 137.41, 136.63, 135.97, 135.86, 134.51, 133.73, 132.18, 130.46, 130.37, 128.90, 127.05, 125.86, 
125.03, 123.21, 120.70, 119.31, 50.51, 47.53, 40.15 HRMS: calculated for C23H23N5O2S [M+H]







Prepared according to the general procedure. Yield: 54.3 mg, 120.8 µmol, 30.2%. 1H NMR (400 MHz, CD3OD) δ 
9.51 (s, 1H), 8.71 (d, J = 6.4 Hz, 1H), 8.65 (d, J = 6.4 Hz, 1H), 8.56 (dd, J1 = 1.2 Hz, J2 = 7.6 Hz, 1H), 8.45 (d, J = 8.4 
Hz, 1H), 7.87 (t, J = 8.0 Hz, 1H), 7.66 (s, 1H), 7.57 – 7.54 (m, 1H), 7.40 – 7.33 (m, 4H), 7.08 (dd, J1 = 3.6 Hz, J2 = 5.2 
Hz, 1H), 6.86 (d, J = 16.0 Hz, 1H), 6.36 – 6.28 (m, 1H), 3.86 (d, J = 7.2 Hz, 2H), 3.20 (s, 4H). 13C NMR (101 MHz, 
CD3OD) δ 152.90, 144.71, 141.88, 139.67, 137.53, 136.30, 136.27, 135.81, 135.73, 133.47, 130.48, 130.44, 
129.20, 128.66, 127.11, 126.77, 126.21, 125.17, 124.64, 120.38, 119.78, 50.42, 47.53, 40.12. HRMS: calculated 
for C24H23N3O2S2 [M+H]
+: 450.13044; found: 450.13002. 
 
(E)-N-(2-((3-(3-(benzo[b]thiophen-2-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 84 
Prepared according to the general procedure. Yield: 55.2 mg, 110.4 µmol, 27.6%. 1H NMR (400 MHz, CD3OD) δ 
9.33 (s, 1H), 8.59 (d, J = 6.4 Hz, 1H), 8.54 (d, J = 6.4 Hz, 1H), 7.46 (dd, J1 = 0.8 Hz, J2 = 7.2 Hz, 1H), 8.31 (d, J = 8.4 
Hz, 1H), 7.81 – 7.73 (m, 4H), 7.65 – 7.61 (m, 2H), 7.42 – 7.36 (m, 2H), 7.34 – 7.26 (m, 2H), 6.86 (d, J = 16.0 Hz, 1H),  
6.37 – 6.30 (m, 1H), 3.84 (d, J = 7.2 Hz, 2H), 3.18 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 154.06, 144.49, 144.46, 
142.07, 140.68, 139.48, 136.04, 135.31, 135.12, 134.99, 132.63, 130.57, 127.77, 127.65, 127.58, 127.40, 125.76, 
125.70, 124.79, 123.16, 121.18, 120.01, 119.17, 50.38, 47.53, 40.08. HRMS: calculated for C28H25N3O2S2 [M+H]
+: 
500.14610; found: 500.14564. 
 
(E)-N-(2-((3-(3-(1H-indol-2-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 85 
Prepared according to the general procedure. Yield: 26.8 mg, 55.6 µmol, 13.9%. 1H NMR (400 MHz, CD3OD) δ 
9.50 (s, 1H), 8.70 (d, J = 6.4 Hz, 2H), 8.65 (d, J = 6.0 Hz, 1H), 8.56 (d, J = 7.2 Hz, 1H), 8.44 (d, J = 8.0 Hz, 1H), 7.86 (t, 
J = 7.2 Hz, 2H), 7.73 (d, J = 7.6 Hz, 1H), 7.52 (d, J = 7.6 Hz, 1H), 7.43 – 7.34 (m, 3H), 7.10 (t, J = 7.6 Hz, 1H), 7.00 (t, J 
= 7.6 Hz, 1H), 6.90 (d, J = 16.0 Hz, 1H), 6.40 – 6.33 (m, 1H), 3.86 (d, J = 7.2 Hz, 2H), 3.19 (s, 4H). 13C NMR (101 
MHz, CD3OD) δ 153.00, 142.04, 140.02, 138.91, 138.58, 137.42, 136.26, 135.82, 135.73, 134.73, 133.46, 130.50, 
130.39, 130.36, 128.64, 126.61, 126.48, 124.72, 122.97, 121.25, 120.63, 120.32, 119.53, 122.16, 50.49, 47.54, 
40.13. HRMS: calculated for C28H26N4O2S [M+H]
+: 483.18492; found: 483.18448. 
 
(E)-N-(2-((3-(3-(quinoxalin-6-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 86 
Prepared according to the general procedure. Yield: 80.5 mg, 162.4 µmol, 40.6%. 1H NMR (400 MHz, CD3OD) δ 
9.44 (s, 1H), 8.86 (d, J = 1.6 Hz, 1H), 8.82 (d, J = 1.6 Hz, 1H), 8.65 – 8.61 (m, 2H), 8.52 (dd, J1 = 0.8 Hz, J2 = 7.2 Hz, 
1H), 8.40 (d, J = 8.0 Hz, 1H), 8.19 (s, 1H), 8.09 – 8.05 (m, 2H), 7.83 (t, J = 7.6 Hz, 1H), 7.78 (s, 1H), 7.51 – 7.44 (m, 
2H), 6.93 (d, J = 16.0 Hz, 1H), 6.44 – 6.36 (m, 1H), 3.90 (d, J = 7.2 Hz, 2H), 3.23 (s, 4H). 13C NMR (101 MHz, CD3OD) 
δ 153.27, 146.94, 146.34, 143.91, 143.74, 143.13, 142.76, 140.89, 139.59, 137.72, 135.91, 135.63, 135.50, 
133.13, 130.91, 130.67, 130.49, 130.43, 130.13, 128.86, 128.37, 128.20, 127.77, 127.198, 127.03, 120.05, 119.95, 
50.44, 47.58, 40.13. HRMS: calculated for C28H25N5O2S [M+H]
+: 496.18017; found: 496.17984. 
 
(E)-N-(2-((3-(3-(5-fluoro-1H-indol-2-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 87 
Prepared according to the general procedure. Yield: 20.8 mg, 41.6 µmol, 10.4%. 1H NMR (400 MHz, CD3OD) δ 
9.41 (s, 1H), 8.65 (d, J = 4.4 Hz, 1H), 8.57 (d, J = 4.4 Hz, 1H), 8.51 (dd, J1 = 0.8 Hz, J2 = 4.8 Hz, 1H), 8.42 (d, J = 5.6 
75 
Hz, 1H), 7.89 (s, 1H), 7.84 (t, J = 5.2 Hz, 1H), 7.76 (dt, J1 = 1.2 Hz, J2 = 4.8 Hz, 1H), 7.47 – 7.43 (m, 2H), 7.36 (dd, J1 = 
2.8 Hz, J2 = 5.6 Hz, 1H), 7.20 (dd, J1 = 2.0 Hz, J2 = 6.8 Hz, 1H), 6.94 (d, J = 10.4 Hz, 1H), 6.88 (td, J1 = 2.0 Hz, J2 = 6.4 
Hz, 1H), 6.84 (s, 1H), 6.41 – 6.36 (m, 1H), 3.90 (d, J = 4.8 Hz, 2H), 3.22 – 3.16 (m, 4H). 13C NMR (101 MHz, CD3OD) 
δ 160.12, 158.58, 154.24, 144.71, 140.59, 140.00, 137.49, 135.51, 135.44, 135.35, 135.17, 134.52, 132.70, 
130.77, 130.70, 130.48, 127.86, 126.89, 126.77, 126.61, 124.91, 119.61, 119.14, 112.93, 111.10, 110.92, 105.66, 
105.50, 100.33, 50.50, 47.59, 40.12. HRMS: calculated for C28H25FN4O2S [M+H]
+: 501.17550; found: 501.17552. 
 
(E)-N-(2-((3-(3-(2-(trifluoromethyl)pyridin-4-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 88 
Prepared according to the general procedure. Yield: 37.7 mg, 73.6 µmol, 18.4%. 1H NMR (400 MHz, CD3OD) δ 
9.43 (s, 1H), 8.77 (d, J = 3.2 Hz, 1H), 8.66 (d, J = 4.0 Hz, 1H), 8.57 (d, J = 4.0 Hz, 1H), 8.51 (dd, J1 = 0.4 Hz, J2 = 4.8 
Hz, 1H), 8.44 (d, J = 5.2 Hz, 1H), 8.10 (s, 1H), 7.96 (dd, J1 = 0.8 Hz, J2 = 3.6 Hz, 1H), 7.90 (s, 1H), 7.85 (t, J = 5.2 Hz, 
1H), 7.79 (d, J = 5.2 Hz, 1H), 7.66 (d, J = 5.2 Hz, 1H), 7.58 (t, J = 5.2 Hz, 1H), 6.99 (d, J = 10.4 Hz, 1H), 6.46 – 6.41 
(m, 1H), 3.91 (d, J = 4.4 Hz, 2H), 3.23 – 3.21 (m, 2H), 3.18 – 3.16 (m, 2H). 13C NMR (101 MHz, CD3OD) δ 154.29, 
151.74, 151.64, 149.70 (q, J = 23.23 Hz), 144.80, 139.31, 138.61, 138.17, 135.43, 135.34, 135.14, 132.70, 131.07, 
130.74, 129.28, 128.72, 128.66, 128.08, 127.83, 126.88, 125.87, 123.20 (q, J = 171.7 Hz), 120.58, 119.56, 119.52, 
119.12, 50.39, 47.66, 40.14. HRMS: calculated for C26H23F3N4O2S [M+H]
+: 513.15666; found: 513.15630. 
 
(E)-N-(2-((3-(3-(imidazo[1,2-a]pyridin-7-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 89 
Prepared according to the general procedure. Yield: 39.8 mg, 82.4 µmol, 20.6%. 1H NMR (400 MHz, CD3OD) δ 
9.43 (s, 1H), 9.14 (s, 1H), 8.66 (d, J = 4.0 Hz, 1H), 8.58 (d, J = 4.0 Hz, 1H), 8.52 (dd, J1 = 0.8 Hz, J2 = 4.8 Hz, 1H), 8.44 
(d, J = 5.2 Hz, 1H), 8.30 (dd, J1 = 1.2 Hz, J2 = 6.4 Hz, 1H), 8.26 (s, 1H), 8.08 (s, 1H), 8.03 (d, J = 6.4 Hz, 1H), 7.85 (t, J 
= 4.8 Hz, 1H), 7.72 (d, J = 5.2 Hz, 1H), 7.64 (d, J = 5.2 Hz, 1H), 7.58 (t, J = 5.2 Hz, 1H), 6.99 (d, J = 10.8 Hz, 1H), 6.48 
– 6.43 (m, 1H), 3.91 (d, J = 4.8 Hz, 2H), 3.23 – 3.18 (m, 4H). 13C NMR (101 MHz, CD3OD) δ 154.17, 144.54, 140.80, 
139.24, 138.25, 136.95, 135.45, 135.39, 135.25, 134.92, 132.77, 132.39, 131.07, 130.71, 128.70, 128.47, 127.91, 
127.59, 127.01, 124.41, 120.70, 119.24, 117.08, 113.32, 50.38, 47.68, 40.13. HRMS: calculated for C27H25N5O2S 
[M+H]+: 484.18017; found: 484.17986. 
 
(E)-N-(2-((3-(4-(4-methylnaphthalen-1-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 90 
Prepared according to the general procedure. Yield: 13.0 mg, 25.6 µmol, 6.4%. 1H NMR (400 MHz, CD3OD) δ 9.46 
(s, 1H), 8.66 (s, 1H), 8.62 (d, J = 6.0 Hz, 1H), 8.53 (dd, J1 = 1.2 Hz, J2 = 7.6 Hz, 1H), 8.44 (d, J = 8.0 Hz, 1H), 8.08 (d, J 
= 8.4 Hz, 1H), 7.88 – 7.82 (m, 2H), 7.60 (d, J = 8.0 Hz, 2H), 7.53 (t, J = 7.2 Hz, 1H), 7.46 – 7.40 (m, 3H), 7.37 (d, J = 
7.2 Hz, 1H), 7.28 (d, J = 7.2 Hz, 1H), 6.96 (d, J = 16.0 Hz, 1H), 6.40 – 6.33 (m, 1H), 3.89 (d, J = 7.2, 2H), 3.22 – 3.18 
(m, 4H), 2.72 (s, 3H). 13C NMR (101 MHz, CD3OD) δ 153.92, 144.00, 143.09, 139.90, 139.20, 135.72, 135.52, 
135.47, 135.28, 134.23, 132.92, 132.71, 131.61, 130.66, 128.07, 127.90, 127.4, 127.19, 127.16, 126.77, 125.49, 
119.51, 119.10, 50.57, 47.58, 40.14. HRMS: calculated for C31H29N3O2S [M+H]
+: 508.20532; found: 508.20508. 
 
(E)-N-(2-((3-(4-(4-methoxynaphthalen-1-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 91 
Prepared according to the general procedure. Yield: 20.1 mg, 38.4 µmol, 9.6%. 1H NMR (400 MHz, CD3OD) δ 9.49 
(s, 1H), 8.67 (s, 1H), 8.56 (dd, J1 = 1.2 Hz, J2 = 7.2 Hz, 1H), 8.45 (d, J = 8.0 Hz, 1H), 8.28 (dd, J1 = 1.6 Hz, J2 = 8.4 Hz, 
76 
1H), 7.87 (t, J = 7.6 Hz, 1H), 7.78 (dd, J1 = 1.6 Hz, J2 = 7.6 Hz, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.47 – 7.39 (m, 4H), 7.30 
(d, J = 8.0 Hz, 1H), 6.95 – 6.92 (m, 2H), 6.39 – 6.31 (m, 1H), 4.02 (s, 3H), 3.88 (d, J = 7.2 Hz, 2H), 3.20 (s, 4H). 13C 
NMR (101 MHz, CD3OD) δ 156.46, 153.47, 143.05, 142.93, 139.92, 135.88, 135.66, 135.61, 135.47, 133.51, 
133.18, 133.07, 131.64, 128.37, 128.12, 127.91, 127.56, 127.03, 126.32, 126.09, 123.25, 119.94, 118.94, 104.55, 
56.06, 50.57, 47.55, 40.13. HRMS: calculated for C31H29N3O3S [M+H]
+: 524.20024; found: 524.20000. 
 
(E)-N-(2-((3-(4-(6-methoxynaphthalen-2-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 92 
Prepared according to the general procedure. Yield: 13.4 mg, 25.6 µmol, 6.4%. 1H NMR (400 MHz, CD3OD) δ 9.58 
(s, 1H), 8.76 (d, J = 6.0 Hz, 1H), 8.70 (s, 1H), 8.60 (dd, J1 = 1.2 Hz, J2 = 7.6 Hz, 1H), 8.51 (d, J = 8.0 Hz, 1H), 8.02 (d, J 
= 1.6 Hz, 1H), 7.92 (t, J = 7.6 Hz, 1H), 7.82 (t, J = 9.2 Hz, 2H), 7.75 – 7.71 (m, 3H), 7.57 (d, J = 8.4 Hz, 1H), 7.24 (d, J 
= 2.4 Hz, 1H), 7.14 (dd, J1 = 2.4 Hz, J2 = 8.8 Hz, 1H), 6.90 (d, J = 15.6 Hz, 1H), 6.36 – 6.29 (m, 1H), 3.91 (s, 3H), 3.87 
(d, J = 7.2 Hz, 2H), 3.20 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 159.46, 152.77, 142.85, 141.44, 139.85, 136.57, 
136.55, 135.97, 135.86, 135.56, 133.68, 130.77, 130.62, 128.89, 128.56, 128.31, 126.41, .126.33, 120.66, 120.23, 
118.79, 106.57, 55.78, 50.60, 47.56, 40.15. HRMS: calculated for C31H29N3O3S [M+H]




Prepared according to the general procedure. Yield: 14.0 mg, 26.0 µmol, 6.5%. 1H NMR (400 MHz, CD3OD) δ 9.53 
(s, 1H), 8.71 – 8.67 (m, 2H), 8.57 (dd, J1 = 1.2 Hz, J2 = 7.2 Hz, 1H), 8.48 (d, J = 8.0 Hz, 1H), 8.01 (s, 1H), 7.89 (t, J = 
8.0 Hz, 1H), 7.80 (d, J = 8.8 Hz, 2H), 7.75 – 7.70 (m, 3H), 7.56 (d, J = 8.0 Hz, 2H), 7.21 (s, 1H), 7.13 (dd, J1 = 2.4 Hz, 
J2 = 9.2 Hz, 1H), 6.90 (d, J = 15.6 Hz, 1H), 6.36 – 6.28 (m, 1H), 4.15 (q, J = 7.2 Hz, 2H), 3.86 (d, J = 6.8 Hz, 2H), 3.19 
(s, 4H), 1.45 (t, J = 6.8 Hz, 3H). 13C NMR (101 MHz, CD3OD) δ 158.70, 153.18, 142.88, 142.46, 139.86, 136.47, 
136.18, 135.80, 135.72, 135.59, 135.54, 133.40, 130.74, 130.57, 128.5,4 128.30, 128.04, 126.36, 126.32, 120.50, 
120.24, 118.77, 107.33, 64.56, 50360, 47.55, 40.14. HRMS: calculated for C32H31N3O3S [M+H]




Prepared according to the general procedure. Yield: 3.6 mg, 6.0 µmol, 1.5%. 1H NMR (400 MHz, CD3OD) δ 9.46 (s, 
1H), 8.67 (br s, 1H), 8.60 (d, J = 6.4 Hz, 1H), 8.52 (dd, J1 = 1.2 Hz, J2 = 7.6 Hz, 1H), 8.44 (d, J = 8.4 Hz, 1H), 8.02 (d, J 
= 2.0 Hz, 1H), 7.92 – 7.80 (m, 2H), 7.76 – 7.72 (m, 3H), 7.66 (dd, J1 = 2.0 Hz, J2 = 8.8 Hz, 1H), 7.56 (d, J = 8.4 Hz, 
2H), 7.23 – 7.12 (m, 5H), 7.08 (t, J = 6.8 Hz, 1H), 6.90 (d, J = 15.6 Hz, 1H), 6.35 – 6.27 (m, 1H), 4.44 (s, 2H), 3.87 (d, 
J = 6.8 Hz, 2H), 3.18 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 154.30, 154.05, 144.25, 142.94, 142.78, 139.97, 135.51, 
135.39, 135.36, 135.30, 134.61, 130.63, 129.54, 129.38, 129.16, 128.50, 128.23, 128.01, 127.10, 126.55, 126.06, 





Prepared according to the general procedure. Yield: 5.7 mg, 10.4 µmol, 2.6%. 1H NMR (400 MHz, CD3OD) δ 9.55 
(s, 1H), 8.73 (t, J = 6.0 Hz, 2H), 8.60 (dd, J1 = 1.2 Hz, J2 = 7.6 Hz, 1H), 8.51 – 8.49 (m, 2H), 8.05 (d, J = 8.4 Hz, 2H), 
77 
7.92 (t, J = 7.6 Hz, 1H), 7.70 (d, J = 7.6 Hz, 2H), 7.57 (d, J = 8.8 Hz, 2H), 7.44 (t, J = 6.8 Hz, 2H), 7.38 – 7.31 (m, 4H), 
7.03 (d, J = 16.0 Hz, 1H), 6.48 – 6.40 (m, 1H), 3.93 (d, J = 7.2 Hz, 2H), 3.27 – 3.20 (m, 4H). 13C NMR (101 MHz, 
CD3OD) δ 153.13, 142.26, 140.83, 139.86, 137.28, 136.27, 136.23, 135.82, 135.74, 133.46, 132.83, 132.79, 
131.30, 130.59, 129.55, 128.64, 128.08, 127.89, 127.27, 126.60, 126.20, 120.31, 119.53, 50.56, 47.62, 40.18. 
HRMS: calculated for C34H29N3O2S [M+H]
+: 544.20532; found: 544.20500. 
 
(E)-N-(2-((3-(4-(9H-fluoren-2-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 96 
Prepared according to the general procedure. Yield: 17.0 mg, 32.0 µmol, 8.0%. 1H NMR (400 MHz, CD3OD) δ 9.51 
(s, 1H), 8.68 (s, 2H), 8.56 (d, J = 7.2 Hz, 1H), 8.48 (d, J = 8.4 Hz, 1H), 7.91 – 7.80 (m, 4H), 7.69 (d, J = 8.4 Hz, 2H), 
7.64 (d, J = 8.0 Hz, 1H), 7.55 (d, J = 8.0 Hz, 3H), 7.64 (t, J = 7.2 Hz, 1H), 7.30 (t, J = 7.2 Hz, 1H), 6.90 (d, J = 15.6 Hz, 
1H), 6.35 – 6.28 (m, 1H), 3.93 (s, 2H), 3.87 (d, J = 7.2 Hz, 2H), 3.19 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 153.33, 
145.38, 144.85, 143.19, 142.69, 142.55, 142.47, 140.18, 139.85, 136.03, 135.76, 135.66, 135.61, 133.31, 130.58, 
128.50, 128.31, 127.98, 127.93, 126.77, 126.09, 124.46, 121.17, 120.94, 120.07, 118.79, 50.60, 47.56, 40.14, 
37.69. HRMS: calculated for C33H29N3O2S [M+H]
+: 532.20532; found: 532.20511. 
 
(E)-N-(2-((3-(4-(phenanthren-9-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 97 
Prepared according to the general procedure. Yield: 21.5 mg, 39.6 µmol, 9.9%. 1H NMR (400 MHz, CD3OD) δ 9.51 
(s, 1H), 8.79 (d, J = 8.4 Hz, 1H), 8.74 – 8.66 (m, 3H), 8.57 (d, J = 7.2 Hz, 1H), 8.46 (d, J = 8.0 Hz, 1H), 7.89 – 7.86 (m, 
2H), 7.82 (d, J = 8.0 Hz, 1H), 7.67 – 7.57 (m, 6H), 7.52 – 7.48 (m, 3H), 6.95 (d, J = 15.6 Hz, 1H), 6.41 – 6.33 (m, 1H), 
3.88 (d, J = 7.2 Hz, 2H), 3.21 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 153.10, 142.69, 142.27, 139.79, 139.31, 136.18, 
136.02, 135.77, 135.69, 133.39, 132.83, 132.00, 131.51, 131.29, 130.52, 129.76, 128.58, 128.46, 128.02, 127.99, 
127.92, 127.74, 127.63, 127.50, 124.15, 123.60, 120.24, 119.30, 50.54, 47.58, 40.14. HRMS: calculated for 
C34H29N3O2S [M+H]
+: 544.20532; found: 544.20505. 
 
(E)-N-(2-((3-(4-(dibenzo[b,d]furan-4-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 98 
Prepared according to the general procedure. Yield: 32.7 mg, 61.2 µmol, 15.3%. 1H NMR (400 MHz, CD3OD) δ 
9.40 (s, 1H), 8.63 (br s, 1H), 8.59 (d, J = 6.0 Hz, 1H), 8.49 (d, J = 7.2 Hz, 1H), 8.37 (d, J = 8.4 Hz, 1H), 8.00 (d, J = 7.6 
Hz, 1H), 7.96 (d, J = 7.6 Hz, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.80 (t, J = 8.0 Hz, 1H), 7.62 – 7.57 (m, 4H), 7.47 (t, J = 7.2 
Hz, 1H), 7.41 (t, J = 7.6 Hz, 1H), 7.35 (t, J = 7.6 Hz, 1H), 6.89 (d, J = 16.0 Hz, 1H), 6.37 – 6.30 (m, 1H), 3.86 (d, J = 7.2 
Hz, 2H), 3.19 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 157.36, 154.42, 153.85, 143.96, 139.71, 138.08, 136.16, 
135.44, 132.84, 130.57, 130.05, 128.54, 128.18, 128.00, 127.62, 126.23, 126.12, 125.58, 124.14, 121.81, 121.11, 
119.46, 119.30, 112.56, 50.52, 47.54, 40.10. HRMS: calculated for C32H27N3O3S [M+H]




Prepared according to the general procedure. Yield: 31.0 mg, 54.8 µmol, 13.7%. 1H NMR (400 MHz, (CD3)2SO) δ 
9.50 (s, 1H), 8.73 (d, J = 5.6 Hz, 1H), 8.47 – 8.42 (m, 2H), 8.38 (d, J = 7.2 Hz, 1H), 7.86 (t, J = 7.6 Hz, 1H), 7.60 – 7.56 
(m, 4H), 7.35 – 7.31 (m, 3H), 7.27 – 7.21 (m, 2H), 7.15 (t, J = 7.6 Hz, 1H), 6.99 (d, J = 7.6 Hz, 1H), 6.84 (d, J = 15.6 
Hz, 1H), 6.35 – 6.28 (m, 1H), 3.79 (d, J = 6.4 Hz, 2H), 3.10 (t, J = 5.2 Hz, 2H), 3.04 (d, J = 4.4 Hz, 2H). 13C NMR (101 
78 
MHz, (CD3)2SO) δ 153.47, 151.85, 148.52, 144.74, 136.52, 136.41, 134.78, 133.84, 133.79, 132.84, 130.50, 130.31, 
129.74, 129.33, 128.74, 128.42, 127.13, 126.60, 126.46, 125.37, 125.13, 121.28, 120.43, 120.01, 117.49, 117.06, 
48.34, 45.35, 38.66. HRMS: calculated for C32H27N3O3S2 [M+H]
+: 566.15666; found: 566.15645. 
 
(E)-N-(2-((3-(4-(2,3-dihydrobenzofuran-5-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 100 
Prepared according to the general procedure. Yield: 25.8 mg, 53.2 µmol, 13.3%. 1H NMR (400 MHz, CD3OD) δ 
9.49 (s, 1H), 8.67 (s, 2H), 8.55 (d, J = 7.2 Hz, 1H), 8.45 (d, J = 8.4 Hz, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.53 (d, J = 5.6 Hz, 
2H), 7.47 (d, J = 8.8 Hz, 3H), 7.34 (dd, J1 = 2.4 Hz, J2 = 8.4 Hz, 1H), 6.85 (d, J = 15.6 Hz, 1H), 6.76 (d, J = 8.0 Hz, 1H), 
6.31 – 6.23 (m, 1H), 4.55 (t, J = 8.8 Hz, 2H), 3.85 (d, J = 7.2 Hz, 2H), 3.22 (t, J = 8.4 Hz, 2H), 3.19 (s, 4H). 13C NMR 
(101 MHz, CD3OD) δ 161.40, 153.30, 143.05, 142.69, 139.88, 136.00, 135.71, 135.64, 134.91, 134.28, 133.26, 
129.35, 128.45, 128.38, 128.00, 127.78, 124.48, 120.06, 118.39, 110.30, 72.52, 50.59, 47.50, 40.11, 30.49 . 
HRMS: calculated for C28H27N3O3S [M+H]




Prepared according to the general procedure. Yield: 30.1 mg, 58.4 µmol, 14.6%. 1H NMR (400 MHz, CD3OD) δ 
9.51 (s, 1H), 8.67 (t, J = 6.0 Hz, 2H), 8.56 (dd, J1 = 1.2 Hz, J2 = 7.6 Hz, 1H), 8.46 (d, J = 8.4 Hz, 1H), 7.88 (t, J = 7.6 Hz, 
1H), 7.54 (d, J = 8.0 Hz, 2H), 7.48 (d, J = 8.0 Hz, 2H), 7.21 – 7.17 (m, 2H), 6.99 (d, J = 8.4 Hz, 1H), 6.85 (d, J = 15.6 
1H), 6.32 – 6.25 (m, 1H), 4.17 (q, J = 5.2 Hz, 4H), 3.85 (d, J = 7.2 Hz, 2H), 3.19 (s, 4H), 2.19 – 2.13 (m, 2H). 13C NMR 
(101 MHz, CD3OD) δ 153.09, 152.96, 152.52, 142.23, 140.82, 139.71, 136.95, 136.20, 135.79, 135.69, 135.52, 
133.39, 130.52, 128.60, 128.42, 127.89, 127.77, 123.11, 122.74, 120.88, 120.27, 118.82, 71.98, 71.95, 50.54, 
47.52, 40.11, 33.20. HRMS: calculated for C29H29N3O4S [M+H]
+: 516.19515; found: 516.19496. 
 
(E)-N-(2-((3-(4'-morpholino-[1,1'-biphenyl]-4-yl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 102 
Prepared according to the general procedure. Yield: 34.9 mg, 66.0 µmol, 16.5%. 1H NMR (400 MHz, CD3OD) δ 
9.65 (s, 1H), 8.82 (d, J = 6.4 Hz, 1H), 8.72 (br s, 1H), 8.64 (d, J = 7.6 Hz, 1H), 8.56 (d, J = 8.4 Hz, 1H), 7.96 (t, J = 8.0 
Hz, 1H), 7.61 (dd, J1 = 2.4 Hz, J2 = 9.2 Hz, 4H), 7.52 (d, J = 8.0 Hz, 2H), 7.16 (d, J = 8.8 Hz, 2H), 6.88 (d, J = 15.6 Hz, 
1H), 6.33 – 6.26 (m, 1H), 3.90 – 3.85 (m, 6H), 3.28 (t, J = 4.8 Hz, 4H), 3.21 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 
152.33, 150.64, 142.25, 140.47, 139.87, 137.01, 136.16, 136.05, 135.26, 134.65, 134.01, 130.51, 129.23, 128.67, 
128.48, 127.66, 121.13, 118.59, 118.00, 67.50, 51.39, 50.61, 47.55, 40.17. HRMS: calculated for C30H32N4O3S 
[M+H]+: 529.22679; found: 529.22648. 
 
(E)-N-(2-((3-(4''-ethoxy-[1,1':4',1''-terphenyl]-4-yl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 103 
Prepared according to the general procedure. Yield: 16.5 mg, 29.2 µmol, 7.3%. 1H NMR (400 MHz, (CD3)2OD) δ 
9.51 (s, 1H), 8.73 (d, J = 6.0 Hz, 1H), 8.73 (d, J = 7.6 Hz, 1H), 8.43 (d, J = 6.4 Hz, 1H), 8.38 (d, J = 7.6 Hz, 1H), 7.87 (t, 
J = 7.6 Hz, 1H), 7.78 – 7.69 (m, 6H), 7.65 (d, J = 8.4 Hz, 2H), 7.55 (d, J = 8.4 Hz, 2H), 7.03 (d, J = 8.4 Hz, 2H),  6.82 
(d, J = 16.0 Hz, 1H), 6.32 – 6.24 (m, 1H), 4.07 (q, J = 7.2 Hz, 2H), 3.77 (br s, 2H), 3.08 (t, J = 5.6 Hz, 2H), 3.03 (s, 2H), 
1.35 (t, J = 6.8 Hz, 3H). 13C NMR (101 MHz, (CD3)2OD) δ 158.33, 153.43, 144.64, 139.62, 139.09, 137.54, 136.49, 
134.51, 133.88, 133.77, 132.88, 131.66, 130.33, 128.73, 127.65, 127.25, 126.97, 126.63, 126.50, 119.59, 117.07, 
79 
114.91, 63.12, 48.40, 45.39, 38.67, 14.67. HRMS: calculated for C34H33N3O3S [M+H]




Prepared according to the general procedure. Yield: 15.8 mg, 28.8 µmol, 7.2%. 1H NMR (400 MHz, CD3OD) δ 9.44 
(s, 1H), 8.65 (br s, 1H), 8.59 (d, J = 6.0 Hz, 1H), 8.51 (dd, J1 = 1.2 Hz, J2 = 7.6 Hz, 1H), 8.43 (d, J = 8.4 Hz, 1H), 7.84 (t, 
J = 8.0 Hz, 1H), 7.61 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 7.2 Hz, 2H), 7.39 – 7.32 (m, 4H), 7.23 – 
7.20 (m, 2H), 6.99 (dd, J1 = 1.2 Hz, J2 = 7.6 Hz, 1H), 6.89 (d, J = 16.0 Hz, 1H), 6.35 – 6.27 (m, 1H), 5.14 (s, 2H), 3.86 
(d, J = 7.2 Hz, 2H), 3.18 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 160.72, 154.10, 144.38, 143.06, 142.74, 139.78, 
138.72, 135.94, 135.47, 135.29, 132.80, 131.00, 129.52, 128.90, 128.60, 128.44, 128.37, 127.95, 120.56, 119.32, 
118.99, 115.09, 114.62, 71.09, 50.56, 47.57, 40.12. HRMS: calculated for C33H31N3O3S [M+H]




Prepared according to the general procedure. Yield: 12.8 mg, 28.8 µmol, 7.2%. 1H NMR (400 MHz, CD3OD) δ 9.57 
(s, 1H), 9.14 (s, 1H), 8.77 (d, J = 8.4 Hz, 2H), 8.73 – 8.68 (m, 2H), 8.60 (d, J = 7.2 Hz, 1H), 8.53 (d, J = 8.4 Hz, 1H), 
8.05 (t, J = 6.4 Hz, 1H), 7.93 (t, J = 7.6 Hz, 1H), 7.83 (d, J = 8.4 Hz, 2H), 7.69 (d, J = 8.4 Hz, 2H), 6.95 (d, J = 15.6 Hz, 
1H), 6.47 – 6.39 (m, 1H), 3.90 (d, J = 7.2 Hz, 2H), 3.21 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 153.15, 143.40, 
142.89, 142.48, 142.25, 138.86, 135.46, 136.25, 135.92, 135.87, 135.78, 133.50, 129.11, 128.86, 128.67, 128.10, 
121.06, 120.34, 50.41, 47.73, 40.16. HRMS: calculated for C25H24N4O2S [M+H]
+: 445.16927; found: 445.16925. 
 
(E)-N-(2-((3-(4-(pyridin-4-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 106 
Prepared according to the general procedure. Yield: 28.8 mg, 64.8 µmol, 16.2%. 1H NMR (400 MHz, CD3OD) δ 
9.46 (s, 1H), 8.81 (s, 2H), 8.66 (s, 1H), 8.61 (d, J = 6.0 Hz, 1H), 8.53 (dd, J1 = 1.2 Hz, J2 = 7.2 Hz, 1H), 8.45 (d, J = 8.0 
Hz, 1H), 8.29 (d, J = 6.4 Hz, 2H), 7.97 (d, J = 8.4 Hz, 2H), 7.87 (t, J = 7.6 Hz, 1H), 7.72 (d, J = 8.4 Hz, 2H), 6.96 (d, J = 
16.0 Hz, 1H), 6.52 – 6.44 (m, 1H), 3.91 (d, J = 7.2 Hz, 2H), 3.23 – 3.18 (m, 4H). 13C NMR (101 MHz, CD3OD) δ 
156.88, 153.92, 144.39, 144.00, 140.17, 138.54, 136.34, 135.53, 135.49, 132.91, 129.44, 127.14, 124.90, 122.05, 
119.52, 50.32, 47.74, 40.12. HRMS: calculated for C25H24N4O2S [M+H]
+: 445.16927; found: 445.16901. 
 
(E)-N-(2-((3-(4-(6-methoxypyridin-3-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 107 
Prepared according to the general procedure. Yield: 28.7 mg, 60.4 µmol, 15.1%. 1H NMR (400 MHz, CD3OD) δ 
9.56 (s, 1H), 8.73 – 8.68 (m, 2H), 8.59 (dd, J1 = 1.2 Hz, J2 = 7.6 Hz, 1H), 8.52 (d, J = 8.0 Hz, 1H), 8.40 (d, J = 2.4 Hz, 
1H), 7.99 (dd, J1 = 2.8 Hz, J2 = 8.8 Hz, 1H), 7.93 (t, J = 8.0 Hz, 1H), 7.62 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.0 Hz, 2H), 
6.93 (s, 1H), 6.89 (d, J = 8.8 Hz, 1H), 6.37 – 6.29 (m, 1H), 3.96 (s, 3H), 3.87 (d, J = 7.2 Hz, 2H), 3.20 (s, 4H). 13C NMR 
(101 MHz, CD3OD) δ 165.17, 153.08, 145.41, 142.09, 139.59, 139.19, 139.15, 136.33, 136.04, 135.88, 135.77, 
133.51, 130.86, 130.64, 128.68, 127.76, 120.36, 119.25, 111.78, 54.40, 50.54, 47.59, 40.14. HRMS: calculated for 
C26H26N4O3S [M+H]





Prepared according to the general procedure. Yield: 25.5 mg, 55.2 µmol, 13.8%. 1H NMR (400 MHz, CD3OD) δ 
9.49 (s, 1H), 8.67 (br s, 1H), 8.62 (d, J = 5.6, 1H), 8.54 (dd, J1 = 0.8 Hz, J2 = 7.6 Hz, 1H), 8.47 (d, J = 8.0 Hz, 1H), 8.25 
(d, J = 5.2, 1H), 7.88 (t, J = 7.6 Hz, 1H), 7.80 (d, J = 8.0 Hz, 2H), 7.65 – 7.62 (m, 3H), 7.39 (s, 1H), 6.94 (d, J = 16.0 
Hz, 1H), 6.44 – 6.37 (m, 1H), 3.89 (d, J = 7.2 Hz, 2H), 3.22 – 3.16 (m, 4H). 13C NMR (101 MHz, CD3OD) δ 167.15, 
164.79, 155.21, 155.13, 153.86, 149.01, 148.87, 143.84, 139.06, 138.46, 135.15, 135.58, 135.49, 132.96, 128.84, 
128.65, 128.15, 120.66, 120.62, 107.97, 107.59, 50.41, 47.68, 40.12. HRMS: calculated for C25H23FN4O2S [M+H]
+: 
463.15985; found: 463.15927. 
 
(E)-N-(2-((3-(4-(pyrimidin-5-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 109 
Prepared according to the general procedure. Yield: 37.6 mg, 84.4 µmol, 21.1%. 1H NMR (400 MHz, CD3OD) δ 
9.54 (s, 1H), 9.14 (s, 1H), 9.09 (s, 2H), 8.69 (s, 2H), 8.58 (dd, J1 = 1.2 Hz, J2 = 7.2 Hz, 1H), 8.51 (d, J = 8.0 Hz, 1H), 
7.92 (t, J = 8.0 Hz, 1H), 7.76 (d, J = 8.4 Hz, 2H), 7.66 (d, J = 8.4 Hz, 2H), 6.94 (d, J = 16.0 Hz, 1H), 6.44 – 6.36 (m, 
1H), 3.89 (d, J = 7.2 Hz, 2H), 3.24 – 3.18 (m, 4H). 13C NMR (101 MHz, CD3OD) δ 158.02, 155.98, 153.31, 142.59, 
139.12, 135.75, 136.11, 135.80, 135.68, 135.49, 135.34, 133.36, 129.00, 128.55, 128.51, 120.48, 120.13, 50.43, 
47.68, 40.14. HRMS: calculated for C24H23N5O2S [M+H]
+: 446.16452; found: 446.16479. 
 
(E)-N-(2-((3-(4-(2-methoxypyrimidin-5-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 110 
Prepared according to the general procedure. Yield: 35.2 mg, 74.0 µmol, 18.5%. 1H NMR (400 MHz, CD3OD) δ 
9.56 (s, 1H), 8.85 (s, 2H), 8.70 (s, 2H), 8.58 (dd, J1 = 1.2 Hz, J2 = 7.2 Hz, 1H), 8.51 (d, J = 8.0 Hz, 1H), 7.92 (d, J = 8.0 
Hz, 1H), 7.67 (d, J = 8.4 Hz, 2H), 7.61 (d, J = 8.4 Hz, 2H), 6.92 (d, J = 15.6 Hz, 1H), 6.40 – 6.33 (m, 1H), 4.06 (s, 3H), 
3.88 (d, J = 7.6 Hz, 2H), 3.20 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 166.21, 158.53, 158.48, 153.31, 142.60, 139.35, 
136.84, 136.10, 135.81, 135.71, 133.35, 129.09, 128.89, 128.56, 127.91, 119.86, 55.69, 50.48, 47.65, 40.15. 
HRMS: calculated for C25H25N5O3S [M+H]
+: 476.17509; found: 476.17537. 
 
(E)-N-(2-((3-(4-(2-morpholinopyridin-3-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 111 
Prepared according to the general procedure. Yield: 26.7 mg, 50.4 µmol, 12.6%. 1H NMR (400 MHz, CD3OD) δ 
9.58 (s, 1H), 8.71 (s, 2H), 8.59 (dd, J1 = 1.2 Hz, J2 = 7.2 Hz, 1H), 8.52 (d, J = 8.4 Hz, 1H), 8.16 (dd, J1 = 1.6 Hz, J2 = 5.6 
Hz, 1H), 7.95 – 7.91 (m, 2H), 7.68 – 7.61 (m, 4H), 7.27 (dd, J1 = 6.0 Hz, J2 = 7.6 Hz, 1H), 6.93 (d, J = 16.0 Hz, 1H), 
6.44 – 6.36 (m, 1H), 3.89 (d, J = 7.2 Hz, 2H), 3.64 (t, J = 4.4 Hz, 4H), 3.23 – 3.18 (m, 8H). 13C NMR (101 MHz, 
CD3OD) δ 157.16, 153.30, 146.03, 142.57, 141.13, 139.11, 137.39, 136.12, 135.82, 135.71, 130.74, 129.51, 
128.88, 128.57, 120.44, 118.43, 66.95, 50.43, 50.33, 47.71, 40.15. HRMS: calculated for C29H31N5O3S [M+H]
+: 
530.22204; found: 530.22190. 
 
(E)-N-(2-((3-(4-(isoquinolin-3-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 112 
Prepared according to the general procedure. Yield: 41.9 mg, 84.8 µmol, 21.2%. 1H NMR (400 MHz, CD3OD) δ 
9.66 (s, 1H), 9.56 (d, J = 2.4 Hz, 1H), 9.25 (d, J = 2.0 Hz, 1H), 8.82 (d, J = 6.0 Hz, 1H), 8.78 (br s, 1H), 8.65 (dd, J1 = 
1.2 Hz, J2 = 7.6 Hz, 1H), 8.57 (d, J = 8.4 Hz, 1H), 8.31 (d, J = 8.0 Hz, 1H), 8.24 (d, J = 8.4 Hz, 1H), 8.08 (td, J1 = 1.2 Hz, 
J2 = 6.8 Hz, 1H), 7.98 (t, J = 7.6 Hz, 1H), 7.94 – 7.90 (m, 2H), 7.70 (d, J = 8.4 Hz, 2H), 6.95 (d, J = 16.0 Hz, 1H), 6.48 – 
81 
6.40 (m, 1H), 3.91 (d, J = 7.2 Hz, 2H), 3.23 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 152.28, 146.20, 142.24, 140.56, 
140.36, 138.92, 138.06, 137.09, 136.27, 136.18, 136.01, 135.39, 134.93, 134.01, 130.89, 130.50, 130.40, 129.26, 
129.12, 128.91, 128.79, 123.25, 121.23, 120.87, 50.43, 47.69, 40.16. HRMS: calculated for C29H26N4O2S [M+H]
+: 
495.18492; found: 495.18465. 
 
(E)-N-(2-((3-(4-(6-fluoropyridin-3-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 113 
Prepared according to the general procedure. Yield: 38.7 mg, 83.6 µmol, 20.9%. 1H NMR (400 MHz, CD3OD) δ 
9.67 (s, 1H), 8.84 (d, J = 6.4 Hz, 1H), 8.72 (br s, 1H), 8.65 (dd, J1 = 1.2 Hz, J2 = 7.6 Hz, 1H), 8.57 (d, J = 8.4 Hz, 1H), 
8.43 (d, J = 2.8 Hz, 1H), 7.16 (td, J1 = 2.4 Hz, J2 = 7.6 Hz, 1H), 7.98 (t, J = 7.6 Hz, 1H), 7.63 (d, J = 8.4 Hz, 2H), 7.58 (d, 
J = 8.4 Hz, 2H), 7.14 (dd, J1 = 2.4 Hz, J2 = 8.4 Hz, 1H), 6.90 (d, J = 16.0 Hz, 1H), 6.40 – 6.32 (m, 1H), 3.88 (d, J = 7.2 
Hz, 2H), 3.23 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 165.70, 163.33, 152.06, 146.39, 146.24, 141.58, 141.50, 
139.88, 139.27, 137.99, 137.28, 136.81, 136.24, 136.06, 135.71, 135.67, 134.15, 130.43, 129.39, 128.76, 128.35, 





Prepared according to the general procedure. Yield: 141.4 mg, 284.4 µmol, 71.1%. 1H NMR (400 MHz, CD3OD) δ 
9.49 (s, 1H), 8.74 (d, J = 6.8 Hz, 1H), 8.61 (d, J = 6.4 Hz, 1H), 8.55 (dd, J1 = 1.2 Hz, J2 = 7.2 Hz, 1H), 8.39 (d, J = 8.0 
Hz, 1H), 7.89 (s, 1H), 7.82 (t, J = 8.0 Hz, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.56 (s, 1H), 7.54 (s, 2H), 7.42 (d, J = 8.0 Hz, 
2H), 7.29 (dd, J1 = 1.2 Hz, J2 = 8.4 Hz, 1H), 6.80 (d, J = 16.0 Hz, 1H), 6.33 – 6.25 (m, 1H), 3.97 (s, 3H), 3.84 (d, J = 7.2 
Hz, 2H), 3.23 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 152.10, 142.44, 141.65, 140.46, 140.13, 139.41, 136.79, 
136.10, 135.92, 135.88, 135.72, 133.68, 133.48, 130.17, 128.96, 128.62, 128.37, 124.31, 122.36, 121.49, 120.89, 
119.19, 107.91, 50.51, 47.52, 40.09, 15.54. HRMS: calculated for C28H27N5O2S [M+H]




Prepared according to the general procedure. Yield: 91.3 mg, 175.6 µmol, 43.9%. 1H NMR (400 MHz, CD3OD) δ 
9.42 (s, 1H), 8.62 (s, 2H), 8.50 (dd, J1 = 0.8 Hz, J2 = 7.6 Hz, 1H), 8.39 (d, J = 8.0 Hz, 1H), 7.83 – 7.78 (m, 2H), 7.63 (t, 
J = 7.6 Hz, 4H), 7.57 – 7.53 (m, 3H), 7.51 – 7.47 (m, 2H), 7.45 – 7.41 (m, 2H), 7.33 (t, J = 7.2 Hz, 1H), 6.86 (d, J = 
16.0, 1H), 6.34 – 6.26 (m, 1H), 3.84 (d, J = 6.8 Hz, 2H), 3.18 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 153.65, 143.54, 
143.12, 142.69, 142.23, 142.12, 139.65, 135.92, 135.58, 135.52, 135.48, 132.97, 130.53, 130.45, 129.89, 128.50, 
128.40, 128.29, 128.14, 128.09, 127.32, 126.83, 126.54, 126.46, 119.65, 119.06, 50.52, 47.53, 40.09. HRMS: 
calculated for C32H29N3O2S [M+H]
+: 520.20532; found: 520.20502. 
 
(E)-N-(2-((3-(4-(1H-pyrazol-4-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 116 
Prepared according to the general procedure. Yield: 59.7 mg, 137.6 µmol, 34.4%. 1H NMR (400 MHz, CD3OD) δ 
9.66 (s, 1H), 8.87 (d, J = 6.8 Hz, 1H), 8.69 (d, J = 6.4 Hz, 1H), 8.65 (d, J = 7.2 Hz, 1H), 8.55 (d, J = 8.4 Hz, 1H), 8.00 (s, 
2H), 7.96 (t, J = 8.0 Hz, 1H), 7.54 (d, J = 8.0 Hz, 2H), 7.42 (d, J = 8.0 Hz, 2H), 6.81 (d, J = 15.6 Hz, 1H), 6.29 – 6.21 
(m, 1H), 3.84 (d, J = 7.2 Hz, 2H), 3.23 – 3.21 (m, 4H). 13C NMR (101 MHz, CD3OD) δ 151.69, 139.79, 139.34, 
82 
137.48, 136.30, 136.10, 134.85, 134.36, 132.18, 130.46, 130.30, 129.52, 128.50, 127.72, 126.73, 123.15, 121.59, 
118.30, 50.59, 46.20, 40.14. HRMS: calculated for C23H23N5O2S [M+H]
+: 434.16452; found: 434.16436. 
 
(E)-N-(2-((3-(4-(thiophen-2-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 117 
Prepared according to the general procedure. Yield: 11.9 mg, 26.4 µmol, 6.6%. 1H NMR (400 MHz, CD3OD) δ 9.49 
(s, 1H), 8.68 (d, J = 6.0 Hz, 1H), 8.63 (d, J = 6.0 Hz, 1H), 8.54 (dd, J1 = 1.2 Hz, J2 = 7.2 Hz, 1H), 8.48 (d, J = 8.0 Hz, 
1H), 7.88 (t, J = 7.6 Hz, 1H), 7.66 (dd, J1 = 2.0 Hz, J2 = 6.4 Hz, 2H), 7.50 (d, J = 8.0 Hz, 2H), 7.44 – 7.37 (m, 2H), 7.11 
(dd, J1 = 4.0 Hz, J2 = 5.2 Hz, 1H), 6.88 (d, J = 16.0 Hz, 1H), 6.34 – 6.26 (m, 1H), 3.86 (d, J = 7.2 Hz, 2H), 3.21 – 3.17 
(m, 4H). 13C NMR (101 MHz, CD3OD) δ 153.87, 143.85, 139.68, 136.36, 135.85, 135.61, 135.57, 133.01, 129.30, 
128.60, 128.16, 126.99, 126.38, 124.69, 119.58, 118.89, 50.57, 47.60, 40.15. HRMS: calculated for C24H23N3O2S2 
[M+H]+: 450.13044; found: 450.13040. 
 
(E)-N-(2-((3-(4-(benzo[b]thiophen-2-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 118 
Prepared according to the general procedure. Yield: 81.3 mg, 162.8 µmol, 40.7%. 1H NMR (400 MHz, CD3OD) δ 
9.51 (s, 1H), 8.73 (d, J = 6.0 Hz, 1H), 8.48 (s, 1H), 8.46 (d, J = 3.2 Hz, 1H), 8.40 (d, J = 7.2 Hz, 1H), 7.94 (d, J = 7.6 Hz, 
1H), 7.88 – 7.83 (m, 2H), 7.78 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 8.0 Hz, 2H), 7.40 – 7.32 (m, 2H), 6.80 (d, J = 16.0 Hz, 
1H),  6.35 – 6.27 (m, 1H), 3.74 (s, 2H), 3.12 (t, J = 5.6 Hz, 2H), 3.06 (d, J = 5.2 Hz, 2H). 13C NMR (101 MHz, CD3OD) δ 
153.32, 144.30, 142.75, 140.56, 138.75, 136.30, 135.66, 134.05, 133.97, 133.90, 133.59, 133.15, 130.58, 128.83, 
127.50, 126.68, 126.49, 124.98, 124.93, 123.92, 122.53, 120.45, 120.28, 117.41, 48.44, 45.54, 38.76. HRMS: 
calculated for C28H25N3O2S2 [M+H]
+: 500.14610; found: 500.14564. 
 
(E)-N-(2-((3-(4-(1H-indol-2-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 119 
Prepared according to the general procedure. Yield: 51.3 mg,  106.4 µmol, 26.6%. 1H NMR (400 MHz, CD3OD) δ 
9.43 (s, 1H), 8.66 (d, J = 6.0 Hz, 1H), 8.62 (d, J = 6.4 Hz, 1H), 8.51 (dd, J1 = 1.2 Hz, J2 = 7.6 Hz, 1H), 8.38 (d, J = 8.0 
Hz, 1H), 7.81 (d, J = 7.6 Hz, 1H), 7.73 (d, J = 8.4 Hz, 2H), 7.50 (d, J = 8.0 Hz, 1H), 7.46 (d, J = 6.4 Hz, 2H), 7.37 (d, J = 
8.0 Hz, 1H), 7.08 (t, J = 8.0 Hz, 1H), 6.98 (t, J = 8.0 Hz, 1H), 6.79 (d, J = 16.0 Hz, 1H), 6.28 – 6.21 (m, 1H), 3.78 (d, J = 
6.8 Hz, 2H), 3.15 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 153.05, 142.27, 139.63, 138.95, 138.44, 136.07, 135.70, 
135.58, 134.44, 133.28, 130.42, 128.46, 126.26, 123.04, 121.27, 120.64, 120.14, 118.65, 112.16, 50.52, 47.48, 
40.07. HRMS: calculated for C28H26N4O2S [M+H]
+: 483.18492; found: 483.18492. 
 
(E)-N-(2-((3-(4-(quinoxalin-6-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 120 
Prepared according to the general procedure. Yield: 134.4 mg, 271.2 µmol, 67.8%. 1H NMR (400 MHz, CD3OD) δ 
9.63 (s, 1H), 8.83 – 8.77 (m, 3H), 8.70 (d, J = 6.4 Hz, 1H), 8.63 (dd, J1 = 1.2 Hz, J2 = 7.2 Hz, 1H), 8.53 (d, J = 8.4 Hz, 
1H), 8.17 (s, 1H), 8.05 (s, 2H), 7.96 (t, J = 8.0 Hz, 1H), 7.71 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 
16.0 Hz, 1H), 6.40 – 6.32 (m, 1H), 3.89 (d, J = 7.2 Hz, 2H), 3.25 (s, 4H). 13C NMR (101 MHz, CD3OD) δ 151.90, 
146.93, 146.27, 143.95, 143.34, 143.16, 140.45, 139.71, 139.24, 137.28, 136.93, 136.19, 136.00, 134.10, 130.67, 
130.49, 130.30, 129.37, 127.73, 128.68, 127.06, 121.3,7, 119.97, 50.49, 47.62, 40.16. HRMS: calculated for 
C28H25N5O2S [M+H]




Prepared according to the general procedure. Yield: 44.7 mg, 89.2 µmol, 22.3%. 1H NMR (400 MHz, CD3OD) δ 
9.44 (s, 1H), 8.66 (s, 1H), 8.59 (d, J = 4.0 Hz, 1H), 8.52 (d, J = 4.8 Hz, 1H), 8.43 (d, J = 5.2 Hz, 1H), 7.85 (t, J = 5.2 Hz, 
1H), 7.80 (d, J = 5.6 Hz, 2H), 7.54 (d, J = 5.6 Hz, 2H), 7.34 (dd, J1 = 3.2 Hz, J2 = 6.0 Hz, 1H), 7.19 (dd, J1 = 2.0 Hz, J2 = 
6.8 Hz, 1H), 6.90 – 6.83 (m, 2H), 6.34 – 6.29 (m, 1H), 3.87 (d, J = 4.8 Hz, 2H), 3.20 – 3.16 (m, 4H). 13C NMR (101 
MHz, CD3OD) δ 160.13, 158.59, 154.14, 144.45, 140.38, 139.74, 135.89, 135.62, 135.47, 135.43, 135.28, 134.35, 
132.79, 130.73, 130.66, 128.54, 127.94, 126.48, 119.302, 118.89, 112.91, 112.84, 111.17, 111.00, 105.64, 105.48, 
50.58, 47.58, 40.13. HRMS: calculated for C28H25FN4O2S [M+H]
+: 501.17550; found: 501.17577. 
 
(E)-N-(2-((3-(4-(2-(trifluoromethyl)pyridin-4-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 122 
Prepared according to the general procedure. Yield: 53.3 mg, 104.0 µmol, 26.0%. 1H NMR (400 MHz, CD3OD) δ 
9.50 (s, 1H), 8.75 (d, J = 3.2 Hz, 1H), 8.68 (s, 1H), 8.64 (d, J = 4.0 Hz, 1H), 8.54 (d, J = 4.8 Hz, 1H), 8.48 (d, J = 5.6 Hz, 
1H), 8.09 (s, 1H), 7.96 (d, J = 3.2 Hz, 1H), 7.89 (t, J = 5.2 Hz, 1H), 7.85 (d, J = 5.6 Hz, 2H), 7.67 (d, J = 5.6 Hz, 2H), 
6.95 (d, J = 10.4 Hz, 1H), 6.44 – 6.39 (m, 1H), 3.89 (d, J = 4.8 Hz, 2H), 3.22 – 3.18 (m, 4H). 13C NMR (101 MHz, 
CD3OD) δ 153.77, 151.73, 151.22, 149.71 (q, J = 23.23 Hz), 143.63, 139.03, 138.60, 138.00, 135.63, 135.55, 
133.05, 130.71, 128.97, 128.74, 128.22, 125.53, 123.10 (q, J = 182.81 Hz), 120.86, 119.70, 119.28, 118.24, 50.42, 
47.71, 40.14. HRMS: calculated for C26H23F3N4O2S [M+H]
+: 513.15666; found: 513.15610. 
 
(E)-N-(2-((3-(4-(imidazo[1,2-a]pyridin-7-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide 123 
Prepared according to the general procedure. Yield: 43.9 mg, 90.8 µmol, 22.7%. 1H NMR (400 MHz, CD3OD) δ 
9.51 (s, 1H), 9.14 (s, 1H), 8.68 (s, 1H), 8.65 (d, J = 4.0 Hz, 1H), 8.56 (dd, J1 = 0.8 Hz, J2 = 5.2 Hz, 1H), 8.48 (d, J = 5.6 
Hz, 1H), 8.31 (dd, J1 = 1.2 Hz, J2 = 6.0 Hz, 1H), 8.08 (d, J = 1.2 Hz, 1H), 8.02 (d, J = 6.4 Hz, 1H), 7.90 (t, J = 4.8 Hz, 
1H), 7.79 (d, J = 5.6 Hz, 2H), 7.68 (d, J = 5.6 Hz, 1H), 6.95 (d, J = 10.4 Hz, 1H), 6.44 – 6.39 (m, 1H), 3.89 (d, J = 4.8 
Hz, 2H), 3.23 – 3.18 (m, 4H). 13C NMR (101 MHz, CD3OD) δ 153.62, 143.32, 140.69, 139.00, 137.81, 136.44, 
135.79, 135.67, 135.60, 134.80, 133.15, 132.17, 130.67, 129.02, 128.73, 128.32, 127.41, 124.25, 120.63, 119.84, 
117.12, 113.27, 50.43, 47.70, 40.14. HRMS: calculated for C27H25N5O2S [M+H]
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Protein kinase B (PKB/AKT) is an essential factor in the phosphatidylinositol-3-kinase 
(PI3K)-PKB signaling pathway. This pathway is altered in many human cancers, to inlcude 
breast, colorectal, ovarian
1
 and prostate cancers
2
, and aberrant activation of the PI3K-PKB 
pathway promotes cell growth and survival, invasion, metastasis and angiogenesis in these 
tumors. PKB/AKT also plays an important role in diabetes
3
 and intracellular bacterial 
infections
4
, underscoring its relevance as a target for clinical drug development. 
Most cells express three isoforms of PKB/AKT, namely, AKT1, AKT2 and AKT3.
5
 Genetic 
deletion of both AKT1 and AKT2 in mice is lethal, whereas elimination of only AKT1 
4 
86 
appeared to have no detrimental effect on the development and health of the thus 
genetically modified mice.
6
 Given the importance of PKB/AKT activation in cancer and 
other diseases, several studies have been conducted in the past that aimed to develop 
active and selective PKB/AKT1 inhibitors.
7
 Kuijl et al.
4
 have, for instance, revealed that the 
isoquinoline derivative, H-89 (3), which was originally identified as an inhibitor of protein 
kinase A (PKA),
8
 inhibited AKT1 quite efficiently.
9 
Following the discovery that H-89 inhibits AKT1, a systematic library of H-89 analogues (1 
– 239)
10
 was synthesized with the aim to identify inhibitors selective for AKT1 over both 
AKT2 and PKA. In this ligand-based drug discovery approach, focused libraries were 
assembled based on H-89 as a lead structure and by varying the linker in length and distal 
phenyl ring as well as by modifying the styrene moiety, while keeping the isoquinoline 
moiety intact (Figure 1). This isoquinoline moiety was kept intact, since co-crystallisation 
studies of isoquinoline sulfonamides (H-series) complexed with PKA, which shares a close 
sequence (± 68%) homology in the kinase domain and within the adenine binding site 
itself only three residues differ between AKT2 and PKA, revealed that a single hydrogen 
bond is formed between the heteroaromatic nitrogen of the isoquinoline and a backbone 
amide on the kinase hinge (Val123 in PKA), an interaction that is highly conserved in 
kinase-inhibitor recognition.
11,12,13
 With the aim to establish their selectivity, H-89 and 
selected members of the focused library that were found to be effective AKT1 inhibitors 
were tested in a commercial kinase-panel screen (Kinomescan)
14
, in which their inhibitory 
activity at 10 micromolar against 100+ kinases was assessed (see Chapter 2). One of these 
H-89 analogues that contains a bulky naphthalene group instead of a bromide, namely 
compound 195 proved to inhibit, next to AKT1, also FMS-like tyrosine kinase 3 (FLT3)
15
, 
which is an interesting drug target in its own right (see Chapter 3). FLT3 is a membrane-
bound receptor tyrosine kinase expressed on hematopoietic cells. Upon binding to the 
FLT3 ligand, the activated receptor triggers both Ras/Raf and PI3K-PKB pathways resulting 
in cell proliferation and inhibition of apoptosis.
16,17 FLT3 mutations have been found in 
acute lymphoblastic leukemia (ALL)
18
 and acute myeloid leukemia (AML)
19
 patients. FLT3 
inhibitors are currently in clinical trials for the treatment of ALL and AML patients. 
Moreover, inhibitors that target at the same time both AKT1 and FLT3 may act in a 
synergistic fashion, since both AKT1 and FLT3 activate the PI3K-PKB pathway. 
87 
Figure 1. H-89-based libraries. A) H-89 (3) was modified by varying the linker length (A) or at the styrene moiety 
(B – E). B) FLT3 lead compound 195 was modified at the bulky naphthalene side (F – H) or it was displaced by 
thiophene or pyrrole containing moieties (I – K).   
 
Based on the interest in AKT1 inhibitors, FLT3 inhibitors as well as the potential of dual 
active inhibitors targeting both kinases, a study was initiated in which focused libraries 
were synthesized based on lead structure 195. Synthesis details on these compounds are 
given in the preceding chapter. This chapter describes the inhibitor activities towards PKA, 
AKT1, AKT2 and FLT3 of the full set of isoquinolinesulfonamide derivatives prepared over 
the years – both those whose synthesis was described previously and the set of  
88 
Figure 2. TR-FRET kinase assay. A) In presence of ATP, Ser/Thr kinase AKT1 phosphorylates the acceptor dye-
labeled substrate, which is a ULight-labeled peptide containing residues surrounding Ser235 and Ser236 of 
human 40S ribosomal protein S6 (ULight Ser236 rpS6). The phosphorylated Ser236 will be bound by Eu-chelate 
donor dye containing rabbit monoclonal antibody. Upon irradiation at 320 nm, a FRET signal will be transferred 
from the Eu chelate to the ULight fluorophore, which, in turn, generates a light signal at 665 nm. B) In case of 
addition of an AKT1 inhibitor (e.g. H-89, 3) to AKT1, phosphorylation of Ulight-substrate is (partially) blocked, 
with (partial) abolishment of the FRET signal as the result. 
 
compounds described in Chapter 2. The inhibitor activities are all determined using 




This assay is illustrated in Figure 2, in which AKT1 has been taken as the example 
kinase. A synthetic ULight-labeled peptide containing residues surrounding Ser235 
and Ser236 of human 40S ribosomal protein S6 (ULight Ser236 rpS6) has been used 
as the acceptor-fluorophore substrate for the Ser/Thr kinases PKA, AKT1 and AKT2. 
By adding this substrate to a Ser/Thr kinase, the kinase recognizes and in turn 
phosphorylates amino acid Ser236 in the presence of ATP. Subsequently, the 
phosphorylated Ser235 will be recognized by the europium chelate donor dye 
89 
containing rabbit monoclonal antibody. The binding of this antibody to the ULight-
labeled substrate brings donor and acceptor dyes into close proximity, which leads 
to energy transfer for the Eu donor to the ULight acceptor after irradiation of the 
kinase reaction at 320 nm. The generated light at 665 nm is measured and the 
intensity of the light emission is proportional to the level of ULight-substrate 
phosphorylation, which is a measure of kinase activity (Figure 2A). 
Figure 2B describes the situation wherein an inhibitor (for instance, H-89) is 
present. In this situation, AKT1 is not able to phosphorylate Ser236 of the ULight-
containing peptide, which in turn will not be recognized by the Eu-containing 
antibody. As a result, no FRET signal will be generated. A similar assay was used to 
determine FLT3 inhibitory activities. However, in that case, a tyrosine containing 
ULight peptide (ULight-TK peptide) and an europium-labeled anti-phospho-tyrosine 
antibody were used instead. 
 
 
In total, the inhibitor activities of 239 isoquinolinesulfonamides were determined. 
All structures feature the same isoquinoline moiety (left hand part of the structure 
of the lead compound, H-89) and vary in the nature of the spacer (length, 
substitution, saturation) and/or the aryl moiety that makes up the right hand part 
of the molecules (para-bromobenzene in H-89). H-89 (3 in Figure 1) and its 238 
analogues were comparatively investigated with respect to their ability to inhibit 
the Ser/Thr kinases PKA, AKT1 and AKT2 and the Tyr kinase FLT3. In the first 
instance, relative inhibition percentages of the four kinases were measured at 2 M 
final concentrations of each compound. These numbers are given in Figures 3-11, in 
which the isoquinoline derivatives are grouped around common themes (linker 
substitutions, nature and regiochemistry of substituted phenyls, etc.). Following 
these studies, the most effective AKT1 inhibitors (both in terms of activity and 
selectivity) were selected and inhibition constants were determined. These 
numbers are given in Table 1 and the chapter will end with a structure-activity 
relationship evaluation of the data, with a projection on the use of the most 
promising compounds as either AKT1 inhibitors or FLT3 inhibitors. All inhibition 







Unsubstituted alkene series 
 
The eight analogues of H-89 (3), in which the bromide group is substituted with 
other halogens, alkyl or phenolic groups, were evaluated and compared to 3 in the 

















Figure 3. Unsubstituted alkene. Relative remaining activity (%) towards PKA, PKB/AKT1, PKB/AKT2 and 
FLT3 in an in vitro kinase reaction in the absence or presence of 2 µM compound. Relative remaining 
activity ranges from 0 – 25%, 25 – 50%, 50 – 75%, > 75% are in bold and underlined, bold, italics and 
normal, respectively. Results are normalized to the activity detected in the absence of any compound, 
containing DMSO only, from n = 3 experiments performed. Negative control: absence of ATP. Positive 
control: 2 µM commercial H-89. 
 
Based on the results of Figure 3, substitution of the bromide group with other 
halogens or other small groups does not improve the relative activity towards all 
the four different kinases when compared to H-89 (3).  
In fact and excepting compound 8 in all cases this substitution led to less potent 
inhibition. Compound 8 showed to be two times more active against FLT3 than 







Alkylated alkene series 
 
The relative remaining enzymatic activity towards PKA, AKT1, AKT2 and FLT3 of a 
set of compounds with methyl (10 – 24), ethyl (25 – 39) or isopropyl (40 – 55) 
substitution at the double bond and with replacement of the bromide group were 
determined (Figure 4 – 6 respectively). In the synthesis of these compounds (see 
the preceding chapter) it was observed that E/Z stereoisomers with respect to the 
alkene configuration could not always be separated. Accordingly, where possible 
pure E and Z isomers were evaluated and otherwise E/Z mixtures were put to the 
test. 
Figure 4. Methylated alkene. Relative remaining activity (%) towards PKA, PKB/AKT1, PKB/AKT2 and 
FLT3 in an in vitro kinase reaction in the absence or presence of 2 µM compound. Relative remaining 
activity ranges from 0 – 25%, 25 – 50%, 50 – 75%, > 75% are in bold and underlined, bold, italics and 
normal, respectively. Results are normalized to the activity detected in the absence of any compound, 
containing DMSO only, from n = 3 experiments performed. Negative control: absence of ATP. Positive 








Figure 5. Ethylated alkene. Relative remaining activity (%) towards PKA, PKB/AKT1, PKB/AKT2 and FLT3 
in an in vitro kinase reaction in the absence or presence of 2 µM compound. Relative remaining activity 
ranges from 0 – 25%, 25 – 50%, 50 – 75%, > 75% are in bold and underlined, bold, italics and normal, 
respectively. Results are normalized to the activity detected in the absence of any compound, containing 


















Figure 6. Isopropylated alkene. Relative remaining activity (%) towards PKA, PKB/AKT1, PKB/AKT2 and 
FLT3 in an in vitro kinase reaction in the absence or presence of 2 µM compound. Relative remaining 
activity ranges from 0 – 25%, 25 – 50%, 50 – 75%, > 75% are in bold and underlined, bold, italics and 
normal, respectively. Results are normalized to the activity detected in the absence of any compound, 
containing DMSO only, from n = 3 experiments performed. Negative control: absence of ATP. Positive 
control: 2 µM commercial H-89. 
 
The results that are given in Figure 4 – 6 show that addition of an alkyl group to the 
double bond does not improve the inhibition potency towards PKA, AKT1, AKT2 or 
FLT3 remarkably. Also the influence of the E or Z confirmation appeared to be 
negligible. An exception can be made for compound 44, which showed to be twice 
as active against FLT3 as its lead compound 195 and it is remarkable that the E 
compound is five times more active that its corresponding Z isomer.  
 
Ortho/meta/para-phenyl sulphonamide series 
 
To obtain more insight into the size and electronics of the pocket that 
accommodates the distal phenyl ring of H-89 (3), this aryl ring has been 
systematically modified by introducing various large substituents, including bulky 
aromatic and/or hetero-aromatic groups at the ortho (56 – 112), meta (113 – 169) 








Figure 7. Ortho-phenyl sulphonamide inhibitors. Relative remaining activity (%) towards purified PKA, 
PKB/AKT1, PKB/AKT2 and FLT3 in an in vitro kinase reaction in the absence or presence of 2 µM 
compound. Relative remaining activity ranges from 0 – 25%, 25 – 50%, 50 – 75%, > 75% are in bold and 
underlined, bold, italics and normal, respectively. Results are normalized to the activity detected in the 
absence of any compound, containing DMSO only, from n = 3 experiments performed. Negative control: 















Figure 8. Meta-phenyl sulphonamide inhibitors. Relative remaining activity (%) towards PKA, PKB/AKT1, 
PKB/AKT2 and FLT3 in an in vitro kinase reaction in the absence or presence of 2 µM compound. Relative 
remaining activity ranges from 0 – 25%, 25 – 50%, 50 – 75%, > 75% are in bold and underlined, bold, 
italics and normal, respectively. Results are normalized to the activity detected in the absence of any 
compound, containing DMSO only, from n = 3 experiments performed. Negative control: absence of ATP. 



















Figure 9. Para-phenyl sulphonamide inhibitors of first (A) and second (B) generation library. Relative 
remaining activity (%) towards PKA, PKB/AKT1, PKB/AKT2 and FLT3 in an in vitro kinase reaction in the 
absence or presence of 2 µM compound. Relative remaining activity ranges from 0 – 25%, 25 – 50%, 50 – 
75%, > 75% are in bold and underlined, bold, italics and normal, respectively. Results are normalized to 
the activity detected in the absence of any compound, containing DMSO only, from n = 3 experiments 
performed. Negative control: absence of ATP. Positive control: 2 µM commercial H-89. 
 
It can be seen from Figure 7 - 9 that the compounds having a functional group at 
the meta position have the least activity against the kinases PKA, AKT1, and AKT2 
when compared to its corresponding ortho and para analogues. Analogues having 
an aromatic group at the ortho position appear to have the most activity for AKT1 
and AKT2. Of note, all compounds are poor PKA inhibitors. This indicates that 
substitution of the bromide in H-89 (3) for an aromatic moiety is detrimental for 
PKA/AKT1/AKT2 inhibition. In addition, bulky aromatic groups at the para position 
result in active inhibitors against FLT3. Compounds with nitrogen-containing 
aromatic rings at the para position are amongst the most active FLT3 inhibitors. 
100 
Introduction of functional groups at the ortho position seems to be least favourable 
for gaining active FLT3 inhibitors. Finally, a few activators for FLT3 has been 
observed, namely compounds 198, 202, 208, 209 and 224.   
 
Linker length alteration 
 
The linker length has been altered and the double bond has been excluded in 
compounds 230 – 236 (Figure 10). This will give information about the importance 












Figure 10. Variation in linker length. Relative remaining activity (%) towards PKA, PKB/AKT1, PKB/AKT2 
and FLT3 in an in vitro kinase reaction in the absence or presence of 2 µM compound. Relative remaining 
activity ranges from 0 – 25%, 25 – 50%, 50 – 75%, > 75% are in bold and underlined, bold, italics and 
normal, respectively. Results are normalized to the activity detected in the absence of any compound, 
containing DMSO only, from n = 3 experiments performed. Negative control: absence of ATP. Positive 
control: 2 µM commercial H-89. 
 
Figure 10 shows that changes in linker length and double bond have drastic 
influence on the activity towards the four different kinases. The linker length in H-
89 (3) appears to be optimal and the double bond, which leads to rigidity in the 








Boc protected analogues 
 
The amine group in compounds 237 – 239 have been protected by a Boc group 
(Figure 11). According to the relative activities given in Figure 11, it seems that the 
amine functionality needs to be unprotected and or the bulky Boc-group seems to 
give steric hindrance with the active site. Thus a free amine contributes to the 
inhibition towards PKA, AKT1, AKT2 and FLT3.  
 
Figure 11. Boc protected isoquinoline sulfonamide analogues. Relative remaining activity (%) towards 
PKA, PKB/AKT1, PKB/AKT2 and FLT3 in an in vitro kinase reaction in the absence or presence of 2 µM 
compound. Relative remaining activity ranges from 0 – 25%, 25 – 50%, 50 – 75%, > 75% are in bold and 
underlined, bold, italics and normal, respectively. Results are normalized to the activity detected in the 
absence of any compound, containing DMSO only, from n = 3 experiments performed. Negative control: 
absence of ATP. Positive control: 2 µM commercial H-89. 
 
 
Ki and IC50 values of selected compounds 
 
An estimation of the activities of the 239 inhibitors has been made by determining 
the relative activities towards PKA, AKT1, AKT2 and FLT3. However, to compare the 
activity and the selectivity between these compounds, it is necessary to determine 
their Ki values. Ki values were only determined for potential active and selective 
compounds, that is to say, only compounds showing > 50% inhibitory activity 










Table 1. Inhibition constant (Ki) values in µM of H-89 analogues. The mean Ki values are calculated 
using the Cheng-Prusoff equation from the IC50 values from n = 3 experiments performed. The 
conditions are: KM = 10.35, 207.8 and 0.82 µM for AKT1, AKT2 and PKA respectively and [ATP] was 100 
µM. 
Compound AKT1 AKT2 PKA 
24 0.06 ± 0.01 1.40 ± 0.26 0.04 ± 0.01 
9 0.08 ± 0.01 1.28 ± 0.21 0.05 ± 0.01 
38 0.09 ± 0.02 2.17 ± 0.55 0.46 ± 0.30 
23 0.10 ± 0.03 1.76 ± 0.48 0.07 ± 0.01 
68 0.09 ± 0.01 1.30 ± 0.21 0.28 ± 0.12 
62 0.08 ± 0.02 1.19 ± 0.33 > 0.16 
3 0.11 ± 0.02 2.25 ± 0.37 0.02 ± 0.00 
96 0.07 ± 0.01 0.78 ± 0.16 0.20 ± 0.09 
61 0.07 ± 0.02 1.34 ± 0.30 > 0.16 
65 0.10 ± 0.01 1.86 ± 0.30 0.17 ± 0.06 
56 0.17 ± 0.05 2.63 ± 0.63 0.20 ± 0.09 
4 0.17 ± 0.04 3.40 ± 0.87 - 
60 0.19 ± 0.03 2.87 ± 0.59 - 
58 0.14 ± 0.03 2.16 ± 0.26 - 
3 (H-89) 0.09 ± 0.01 1.67 ± 0.26 0.02 ± 0.01 
236 0.13 ± 0.02 2.22 ± 0.34 0.02 ± 0.01 
59 0.12 ± 0.02 1.74 ± 0.40 - 
191 0.10 ± 0.01 1.64 ± 0.33 0.02 ± 0.01 
218 0.08 ± 0.01 1.22 ± 0.19 0.01 ± 0.00 
66 0.14 ± 0.03 1.76 ± 0.30 - 
64 0.13 ± 0.02 2.12 ± 0.41 - 
63 0.08 ± 0.02 1.17 ± 0.21 0.18 ± 0.04 
103 0.06 ± 0.01 1.13 ± 0.19 0.36 ± 0.20 
15 0.08 ± 0.01 2.22 ± 0.36 0.03 ± 0.01 
89 0.05 ± 0.01 1.12 ± 0.23 > 0.16 
54 0.19 ± 0.05 5.34 ± 0.96 0.10 ± 0.02 
72 0.09 ± 0.01 1.51 ± 0.42 0.26 ± 0.14 
67 0.11 ± 0.02 2.12 ± 0.35 - 
55 0.13 ± 0.02 3.88 ± 0.65 - 
29 0.09 ± 0.01 2.63 ± 0.37 - 
16 0.09 ± 0.01 2.19 ± 0.23 0.04 ± 0.02 
53 0.16 ± 0.02 3.74 ± 0.83 - 
30 0.16 ± 0.04 4.42 ± 1.30  
45 0.08 ± 0.01 2.32 ± 0.36 0.04 ± 0.01 
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106 0.13 ± 0.01 1.64 ± 0.29 - 
46 0.09 ± 0.02 2.13 ± 0.39 - 
12 0.13 ± 0.01 6.15 ± 4.18 - 
101 0.17 ± 0.03 2.76 ± 0.49 - 
6 0.12 ± 0.02 1.91 ± 0.26 - 
90 0.10 ± 0.01 1.72 ± 0.22 - 
34 0.14 ± 0.02 3.11 ± 0.54 - 
74 0.35 ± 0.10 7.93 ± 2.52 0.08 ± 0.02 
39 0.15 ± 0.03 2.97 ± 1.34 - 
2 0.14 ± 0.05 6.41 ± 1.77 - 
27 0.33 ± 0.07 6.34 ± 1.43 - 
31 0.22 ± 0.06 5.55 ± 1.54 - 
45 0.47 ± 0.18 9.25 ± 2.55 - 
57 0.41 ± 0.13 7.05 ± 2.49 - 
76 0.36 ± 0.10 6.74 ± 2.31 - 
190 0.10 ± 0.04 0.97 ± 0.13 0.04 ± 0.01 
99 0.55 ± 0.30 - - 
224 0.42 ± 0.07 1.71 ± 0.43 0.05 ± 0.01 
13 0.24 ± 0.10 20.42 ± 12.91 - 
97 0.69 ± 0.22 12.25 ± 2.63 - 
77 0.95 ± 0.27 14.97 ± 7.08 - 
69 0.74 ± 0.24 8.47 ± 2.04 - 
109 0.38 ± 0.06 5.04 ± 1.46 - 
95 0.25 ± 0.04 5.37 ± 1.47 - 
94 0.23 ± 0.03 3.03 ± 0.73 - 
130 0.73 ± 0.08 6.61 ± 1.56 - 
209 0.72 ± 0.18 1.47 ± 0.29 0.05 ± 0.01 
199 3.10 ± 2.04 - - 
44 0.10 ± 0.02 1.92 ± 0.39 - 
 
Based on the results shown in Table 1, a selection of most active AKT1 inhibitors 
has been made (Figure 12). These compounds (24, 61, 89, 96 and 103) showed to 
have a significantly lower Ki value, which varies between 1.3 – 1.8 times more 
activity, than the lead compound H-89 (3). 
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Figure 12. Selection of AKT1 inhibitors, which are more active than lead compound H-89 (3) based on 
their Ki values. 
 
The ortho-phenyl substituted compounds are the most active inhibitors towards 
AKT1 in this library (Figure 10). It appears that bulky and electron-donating groups 
are favoured in the active site of AKT1. In addition, methyl-alkene derivatives 
appear to be more active AKT1 inhibitors compared to their non-substituted (at the 
alkene) counterparts. In general, the E configuration is preferred over the Z 
configuration.  
 
Figure 13. Selection of AKT2 inhibitors, which are more active than lead compound H-89 (3) based on 
their Ki values.  
 
The six compounds (62, 63, 89, 96, 103 and 190) that are shown in Figure 13 are the 
most active AKT2 inhibitors found in this library. They are all significant more active 
than H-89 (3) showing an increase varying from 1.5 – 2.1 times. Based on these 
structures it can be seen that bulky, electron negative containing phenyl groups 
which are on the ortho position are preferred in the active site of AKT2. Compound 
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190 is the only compound in the top six having an aromatic group on the para 






Figure 14. Selection of PKA inhibitors, which are more active than lead compound H-89 (3) based on 
their Ki values. 
 
The lead compound H-89 (3) is already a potent PKA inhibitor, and it is therefore 
not surprising (also given that optimization was conducted towards AKT1, and not 
PKA) that stronger PKA inhibitors are scarce in the evaluated series of compounds. 
In fact, only compound 218 (Figure 14) showed a significant lower Ki value than lead 
compound H-89 (3). According to the results presented in Table 1, the most active 
PKA inhibitors are all containing a functional group at the para position, for 
instance, compound 191 (Figure 14). This is perhaps not surprising since the lead 
compound H-89 (3), which is a PKA inhibitor, contains a bromide on the para 
position.  
Both AKT1 and AKT2 prefer roughly the same compounds (compounds 89, 96 and 
103). Since inhibition of AKT2 is lethal in mice, it is important to find active and 
selective compounds towards AKT1. In Figure 15 the three most selective AKT1 over 
AKT2 compounds are shown. 
Figure 15. Most selective AKT1 over AKT2 inhibitors based on their Ki values difference.  
 
It appears that a methyl substituent at the linker alkene contributes to AKT1 
selectivity over AKT2. Next to this, introduction of a para-halogen at the phenyl ring 
appears to improve the selectivity of AKT1 over AKT2. Compared to the selectivity 
of the lead compound H-89 (3), which is 18 times more selective for AKT1 over 
AKT2, these compounds showed to have at least twice as selective as their lead 
compound. As can be seen in Figure 16, the most selective AKT1 over PKA inhibitors 
prefer to contain aromatic groups having oxygen or nitrogen groups at an ortho 
position.  
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Figure 16. The most selective AKT1 over PKA inhibitors based on their Ki values difference.  
 
Since FLT3 plays a role in the same pathway as AKT1, IC50 values of a few 
compounds showing a lower relative activity value than the FLT3 lead compound 
195 and other relevant compounds have been determined (Table 2). This Table 
shows the importance of the position at which the aryl side is substituted. When 
comparing compounds 101, 158 and 218, which all contain an isoquinoline group at 
the ortho, meta or para position respectively, it becomes evident that the 
compound having a para-isoquinoline group (218) is more than 40 times more 
active than the ortho and meta analogues (101 and 158).  
 
 Table 2. IC50 values of selected isoquinolinesulfonamide compounds for FLT3. 
Compound IC50 (nM) Compound IC50 (nM) 
101 3500 ± 3043 215 42.5 ± 15.3 
158 715.5 ± 66.1 216 202.8 ± 73.6 
195 290.7 ± 92.2 218 15.4 ± 1.4 
211 17.8 ± 7.2 222 28.0 ± 10.3 
 
Figure 17 shows the structures of the most active FLT3 compounds based on their 
IC50 values. These compounds are 5x or more active than 195 and it seemed that 
bulky, nitrogen containing aromatic groups at the para position leads to more 
inhibition of FLT3.  
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This chapter describes the biological evaluation of 239 H-89-based compounds 1 – 
239. Evaluation of these compounds reveal that the structure-activity relationship 
(SAR) of AKT1 inhibition favours a hetero-aromatic group at the ortho position, 
which gives a more active AKT1 inhibitor and a more selective AKT1 over PKA 
inhibitor. The most active AKT1 inhibitor in this study is compound 89, which has a 
benzofuran group at the ortho position, and the most selective AKT1 over PKA 
inhibitor is compound 103, which has a methyl indazole group at the ortho position. 
Substitution of the double bond with a methyl or isopropyl group gives a more 
selective AKT1 over AKT2 inhibitor. This finding is applicable on the most selective 
AKT1 over AKT2 inhibitor 13, which has a methyl group at the double bond. These 
results indicate that the ATP binding pocket of AKT1, in contrast with AKT2, does 
contain an additional cavity that can be occupied by a bulkier apolar group.  
Furthermore, the SAR of FLT3 inhibition prefers bulky hetero-aromatic groups at 
the para position, especially nitrogen-containing aromatic groups are favourable. In 
this study, the most active FLT3 inhibitor is compound 218. 
In summary, thus far the two kinases AKT1 and FLT3, which act in the same 
biological pathway, cannot be inhibited by the same compound having this 
isoquinolinesulfonamide scaffold, since one prefers substitution at the para 
position and the other the ortho position, respectively. Therefore, new scaffolds 








Compounds 1 – 76, 113 – 133, 170 – 193 and 230 – 239: see thesis “Synthetic studies on kinase inhibitors and 
cyclic peptides: strategies towards new antibiotics”, Adriaan W. Tuin, 2008, 
https://openaccess.leidenuniv.nl/bitstream/handle/1887/13365/Proefschrift%2BAW_Tuin%2Balles.pdf?sequenc
e=7. 




Kinase assay: Determination of the relative activity, IC50 and Ki of inhibitors 1 – 239 at 2 µM final concentration 
towards PKA, AKT1 and AKT2 
A solution of 2 µM of inhibitor,10 nM ULight-rpS6 (pSer235/Ser236) peptide (Perkin-Elmer, human 40S ribosomal 
protein), 2 nM Eu-labeled anti-phospho-rpS6 antibody (Perkin-Elmer, Europium-labeled rabbit monoclonal 
antibody) and 100 µM ATP in 50 mM HEPES buffer pH 7.5 was incubated with 0.5 nM/min AKT1, AKT2 or 0.05 
nM/min of PKA (SignalChem) for 6 h at RT. During these 6 h of incubation, the intensity of the light emission was 
measured with intervals of 30 min on a PE Envision reader using the Lance Ultra kinase assay settings (λex 320 
nm; λem 665 nm) and a secondary control emission was measured at 615 nm. In control experiments, no ATP was 
added into the buffer (negative control) or DMSO was added to the reaction instead of an inhibitor (background 
control). Alternatively, the kinases were incubated with 2 µM commercial H-89 (CalBiochem) (positive control).  
To determine the KM for the kinases, the same assay was performed using 0, 0.1, 0.2, 0.5, 1, 2, 5, 10, 20, 50, 100, 
200, 500, 1000 µM ATP. KM values were calculated using GraphPad Prism 5 (GraphPad software, La Jolla, USA). 
To determine Ki values for inhibitors 1 - 239, they were tested at a concentration ranging from 0.05 to 20 µM. 
Data was analyzed using GraphPad Prism 5 (GraphPad software, La Jolla, USA).  
Ki values were calculated via equation 3.1: 
 
Ki = IC50 / (1 + ([S]/KM))                                                                                                                                              (3.1) 
 
where Ki is the inhibition constant, IC50  is the half maximal inhibitory concentration, S is the concentration of 
substrate and KM is the Michaelis-Menten constant, which is the substrate concentration at which the reaction 
rate is half maximum. All experiments were conducted in triplicate and curves were corrected for background 
fluorescent of the solvent.  
 
Kinase assays for FLT3 
A solution of 2 µM of inhibitors 101, 158, 195, 211, 215, 216, 218 or 222, 10 nM ULight-TK peptide (Perkin-Elmer, 
phosphorylated tyrosine residues), 2 nM Eu-labeled anti-phospho-tyrosine antibody (Perkin-Elmer, Europium-
labeled rabbit monoclonal antibody) and 100 µM ATP in 50 mM HEPES buffer pH 7.5 was incubated with 0.05 
nM/min FLT3 (Signalchem) for 6 h at RT. During these 6 h of incubation, the intensity of the light emission was 
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measured with intervals of 30 min similar to as for AKT1. In control experiments, no ATP was added into the 
buffer (negative control) or DMSO was added to the reaction instead of an inhibitor (background control). 
Alternatively, the kinases were incubated with 2 µM H-89 (CalBiochem) (positive control). To determine the IC50 
values, inhibitors were tested at a concentration range from 0.3 to 10000 nM. All experiments were conducted in 
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Bruton’s tyrosine kinase (BTK), a nonreceptor tyrosine kinase member of the Tec 
kinase family, is involved in B cell receptor (BCR) signaling and governs B-
lymphocyte development, differentiation, signaling and survival.
1,2,3 
Aberrant BTK 
activity is a fundamental feature of the human B-cell malignancies; chronic 
lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), follicular lymphoma (FL), 






The First-in-Class BTK-inhibitor ibrutinib (Imbruvica®, PCI-32765, 1, Figure 1) has 
recently been approved for the treatment of WM, MCL and CLL by the FDA.
8,9,10,11
 
Apart from its clinical efficacy, ibrutinib is of interest because of its mechanism of 
action. Ibrutinib irreversibly blocks BTK activity through covalent modification of 
Cys481 within the enzyme ATP-binding pocket following conjugate addition of the 
cysteine thiol to the acrylamide moiety in 1 (Figure 1), an event that prevents 
phosphorylation of Tyr223, an essential step for BTK activation. At present, 
numerous covalent kinase inactivators are pursued for a range of human 
malignancies.
12
 Besides the clinical relevance of mechanism-based inhibitors (long 
residence time, lasting inhibitory effect which is only dependent on de novo 
synthesis of the protein target), covalent and irreversible enzyme inhibitors are 
highly useful starting points for the development of activity-based protein profiling 
(ABPP) probes.
13,14,15
 Such probes, also termed activity-based probes (ABPs), are 
composed of a mechanism-based enzyme inhibitor modified to contain an 
identification tag, which can be a biotin (for visualisation and/or enrichment), a 
fluorophore (for visualisation), or a bioorthogonal tag (to install a fluorophore or 




















































Figure 1. Mechanism-based inactivation of Bruton’s tyrosine kinase (BTK) by ibrutinib (1) (left) and the 
direct (2) and two-step (3) BTK activity-based probes reported to date (right).  
 
In the recent literature both direct and two-step bioorthogonal ibrutinib-based 
ABPs have been described. Honigberg and co-workers reported on the 
development of BODIPY-FL-ibrutinib 2 and its application in detection of BTK in 
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BTK-positive tumor cells and mouse models of autoimmune disease.
10
  Cravatt and 
co-workers in turn described ibrutinib-alkyne 3 as part of a series of alkyne-
modified covalent kinase inhibitors in a broad-spectrum Huisgen [2+3]-
cycloaddition ‘click’-based two-step ABPP study on kinase activities in a variety of 
tumor tissues.
16
 Recently, a near infra-red (IR) fluorescent agent has been 
developed that can be used for spatial profiling of BTK expression in malignancies 
or other inflammatory tissues and pharmacokinetic and pharmacodynamic studies 
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Figure 2. Direct (4 and 5) and two-step bioorthogonal (6-8) BTK activity-based probes that are subject of 
the here presented study. 
 
The ABPP research in this chapter describes a head-to-head comparison of direct 
and two-step bioorthogonal ABPP methodologies.
18
 In these studies, assessment of 
the relative efficiency of Cu(I)-catalyzed and strain-promoted azide-alkyne [2+3] 
cycloaddition, Staudinger-Bertozzi ligation and inverse-electron demand Diels-Alder 
ligation have been included. Previously it has been shown that with the exception 
of strain-promoted alkyne-azide cycloadditions all of the above are effective 
bioorthogonal chemistries in the two-step ABPP modification of the catalytic 
activities of mammalian proteasomes and moreover that these reactions can be 
executed consecutively in a multiplexing fashion in a single biological sample.
19
 This 
chapter describes a comparative study in which BTK-positive Ramos cells have been 
probed for catalytically active BTK levels with direct ABPs 4 and 5 (Figure 2) as well 
as with two-step ABPs 6 and 7 (Cu(I)-catalyzed azide-alkyne [2+3] cycloaddition) 




Synthesis of ibrutinib and ibrutinib-based ABPs 
Perusal of the literature on structure-activity relationship studies on ibrutinib 
revealed that analogues featuring a piperazinyl extension at the acrylamide side of 
the parent compound are well tolerated by the target enzyme, BTK. Weissleder and 





Scheme 1. Reagents and conditions: a) N-iodosuccinimide, DMF, 80 °C, 87%; b) K3PO4, 4-
phenoxybenzene boronic acid, Pd(PPh3)4, dioxane, 180 °C, 79%; c) 12, PPh3 polymer-bound, DIAD, THF, 
56%; d) 4.0 M HCl in dioxane, 100%; e) acryloyl chloride, TEA, DCM, 46%; f) i) benzaldehyde, Cbz-Cl, 
toluene, 38%; ii) Boc2O, THF, 79%; iii) Pd/C, H2, MeOH, 94%; g) 17, TEA, THF; h) 14, HATU, TEA, DMF, 
87%; i) 4.0 M HCl in dioxane, 100%; j) HATU, DiPEA, DMF, 21, 4: 17%, 5: 10%, 6: 36%, 7: 22%, 8: 10%; k) 
23, PPh3 polymer-bound, DIAD, THF, 61%. 
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Based on these literature findings ibrutinib derivative 20 (Scheme 1) has been used 
as common core onto which the BODIPY fluorophores and two-step bioorthogonal 
ligation handles as depicted in Figure 2 are grafted. Thus the first research objective 
was to synthesise amine 20 (Scheme 1). 
Iodide 10 was prepared from commercially available aminopyrazolopyrimidine 9 in 
an electrophilic aromatic substitution using N-iodosuccinimide as the iodinating 
agent. Ensuing Suzuki coupling with 4-phenoxybenzene boronic acid according to 
the literature procedure provided diphenyl ether 11, which was reacted with 
enantiopure (S)-N-Boc-3-hydroxypiperidine 12 under Mitsunobu conditions to give 






 To prove that the 
Mitsunobu reaction gives enantiopure product, chiral HPLC was used to analyze and 
separate R-enantiomer 13 from S-enantiomer 22, which was obtained in the same 
way as compound 13 except that enantiopure (R)-N-Boc-3-hydroxypiperidine 23 
was used as the starting material (scheme 1). Figure 3 shows that the different 
chiral products 13 and 22 can be separated using chiral HPLC and that the used 
Mitsunobu reaction conditions give full inversion of stereochemistry in both 
situations. 
 
Figure 3. Chiral HPLC analysis of R-enantiomer 13 (A), S-enantiomer 22 (B), and a mixture of compound 
13 and 22 (C). 
 
The Boc protective group of the enantiopure R-enantiomer 13 was removed under 
acidic conditions. Subsequently, condensation of the thus liberated secondary 
amine with acryloyl chloride gave ibrutinib 1, the analytical and spectral data of 
which were in full agreement with those reported in the literature.
25,26 
The 
synthesis of ABPs 4-8 requires access to piperazine-functionalised acrylate 18, for 
which a synthesis scheme adapted from the patent literature by Astrazeneca was 
used.
27
 In the first instance, it was attempted to prepare the precursor, single Boc-
protected aminoethylpiperazine 16, as described by treatment of 
aminoethylpiperazine with di-tert-butyldicarbonate in the presence of benzyl 
aldehyde. However, this one-step procedure, not unexpectedly,
28
 failed. In this 







the primary amine reacted with benzaldehyde to form a benzylimine in situ. 
Therefore, the following three-step procedure has been used as depicted in scheme 
1.
29
 Thus, in situ formation of the primary benzylimine, ensuing Cbz protection of 
the secondary amine and liberation of the primary amine yielded mono-Cbz-
aminoethylpiperazine, with the secondary amine temporarily protected as the 
benzyloxycarbamate. Introduction of the Boc protective group at this stage 
followed by hydrogenolysis of the Cbz group afforded compound 16, which was N-
alkylated with E-bromobutenoic acid 17
30
 to yield compound 18. Condensation of 
14 and 18 under the agency of HATU and triethylamine followed by acidic removal 
of the Boc group afforded ibrutinib derivative 20. Condensation (HATU, DiPEA) with 
the appropriately modified tags 21 (see for the used tags the experimental section) 
afforded target direct ABPs 4 and 5 as well as the two-step bioorthogonal ABPs (6-
8) in moderate yield but good purity after HPLC purification. 
 
 
Evaluation of the inhibitory potency and labeling efficiency 
In the first instance, the ability of the potential ABPs 4-8 to inhibit BTK was 
established. Non-fluorescent derivatives 6-8 were measured in an immobilized 
metal ion affinity-based fluorescence polarization (IMAP) assay using recombinantly 
expressed human BTK with ibrutinib 1 included as benchmark. Fluorescent, direct 
ABPs 4 and 5 were added to Ramos cell extract, which contains endogenously 













Figure 4. A) BTK inhibitory potency (IC50) of ibrutinib 1 and two-step bioorthogonal ABPs 6-8. The mean 
IC50 values are calculated from two independent experiments performed in duplicate. B) BTK labeling 
efficiency of direct ABPs 4 and 5 in Ramos cell extract. Ramos cell extracts were exposed for 1 hr at room 
temperature to the indicated concentrations of ABP 4 or 5. Three independent experiments were 
performed. C) Competition experiments of ibrutinib 1 versus fluorescent ABP 4 in Ramos cell lysates. 
Three independent experiments were performed. Ramos cell extracts were exposed to the indicated 
concentrations of ibrutinib 1 for 1 hr at room temperature and then incubated with ABP 4 (1 µM) for 1 
hr at room temperature. Proteins were analysed by SDS-PAGE using detection by in-gel fluorescent 
readout. Coomassie staining was used as a loading control. Lane 1: Dual Color protein standard. 
Compound IC50  (nM)
1 0.17  0.2
6 0.20  0.04
7 0.32  0.2
8 0.64  0.12
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 As can be seen from Figure 4A, ibrutinib analogues 6-8 inhibit recombinant, 
purified BTK with IC50 values in the same range as ibrutinib 1. The fluorescent 
analogues 4 and 5 are not compatible with the IMAP assay and thus in an activity-
based protein profiling setting, it was established whether these compounds would 
be able to detect ibrutinib. As can be seen (Figure 4B) both compounds label a 
single band with an apparent molecular weight corresponding to that of BTK. Of 
note, labeling of this protein could be prevented in a dose-dependent manner by 
pre-incubation with ibrutinib, strongly suggesting BTK specificity of these probes in 
live cells (Figure 4C). 
Next, the ability of compounds 4-8 to target BTK in living cells was evaluated. Figure 
5A shows that both green (4) and red (5) fluorescent probes readily and selectively 
modify BTK in a concentration-dependent manner. They do so at concentrations as 
low as 100 nM (for ABP 4). Thus both direct ABPs behave as expected, given the 
literature precedent.
 31
 This makes the probes also useful for the assessment of the 
inhibitory potency and cell permeability of putative BTK inhibitors in a competitive 
ABPP setting. To establish whether putative two-step ABPs 6-8 are able to reach 
and modify BTK in living cells, living Ramos cells were treated in culture with varying 
concentration of these compounds, prior to treatment with BODIPY-FL-ibrutinib 4, 
cell lysis and SDS-PAGE. As is evident from Figure 5B, the three compounds abolish 
labeling at the lowest concentration (4 µM; approximately 6000x IC50 value for all 
compounds, see Figure 4A) applied and it can thus be concluded that all 5 




Figure 5. A) In situ labeling of BTK in Ramos cells by 4 and 5. Ramos cells were exposed to the indicated 
concentrations of 4 or 5 for 4 hrs at 37° C. Proteins were analysed by SDS-PAGE using detection by in-gel 
fluorescent readout. Three independent experiments were performed. B) Competition experiments of 
BODIPY-FL-ibrutinib 4 versus compounds 6-8 in Ramos cells. Ramos cells were exposed to the indicated 
concentrations of ABP 6, 7, or 8 for 3 hrs at 37° C and then lysed. The cell lysates were exposed to 1 µM 
of BODIPY-FL-ibrutinib 4 for 1 hr at room temperature. Two independent experiments were performed. 
Labeled proteins were analyzed by SDS-PAGE and detected by in-gel fluorescent read-out. Coomassie 
staining was used as a loading control. Lane 1: Dual Color protein standard. 
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The efficiency and selectivity of the two-step ABPs 6-8 to modify BTK in living 
Ramos cells was assessed next. Figure 6 depicts the complementary reagents used 
in these experiments, that is, BODIPY-FL-modified bioorthogonal reagent 22
32
 (for 
copper(I)-catalyzed alkyne-azide [2+3] cycloaddition (CuAAC) ligation to alkyne-
modified ibrutinib 6), BODIPY-green-alkyne 23
33
 (for copper(I)-catalyzed click 
ligation to azide-modified ibrutinib 7) and BODIPY-FL-tetrazine 24
32
 (for inverse-
electron demand Diels-Alder ligation to norbornene-modified ibrutinib 8). 
 
Figure 6. Ligation reagents used in the study described in this Chapter. 
 
Ramos cell lysates were treated with ibrutinib-alkyne 6, ibrutinib-azide 7 or 
ibrutinib-norbonene 8 at 4 micromolar final concentrations for one hour at room 
temperature. Next the samples were treated with the complementary 
bioorthogonal ligation handles 22-24 at various final concentrations for one hour. 
The proteins were resolved on SDS-PAGE and the wet gel slabs were analyzed by 
fluorescence read-out. As can be seen (Figure 7A) both copper(I)-catalyzed click 
reactions give BTK labeling in a concentration-dependent manner, as does the 
inverse-electron demand Diels-Alder (IEDDA) ligation. Though the two click ligation 
steps appear about equally effective in terms of activity, differences are apparent 
when considering aspecific reaction of the (click/tetrazine) ligation handles, with 
alkyne-azide click ligation giving the optimal result. The IEDDA ligation appears to 
proceed equally selective though the labeling intensity appears somewhat lower. 
As a final set of experiments the ability of the two-step BTK ABPs to modify BTK in 
situ in living Ramos cells has been explored (Figure 7D). For this purpose, Ramos 
cells were treated with 4 micromolar 6-8 for 1 hour at 37 °C. For the purpose of the 
two CuAAC click ligations the cells were lysed, whereas IEDDA ligation (addition of 
norbornene 24) was performed in situ and in vitro. As can be seen (Figure 7D) also 
these partial or complete in situ ligations proved successful, with here the two 
CuAAC ligations more selective compared to the IEDDA ligation. 
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[1] - - - - - - - 20     -
[4] - - - - - - - - 1
[6] 4        4      - 4      - 4      - 4 -










[4] - - - - - - - - - - - 1
[6] - - - - - - - - 4 4 - -
[22 ] - - - - - - - - - 25 25 -
[7] - - - - - 4 4 - - - - -
[23] - - - - - - 25 25 - - - -
[8] - 4 4 4 - - - - - - - -










[1] - - - - - - - 20     -
[4] - - - - - - - - 1
[7] 4        4       - 4       - 4       - 4 -
[23] - 10     10    20    20    50    50     50     -
[1] - - - - - - - 20     -
[4] - - - - - - - - 1
[8] 4        4      - 4       - 4      - 4 -
[24] - 10    10    20    20    50    50    50     -
 
Figure 7. A-C) In vitro two-step bioorthogonal labeling of BTK in Ramos cell extract using reagent pairs 
(6/22), (7/23) and (8/24). Ramos cell lysates were exposed to ABP 6 or 7 for 1 hr at room temperature 
and then reacted with the indicated concentrations of BODIPY-azide 22 or BODIPY-alkyne 23 for 1 hr at 
room temperature. Copper-catalyzed click reactions were performed in the presence of CuSO4 (6.5 mM), 
Tris(3-hydroxypropyltriazolylmethyl) amine (THPTA, 6.5 mM) and sodium L-ascorbate (6.5 mM). 
Alternatively, ABP 8 (4 µM) was used for ligation with tetrazine 24. In control experiments different 
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ligation strategies were performed in the absence of ABP 6-8 or after competition by an excess of 
ibrutinib 1. As a positive control, extracts were labelled with fluorescent ABP 4 (1 µM). Three 
independent experiments were performed. D) Two-step bioorthogonal profiling of BTK activity by 
different ligation strategies. Ramos cells were exposed to ABP 6-8 (4 µM) for 3 hrs at 37 °C, washed, 
lysed, and then reacted with their corresponding ligation reagent 22-24 (25 µM) for 1 hr at room 
temperature. Alternatively, cells were consecutively exposed to ABP 8 and ligation reagent 24 in situ 
(lane 5).  In control experiments different ligation strategies were performed in the absence of ABP 6-8 
and/or ligation reagent. As a positive control, cells were labelled with fluorescent ABP 4 (1 µM). Three 
independent experiments were performed. Proteins were analysed by SDS-PAGE using detection by in-





The BTK activity-based probe set has been expanded by the development of two 
direct ABPs 4 and 5 equipped with BODIPY fluorophores that emit at two distinct 
wavelengths, as well as three bioorthogonal two-step ABPs that can be addressed 
through either CuAAC or IEDDA bioorthogonal chemistry. As such this BTK imaging 
toolset adds to the existing BTK probes – both direct and two-step – for measuring 
catalytically active BTK in various settings. Though direct imaging with BODIPY-
ibrutinib derivatives 4 and 5 appears most effective in live cells, the situation may 
differ in case live animals are to be subject of study and for this purpose the IEDDA 
bioorthogonal ABP pair 8/24 may be most effective – even though labeling 
efficiency appears the lowest. In an alternative setting, BTK occupancy may be 
monitored in conjunction with other enzymatic activities in a multiplexing setting, 
using either the direct probes in conjunction with ABPs targeting other enzymes 
and equipped with complementary fluorophores, or by making use of a number of 
mutually exclusive bioorthogonal ligations. 
 
General: Tetrahydrofuran (THF) was distilled over LiAlH4 before use. Acetonitrile (ACN), dichloromethane (DCM), 
N,N-dimethylformamide (DMF), methanol (MeOH) and trifluoroacetic acid (TFA) were of peptide synthesis grade, 
purchased at Biosolve, and used as received. All general chemicals (Fluka, Acros, Merck, Aldrich, Sigma) were 
used as received. Traces of water were removed from reagents used in reactions that require anhydrous 
conditions by coevaporation with toluene. Solvents that were used in reactions were stored over 4Å molecular 
sieves, except methanol and acetonitrile, which were stored over 3Å molecular sieves. Molecular sieves were 
flame dried before use. Unless noted otherwise all reactions were performed under an argon atmosphere. 
Column chromatography was performed on Silicycle Silia-P Flash Silica Gel, with a particle size of 40 – 63 µm. The 
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eluent toluene and ethyl acetate were distilled prior to use. TLC analysis was conducted on Merck aluminium 
sheets (Silica gel 60 F254). Compounds were visualized by UV absorption (254 nm), by spraying with a solution of 
(NH4)6Mo7O24·4H2O (25 g/L) and (NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% sulphuric acid, a solution of KMnO4 (20 g/L) 
and K2CO3 (10 g/L) in water, or ninhydrin (0.75 g/L) and acetic acid (12.5 mL/L) in ethanol, where appropriate, 
followed by charring at ca. 150 °C. 1H- and 13C-NMR spectra were recorded on a Bruker DMX-400 (400 MHz) or a 
Bruker DMX-600 (600 MHz) spectrometer. Chemical shifts are given in ppm (δ) relative to tetramethylsilane (1H-
NMR) or CDCl3 (
13C-NMR) as internal standard. Mass spectra were recorded on a PE/Sciex API 165 instrument 
equipped with an Electrospray Interface (ESI) (Perkin-Elmer). High-resolution MS (HRMS) spectra were recorded 
with a Finnigan LTQ-FT (Thermo Electron). IR spectra were recorded on a Shimadzu FTIR-8300 and absorptions 
are given in cm-1. Optical rotations [α]D
23 were recorded on a Propol automatic polarimeter at room temperature. 
LC-MS analysis was performed on a Jasco HPLC system with a Phenomenex Gemini 3 µm C18 50 x 4.6 mm 
column (detection simultaneously at 214 and 254 nm), coupled to a PE Sciex API 165 mass spectrometer with ESI. 
HPLC gradients were 10 → 90%, 0 → 50% or 10 → 50% ACN in 0.1% TFA/H2O. Chiral HPLC analysis was 
performed on a Spectroflow 757 system (ABI Analytical Kratos Division, detection at 254 nm) equipped with a 
Chiralcel OD column (150 x 4.6 mm). The compounds were purified on a Gilson HPLC system coupled to a 
Phenomenex Gemini 5 µm 250 x 10 mm column and a GX281 fraction collector. The used gradients were either 0 
→ 30% or 10 → 40% ACN in 0.1% TFA/water, depending on the lipophilicity of the product. Appropriate fractions 
were pooled, and concentrated in a Christ rotary vacuum concentrator overnight at room temperature at 0.1 
mbar. 
 
3-Iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (10)  
To a solution of 4-aminopyrazolo[3,4-d]pyrimidine (9, 2.50 g, 18.5 mmol) in DMF (43 mL) was added N-
iodosuccinimide (1.5 eq., 6.24 g, 27.7 mmol) and the mixture was heated to 80 °C overnight, before being cooled 
to 0 °C. H2O (110 mL)  was added and the mixture was allowed to stand at 0 °C for 30 min followed by filtration of 
the solid. The residue was washed with ice-cold EtOH, Et2O and EtOAc and dried in vacuo. The title compound 
was obtained without further purification as a pale yellow solid (yield: 4.22 g, 16.17 mmol, 87%). RF = 0.30 (10% 
MeOH/DCM). 1H NMR (400 MHz, DMSO-d6) δ 13.84 (s, 1H, NH), 8.17 (s, 1H, CH). 
13C NMR (101 MHz, DMSO-d6) δ 
157.50, 155.90, 155.0, 102.51, 89.88. 
3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (11) 
Compound 10 (0.20 g, 0.77 mmol), K3PO4 (3 eq., 0.49 g, 2.30 mmol), 4-phenoxybenzene boronic acid (3 eq., 0.49 
g, 2.29 mmol) and Pd(PPh3)4 (0.14 eq., 0.12 g, 0.11 mmol) were dissolved in sonicated dioxane (2.5 mL) in a 
microwave vial. The resulting mixture was heated to 180 °C for 10 min under microwave irradiation. EtOAc (10 
mL) was added and the mixture was washed with H2O and brine before being dried over MgSO4, filtered and 
concentrated under reduced pressure. The title compound was obtained after purification by column 
chromatography (100% DCM  4% MeOH/DCM) as a white solid (yield: 0.18 g, 0.61 mmol, 79%). RF = 0.19 (5% 
MeOH/DCM). 1H NMR (400 MHz, DMSO-d6) δ 13.58 (s, 1H, NH), 8.22 (s, 1H, CH), 7.67 (d, J = 8.8 Hz, 2H, 2xCH), 
7.43 (t, J = 8.0 Hz, 2H, 2xCH), 7.20 – 7.11 (m, 5H, 5xCH). 13C NMR (101 MHz, DMSO-d6) δ 158.11, 157.04, 156.33, 
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155.82, 143.99, 130.17, 128.48, 123.82, 119.05, 96.95. LC-MS analysis: Rt 5.63 min (linear gradient 10-90% 




To a suspension of (S)-1-Boc-3-hydroxypiperidine 12 (2 eq., 1.24 g, 6.2 mmol) and polymer-bound 
triphenylphosphine (3 eq., 3.08 g, 9.2 mmol) in THF (20 mL) was added dropwise diisopropyl diazodicarboxylate 
(2 eq., 1.21 mL, 6.1 mmol) and the reaction mixture was stirred for 5 min.  Compound 11 (0.93 g, 3.08 mmol) was 
added and the resulting mixture was heated with a heatgun for 5 min. The suspension was stirred overnight 
before being filtered over Celite to remove the resins and the resins were washed with MeOH and DCM. The 
filtrate was concentrated and the target compound was obtained by column chromatography (40%  55% 
EtOAc/Pentane) as a yellow solid (yield: 0.84 g, 1.72 mmol, 56%). RF = 0.50 (90% EtOAc/Pentane). 
1H NMR (400 
MHz, CDCl3) δ 8.31 (s, 1H, CH), 7.65 (d, J = 8.4 Hz, 2H, 2xCH), 7.35 (t, J = 8.0 Hz, 2H, 2xCH), 7.15 – 7.12 (m, 3H, 
3xCH), 7.06 (d, J = 8.0 Hz, 2H, 2xCH), 4.90 – 4.81 (m, 1H, CH), 4.36 – 4.19  (m, 1H), 4.12 – 4.06 (m, 1H), 3.50 – 3.34 
(m, 1H), 2.86 (t, J = 10.8 Hz, 1H), 2.31 – 2.16 (m, 2H), 1.93 – 1.88 (m, 1H), 1.72 – 1.67 (m, 1H), 1.44 (s, 9H). 13C 
NMR (101 MHz, CDCl3) δ 158.10, 157.97, 156.02, 154.87, 154.30, 143.63, 130.60, 128.50, 124.44, 119.37, 98.09, 
79.51, 52.51, 48.20, 44.05, 29.90, 28.95, 24.51. LC-MS analysis: Rt 8.26 min (linear gradient 10-90% acetonitrile in 




Compound 13 (0.05 g, 0.1 mmol) was stirred in 4.0 M HCl in dioxane (1 mL) for 2 hrs. The reaction mixture was 
concentrated in vacuo and the residue was suspended in EtOAc before being filtered. The residue was washed 
with EtOAc and dried under reduced pressure. The title compound was obtained without further purification as a 
white solid (yield: 0.042 g, 0.1 mmol, 100%). RF = 0.05 (90% EtOAc/Pentane). LC-MS analysis: Rt 5.34 min (linear 




To a solution of crude amine 14 (0.20 mmol) in DCM (1 mL) were added TEA (3.0 eq., 84 uL, 0.6 mmol) and 
acryloyl chloride (1.3 eq., 20 uL, 0.26 mmol). The resulting mixture was stirred overnight prior to washing with 
aqueous solution of citric acid (5%, 5 mL) and brine. The title compound was obtained after RP-HPLC purification 
(linear gradient 40%  60% ACN in H2O, 0.1% TFA, 15 min) as a white solid (yield: 12.0 g, 92.0 µmol, 46%). 
1H 
NMR (600 MHz, DMSO-d6): δ 8.42 (s, 1H), 7.67 (d, J = 7.2 Hz, 2H), 7.44 (t, J = 7.2 Hz, 2H), 7.19 (t, J = 7.2 Hz, 1H), 
7.16 (d, J = 9.0 Hz, 2H), 7.13 (d, J = 9.0 Hz, 2H), 6.85 (t, J= 13.2, 0.5 H), 6.69 (t, J = 15.6 Hz, 0.5 H), 6.13 (d, J = 16.2 
Hz, 0.5H), 6.06 (d, J = 16.8 Hz, 0.5H), 5.70 (d, J = 10.2 Hz, 0.5H), 5.59 (d, J = 9.6 Hz, 0.5H), 4.79 – 4.71 (m, 1H), 4.56 
(d, J = 10.8 Hz, 1H), 4.19 (br s, 1H), 4.06 (d, J = 13.2 Hz, 0.5H), 3.71 (t, J = 10.8Hz, 0.5H), 3.26 – 3.19 (m, 1H), 3.04 
(t, J = 12.0 Hz, 0.5H), 2.30 – 2.23 (m, 1H), 2.15 – 2.13 (m, 1H), 1.95 – 1.92 (m, 1H), 1.66 – 1.54 (m, 1H). 13C NMR 
(150 MHz, DMSO-d6): δ 164.64, 157.48, 156.15, 152.66, 144.73, 130.11, 128.28, 127.49, 127.21, 126.95, 126.12, 
123.86, 119.02, 115.76, 97.06, 53.03, 52.41, 49.220, 45.65, 45.12, 41.54, 29.49, 29.27, 24.74, 23.13. IR film (cm-1): 
2936.8, 1688.8, 1609.7, 1586.58, 1516.1, 1489.1, 1436.1, 1233.5, 1197.9, 1134.2, 856.9, 801.6, 759.6, 725.3, 
698.6. HRMS: calculated for C25H24N6O2 [M+H
+]: 441.20335; found: 441.20315. 
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Tert-butyl (2-(piperazin-1-yl)ethyl)carbamate (16) 
1-(2-Aminoethyl)piperazine (15, 32.8 mL, 250 mmol) and benzaldehyde (1 eq., 25.5 mL, 250 mmol) were 
dissolved in toluene (200 mL) and the reaction mixture was refluxed over a Dean-Stark apparatus in 3 hrs, cooled 
to 0 °C, and treated with dropwise addition of benzylchloroformate (1 eq., 38 mL, 250 mmol). The resulting 
mixture was stirred overnight before being concentrated. The residue was dissolved in MeOH (500 mL), cooled to 
0 °C and treated with 2 N HCl (125 mL). The resulting mixture (pH 1-2) was allowed to warm up to RT and 
concentrated under reduced pressure. The aqueous layer was washed with DCM before being made basic with 
NH4OH (pH = 10) and extracted with DCM (3x), washed with brine, dried, filtered and evaporated. The residue 
was applied to silica column chromatography (4%  6% MeOH/DCM + 1% TEA) to afford benzyl 4-(2-
aminoethyl)piperazine-1-carboxylate as a yellowish oil (yield: 25.15 g, 95.5 mmol, 38%). RF = 0.20 (20% 
MeOH/DCM). 1H NMR (400 MHz, CDCl3) δ 7.36 – 7.28 (m, 5H, CHar), 5.12 (s, 2H, CH2), 3.51 (t, J = 4.8 Hz, 4H, 
2xCH2), 2.79 (t, J = 6.0 Hz, 2H, CH2), 2.44 (t, J = 6.0 Hz, 2H, CH2), 2.40 (br s, 4H, 2xCH2), 2.30 (s, 2H, NH2). 
13C NMR 
(101 MHz, CDCl3) δ 154.76, 136.32, 128.09, 127.59, 127.44, 67.10, 60.06, 52.48, 43.42, 38.03. After the solution 
of the carboxylate product (12.58 g, 47.75 mmol) in THF (200 mL) was cooled to 0 °C, Boc2O (1.2 eq., 12.51 g, 
57.30 mmol) was added portion wise and the reaction mixture was allowed to warm up to RT overnight before 
being concentrated. The residue was further purified by silica column chromatography (20%  30% 
EtOAc/Pentane) to afford benzyl 4-(2-((tert-butoxycarbonyl)amino)ethyl)piperazine-1-carboxylate as a yellowish 
oil (13.71 g, 37.72 mmol, 79%). RF = 0.30 (80% EtOAc/Pentane).
 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.30 (m, 5H, 
CHar), 5.13 (s, 2H, CH2), 4.98 (br s, 1H, NH), 3.51 (t, J = 5.2 Hz, 4H, 2xCH2), 3.25 – 3.21 (m, 2H, CH2), 2.46 (t, J = 6.0 
Hz, 2H, CH2), 2.41 (br s, 4H, 2xCH2). 
13C NMR (101 MHz, CDCl3) δ 155.85, 155.11, 136.59, 128.42, 127.96, 127.82, 
79.17, 67.05, 57.14, 52.53, 43.67, 36.93, 28.35. HRMS: calculated for C19H29N3O4 [M+H
+]: 364.21581; found: 
364.20315.   
 To a solution of 4-(2-((tert-butoxycarbonyl)amino)ethyl)piperazine-1-carboxylate (1.82 g, 5.0 mmol) in MeOH (20 
mL) Pd/C (10% w/w, 150 mg) was added. Hydrogen gas was then bubbled through the mixture overnight. The 
reaction mixture was filtered over Celite and concentrated to obtain the target compound as a yellowish oil 
(yield: 1.08 g, 4.71 mmol, 94%). The target compound was used without further purification. RF = 0.29 (1/1/1 
v/v/v H2O/ACN/tBuOH). 
1H NMR (400 MHz, MeOD) δ 3.80 - 3.65 (m, 6H, 3xCH2), 3.57 – 3.51 (m, 4H, 2xCH2), 3.38 
(t, J = 7.6 Hz, 2H, CH2), 1.46 (s, 9H, 3xCH3). 
13C NMR (101 MHz, MeOD) δ 158.03, 80.43, 57.74, 54.59, 53.30, 49.87, 
41.93, 36.11, 35.09, 28.67. HRMS: calculated for C11H23N3O2 [M+H
+]: 230.17903; found: 230.17907. 
 
(E)-4-bromobut-2-enoic acid (17) 
To a solution of commercially available crotonic acid (10 g, 116 mmol) in benzene (150 mL) was added N-
bromosuccinimide (1.1 eq., 22.74 g, 120 mmol) and benzoyl peroxide (0.01 eq, 0.45 g, 1.4 mmol) and the 
resulting mixture was refluxed for 4 hrs. The reaction mixture was then allowed to cool to 0 °C, which resulted in 
precipitation of succinimide crystals. The crystals were filtered over Celite and washed with toluene. The filtrate 
was concentrated and the residue was recrystallized from hexanes yielding the title compound as a pale yellow 
solid (yield: 9.55 g, 57.9 mmol, 50%). RF = 0.79 (1/1/1 v/v/v H2O/ACN/tBuOH). 
1H NMR (400 MHz, CDCl3) δ 9.04 
(bs, 1H), 7.12 (m, 1H), 6.05 (d, J = 15.2 Hz, 1H), 4.04 (dd, J1 = 1.2 Hz, J2 = 7.2 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ 
170.41, 144.20, 123.79, 28.72. 
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(E)-4-(4-(2-((tert-butoxycarbonyl)amino)ethyl)piperazin-1-yl)but-2-enoic acid (18) 
Compound 17 (1 eq., 0.22 g, 1 mmol) was dissolved in THF (5 mL). A solution of compound 16 (0.27 g, 1 mmol) 
and TEA (3 eq., 0.42 mL, 3.0 mmol) in THF (2 mL) was added and the mixture was stirred overnight and 
concentrated under reduced pressure. The title compound was used without further purification. RF = 0.29 
(1/1/1 v/v/v H2O/ACN/tBuOH). LC-MS analysis: Rt 5.69 min (linear gradient 0-50% acetonitrile in H2O, 0.1% TFA, 




HATU (2.2 eq., 1.25 g, 3.3 mmol) was added to a solution of compound 18 (4 eq., 1.88 g, 6.0 mmol) and TEA (7 
eq., 1.46 mL, 10.5 mmol) in DMF (5 mL) and the reaction mixture was allowed to stir for 1 min. A solution of 
amine 14 (0.63 g, 1.5 mmol) in DMF (2 mL) was added and the resulting mixture was stirred overnight. EtOAc (25 
mL) was added and the organic layer was washed with sat. aq. NaHCO3 and brine, dried over MgSO4, filtered and 
concentrated in vacuo. The title compound was obtained after column chromatography (4%  8% MeOH/DCM) 
as a brown solid (yield: 0.89 g, 1.31 mmol, 87%). RF = 0.55 (10% MeOH/DCM).
 1H NMR (400 MHz, DMSO-d6) δ 
8.26 (s, 1H), 7.68 (d, J = 8.8 Hz, 2H), 7.42 (t, J = 7.6Hz, 2H), 7.20 – 7.11 (m, 5H), 6.52 (t, J = 9.8 Hz, 1H), 6.48 – 6.42 
(m, 2H), 5.88 (br s, 1H), 4.78 – 4.72 (m, 1H), 4.33 (d, J = 12.0 Hz, 1H), 4.01 (dt, J = 16, 8 Hz, 1H), 3.60 – 3.57 (m, 
1H), 3.51 (t, J = 12 Hz, 1H), 3.27 – 3.18 (m, 1H), 3.10 – 3.04 (m, 6H), 2.42 – 2.37 (m, 6H), 2.21 – 2.17 (m, 1H), 2.03 
– 1.96 (m, 1H), 1.70 – 1.59 (m, 1H), 1.41 (s, 9H). 13C NMR (101 MHz, DMSO-d6) δ 164.36, 157.69, 156.91, 154.96, 
153.82, 142.61, 139.95, 129.39, 127.66, 123.12, 122.37, 118.42, 97.38, 77.08, 57.99, 56.64, 52.32, 52.07, 47.51, 
42.81, 37.39, 28.57, 27.73, 23.18. HRMS: calculated for C37H47N9O4 [M+H
+]: 682.37510; found: 682.37513. LC-MS 





Compound 19 (0.015 g, 0.022 mmol) was stirred in 4.0 M HCl in dioxane (2 mL) for 2 hrs. The reaction mixture 
was concentrated in vacuo and the residue was suspended in EtOAc before being filtered. The residue was 
washed with EtOAc and dried under reduced pressure. The title compound was obtained without further 
purification as a white solid (yield: 0.013 g, 0.022 mmol, 100%). RF = 0.05 (90% EtOAc/Pentane). LC-MS analysis: 






Carboxaldehyde pyrrole34 (90 mg, 0.43 mmol, 1 eq)  was dissolved in MeOH (5 mL) 
and 2,4-dimethylpyrrole (41 mg, 44 μL, 0.43 mmol, 1 eq) was added. The resulting 
mixture was cooled to 0°C, and hydrobromic acid, 48% solution in water (0.072 mL, 
0.64 mmol, 1.5 eq) was added. After 2 h of stirring a yellowish precipitate formed 
and TLC analysis showed complete consumption of the starting materials. The crude dipyrrole HBr salt was 
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concentrated and coevaporated with DCE (3x) and dissolved in DCE (10 mL) under an argon atmosphere. 
Triethylamine (0.178 mL, 1.29 mmol, 3 eq) and BF3 
.Et2O (0.57 mL, 2.15 mmol, 5 eq) were added, and the reaction 
was subsequently stirred at room temperature until TLC showed completion of the reaction. The solution was 
concentrated and the product purified by silica gel column chromatography (0% → 2% EtOAc in toluene) which 
gave 4,4-Difluoro-1,3,7,9-tetramethyl-2-(2-(ethoxycarbonylmethyl))-4-bora-3a,4a-diaza-s-indacene (106 mg, 0.32 
mmol, 74%). Rf = 0.4 (6:1 toluene:EtOAc). 
1H-NMR (400 MHz, CDCl3) δ 6.99 (s, 1H), 6.00 (s, 1H), 3.66 (s, 3H), 2.70 
(t, J = 7.8 Hz, 2H), 2.50 (s, 6H), 2.43 (t, J = 7.8, 2H), 2.18 (d, J = 15.4, 6H). 13C-NMR (101 MHz, CDCl3) δ 173.41, 
156.51, 155.86, 141.20, 138.54, 133.59, 133.07, 128.61, 120.05, 119.08, 77.80, 77.48, 77.16, 52.04, 34.45, 19.86, 
14.96, 13.03, 11.56, 9.87. LC-MS analysis (10%  90% ACN) Rt: 9.18 min, ESI-MS (m/z): [M+H]+: 335.0; [M-F]+: 
315.2. 
4,4-Difluoro-1,3,7,9-tetramethyl-2-(2-(ethoxycarbonylmethyl))-4-bora-3a,4a-diaza-
s-indacene (106 mg, 0.32 mmol) was dissolved in MeOH (20 mL) and aq. NaOH 
(3.68 mL, 0.1 M, 1.15 eq, 0.37 mmol) was added. The mixture was heated to reflux 
for 1.5 h, after which by-product formation started to occur. The reaction was 
quenched by the addition of aq. HCl (3.68 mL, 0.1 M, 1.15 eq), followed by extraction with EtOAc (3x). The 
organic layers were dried (MgSO4), concentrated and 4,4-Difluoro-1,3,7,9-tetramethyl-2-(2-(carboxyethyl))-4-
bora-3a,4a-diaza-s-indacene was obtained by silica column chromatography (0 1% EtOAc in toluene (starting 
material) 1% EtOAc in toluene + 1% AcOH (product)) as a red powder (65 mg, 0.2 mmol, 64% (74% based on 
recovered starting material)). Rf = 0.2 (6:1 toluene:EtOAc + AcOH). λabs 514 nm/λem 523 nm (MeOH). 
1H-NMR (400 
MHz, CDCl3) δ 7.01 (s, 1H), 6.02 (s, 1H), 2.72 (t, J = 7.7 Hz, 2H), 2.56 – 2.40 (m, 8H), 2.21 (d, J = 14.7 Hz, 6H).
 13C-
NMR (101 MHz, CDCl3) δ 178.68, 156.57, 155.48, 141.10, 138.22, 133.42, 132.77, 127.97, 119.84, 118.95, 34.16, 
19.37, 14.76, 12.81, 11.36, 9.69. LC-MS analysis (10%  90% ACN) Rt: 7.94 min, ESI-MS (m/z): [M+H]+: 320.93; 
[M-F]+: 301.13. 
HATU (1.3 eq., 49 mg, 0.13 mmol) was added to a solution of compound 4,4-Difluoro-1,3,7,9-tetramethyl-2-(2-
(carboxyethyl))-4-bora-3a,4a-diaza-s-indacene (2 eq., 64 mg, 0.20 mmol) and TEA (5 eq., 70 µL, 0.5 mmol) in DMF 
(0.4 mL) and the reaction mixture was allowed to stir for 1 min. A solution of amine 20 (42 mg, 0.1 mmol) in DMF 
(0.3 mL) was added and the resulting mixture was stirred overnight. EtOAc (10 mL) was added and the organic 
layer was washed with sat. aq. NaHCO3 and brine, dried over MgSO4, filtered and concentrated under reduced 
pressure. The title compound was obtained after RP-HPLC purification (linear gradient 40%  60% ACN in H2O, 
0.1% TFA, 15 min) as a red/brown solid (yield: 15.60 mg, 16.51 µmol, 16.5%). RF = 0.05 (90% EtOAc/Pentane). 
1H 
NMR (600 MHz, DMSO-d6): δ 8.38 (s, 1H), 8.10 (br s, 1H), 7.66 (t, J = 7.8 Hz, 2H), 7.61 (s, 1H), 7.44 (t, J = 7.2 Hz, 
2H), 7.19 (t, J = 7.2 Hz, 1H), 7.17 (d, J = 8.4 Hz, 2H), 7.13 (d, J = 7.8 Hz, 2H), 6.84 (d, J = 15.0 Hz, 0.5H), 6.69 (d, J = 
15.0 Hz), 6.62 – 6.58 (m, 0.5H), 6.55 – 6.52 (m, 0.5H), 6.15 (s, 1H), 4.76 – 4.66 (m, 1H), 4.57 (d, J = 11.4 Hz, 1H), 
4.20 – 4.19 (m, 2H), 4.06 (d, J = 12.6 Hz, 1H), 3.77 (t, J = 12 Hz, 1H), 3.53 (br s, 1H), 3.40 (br s, 1H), 3.37 – 3.32 (m, 
4H), 3.24 – 3.21 (m, 2H), 3.04 (m, 1H), 2.98 – 2.88 (m, 4H), 2.61 – 2.60 (m, 2H), 2.42 (s, 3H), 2.40 (s, 1H), 2.25 (s, 
6H), 2.22 (s, 3H), 2.14 - -2.12 (m, 1H), 1.95 – 1.93 (m, 1H), 1.63 – 1.56 (m, 1H). 13C NMR (150 MHz, DMSO-d6): δ 
172.0, 163.79, 158.79, 158.56, 157.40, 156.76, 156.24, 155.70, 154.55, 153.38, 153.07, 144.43, 144.03, 140.94, 
139.24, 132.43, 130.09, 129.22, 127.24, 126.87, 123.90, 121.47, 119.04, 118.45, 117.45, 97.22, 56.69, 55.02, 
52.96, 52.32, 50.16, 49.32, 45.77, 45.21, 41.63, 35.16, 34.13, 29.47, 24.88, 23.25, 19.57, 14.21, 12.51, 10.96, 
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9.25. IR film (cm-1): 1670.4, 1603.9, 1517.1m 1471.8, 1436.1, 1227.7, 1199.8, 1131.3, 974.1, 832.3, 799.5, 720.4, 
666.4. HRMS: calculated for C48H56BF2N11O3 [M+2H
2+]: 442.73912; found: 442.73849. 
 
Ibrutinib-BODIPY-TMR (5) 
DiPEA (3.5 eq., 60 µL, 0.35 mmol) and BODIPY-TMR-OSu35 (2.2 eq., 0.11 g, 0.22 mmol) were added to a solution 
of crude amine 20 (42 mg, 0.1 mmol) in DMF (0.5 mL). The reaction mixture was stirred overnight before being 
evaporated. The title compound was obtained after RP-HPLC purification (linear gradient 40%  60% ACN in 
H2O, 0.1% TFA, 15 min) as a purple solid (yield: 12.19 mg, 10.25 µmol, 10.3%). RF = 0.05 (90% EtOAc/Pentane). 
1H 
NMR (600 MHz, DMSO-d6): δ 8.26 (s, 1H), 7.85 (d, J = 6.6 Hz, 2H), 7.66 (d, J = 7.8 Hz, 3H), 7.43 (t, J = 10.8 Hz, 2H), 
7.19 (t, J = 7.2 Hz, 1H), 7.16 – 7.11 (m, 5H), 7.02 (d, J = 7.8 Hz, 2H), 6.69 (br s, 1H), 6.61 – 6.58 (m, 1H), 6.5 (br s, 
1H), 4.73 – 4.67 (m, 1H), 4.54 (d, J = 11.4 Hz, 1H), 4.14 (d, J = 10.2 Hz, 1H), 4.03 (d, J = 11.4 Hz, 1H), 3.82 (s, 3H), 
3.76 – 3.72 (m, 1H), 3.24 – 3.19 (m, 3H), 3.09 (q, J = 7.8 Hz, J = 15.0 Hz, 4H), 2.66 – 2.61 (m, 3H), 2.55 - 2.54 (m, 
2H), 2.49 (s, 3H), 2.26 (d, J = 6.6 Hz, 3H), 2.22 (s, 3H), 2.12 (d, J = 10,2 Hz, 1H), 1.96 – 1.89 (m, 1H), 1.63 – 1.52 (m, 
1H), 1.18 (t, J = 7.2 Hz, 4H). 13C NMR (150 MHz, DMSO-d6): δ 159.97, 158.18, 157.14, 156.28, 155.66, 153.96, 
143.34, 143.20, 140.58, 134.68, 133.92, 131.07, 130.39, 130.12, 128.30, 127.89, 124.90, 124.19, 123.80, 118.97, 
117.98, 113.78, 97.39, 55.71, 45.76, 40.06, 34.93, 19.80, 12.90, 9.25, 8.59. IR film (cm-1): 1672.3, 1604.8, 1523.8, 
1464.0, 1234.4, 1201.7, 1180.4, 1139.9, 1045.4. HRMS: calculated for C53H58BF2N11O4 [M+2H




DiPEA (4.0 eq., 70 µL, 0.4 mmol) and 6-heptynoic-OSu36 (2.2 eq., 4.9 mg, 0.25 mmol) were added to a solution of 
crude amine 20 (42 mg, 0.1 mmol) in DMF (0.5 mL). The reaction mixture was stirred overnight before being 
evaporated. The title compound was obtained after RP-HPLC purification (linear gradient 40%  60% ACN in 
H2O, 0.1% TFA, 15 min) as a white solid (yield: 32.92 mg, 35.87 µmol, 35.9%). RF = 0.05 (90% EtOAc/Pentane). 
1H 
NMR (600 MHz, DMSO-d6): δ 8.39 (s, 1H), 8.03 (br s, 1H), 7.67 - 7.66 (m, 2H), 7.44 (t, J = 7.2 Hz, 2H), 7.19 (t, J = 
7.2 Hz, 1H), 7.16 (d, J = 9.0 Hz, 2H), 7.13 (d, J = 8.4 Hz, 2H), 6.85 (d, J = 15.0 Hz, 0.5H), 6.70 (d, J = 15.0 Hz, 0.5H), 
6.63 - 6.61 (m, 0.5H), 6.56 – 6.54 (m, 0.5H), 4.77 – 4.71 (m, 2H), 4.57 (d, J = 12 Hz, 1H), 4.19 (d, J = 12.0 Hz, 2H), 
4.06 (d, J = 12.6 Hz, 1H), 3.75 (t, J = 11.4 Hz, 1H), 3.58 (s, 1H), 3.44 (s, 1H), 3.35 (br s, 3H), 3.23 (q, J = 11.4 Hz, J = 
22.2 Hz,3H), 3.07 – 2.93 (m, 4H), 2.73 (s, 1H), 2.28 – 2.24 (m, 1H), 2.20 (br s, 3H), 2.12 – 2.11 (m, 2H), 1.95 – 1.93 
(m, 1H), 1.63 – 1.58 (m, 3H), 1.47 – 1.44 (m, 2H). 13C NMR (150 MHz, DMSO-d6): δ 174.26, 163.81, 157.40, 
156.58, 156.18, 152.98, 144.44, 130.12, 127.16, 126.12, 123.63, 119.00, 115.78, 97.15, 85.35, 71.18, 62.04, 
61.17, 52.95, 52.33, 50.06, 19.23, 45.70, 45.19, 41.60, 34.66, 34.35, 29.53, 27.51, 24.80, 24.51, 23.48, 17.43. IR 
film (cm-1): 3290.7, 2940.0, 1663.7, 1614.5, 1520.9, 1490.1, 1455.4, 1235.5, 1198.8, 1131.3, 831.4, 711.2. HRMS: 
calculated for C39H47N9O3 [M+2H
2+]: 345.69737; found: 345.69732. 
 
Ibrutinib-N3 (7) 
DiPEA (4.0 eq., 70 µL, 0.4 mmol) and azido-PNP ester37  (2.5 eq., 63 mg, 0.25 mmol) were added to a solution of 
crude amine 20 (42 mg, 0.1 mmol) in DMF (0.5 mL). The reaction mixture was stirred overnight before being 
evaporated. The title compound was obtained after RP-HPLC  purification (linear gradient 40%  60% ACN in 
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H2O, 0.1% TFA, 15 min) as a white solid (yield: 20.39 mg, 22.14 µmol, 22.1%). 
1H NMR (600 MHz, DMSO-d6): δ 
8.37 (s, 1H), 8.08 (br s, 1H), 7.66 (br s, 2H), 7.44 (t, J = 8.4 Hz, 2H), 7.20 (t, J = 7.2 Hz, 1H), 7.16 (d, J = 9.0 Hz, 2H), 
7.13 (d, J = 8.4 Hz, 2H), 6.84 (d, J= 15.0 Hz, 0.5H), 6.70 (d, J = 14.4 Hz, 0.5H), 6.63 – 6.60 (m, 0.5H), 6.56 – 6.52 (m, 
0.5H), 4.76 – 4.71 (m, 1H), 4.56 (d, J = 12.0 Hz, 0.5H), 4.19 (d, J = 12.0 Hz, 0.5H), 4.06 (d, J = 12.6 Hz, 0.5H), 3.75 (t, 
J = 10.2 Hz, 0.5H), 3.37 – 3.33 (m, 4H), 3.23 – 3.20 (m, 2H), 3.07 – 2.97 (m, 4H), 2.31 – 2.24 (m, 2H), 2.19 – 2.13 
(m, 6H), 1.95 – 1.93 (m, 2H), 1.77 – 1.75 (m, 4H), 1.63 – 1.53 (m, 2H). 13C NMR (150 MHz, DMSO-d6): δ 171.95, 
163.81, 157.37, 156.19, 153.07, 152.79, 144.31, 143.91, 130.12, 127.25, 126.13, 123.85, 119.00, 115.78, 97.17, 
56.67, 55.04, 52.92, 52.30, 50.16, 49.30, 45.71, 45.19, 41.60, 34.07, 32.12, 29.54, 29.38, 24.81, 24.29, 23.18, 
22.94. IR film (cm-1): 3317.7, 2097.7, 1671.4, 1587.5, 1520.9, 1490.1, 1437.0, 1236.4, 1201.7, 1131.3, 760.3, 
613.4. HRMS: calculated for C36H44N12O3 [M+2H
2+]: 347.19024; found: 347.19022. 
 
Ibrutinib-norbornene (8) 
Azido-ibrutinib 7 (69 mg, 0.1 mmol) and N-(2-propynyl)-5-norbornene-2-carboxamide32 (1.5 eq., 26.3 mg, 0.15 
mmol) were dissolved in DMF (0.5 mL). The reaction mixture was stirred overnight after addition of CuSO4·5 H2O 
(0.2 eq., 20 uL 1 M in H2O, 20 umol) and sodium ascorbate (0.4 eq., 40 uL 1 M in H2O, 40 umol). The mixture was 
then concentrated and purified by RP-HPLC (linear gradient 40%  60% ACN in H2O, 0.1% TFA, 15 min) to yield 
the title compound as a white solid (yield: 10.75 mg, 9.81 µmol, 10.2%). 1H NMR (600 MHz, DMSO-d6): δ 8.34 (s, 
1H), 8.09 (br s, 1H), 8.00 (br s, 1H), 7.08 (s, 1H), 7.67 – 7.66 (m, 2H), 7.45 (t, J = 7.2 Hz, 2H), 7.19 (t, J = 7.2 Hz, 1H), 
7.16 (d, J = 9.0 Hz, 2H), 7.13 (d, J = 8.4 Hz, 2H), 6.84 (d, J = 14.4 Hz, 0.5H), 6.69 (d, J = 14.4 Hz, 0.5 H), 6.63 – 6.61 
(m, 0.5H), 6.56 – 6.53 (m, 0.5H), 6.10 – 6.08 (m, 1H), 5.80 – 5.78 (m, 1H), 4.75 – 4.70 (m, 1H), 4.56 (br s, 1H), 4.33 
(br s, 2H), 4.23 (br s, 2H), 4.08 – 4.05 (m, 1H), 3.78 (dd, J = 2.4 Hz, J = 5.4 Hz, 2H), 3.34 (br s, 2H), 3.25 – 3.21 (m, 
1H), 3.17 (br s, 1H), 3.14 (br s, 1H), 2.97 – 2.92 (br s, 2H), 2.82 – 2.79 (m, 2H), 2.28 – 2.23 (m, 1H), 2.16 9 2.14 (m, 
1H), 2.12 – 2.09 (m, 4H), 2.07 (s, 1H), 2.11 (br s, 2H), 2.00 – 1.93 (m, 1H), 1.78 – 1.72 (m, 3H), 1.68 – 1.54 (m, 2H), 
1.33 – 1.22 (m, 9H). 13C NMR (150 MHz, DMSO-d6): δ 172.87, 172.66, 171.70, 163.80, 158.32, 158.10, 157.32, 
156.19, 153.20, 147.73, 145.42, 136.83, 132.21, 132.02, 130.12127.73, 127.47, 126.59, 123.84, 122.51, 118.99, 
97.23, 81.61, 72.37, 69.75, 55.08, 54.03, 49.34, 48.71, 47.37, 46.64, 45.48, 43.23, 42.07, 34.33, 31.85, 28.41, 
27.83, 25.72. IR film (cm-1): 3337.0, 2945.4, 1663.7, 1518.0, 1490.1, 1446.7, 1418.7, 1235.5, 1199.8, 1185.3, 
839.1, 799.5, 720.4. HRMS: calculated for C47H57N13O4 [M+2H
2+]: 434.74010; found: 434.74012. 
 
Experimental procedures: biochemistry 
 
General 
Ramos cells, a Burkitt’s lymphoma B lymphocyte cell line, were cultured on Dulbecco's Modified Eagle Medium: 
Nutrient Mixture F-12 (DMEM/F-12) supplemented with 10% Fetal Bovine Serum, 0.1 mg/mL penicillin, 0.1 
mg/mL streptomycin in a 5% CO2 humidified incubator at 37° C. Cell lysates were prepared from cell pellets by 
resuspension in cold digitonin lysis buffer (50 mM Tris pH 7=0, 250 mM sucrose, 5 mM MgCl2, 1 mM DTT, 0.025% 
digitonin; 3x pellet volume), incubation on ice for 30 min and centrifugation for 15 min at 16, 000 g (4° C), after 
which the supernatants containing the cytosolic fractions were collected and the protein concentration was 
determined by Qubit® Protein Assay kit. Precipitations of proteins was done using a chloroform/methanol (c/m) 
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precipitation protocol.38 SDS-PAGE analysis: in-gel fluorescence was measured on a ChemiDoc MP system (Cy2 
settings, 530/30 filter and Cy3 settings, 605/50 filter) and analysed using Image Lab 4.1. As a loading control gels 
were stained with Coomassie Blue. Protein standard is Dual Color protein standard (DC, Bio-Rad).  
IMAP Reaction Buffer (10 mM Tris-HCl, 10 mM MgCl2, 0.01% Tween-20, 0.05% NaN3 pH 7.2) and the IMAP 
Progressive Binding System (IMAP Progressive Binding Buffer A, IMAP Progressive Binding Buffer B, and IMAP 
Progressive binding Reagent), were all from Molecular Devices. 
 
IMAP FP assay 
Compounds 1, 6, 7 and 8 (5 µL 10x solution in DMSO/kinase reaction (KR)-buffer, such that the final 
concentration of DMSO was 4%) and 100 mU/mL BTK (5 µL 100 mU/mL in KR-buffer) were incubated for 60 min 
at room temperature. Next, 50 nM of Fluorescein labeled Blk/Lyntide substrate (5FAM-EFPIYDFLPAKKK-NH2, 5 µL 
200 nM in KR-buffer) and 5 µM ATP (5 µL  20 µM in KR-buffer) were added to the mixture and incubated for 120 
min at room temperature. The reaction was stopped after 120 min by a 40 µL addition of IMAP binding reagent 
in binding buffer and read on the Envision 2102 Multilabel Reader, Dichroic mirror D505FP/D535, exitation filter: 
480 nm cwl. Parallel and perpendicular filters 535 nm cwl. For every measurement 18 wells were used as 
minimum wells (wells with ATP, 0% effect), 18 wells were used as maximum wells (wells without ATP, 100% 
effect). 16 wells were used to measure the background signal, which contained no substrate. Enzyme, substrate, 
and ATP were prepared in kinase reaction buffer containing 1 mM DTT. The IMAP binding reagent was 2000x 
diluted in the binding buffer. 
 
In vitro labeling of BTK in Ramos cells (ABPs 4 and 5) 
Ramos cell lysates (30 µg total protein per experiment) in lysis buffer (9 µL) were exposed to the indicated 
concentrations of the ABP (1 µL 10x solution in DMSO) for 1 hr at room temperature. The reaction mixtures were 
then boiled for 5 min at 95° C with 3.3 µL 4x Laemmli’s sample buffer containing 2-mercaptoethanol and resolved 
on 10% SDS-PAGE, followed by fluorescence scanning (Cy2 or Cy3 settings) and CBB staining. 
 
In situ labeling of BTK in Ramos cells (ABPs 4 and 5) 
Ramos cells (±1x107 cells per experiment) were exposed to the indicated concentrations of the ABP (1 µL 10000x 
solution in DMSO) in 10 mL fresh medium for 4 hrs at 37° C, before being centrifuged for 5 min at 1200 rpm, and 
washed with PBS (3x). The cell pellets were then flash frozen in liquid nitrogen and lysed in 30 µL lysis buffer. The 
lysates (30 µg total protein per experiment) in lysis buffer (10 µL) were boiled for 5 min at 95° C with 3.3 µL 4x 
Laemmli’s sample buffer containing 2-mercaptoethanol and resolved on 10% SDS-PAGE. In-gel visualization of 
the fluorescent labeling was performed in the wet gel slabs directly using Cy2 or Cy3 settings. 
 
Competition experiments of ABP 4 versus ABPs 6-8: in situ modification of BTK by ABP 4 and in vitro 
competition by ABPs 6-8 . 
Ramos cells (±5x106 cells per experiment) were seeded in 6 cm petri dishes and grown 2 hrs at 37° C, before 
being exposed to the indicated concentrations of ABP (2 µL 1000x solution in DMSO) in 2 mL fresh medium for 3 
hrs at 37° C. Next, the cells were centrifuged for 5 min at 1200 rpm, and washed with PBS (3x), before flash 
131 
freezing the cell pellets in liquid nitrogen and cell lysis in 15 µL lysis buffer. The lysates (30 µg total protein per 
experiment) in lysis buffer (10 µL) were exposed to 1 µM ABP 4 (1.11 µL 10x solution in DMSO) for 1 hr at room 
temperature, boiled for 5 min at 95° C with 3.7 µL 4x Laemmli’s sample buffer containing 2-mercaptoethanol and 
resolved on 10% SDS-PAGE. In-gel visualization of the fluorescent labeling was directly performed in the wet gel 
slabs using Cy2 or Cy3 settings. 
 
In vitro tetrazine ligation  
Ramos lysates (50 µg total protein per experiment) in lysis buffer (9 µL) were exposed to 4 µM ABP 8 (1 µL 40 µM 
in DMSO) for 1 hr at room temperature, followed by addition of 1% SDS (1.11 µL 10% SDS in H2O) and boiling for 
5 min at 95° C. Hereafter, the lysates  were exposed for 1 hr at room temperature to the indicated 
concentrations of tetrazine 24 (1.23 µL 10x solution in DMSO). In control experiments, lysates were treated with 
ABP 4 (1 µM) (positive control) or subjected to tetrazine labeling in the absence of ABP 8 (background control). 
As a negative control, tetrazine ligation was performed on lysates pretreated with 20 µM ibrutinib (1). After the 
ligation reaction proteins were precipitated by c/m precipitation and taken up in 10 µL 8 M urea and 3.5 µL 4x 
Laemmli’s sample buffer containing 2-mercaptoethanol, boiled for 5 min at 95° C and resolved on 10% SDS-
PAGE. In-gel visualization of the fluorescent labeling was performed in the wet gel slabs directly using Cy2 
settings. 
 
In situ and post-lysis tetrazine ligation  
Ramos cells (±5x106 cells per experiment) were seeded in 6 cm petri dishes and grown 2 hrs at 37° C, before 
being exposed to 4 µM ABP 8  (2 µL 1000x solution in DMSO) in 2 mL fresh medium for 3 hrs at 37° C. After 
centrifugation of the cells for 5 min at 1200 rpm, the cells were washed with fresh medium for 5 min at 37° C 
(3x), and then exposed to 25 µM of tetrazine 24 (4 µL 10x solution in DMSO) in 4 mL fresh medium for 1 hr at 37° 
C. As a positive control, cells were exposed to ABP 4 (1 µM) for 3 hrs at 37° C. As a background control, cells were 
lysed and subjected to tetrazine labeling in the absence of ABP 8. Next, cells were harvested in PBS, centrifuged 
for 5 min at 1200 rpm, and washed with PBS (3x), before flash freezing the cell pellets in liquid nitrogen and cell 
lysis in 15 µL lysis buffer. The lysates (50 µg total protein per experiment) in lysis buffer (10 µL) were precipitated 
by c/m precipitation and taken up in 10 µL 8 M urea and 3.5 µL 4x Laemmli’s sample buffer containing 2-
mercaptoethanol, boiled for 5 min at 95° C. the proteins were resolved on 10% SDS-PAGE. Fluorescence was 
measured in the wet gel slabs  using Cy2 settings. 
For post-lysis ligation experiments, cells were harvested directly after treatment with ABP 8 and lysed. The 
lysates (50 µg total protein per experiment) in lysis buffer (10 µL) were boiled for 5 min at 95° C after addition of 
1% SDS (1.11 µL 10% SDS in H2O) and boiling for 5 min at 95° C. Next, the lysates were exposed for 1 hr at room 
temperature to 25 µM of tetrazine 24 (1.23 µL 10x solution in DMSO). After the ligation reaction proteins were 
precipitated by c/m precipitation and taken up in 10 µL 8 M urea and 3.5 µL 4x Laemmli’s sample buffer 
containing 2-mercaptoethanol, boiled for 5 min at 95° C and resolved on 10% SDS-PAGE. In-gel visualization of 




Copper(I)-catalyzed click ligation in vitro 
Ramos lysates (50 µg total protein per experiment) in lysis buffer (9 µL) were exposed to 4 µM ABP 6 or 7 (1 µL 
40 µM in DMSO) for 1 hr at room temperature. The reaction mixtures were subsequently diluted with an 
additional 9 µL buffer containing 6.5 mM CuSO4 (0.58 µL 100 mM in H2O), 6.5 mM THPTA (0.58 µL 100 mM in 
H2O), 6.5 mM sodium L-ascorbate (0.58 µL 100 mM in H2O) and exposed for 1 hr at room temperature to the 
indicated concentrations of azide 22 (reaction with 6) or alkyne 23 (reaction with 7) (1 µL 20x solution in DMSO). 
In control experiments, lysates were treated with ABP 4 (1 µM) (positive control) or subjected to azide or alkyne 
labeling in the absence of an ABP (background control). Alternatively, click ligation was performed on lysates 
pretreated with 20 µM ibrutinib (1) (negative control). Next, proteins were precipitated by c/m precipitation and 
taken up in 10 µL 8 M urea and 3.5 µL 4x Laemmli’s sample buffer containing 2-mercaptoethanol, boiled for 5 
min at 95° C and resolved on 10% SDS-PAGE. In-gel visualization of the fluorescent labeling was performed in the 
wet gel slabs directly using Cy2 settings. 
 
In situ modification of BTK by ABPs 6 or 7 followed by in vitro copper(I)-catalyzed click ligation  
Ramos cells (±5x106 cells per experiment) were seeded in 6 cm petri dishes and grown 2 hrs at 37° C, before 
being exposed to 4 µM ABP 6 or 7  (2 µL 1000x solution in DMSO) in 2 mL fresh medium for 3 hrs at 37° C. As a 
positive control, cells were exposed to ABP 4 (1 µM) for 3 hrs at 37° C. As a background control, cells were lysed 
and subjected to click labeling in the absence of ABP 6 or 7. Next, the cells were centrifuged for 5 min at 1200 
rpm, and washed with PBS (3x), before flash freezing the cell pellets in liquid nitrogen and cell lysis in 15 µL lysis 
buffer. The lysates (50 µg total protein per experiment) in lysis buffer (10 µL) were diluted with an additional 9 µL 
buffer containing 6.5 mM CuSO4 (0.58 µL 100 mM in H2O), 6.5 mM THPTA (0.58 µL 100 mM in H2O), 6.5 mM 
sodium L-ascorbate (0.58 µL 100 mM in H2O) and exposed for 1 hr at room temperature to 25 µM of azide 22 
(reaction with 6) or alkyne 23 (reaction with 7) (1 µL 20x solution in DMSO). Next, proteins were precipitated by 
c/m precipitation and taken up in 10 µL 8 M urea and 3.5 µL 4x Laemmli’s sample buffer containing 2-
mercaptoethanol, boiled for 5 min at 95° C and resolved on 10% SDS-PAGE. In-gel visualization of the fluorescent 
labeling was performed in the wet gel slabs directly using Cy2 settings. 
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The isoquinolinesulfonamide-based kinase inhibitor H-89 (1, Scheme 1) was 
originally identified as a selective and potent inhibitor of protein kinase A (PKA)
1
 
and has been used to study the role of PKA in various physiological processes.
2
 H-89 
inhibits PKA in an ATP-competitive manner with the bromocinnamoyl side chain 
being a crucial factor for the potency and selectivity over other kinases.
3
 Though 
initially presented as a selective PKA inhibitor, H-89 also inhibits a number of other 
kinases, which is not surprising taking into account that the ATP binding site is 
6 
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Scheme 1. Structures of the lead compounds: H-89 (1) and ETB067 (2) and structures of target 
compounds: diazerine-functionalized photocrosslinking probes 3 (E) and 4 (Z).   
 
conserved in all kinases.
2,4
 PKBα, also referred to as AKT1, is a prominent target of 
H-89 because of its importance in cancer therapy research. The PI3K/AKT signaling 
pathway, hyper-activated in many cancer types
5
, has effects on vital cellular 
processes such as survival, metabolism, growth and proliferation.
6
 AKT signaling 
also influences angiogenesis and is involved in metastasis formation via the isoform 
AKT2. In addition, the PI3K/AKT pathway connects to another critical cell signaling 
pathway: the Ras/Raf/MEK/ERK signaling cascade.
7
 Aside from its involvement in 
cancer, AKT1 has also been shown to be a key player in bacterial infections by 
regulation of a network of enzymes essential for the survival of pathogens in 
phagosomes of host cells. In this context, H-89 and its derivative ETB067 (Scheme 1) 
were used to distinguish AKT1 from PKA as the crucial enzyme in the control of 
intracellular bacteria such as Salmonella typhimurium and M. tuberculosis.
8 
AKT1 
inhibitors are the first lead antibiotics described that target host proteins rather 
than bacterial processes. 
In the last years, a number of techniques to profile kinases have emerged, such as 
the kinobead approach that has recently been used to cluster the activity of well-
known inhibitors in a kinome-wide screen.
9
 Another important technique is capture 
compound mass spectrometry (CCMS), which is based on combining photo-affinity 
labeling with biotin-based capture techniques in order to pull-down proteins that 
bind to an inhibitor and have been covalently captured following photo-affinity 
labeling. This approach has been used to identify targets of dasatinib, imatinib and 
staurosporine by converting the inhibitors into capture compounds.
10
 The 
staurosporine capture compound could also be used in comprehensive kinase 





Finally, covalent irreversible kinase inhibitors have received increasing attention 
both in drug discovery programs and as starting points for kinase bait design. Most 
of these mechanism-based inhibitors rely on a cysteine thiol in proximity of the 
binding site that is covalently modified upon binding of the inhibitor.
12
 This 
approach was recently used to target Bruton’s tyrosine kinase with Ibrutinib-
derived mechanism-based probes.
13
 However, not all kinases possess cysteines 
near the active site, and this holds true as well for PKA and AKT1.
12
 
This study aimed at developing a probe derived from H-89 that a) binds efficiently 
to the target kinases PKA and AKT1; b) contains a photo-activatable group enabling 
a covalent modification of a captured kinase and c) carries a conjugation handle to 
attach a reporter moiety such as a fluorophore or biotin using copper-catalysed 
click chemistry. The studies on H-89 clearly show that the cinnamoyl side chain has 
an effect on potency and selectivity,
3
 so this moiety in the design was kept and the 
aromatic part of the side chain was modified into an aryl trifluoromethyldiazirine 
(Scheme 1). Based on the previous studies on ETB067, modification on the double 
bond of the cinnamoyl system should not have a major influence on activity and 
therefore a short alkyl chain bearing an azide moiety to enable click labeling has 
been placed. 
 
Synthesis of H-89-based kinase photo-affinity based probes 
The synthetic route towards H-89-based photo-affinity based probes 3 and 4 is 
depicted in Scheme 2. The synthesis commenced from commercially available 
diethyl cyanomethylphosphonate 5, which was reacted with trityl-protected 
bromopropanol 6
14
 to obtain monoalkylated cyanomethylphosphonate 7 in 53% 
yield. The yield is affected by the fact that dialkylation also occurred, and 
separation of the two products by column chromatography appeared cumbersome. 
Before installing the photo-affinity moiety into the probes, 
trifluoromethylphenyldiazirine functionalised alcohol 8, which was synthesized by 
applying a seven step literature procedure
15
, was converted into its corresponding 
aldehyde 9 by Swern oxidation. Next, a Horner-Wadsworth-Emmons (HWE) 
reaction between p-substituted benzaldehyde 9 and phosphonate 7 resulted in α-
substituted cinnamonitrile 10 as a 3/2 mixture of E/Z isomers in 79% yield. Since 
separation of the isomers in the nitrile-stage was partially successful, and the 
nitriles were observed to isomerise during the ensuing transimination, the nitriles 
were used in the following reaction as an E/Z mixture. Subsequently, E/Z 
cinnamonitrile mixture 10 was used in the four-step-one-pot trans-imination  
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Scheme 2. Reagents and conditions: a) NaH, 6, 0 °C, DMF, 53%; b) DMSO, (COCl)2, TEA, -78 °C, 89%; c) 
NaH, 9, 0 °C, THF, E/Z = 3/2, 79%; d) i) DiBAlH, -78 °C, Et2O/DCM 1:1 v/v; ii) MeOH, -100 °C; e) SOCl2, 
reflux, DMF; ii) ethylenediamine, DCM, 0 °C, 69%; f) i) 13, MeOH, RT; ii) NaBH4, -10 °C to RT; ii) TFA, DCM, 
H2O; vi) Boc2O, TEA, DCM, 0 °C, 16% (18), 14% (19); f) i) TEA, DMAP, TsCl, -20 °C, DCM; ii) NaN3, DMF, RT, 
14% (20), 14% (21); g) TFA, DCM, RT, 14% (3), 14% (4).  
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procedure according to Brussee et al.
16
, which started with the reduction of nitrile 
10 with DiBAlH to form its corresponding aluminated iminium salt intermediate. 
Excess reagent was then quenched at -100 °C with methanol to obtain the primary 
imine 11. The latter was reacted with amine 13, which was obtained by activating 
isoquinoline sulfonic amine 12 with thionyl chloride and reacting with 
ethylenediamine. Next, the resulting secondary imine was reduced by NaBH4 and 
the crude trityl-protected isoquinolinesulfonamide mixture of 14 and 15 was 
deprotected under acidic conditions to obtain a crude mixture of 16 and 17 before 
instalment of the Boc-group to yield isoquinolinesulfonamide 18 and 19 as crude 
E/Z mixture. HPLC purification allowed separation and isolation of both isomers. 
Both alcohols 18 and 19 were tosylated followed by substitution using NaN3 to 
obtain compounds 20 and 21. At last, deprotection of the Boc-group furnished the 
photo-affinity based probes 3 and 4 in 14% yield after HPLC purification. 
 
 
Evaluation of the inhibitory potency and labeling efficiency 
 
With probes 3 and 4 in hand, their biological activity was evaluated. First, the 
capability of these probes to label a panel of 111 human kinases was examined, 
which was performed by the company LeadHunter discovery services using a single 
point kinase active site-directed competition binding Kinomescan
TM
 assay (see 
Chapter 2 for a detailed description)
17
. Briefly, purified recombinant kinases (111 in 
total) tagged with DNA for qPCR detection are incubated with 10 µM of test 
compound (here: probe 3 or 4) and subsequently the mixture of kinases and test 
compound is transferred to an immobilized ligand that competes with probes for 
binding to kinases. The results for binding interactions are reported as relative 
activity percentage, where lower numbers indicate stronger hits in the matrix 
(Table 1). From Table 1, it can be concluded that the probes 3 and 4 have a 
preference to inhibit Ser/Thr kinases, since the top ten hits all belong to this family. 
As expected probe 3, of which the structure and conformation is most similar to 
PKA inhibitor H-89 (1), inhibits PKA and AKT1 more than its Z-analogue 4. Both 
probes also inhibited the related kinases AKT2 and AKT3, however at a much lower 




Table 1. Relative kinase activity compared to control sample (%) after inhibition by compounds 3 and 4 
(10 µM).a  
Kinase 3 4 Kinase 3 4 
PKAc-α 1.5 3.4 TAOK1 72 52 
AKT1 2.6 18 MEK2 73 72 
ROCK2 3 1.7 FAK 74 100 
AKT3 3.4 25 VEGFR2 75 85 
PRKCH 5 2.8 CLK2 76 72 
PRKCE 20 10 JNK1 78 82 
PRKCD 23 14 TYK2 78 97 
SNARK 23 24 TRKA 79 82 
SGK3 31 32 AURKB 80 79 
CDK11 35 78 GSK3B 80 74 
PRKCI 35 35 PCTK1 80 84 
CSNK1D 39 38 JNK3 81 89 
MARK3 40 53 FGFR3 82 84 
CDK7 43 48 PIK3CG 82 78 
DYRK1B 45 74 PLK1 82 83 
ALK 50 62 YANK3 82 88 
FLT3 50 60 MAPKAPK2 83 95 
MLCK 50 76 PIM1 83 81 
CSF1R 51 96 ULK2 83 65 
TSSK1B 53 56 ZAP70 83 94 
AXL 54 74 DYRK1A 84 85 
CHEK1 56 72 ERBB4 84 90 
SRPK3 57 86 ERN1 85 57 
CDK9 58 70 LKB1 85 94 
PDGFRB 58 57 PAK4 86 98 
PIP5K1A 58 37 ACVR1B 87 100 
PDPK1 59 69 p38-beta 87 100 
PLK4 59 57 CSNK1G3 89 91 
RET 59 76 ERBB2 89 64 
FGFR2 60 67 INSR 89 81 
KIT 61 70 PAK2 89 96 
AMPK-α2 63 83 TGFBR1 89 88 
DCAMKL1 63 86 PIM3 90 94 
PRKCQ 63 46 AURKA 91 69 
EPHA2 65 66 JAK3 91 84 
MAP3K4 65 68 PDGFRA 91 98 
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AKT2 66 91 RAF1 91 78 
CDK2 66 92 BMPR2 92 89 
CDK3 66 78 PIK3CA 93 94 
ABL1-p 67 81 CSNK1G2 94 80 
JAK2 67 90 MEK1 95 83 
MET 67 55 PAK1 95 95 
RSK2 67 72 BTK 96 92 
TIE2 68 86 p38-α 96 94 
ERK1 69 70 HIPK2 97 95 
JNK2 69 86 EGFR 98 100 
PLK3 69 73 PIK3C2B 98 94 
PIM2 70 62 IKK-beta 99 80 
SRC 70 70 MKNK1 99 92 
ADCK3 71 96 PIK4CB 99 97 
MKNK2 71 71 BRAF 100 93 
MST2 71 73 IKK-alpha 100 86 
FLT1 72 69 MTOR 100 100 
IGF1R 72 63 MYO3A 100 100 
MLK1 72 69 RIOK2 100 88 
MUSK 72 77    
To further establish the potency of the probes and lead compound H-89 (1) for the 
kinases, PKA, AKT1 and AKT2, their IC50 values were determined in a FRET-based 
assay and their corresponding Ki values were calculated. The results are presented 
in Table 2.  
 
Table 2. Inhibitory activities of compounds H-89, 3 and 4 against PKA, AKT1 and AKT2 (IC50 and Ki values 
in µM). 





1.88 ± 0.64 
0.02 ± 0.01 
0.97 ± 0.12 
0.09 ± 0.01 
2.47 ± 0.38 





75.5 ± 12.54 
0.61 ± 0.10 
3.2 ± 1.13 
0.02 ± 0.00 
23.1 ± 1.06 





74.7 ± 23.12 
0.60 ± 0.10 
10.5 ± 4.58 
0.04 ± 0.01 
34.4 ± 2.38 
0.23 ± 0.03 
 
This kinase assay revealed that probes 3 and 4 are highly potent inhibitors of AKT1 
having Ki values varying from 0.02 to 0.04 µM, which are significantly lower than the 
ones observed for PKA. The trend observed in the Kinomescan for AKT1 is however 
142 
preserved with probe 4 being the less potent of the two. A possible explanation for 
the discrepancy between the assays might be the use of the natural substrate ATP 
as a competitor to the probes in the FRET-based assay. By comparing the IC50 and Ki 
values of probes 3 and 4 with the lead compound H-89 (1), both probes show less 
activity against PKA, AKT1 and AKT2, but have higher selectivity. Having confirmed 
the activity of the two probes, a protocol for the photo-labeling of the kinases PKA 
and AKT1 was designed to validate these compounds as potential photo-affinity 
based probes.  
Using recombinant PKA and AKT1 a robust protocol for the labeling of the kinases 
with the respective probe was first elucidated, followed by photo-crosslinking at 




 (Caprotec Bioanalytics GmbH, 
Berlin) and a final click reaction with an alkyne-modified Cy5 reporter for in-gel 
analysis. Using different concentrations of probe the amounts of probe equivalents 
required to label the respective kinases was determined. For both PKA and AKT1 5 
equivalents of probe (390 nM, PKA; 295 nM AKT1) with respect to the molar 
amount of kinase were sufficient to label and detect the kinases by in-gel 
fluorescence (Figure 1, lane 3). Already in these initial experiments it became 
apparent that probe 3 labels both kinases with a higher affinity than probe 4, 
especially in the case of AKT1. The overall stronger labeling of PKA compared to 
AKT1 can be explained with a higher specific activity of the commercially obtained 
kinase. The differences in AKT1 labeling are in accordance with the kinetics data. 
Taking these first results into account, a focus was set on the evaluation of probe 3 
in the following experiments. 
 
Figure 1. Initial photo-labeling experiments on recombinant kinases using different probe 
concentrations. Left panel: photolabeling of recombinant PKA using probes 3 and 4. Right panel: photo-
labeling of recombinant AKT1 using probes 3 and 4. 
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Subsequently, to prove that the labeling that had been observed in the initial 
experiments is truly based on affinity to the target kinases and requires active 
kinases, a number of control experiments have been conducted. First, in order to 
establish if the labeling is affinity-based, the kinases were mixed with increasing 
amounts (w/w) of a control protein of similar size and incubated with 5 eq. of 3 
(Figure 2, lanes 5-10). The 1:1 controls were also used for further control 
experiments: one sample was incubated with DMSO and the click mixture to 
visualize background from association of the proteins with the Cy5 dye (Figure 2, 
lane 2). A second sample was not irradiated after incubation with the probe, to 
establish that the UV activation is necessary for labeling (Figure 2, lane 3). Finally, a 
third sample was denatured by the addition of SDS and subsequent boiling and 
then treated with the probe to prove that an active enzyme is required for the 
labeling (Figure 2, lane 4). For both PKA and AKT1 the co-incubation experiment 
with equivalent amounts of a control protein reveals that the labeling of the 
targeted kinases with our probes is based on the affinity of the probe towards the 
target. At higher concentrations of control protein an unspecific reaction of the  
 
Figure 2. Control experiments using increasing concentrations of Transferrin (PKA, left panel) and β-
Galactosidase (AKT1, right panel) as control proteins to determine probe specificity (lanes 5-10). Further 
controls with 1:1 (w/w) mixtures of kinase and control protein were used to check for background 
labeling (lane 2), requirement of UV activation (lane 3) and requirement of an active kinase (lane 4). 
 
probe with the control protein and a partial loss of signal for the kinase is observed, 
especially in the case of AKT1. It has to be noted, that throughout all experiments 
the labeling of AKT1 was less intense than the labeling of PKA. Since the IC50 values 
that have been determined for both kinases are in the same range for probe 3, this 
observation could be explained with different specific activities of the recombinant 
kinases used in the experiments.  
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The additional control experiments proved that an active enzyme is indeed required 
to achieve labeling proven by the disappearance of the labeled kinase when 
denaturing the sample before incubation with the probe. Also, the labeling relies on 
UV irradiation proven by the absence of bands in the non-irradiated samples. 
In the next set of experiments, competition between 3 and the well-known broad-
spectrum kinase inhibitor staurosporine
17
 and the parent inhibitors to our probes, 
H-89 (1) and ETB067 (2), were visualized. For PKA a very clear competition when 
pre-incubating with staurosporine was observed, already at 0.5 equivalents to 
probe 3 (Figure 3, upper panel). For AKT1 a competition is observed as well, 
however, higher concentrations of staurosporine would be required to achieve full 
competition (Figure 3, middle panel). Furthermore, the already mentioned lower 
intensity of labeling for AKT1 not only hampers the visual detection of the 
competition, it also hinders an accurate quantification by fluorescent densitometry 
of the bands due to their low intensity (Figure 3, lower panel).  
 
Figure 3 Competition experiments on PKA (upper panel) and AKT1 (middle panel) using Staurosporine as 
competitor to probe 3. Quantification of residual activity (lower panel) by fluorescent densitometry from 




In the competition experiments with H-89 and ETB067, H-89 showed a higher 
inhibition than ETB067 for both kinases, which is in accordance with previously 
reported IC50 data (Figure 4).
8
 For PKA (Figure 4, left panel) a distinct inhibition 
profile for increasing concentrations of the competitors both in the visual detection 
of the bands as well as in the quantification of the detected bands was observed. 
The apparent poorer inhibition of AKT1 can again be explained with the lower signal 
intensity. 
 
Figure 4 Competition experiments on PKA (left panel) and AKT1 (right panel) using H-89 and ETB067 as 
competitors to probe 3. Quantification of residual activity (lower panel) by fluorescent densitometry 




Two photo-affinity probes based on the well-known kinase inhibitor H-89 (1) have 
been designed and synthesized. The probes were tested on a panel of kinases and 
proved to be inhibitors of both PKA and AKT1. Probe 3 has the same double bond 
geometry as the parent inhibitor H-89 (1) and inhibits both PKA and AKT1 with a 
high potency. A change of the double bond configuration to (Z) does not have 
significant influence on the inhibition of PKA but for AKT1 a partial loss of potency 
was observed. This indicates a difference in the periphery of the two kinases and 
offers a possibility to improve selectivity towards AKT1. Furthermore, the efficacy 
of both probes in the photolabeling of the clinically relevant kinases PKA and AKT1 
is shown. The performed experiments however also show that photolabeling 
conditions need to be adjusted for every new target enzyme. In this study, the 
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recombinant kinases in pure form as well as in mixtures with control proteins could 
be labelled; additionally a variety of control experiments reveal that the probes act 
in an affinity-based manner on active enzymes and that UV activation is required 
for labeling have been performed. Furthermore, competition experiments with 
different kinase inhibitors have been performed.  
Generating photo-affinity labelled kinase inhibitors is an attractive way to identify 
other kinase inhibitors and – when used in cell lysates in combination with a 
conjugation handle – to identify novel inhibitor-novel kinase targets in a relatively 
unbiased manner. The isolation and identification then have to be improved for 
reliable detection of targets. This may be achieved by optimizing the probes with in 
silico methods for an optimal placement of the photo-affinity group and the 
isolation handle. Furthermore, alternative bioconjugation handles could improve 





General materials and methods 
Tetrahydrofuran (THF) was distilled over LiAlH4 before use. Acetonitrile (ACN), dichloromethane (DCM), 
N,N-dimethylformamide (DMF), methanol (MeOH) and trifluoroacetic acid (TFA) were of peptide 
synthesis grade, obtained from Biosolve, and were used as received. All general chemicals (Fluka, Acros, 
Merck, Aldrich, Sigma) were used as received. Traces of water were removed from reagents used in 
reactions that require anhydrous conditions by co-evaporation with toluene. Solvents that were used in 
reactions were stored over activated 4Å molecular sieves, with the exception of methanol and 
acetonitrile which were stored over activated 3Å molecular sieves. Unless noted otherwise all reactions 
were performed under an argon atmosphere. Column chromatography was performed on Silicycle Silia-P 
Flash Silica Gel, with a particle size of 40 – 63 µm. The eluents toluene and ethyl acetate were distilled 
prior to use. TLC analysis was conducted on Merck aluminium sheets (Silica gel 60 F254). Compounds 
were visualized by UV absorption (254 nm), by spraying with a solution of (NH4)6Mo7O24·4H2O (25 g/L) 
and (NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% sulphuric acid, a solution of KMnO4 (20 g/L) and K2CO3 (10 g/L) 
in water, or ninhydrin (0.75 g/L) and acetic acid (12.5 mL/L) in ethanol, where appropriate, followed by 
charring at ca. 150 °C. 1H- and 13C-NMR spectra were recorded on a Bruker DMX-400 (400 MHz) or a 
Bruker DMX-600 (600 MHz) spectrometer. Chemical shifts are given in ppm (δ) relative to 
tetramethylsilane (1H-NMR) or CDCl3 (
13C-NMR) as internal standard. Mass spectra were recorded on a 
PE/Sciex API 165 instrument equipped with an Electrospray Interface (ESI) (Perkin-Elmer). High-
resolution MS (HRMS) spectra were recorded with a Finnigan LTQ-FT (Thermo Electron). IR spectra were 
recorded on a Shimadzu FTIR-8300 and absorptions are given in cm-1. Optical rotations [α]D23 were 
recorded on a Propol automatic polarimeter at room temperature. LC-MS analysis was performed on a 
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Jasco HPLC system with a Phenomenex Gemini 3 µm C18 50 x 4.6 mm column (detection simultaneously 
at 214 and 254 nm), coupled to a PE Sciex API 165 mass spectrometer with ESI. HPLC gradients were 10 
→ 90%, 0 → 50% or 10 → 50% ACN in 0.1% TFA/H2O. Chiral HPLC analysis was performed on a 
Spectroflow 757 system (ABI Analytical Kratos Division, detection at 254 nm) equipped with a Chiralcel 
OD column (150 x 4.6 mm). The compounds were purified on a Gilson HPLC system coupled to a 
Phenomenex Gemini 5 µm 250 x 10 mm column and a GX281 fraction collector. The used gradients were 
either 0 → 30% or 10 → 40% ACN in 0.1% TFA/water, depending on the lipophilicity of the product. 
Appropriate fractions were pooled, and concentrated in a Christ rotary vacuum concentrator overnight 
at room temperature at 0.1 mbar. 
 
Diethyl (1-cyano-4-(trityloxy)butyl)phosphonate (7) 
To an ice-cold solution of NaH (1 eq., 0.20 g, 5.1 mmol, 60% mineral oil) in DMF (15 mL) diethyl 
cyanomethylphosphonate 5 (0.89 g, 5.0 mmol) was added slowly and allowed to stir for 30 min before 
addition of ((3-bromopropoxy)methanetrityl) tribenzene 6 (1 eq., 1.94 g, 5.1 mmol). The reaction 
mixture was allowed to warm to RT and then stirred overnight. The mixture was diluted with H2O (75 
mL) and Et2O (25 mL), the layers were separated, the aqueous phase extracted with Et2O (3 x 25 mL) and 
the combined organic phases were washed with sat. aq. NaHCO3 and brine, dried over MgSO4, filtered 
and concentrated in vacuo. The residue was further purified by silica column chromatography (10%  
50% EtOAc/PE) to afford the title compound as pale yellow oil (yield: 1.27 g, 2.7 mmol, 53%). RF = 0.3 
(50% EtOAc/PE). 1H-NMR (400 MHz, CDCl3, Me4Si) δ 7.42 (6H, d, J = 7.2 Hz, 6 x CHar), 7.29 (6H, t, J = 6.8 
Hz, 6 x CHar), 7.22 (3H, t, J = 7.2 Hz, 3 x CHar), 4.26 – 4.15 (4H, m, 2 x CH2CH3), 3.14 (2H, t, J = 5.6 Hz, 
CH2OCPh3), 2.95 (1H, ddd, J1 = 4.8, J2 = 10.4 Hz, J3 = 23.2 Hz, CH), 2.12 – 2.00 (1H, m, CH2-H
a), 1.98 - 1.90 
(2H, m, CH2), 1.84 – 1.75 (1H, m, CH2-H
b), 1.35 (6H, m, 2 x CH3). 
13C-NMR (101 MHz, CDCl3) δ 143.82, 
128.40, 127.66, 126.86, 116.12, 86.47, 63.84, 63.46, 61.91, 30.18, 28.76, 27.74, 24.22, 16.23. HRMS: 
calculated for C28H32NO4P [M+H]
+ 478.20690; found 478.20372. 
 
4-(3-(Trifluoromethyl)-3H-diazirin-3-yl)benzaldehyde (9)  
A solution of DMSO (2.5 eq., 3.22 mL, 45.4 mmol) was cooled to -78 °C and oxalyl chloride (1.3 eq., 2.06 
mL, 24.0 mmol) was added dropwise, the reaction mixture was stirred for 30 min at -78 °C. Next, a 
solution of alcohol 8 (3.93 g, 18.2 mmol) in DCM (10 mL) was added slowly. The reaction was stirred for 
1 h at -78 °C before TEA (5 eq., 12.6 mL, 90.8 mmol) was slowly added at -78 °C. The reaction mixture 
was allowed to warm to 0 °C and was subsequently stirred for 3h. A cold aqueous solution of 20% 
KH2PO4 (50 mL) and cold H2O (200 mL) was added and the resulting mixture was stirred for 15 min at RT. 
The mixture was diluted with Et2O (200 mL) and the layers were separated. The organic layer was 
washed with a cold aqueous solution of 10% KH2PO4 (3 x 50 mL) and brine, dried over MgSO4, filtered 
and evaporated in vacuo. The obtained material was purified by column chromatography (1% EtOAc/PE 
 5% EtOAc/PE) and the product was obtained as pale yellow oil (yield: 3.45 g, 16.12 mmol, 89%). 1H-
NMR (400 MHz, CDCl3, Me4Si) δ 10.05 (1H, s, CHO), 7.91 (2H, d, J = 8.4 Hz, 2 x CHar), 7.34 (2H, d, J = 8.0 
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Hz, 2 x CHar). 
13C-NMR (101 MHz, CDCl3) δ 190.85, 136.73, 134.99, 129.65, 126.77, 121.69 (q, J = 275.73 
Hz), 28.31 (q, J = 41.41 Hz). HRMS: calculated for C9H5F3N2O [M+H]
+
 215.03540; found 215.03549. 
 
(E/Z)-2-(4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzylidene)-5-(trityloxy)pentanenitrile (10) 
To an ice-cold suspension of NaH (1.1 eq., 0.64 g, 15.9 mmol, 60% mineral oil) in THF (75 mL) a solution 
of phosphonate 7 (6.91 g, 14.5 mmol) in THF (25 mL) was added dropwise and stirred for 30 min. Next, a 
solution of aldehyde 9 (1.1 eq., 3.45 g, 16.6 mmol) in THF (10 mL) was added and the reaction mixture 
was allowed to warm to RT and stirred overnight. The solution was quenched by addition of freshly 
prepared sat. aq. Na2HSO3 (60 mL) and diluted with H2O (200 mL) and Et2O (100 mL). The layers were 
separated and the aqueous phase was extracted with Et2O (3 x 100 mL). The combined organic layers 
were washed with sat. aq. NaHCO3 and brine, dried over MgSO4, filtered and evaporated. The residue 
was further purified by silica column chromatography (10%  80% toluene/pentane) to afford the title 
compound as a white solid with an E/Z ratio of 3/2 (yield: 6.16 g, 11.5 mmol, 79%). 1H-NMR (400 MHz, 
CDCl3, Me4Si) δ 7.62 (2H, d, J = 8.4, 2 x CHar), 7.42 (6H, d, J = 7.2 Hz, 6 x CHar), 7.27 – 7.15 (11H, m, 11 x 
CHar), 6.82 (1H, s, CH), 3.14 (2H, t, J = 5.6 Hz, CH2), 2.55 (2H, t, J = 7.2 Hz, CH2), 1.98 – 1.91 (2H, m, CH2). 
13C-NMR (101 MHz, CDCl3) δ 144.02, 142.03, 134.84, 130.34, 128.71, 128.51, 128.16, 126.94, 126.57, 
121.91 (q, 198.97 Hz), 125.24, 118.16, 112.96, 86.46, 61.51, 33.51, 28.23. HRMS: calculated for 
C33H26F3N3O [M+H]
+ 538.20280; found 538.20293. 
 
N-(2-aminoethyl)isoquinoline-5-sulfonamide (13) 
Isoquinoline-5-sulfonic acid 12 (20.92 g, 100 mmol) was treated with thionylchloride (13 eq., 91.5 mL, 
1300 mmol) and a catalytic amount of DMF for 2h at reflux. The reaction mixture was concentrated and 
the residue was thoroughly washed with DCM before being re-suspended in H2O (300 mL) at 0 °C. 
NaHCO3 (1 eq., 8.42 g, 100.2 mmol) was added portion-wise. Next, the mixture was extracted with DCM 
(3x 500 mL) and dried over MgSO4. The filtrate was added dropwise to a cooled solution of ethylene 
diamine (5 eq., 33.4 mL, 500 mL) in DCM (250 mL) and the reaction mixture was allowed to warm to RT 
and stirred for 1h. The mixture was then concentrated before being washed with brine (50 mL). The 
aqueous layer was extracted with DCM (10 x 50 mL) and the combined organic layers were washed with 
brine (50 mL), dried over MgSO4, filtered and concentrated. The title compound was obtained as a thick 
yellow oil (yield: 17.3 g, 69 mmol, 69%) and was used without further purification. 1H-NMR (400 MHz, 
CDCl3, Me4Si) δ 9.36 (1H, s, CHar), 8.67 (1H, d, J = 8.4 Hz, CHar), 8.47 – 8.43 (2H, m, 2 x CHar), 8.21 (1H, d, J 
= 11.2 Hz, CHar), 7.71, (1H, t, J = 10.0 Hz, CHar), 3.45 (3H, bs, NH2 and NH), 3.00 (2H, t, J = 5.2 Hz, CH2), 
2.76 (2H, t, J = 6.0 Hz, CH2). 
13C-NMR (101 MHz, CDCl3) δ 153.26, 145.06, 133.46, 133.19, 131.23, 129.01, 




A solution of nitrile 10 (3.34 g, 6.2 mmol) in anhydrous Et2O (20 mL) and DCM (20 mL) was cooled to -78 
°C. DiBAl-H (2 eq., 12.4 mL, 12.4 mmol, 1M solution in hexanes) was added dropwise and the reaction 
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mixture was allowed to warm to 0 °C and stirred for 2h, after which TLC analysis showed complete 
consumption of the starting material. Next, the mixture was cooled to -100 °C followed by rapid addition 
of MeOH (13 mL). After 5 min a solution of isoquinoline amine 13 (2.5 eq., 3.90 g, 15.5 mmol) in MeOH 
(10 mL) was added dropwise and the reaction mixture was allowed to stir at RT overnight. Hereafter, the 
reaction was cooled to -10 °C and NaBH4 (2 eq., 0.47 g, 12.4 mmol) was added and the mixture was 
allowed to stir for 4h at RT. The reaction mixture was diluted with 0.5 M aq. NaOH (100 mL) and the 
layers were separated. The aqueous layer was extracted with DCM (3 x 50 mL) and the combined organic 
phases were washed with H2O (3 x 50 mL) and brine, dried over MgSO4, filtered and evaporated. The 
crude product was subjected to the next step without further purification. 
The crude product was dissolved in DCM (20 mL) and TFA (20 mL) was added dropwise. The reaction 
mixture was stirred for 30 min at RT before addition of H2O (40 mL), the resulting mixture was stirred for 
1h at RT. Hereafter, the mixture was co-evaporated with toluene dissolved in DCM (70 mL) and cooled in 
an ice bath. To the mixture Boc2O (1.1 eq., 1.49 g, 6.8 mmol) and TEA (4 eq., 3.4 mL, 24.8 mmol) were 
added and the reaction was allowed to warm to RT and stirred overnight. The reaction mixture was 
concentrated under reduced pressure and re-dissolved in H2O (50 mL) and EtOAc (50 mL). The organic 
layer was washed with sat. aq. NaHCO3 and brine, dried over MgSO4, filtered and concentrated in vacuo. 
The title compound was obtained after purification by RP-HPLC purification (linear gradient 40%  60% 
ACN in H2O, 0.1% TFA, 15 min) as a yellow oil (yield: 0.61 g, 0.97 mmol, 15.8%). 
1H-NMR (400 MHz, CDCl3, Me4Si) δ 9.32 (1H, s, CHar), 8.58 (1H, d, J = 6.0 Hz, CHar), 8.39 (1H, d, J = 6.4 Hz, 
CHar), 8.27 (1H, d, J = 7.2 Hz, CHar), 8.18 (1H, d, J = 8.0 Hz, CHar), 7.65 (1H, t, J = 7.6 Hz, CHar), 7.11 (4H, s, 4 
x CHar), 3.99 (2H, s, CH2), 3.65 (2H, t, J = 6.0 Hz, CH2OH), 3.10 (2H, s, CH2), 2.81 (2H, t, 6.0 Hz, CH2), 2.09 
(2H, t, J = 8.0 Hz, CH2), 1.79 – 1.74 (2H, m, CH2), 1.39 (9H, s, 3 x CH3). 
13C-NMR (101 MHz, CDCl3) δ 152.94, 
144.56, 139.76, 138.19, 134.37, 133.24, 132.80, 131.05, 129.12, 128.87, 127.87, 127.21, 126.10, 125.76, 
121.93 (q, J = 275.73 Hz), 117.31, 80.78, 61.67, 45.76, 45.31, 41.48, 31.05, 30.06, 28.18 (q, J = 40.4 Hz), 
28.10. HRMS: calculated for C30H34F3N5O5S [M+H]




This compound was prepared in the same reaction as 18. The title compound was obtained after 
purification by RP-HPLC purification (linear gradient 40%  60% ACN in H2O, 0.1% TFA, 15 min) as a 
yellow oil (yield: 0.44 g, 0.7 mmol, 14%). 1H-NMR (400 MHz, CDCl3, Me4Si) δ 9.31 (1H, s, CHar), 8.59 (1H, 
d, J = 6.0 Hz, CHar), 8.45 (1H, d, J = 6.4 Hz, CHar), 8.37 (1H, d, J = 6.8 Hz, CHar), 8.14 (1H, d, J = 7.6 Hz, CHar), 
7.60 (1H, t, J = 7.6 Hz, CHar), 7.19 (2H, d, J = 8.4 Hz, 2 x CHar), 7.10 (2H, d, J = 8.0 Hz, 2 x CHar), 6.15 (1H, s, 
CH), 3.85 (2H, s, CH2), 3.57 (2H, t, J = 6.0 Hz, CH2OH), 3.35 (2H, bs, CH2), 3.12 (2H, t, J = 5.6 Hz, CH2), 2.08 
(2H, t, J = 7.2 Hz, CH2), 1.67 (2H, bs, CH2), 1.40 (9H, s, 3 x CH3). 
13C-NMR (101 MHz, CDCl3) δ 153.01, 
144.63, 139.57, 138.33, 134.45, 133.30, 132.95, 131.13,129.16, 128.93, 128.78, 127.16, 126.21, 125.83, 
121.98 (q, J = 275.73 Hz), 117.41, 61.93, 53.55, 46.41, 42.09, 30.95, 28.22 (q, J = 40.4 Hz), 28.15. HRMS: 
calculated for C30H34F3N5O5S [M+H]




sulfonamido)ethyl)-carbamate  (20) 
Alcohol 18 (0.16 g, 0.26 mmol) was dissolved in DCM (5 mL). After addition of TEA (1 eq., 36 µL, 0.26 
mmol) and DMAP (0.64 mg, 5 µmol) the resulting mixture was cooled to -20 °C. A solution of TsCl (1 eq., 
0.05 g, 0.26 mmol) in DCM (2 mL) was added dropwise and the reaction was stirred at -20 °C for 18h. 
Subsequently, 0.1 M aq. HCl (10 mL) was added and the layers were separated. The organic layer was 
washed with 0.1 M HCl (10 mL) and brine, dried over MgSO4, filtered and concentrated under reduced 
pressure. The crude product was subjected to the next step without further purification. 
The residue was dissolved in DMF (10 mL). To this was added NaN3 (10 eq., 0.17 g, 2.6 mmol) and the 
reaction was stirred at room temperature for 5h before being concentrated. The resulting residue was 
purified by RP-HPLC gradient (linear gradient 40%  60% ACN in H2O, 0.1% TFA, 15 min) and the title 
compound was obtained as light-yellow oil (yield: 0.44 g, 0.7 mmol, 14%). 1H-NMR (400 MHz, CDCl3, 
Me4Si) δ 9.36 (1H, s, CHar), 8.68 (1H, s, CHar), 8.34 (1H, s, CHar), 8.29 (1H, d, J = 7.2 Hz, CHar), 8.20 (1H, d, J 
= 8.0 Hz, CHar), 7.67 (1H, t, J = 8.0 Hz, CHar), 7.16 – 7.09 (4H, m, 4 x CHar), 6.48 (1H, s, CH), 3.97 (2H, s, 
CH2), 3.29 (2H, t, J = 6.4 Hz, CH2N3), 3.06 (2H, t, J = 5.6 Hz, NHCH2), 2.78 (2H, bs, CH2), 2.05 (2H, t, J = 6.8 
Hz, CH2), 1.78 – 1.75 (2H, m, CH2CH2N3), 1.45 (9H, s, 3 x CH3). 
13C-NMR (101 MHz, CDCl3) δ 162.54, 
153.14, 145.03, 137.93, 134.30, 133.37, 132.92, 131.11, 129.20, 128.97, 128.73, 127.63, 126.31, 125.74, 
122.00 (q, J = 275.7 Hz), 117.20, 81.17, 50.82, 45.66, 44.94, 41.87, 30.90, 28.23, 27.43. HRMS: calculated 
for C30H33F3N8O4S [M+H]




TFA (0.5 mL) was added to a solution of tert-butyl(E)-(5-azido-2-(4-(3-(trifluoromethyl)-3H-diazirin-3-
yl)benzylidene)pentyl)-(2-(isoquinoline-5-sulfonamido)ethyl)-carbamate 20 (95 µg, 0.14 mmol) in DCM 
(0.5 mL). After 1h TLC analysis indicated complete conversion of the starting material. Toluene was 
added and the mixture was co-evaporated under reduced pressure. In order to remove excess TFA the 
mixture was co-evaporated twice with toluene. The resulting mixture was purified by RP-HPLC (linear 
gradient 40%  60% ACN in H2O, 0.1% TFA, 15 min) and the title compound was obtained as a yellowish 
oil (yield: 0.44 g, 0.7 mmol, 14%). 1H-NMR (400 MHz, CDCl3, Me4Si) δ 9.29 (1H, s, CHar), 8.57 (1H, d, J = 4.8 
Hz, CHar), 8.39 (1H, d, J = 5.2 Hz, CHar), 8.35 (1H, d, J = 7.6 Hz, CH), 8.15 (1H, d, J = 8.0 Hz, CHar), 7.64 (1H, 
t, J = 7.6 Hz, CHar), 7.18 (2H, d, J = 8.4 Hz, 2 x CHar), 7.11 (2H, d, J = 8.4 Hz, 2 x CHar), 6.63 (1H, s, CH), 3.74 
(2H, s, CH2), 3.28 (2H, bs, CH2N3), 3.19 (2H, t, J =  6.4 Hz, CH2), 2.33 (2H, t, J = 8.4 Hz, CH2), 1.67 – 1.60 (2H, 
m, CH2). 
13C NMR (101 MHz, CDCl3) δ 153.96, 144.69, 136.72, 133.95, 133.71, 133.35, 132.62, 131.14, 
128.92, 128.85, 128.52, 126.48, 126.03, 121.97 (q, J = 274.7 Hz), 177.40, 52.68, 50.70, 46.88, 39.07, 
31.17, 28.27 (q, J = 41.4 Hz), 26.98, 25.90. HRMS: calculated for C25H25F3N8O2S [M+H]







sulfonamido)ethyl)carbamate (21)  
An identical method was used as for the synthesis of tert-butyl(E)-(5-azido-2-(4-(3-(trifluoromethyl)-3H-
diazirin-3-yl)-benzylidene)-pentyl)(2-(isoquinoline-5-sulfonamido)ethyl)-carbamate except that 
compound 19 (0.39 g, 0.61 mmol) was used as starting material and the amounts of the other reagents 
were adjusted accordingly. Purification by RP-HPLC (linear gradient 40%  60% ACN in H2O, 0.1% TFA, 
15 min) yielded the title compound as light yellow oil (yield: 0.44 g, 0.7 mmol, 14%). 1H-NMR (400 MHz, 
CDCl3, Me4Si) δ 9.35 (1H, s, CHar), 8.65 (1H, d, J = 6.0 Hz, CHar), 8.43 (1H, d, J = 6.0 Hz, CHar), 8.39 (1H, d, J 
= 7.2 Hz, CHar), 8.18 (1H, d, J = 8.0 Hz, CHar), 7.63 (1H, t, J = 7.6 Hz, CHar), 7.19 – 7.13 (4H, m, 4 x CHar), 
6.22 (1H, s, CH), 3.87 (2H, s, CH2), 3.35 (2H, bs, CH2N3), 3.20 (2H, t, J = 6.4 Hz, CH2), 3.11 (2H, bs, CH2), 
2.21 – 2.05 (2H, m, CH2), 1.67 – 1.63 (2H, m, CH2), 1.44 (9H, s, 3 x CH3). 
13C-NMR (101 MHz, CDCl3) δ 
153.06, 144.79, 138.71, 138.13, 134.41, 133.06, 131.23, 129.20, 128.78, 127.89, 127.56, 126.40, 125.83, 
122.04 (q, J = 275.7 Hz), 117.37, 81.02, 53.44, 51.33, 46.09, 42.39, 28.24, 27.26, 25.78. HRMS: calculated 
for C30H33F3N8O4S [M+H]




An identical method was used as for the synthesis of 3 except that tert-butyl(Z)-(5-azido-2-(4-(3-
(trifluoromethyl)-3H-diazirin-3-yl)benzylidene)pentyl)(2-(isoquinoline-5-sulfonamido)ethyl)-carbamate 
(0.56 g, 0.85 mmol) was used as starting material and the amounts of the other materials were adjusted 
accordingly. Purification by RP-HPLC (linear gradient 40%  60% ACN in H2O, 0.1% TFA, 15 min) yielded 
the title compound as light yellow oil (yield: 0.44 g, 0.7 mmol, 14%). 1H-NMR (400 MHz, CDCl3, Me4Si) δ 
9.46 (1H, bs, CHar), 8.59 (1H, bs, CHar), 8.40 (1H, d, J = 7.2 Hz, CHar), 8.31 (2H, d, J = 8.0 Hz, 2 x CHar), 7.76 
(1H, t, J = 7.6 Hz, CHar), 7.17 – 7.12 (4H, m, 4 x CHar), 6.74 (1H, s, CH), 3.82 (2H, s, CH2), 3.31 (2H, t, J = 6.4 
Hz, CH2N3), 3.12 (2H, s, CH2), 2.98 (2H, s, CH2), 2.37 (2H, t, J = 7.2 Hz, CH2), 1.83 – 1.76 (2H, m, CH2). 
13C-
NMR (101 MHz, CDCl3) δ 150.45, 139.88, 136.78, 135.16, 134.62, 134.33, 133.80, 132.40, 132.15, 128.93, 
128.59, 127.54, 126.77, 121.94 (q, J = 275.7 Hz), 119.69, 50.55, 46.71, 45.73, 38.87, 31.13, 31.07, 28.20 
(q, J = 40.4 Hz), 26.98. HRMS: calculated for C25H25F3N8O2S [M+H]




IC50 and Ki determination by FRET assay 
Kinase activity was measured using a FRET-based assay with a peptide from ribosomal protein S6 as 
substrate. 10 nM ULight-rpS6 peptide (Perkin-Elmer) was incubated with 100 µM ATP and 2 nM Eu-
labeled anti-phospho-rpS6 antibody (Perkin-Elmer, recognizing pSer S6 at position 235 and 236) in HEPES 
buffer (50 mM HEPES pH 7.5, 1 mM EGTA, 10 mM MgCl2, 2 mM DTT and 0.01% Tween-20) together with 
0.5 nM/min AKT1 or 0.05 nM/min PKA (SignalChem), in the presence or absence of the probe or H-89. 
During incubation at RT, the intensity of the light emission was measured with intervals of 60 min on a 
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PE Envision reader using the Lance Ultra kinase assay settings (λex 320 nm; λem 665 nm) and a secondary 
control emission was measured at 615 nm. In control experiments, no ATP was added to the buffer.  
Data was analyzed using GraphPad Prism 5 (GraphPad software, La Jolla, USA). 
To determine the KM for the kinases, the same assay was performed using a fixed concentration of probe 
or H-89 (2µM) and 0, 0.1, 0.2, 0.5, 1, 2, 5, 10, 20, 50, 100, 200, 500, 1000 µM ATP. KM values were 
calculated using GraphPad Prism 5 (GraphPad software, La Jolla, USA).  
Ki values were calculated via equation 1.1: 
 
Ki = IC50 / (1 + ([S]/KM))                                                                     (1.1)                                                                          
 
where Ki is the inhibition constant, IC50  is the half maximal inhibitory concentration, S is the 
concentration of substrate and KM is the Michaelis-Menten constant, which is the substrate 
concentration at which the reaction rate is half maximum. All experiments were conducted in triplicate 
and curves were corrected for background fluorescence of the solvent.  
 
Photo-labeling of recombinant kinases (PKA, AKT1) 
PKA (PKAc beta) and AKT1 were purchased from Signalchem, aliquoted, stored at -80 °C and thawed only 
once for an experiment.  
For pre-denatured samples the solutions were treated with 10% SDS (2 μL) and boiled for 5 min before 
addition of the probes. Non-irradiated samples were protected from light by wrapping in aluminium foil. 
Competition experiments were performed in triplicate, quantification of residual activity was achieved 
by fluorescent densitometry using the Biorad Image Lab software (version 5.2.1). 
In a typical experiment, 100 ng (1 μL [100 ng/μL] of recombinant enzyme were added to the assay buffer 
(17 μL) (20 mM HEPES, pH 7.5, 50 mM KCl, 10 mM MgCl2, 10% glycerol)(adapted). For competition 
experiments, the respective inhibitor (1 µL, 20X) was added next and the samples were incubated in the 
dark at RT for 30 min. For all experiments probe 3, probe 4 (2 μL, 10X or 1 µL, 20X in competition 
experiments) or DMSO were added and the samples were incubated for 30 min at RT in the dark. For 
irradiation the samples were transferred to a clear, flat-bottom 96-well plate and diluted with 30 μL 100 
mM HEPES, pH 7.5. The samples were then irradiated for 5 min at 0 °C and transferred back into 
Eppendorf tubes, the concentration was further adjusted by adding 5 μL of 100 mM HEPES, pH 7.5; the 
untreated samples were diluted in the same way. For the attachment of the Cy5 fluorophore by click 
reaction samples were treated with “click mix” (6 μL/sample), prepared freshly as follows: 3 μL 25 mM 
CuSO4 (aq.) were mixed with 1.8 μL 0.25 M sodium ascorbate, resulting in a brown solution, this was 
then vortexed until a colour change to bright yellow was achieved, indicating the reduction of the copper 
ion. Next, THPTA (0.6 μL, 25 mM in DMSO) was added and the mixture vortexed again. Finally, 0.6 μL of a 
150X Cy5 alkyne (relative to the amount of probe used in the experiment) was added, the mixture 
vortexed again, added to the sample, mixed and incubated for 1h at RT in the dark. The final 
concentrations of the click reagents were 1.25 mM CuSO4, 7.5 mM sodium ascorbate, 250 µM THPTA 
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and 1.5 eq. Cy5 alkyne. The reaction was stopped by adding 20 μL of SDS loading buffer and boiling for 5 
min. 
Samples were resolved by 10% SDS-PAGE, for in-gel detection of fluorescent bands, wet gel slabs were 
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Chronic lymphocytic leukemia (CLL) is the most common hematologic disease occurring 





 B cells in the peripheral blood, secondary lymphoid tissues, and bone 
marrow.
1
 This malignancy is still considered incurable, although new treatment 
combinations of monoclonal antibodies and chemotherapy appear promising.
2
 Two 
compartments can be distinguished in CLL: the peripheral blood, in which quiescent CLL 
cells accumulate, and the tumor microenvironment within the lymphoid tissues and bone 





The tissue microenvironment plays a central role in the pathogenesis of CLL. CLL cell 
proliferation occurs in distinct microanatomical sites termed proliferation centers or 
pseudofollicles.
4
 In these areas, CLL cells are in intimate contact with non-tumoral 





 follicular dendritic cells, endothelial cells
11
 and CD40L expressing T cells
12,13
 
that provide the necessary external signals that drive maintenance of the CLL cells.
14,15,16,17
 
Among the various external stimuli in the tissue microenvironments, B-cell receptor (BCR) 
signaling has been recognized as a crucial pathologic mechanism. Activation of BCR 
triggers a cascade of signaling events that promotes survival and growth of the CLL 
clone.
18,19
 As a consequence, BMSCs create niches that protect CLL cells from cytotoxic 
anticancer drugs and this in turn causes resistance to current chemotherapeutics.
15,20
  
Currently, a variety of novel kinase inhibitors aiming to target various components of the 
BCR signaling pathway have been designed and are in clinical development for CLL. In 
previous studies, dasatinib (1, Figure 1), an oral Src/c-Abl tyrosine kinase inhibitor, has 
been demonstrated to induce apoptosis and/or sensitize against cytotoxic drugs.
20,21,22
 
Initially, dasatinib was approved for treatment of chronic myeloid leukemia and second-
line treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia on the 
basis of Bcr-Abl inhibition
23
, but the activity of dasatinib (1) against additional kinases 
provides a rationale for investigating it in other hematologic malignancies, such as CLL. In 
model systems, such as the chronic myeloid leukemia (CML)-derived cell-line K562, the 
spectrum of kinases targeted by dasatinib (1) has been mapped.
24
 A prominent binder 
besides Abl and Src family kinases was the TEC family kinase BTK.
25
 Since these kinases are 
all implicated in BCR- and or CD40-mediated microenvironmental stimuli, it is interesting 
to determine the actual targets of dasatinib and their contribution in mediating CLL 
survival and chemoresistance. 
Figure 1. Affinity-based dasatinib probe 5.  Dasatinib 1 is immobilized by coupling it to sepharose beads 4.  




In this study, dasatinib (1) is coupled to an affinity matrix 4 to obtain the affinity-based 
kinase probe 5, which is used to characterize its spectrum of targets in primary CLL 
by an affinity-based kinase profiling assay (Figure 2). In this assay, the immobilized 
dasatinib probe 5 binds noncovalently to its targets after exposure to CLL cell lysates. The 
interacting kinases are expected to be immobilized by affinity-chromatography, and non-
binding proteins will be washed away. Next the retained proteins are washed from the 
affinity column under protein denaturing conditions and resolved on SDS PAGE. Bands 
from the gel are next excised, trypsinolysed and identified using mass spectometry (MS).  
 
Figure 2.  Affinity-based kinase profiling. Immobilized dasatinib matrix (5) is noncovalently bound to its cellular 
targets. After washing and elution, the targets are profiled by SDS-PAGE followed by LCMS for target 
identification. 
Synthesis of affinity-based dasatinib probe 
 
In order to identify the interacting kinase(s) of dasatinib (1), this drug was modified and 
immobilized by covalent attachment to NHS-activated sepharose (4) via its free amine 
group (Scheme 1). Compound 3 was prepared via a slightly modified literature procedure 
of Kim D. et al.
26
 First, dasatinib (1) was extracted from Sprycel
TM
, which are tablets 
containing dasatinib, and converted to azide 2 via substitution of the corresponding 
mesylate with NaN3. A Staudinger reaction was performed to convert the azide 2 into its 
amine 3 using PMe3 in DMF/H2O. Finally, amine 3 was immobilized on NHS-activated 
Sepharose 4 Fast Flow beads 4, which have a ligand density of 16-23 µmol NHS/mL 























Scheme 1. Synthesis of immobilized dasatinib 3. Reagents and conditions: a) i) MsCl, TEA, DMF, 0 °C – 




In the first instance, the inhibitory potential of dasatinib-amine (3) was compared at 
different concentrations to the parent compound 1 by measuring the inhibitory effect on 
cell viability of K562 human CML cells, which are dependent on the Bcr-Abl fusion protein 
for survival
34
. Figure 3 shows that dasatinib-amine (3) had identical activity as the parent 
compound 1. Thus, it can be assumed that the targets that will be identified with the 
immobilized dasatinib 5 are identical for the parent compound 1 itself.
 
Figure 3. Dasatinib-amine (3) induces apoptosis of K562 human CML cells as effectively as the parent compound 
(1). K562 cells were treated with dasatinib (1) or dasatinib-amine (3) for 48 hr. Cell viability was measured by 
staining for DiOC6/PI. A representative experiment of two independent experiments is shown. 
 
In the next set of experiments, the immobilized dasatinib 5 was used to identify the drug 
targets of dasatinib (1). Therefore, the immobilized dasatinib 5 was incubated with lysates 
of CD40 stimulated primary CLL cells. Without SDS-page analysis, the eluted proteins were 
1                           3 
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identified by liquid chromatography mass spectrometry (LC-MS) with subsequent 
database search of the analyzed MS spectra. Among the eluted kinases, c-Abl and BTK 
were identified as important targets of dasatinib (1) in the total lysates of CD40 stimulated 
CLL cells. Furthermore, other identified peptides mapping to the kinases were Lyn, Csk, 
Fyn, Yes, Src and Lck, which were previously described as specific targets of dasatinib in 
the CML line K562.
31
 
Hereafter, Western blot analysis of pulldown experiments was used to confirm binding of 
c-Abl and BTK to immobilized dasatinib (5) in lysates of CD40-stimulated CLL cells. In 
agreement with previous studies, Lyn and p38MAPK were also identified as targets of 
dasatinib
31
 (1), whereas Syk and ZAP70, although abundantly expressed in CLL, did not 
bind to dasatinib-sepharose 5 (Figure 4A). As a control for specificity, competition 
experiments were performed in which lysates were preincubated with free soluble 
dasatinib 1 prior to exposure to immobilized dasatinib 5. Western blot analysis confirmed 
competition of c-Abl, BTK, Lyn and p38MAPK from immobilized dasatinib (5) by free 








Figure 4.  c-Abl and BTK are specific interactors of dasatinib in CD40-stimulated primary CLL. (A) 
Immunoblots of pull-down experiments with control Sepharose (uncoupled) and immobilized dasatinib 5 
from lysates of CLL cells stimulated with CD40L for 48hrs. In lane 4, lysates were pretreated by addition 
of 10μM soluble dasatinib 30 minutes prior to exposure to dasatinib-sepharose. Western blots of eluates 
were probed for the presence of the indicated kinases. Input lane designates the total lysate. (B) c-Abl 
and BTK are specific targets of dasatinib in CD40L stimulated primary CLL. Anti-BTK and anti-Abl 
immunoblots of CLL pulldown series. Pretreatment was performed by addition of dasatinib (Das.), 
imatinib (Im.) or ibrutinib (Ibr.) to lysates 30 minutes prior to exposure to drug-affinity matrix. 
Representative figure is shown of at least 8 independent experiments. 
 
B 
Das.  Im.  Ibr. 
A 
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Competition experiments were performed as well to compare the selectivity of the 
dasatinib (1) towards c-Abl and BTK with other CLL drugs imatinib and ibrutinib (Figure 
2B). In these experiments CD40L stimulated primary CLL were treated with dasatinib, 
imatinib or ibrutinib prior to exposure to immobilized dasatinib 5. Western blot of the 
eluates provided the kinases that are bound by immobilized dasatinib 5. Imatinib, which 
shows greater selectivity than dasatinib for Abl kinase 
35-37
 in earlier studies, was able to 
inhibit binding of Abl but not of BTK to immobilized dasatinib 5 in lysates of CD40-
stimulated CLL cells (Figure 4B). In a complementary set-up, BTK but not Abl was fully 




In conclusion, an affinity-based probe based on dasatinib has been synthesized and can be 
used to identify the drug targets that are still unknown for primary CLL. This study has 
identified c-Abl and BTK as dominant drug targets of dasatinib in CLL upon stimulation 
with CD40 ligand using the affinity-based dasatinib 5.  
 
General: Tetrahydrofuran (THF) was distilled over LiAlH4 before use. Acetonitrile (ACN), dichloromethane (DCM), 
N,N-dimethylformamide (DMF), methanol (MeOH) and trifluoroacetic acid (TFA) were of peptide synthesis grade, 
purchased at Biosolve, and used as received. All general chemicals (Fluka, Acros, Merck, Aldrich, Sigma) were 
used as received. Traces of water were removed from reagents used in reactions that require anhydrous 
conditions by coevaporation with toluene. Solvents that were used in reactions were stored over 4Å molecular 
sieves, except methanol and acetonitrile, which were stored over 3Å molecular sieves. Molecular sieves were 
flame dried before use. Unless noted otherwise all reactions were performed under an argon atmosphere. 
Column chromatography was performed on Silicycle Silia-P Flash Silica Gel, with a particle size of 40 – 63 µm. The 
eluents toluene and ethyl acetate were distilled prior to use. TLC analysis was conducted on Merck aluminium 
sheets (Silica gel 60 F254). Compounds were visualized by UV absorption (254 nm), by spraying with a solution of 
(NH4)6Mo7O24·4H2O (25 g/L) and (NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% sulphuric acid, a solution of KMnO4 (20 g/L) 
and K2CO3 (10 g/L) in water, or ninhydrin (0.75 g/L) and acetic acid (12.5 mL/L) in ethanol, where appropriate, 
followed by charring at ca. 150°C. 1H- and 13C-NMR spectra were recorded on a Bruker DMX-400 (400 MHz) or a 
Bruker DMX-600 (600 MHz) spectrometer. Chemical shifts are given in ppm (δ) relative to tetramethylsilane (1H-
NMR) or CDCl3 (
13C-NMR) as internal standard. Mass spectra were recorded on a PE/Sciex API 165 instrument 
equipped with an Electrospray Interface (ESI) (Perkin-Elmer). High-resolution MS (HRMS) spectra were recorded 
with a Finnigan LTQ-FT (Thermo Electron). IR spectra were recorded on a Shimadzu FTIR-8300 and absorptions 
are given in cm-1. Optical rotations [α]D
23 were recorded on a Propol automatic polarimeter at room temperature. 
LC-MS analysis was performed on a Jasco HPLC system with a Phenomenex Gemini 3 µm C18 50 x 4.6 mm 
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column (detection simultaneously at 214 and 254 nm), coupled to a PE Sciex API 165 mass spectrometer with ESI. 
HPLC gradients were 10 → 90%, 0 → 50% or 10 → 50% ACN in 0.1% TFA/H2O. Chiral HPLC analysis was 
performed on a Spectroflow 757 system (ABI Analytical Kratos Division, detection at 254 nm) equipped with a 
Chiralcel OD column (150 x 4.6 mm). The compounds were purified on a Gilson HPLC system coupled to a 
Phenomenex Gemini 5 µm 250 x 10 mm column and a GX281 fraction collector. The used gradients were either 0 
→ 30% or 10 → 40% ACN in 0.1% TFA/water, depending on the lipophilicity of the product. Appropriate fractions 




carboxamide (2).  
Compound 1 was obtained by dissolving 20 pulverized Dasatinib tablets (SprycelTM 70 mg) in H2O (200 mL) prior 
to filtration. The residue was washed with DCM/MeOH (1/1 v/v, 5x 150 mL) followed by concentration under 
reduced pressure to give compound 1 (1.27 g, 91% recovery) as a white solid.  
Compound 1 (0.89 g, 1.82 mmol) was dissolved in DMF (20 mL) and cooled to 0 °C. Pre-cooled TEA (3 eq., 0.76 
mL, 5.47 mmol) and MsCl (1.5 eq., 0.21 mL, 2.73 mmol) were added dropwise. The reaction mixture was allowed 
to warm to RT in 5 hrs after which TLC analysis indicated a complete conversion. Hereafter, NaN3 (10 eq., 1.20 g, 
18.2 mmol) was added and the mixture was stirred at RT for 16 hrs until TLC analysis indicated a complete 
conversion. EtOAc and H2O were added and the layers were separated. The aqueous layer was extracted with 
EtOAc (5x), dried over MgSO4 and concentrated in vacuo. The title compound was obtained after RP-HPLC 
purification (gradient: 30% - 70% ACN/0.1% aq. TFA) as a white solid (yield: 0.38 g, 0.75 mmol, 41%). 1H NMR 
(400 MHz, DMSO-d6): δ = 11.64 (br s, 1H), 9.92 (s, 1H), 8.25 (s, 1H), 7.40 (d, J = 7.6 Hz, 1H), 7.27 (m, 2H), 6.17 (s, 
1H), 3.82 (br s, 2H), 3.55 (m, 8H), 3.28 (m, 2H), 2.45 (s, 3H), 2.24 (s, 3H); 13C NMR (100 MHz, DMSO-d6): δ = 
165.44, 162.42, 161.99, 159.91, 157.24, 140.82, 138.83, 133.51, 132.45, 129.06, 128.22, 127.04, 125.96, 83.41, 
54.39, 50.76, 45.08, 40.43, 25.56, 18.31. HRMS: calculated for C22H25ClN10OS [M+ H]




carboxamide (3).  
PMe3 (6 eq., 2.4 mL, 2.4 mmol, 1M in THF) was added to a solution of compound 2 (0.21 g, 0.4 mmol) in 
DMF/H2O (1/1/ v/v, 6 mL). The mixture was stirred at RT until TLC analysis indicated complete consumption of 
starting material after 16 hrs and this was followed by concentration under reduced pressure. Compound 3 was 
obtained after RP-HPLC purification (20 – 50% ACN/0.1% aq. TFA) as a white solid (yield: 0.43 g, 0.89 mmol, 37%). 
1H NMR (400 MHz, DMSO-d6): δ = 11.63 (br s, 1H), 9.92 (s, 1H), 8.24 (s, 1H), 8.09 (br s, 2H), 7.40 (d, J = 7.6 Hz, 
1H), 7.27 (m, 2H), 6.17 (s, 1H), 3.76 (m, 6H), 3.17 (m, 6H), 2.44 (s, 3H), 2.24 (s, 3H); 13C NMR (100 MHz, DMSO-d6): 
δ = 165.38, 162.46, 162.05, 159.92, 157.21, 140.82, 138.84, 133.52, 132.46, 129.07, 128.23, 127.04, 125.94, 
83.31, 53.11, 51.24, 41.63, 34.08, 25.57, 18.32. HRMS: calculated for C22H27ClN8OS [M+ H]




Experimental procedures: biochemistry 
 
Patient material 
After informed consent, patient material was obtained during diagnostic or follow-up procedures at the 
Departments of Hematology and Pathology of the Academic Medical Center Amsterdam. This study was 
approved by the AMC Ethical Review Board and conducted in agreement with the Declaration of Helsinki. PB 
mononuclear cells of patients with CLL, obtained after Ficoll density gradient centrifugation (Pharmacia Biotech) 
were frozen and stored as previously described18. Expression of CD5 and CD19 (both Beckton Dickinson (BD) 
Biosciences) on leukemic cells was assessed by flow cytometry (FACScanto; BD Biosciences). CLL samples 
included in this study contained 81-99% CD5+/CD19+ cells. 
 
Reagents 
The pharmacological inhibitor ibrutinib was obtained under a Material Transfer Agreement from Pharmacyclics 
(Sunnyvale, CA 94085-4521). The kinase inhibitors imatinib and dasatinib were from Novartis (Basel, Switzerland) 
and Bristol-Myers Squibb (New York, NY), respectively. 
 
Immobilization of dasatinib 
The procedure for immobilization of dasatinib was performed as described by Rix et al31. Compounds were 
immobilized on NHS-activated Sepharose 4 Fast Flow (GE Healthcare) via their amine functionalities as follows: 
Beads were washed with dimethyl sulfoxide (DMSO) and incubated overnight at room temperature (RT) with 1 
mM compound and 100 mM triethylamine (TEA). After complete coupling of the compound, the affinity matrix 
was blocked with 0.8 M ethanolamine, washed, and stored at 4°C until use. 
 
Affinity purification 
Cell lysates were prepared immediately prior to incubation with immobilized dasatinib in lysis buffer containing 
50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1% NP-40 (Sigma). Cell suspensions were clarified by centrifugation 
before incubated with immobilized dasatinib or uncoupled control sepharose overnight at 4°C. Pretreatment was 
performed by addition of Dasatinib, Imatinib or ibrutinib to lysates 30 minutes prior to exposure to drug-affinity 
matrix. After incubation, sepharose was washed 3 times with lysis buffer, before beads were drained and 
retained proteins were eluted by heat denaturing with SDS sample buffer. 
 
Western blot analysis 
Western blot analysis was performed using standard techniques18. Membranes were probed with anti-Mcl-1 (Cell 
Signaling), anti-Noxa (Imgenex), anti-Bcl-XL (BD Biosciences), antiserum to β-actin (Santa Cruz Biotechnology), 
anti-A1/Bfl-1 (Cell Signaling) or Bim (Stressgen Bioreagents Canada). Blots were subsequently incubated with 
IRDye 680 or 800 labelled secondary antibodies for 1 hour. Odyssey Imager (Li-Cor Biosciences) was used as a 






An unpaired two-tailed Student’s T test was used to determine the significance of differences between two mean 
values. The one sample T test was used to determine the significance of differences between means and 
normalized values (100%). * p <0,05;** p<0,01; *** p<0,001. 
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Kinases play a role in many diseases including cancer, diabetes and infection diseases. For 
this reason, kinases are interesting drug targets. Inhibitors for some kinases are already in 
use as clinical drugs, however due to resistance and side effects, but also to target kinases 
related to diseases for which there is currently no treatment, research on the discovery of 
new classes of kinase inhibitors is imperative. To achieve this, not only new inhibitor 
classes need to be designed and synthesized, but also tools to profile kinases in their 
physiological context and to determine the selectivity of inhibitors are required. The 
research in this thesis has focused on the development of more potent AKT1 and FLT3 
kinase inhibitors and on the synthesis and application of new chemical tools for the 
profiling of kinases involved in various types of cancers and other diseases.  A brief 
8 
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description of the function and the role of the kinases subject of study in this thesis is 
given in Chapter 1. 
Over the past decades, numerous chemical profiling methods have been developed and 
used to study the biological functional role of kinases, and to profile the selectivity and 
targets of kinase inhibitors. In Chapter 2, the principles of three chemical profiling 
methods applied for kinases are reviewed and compared: activity-based protein profiling 
(ABPP), photoaffinity labeling and affinity-based profiling (AfBP). These three methods 
formed the common thread throughout this thesis.  
H-89, an isoquinolinesulfonamide-based compound, is a well-known, potent PKA inhibitor. 
Analogues of this compound have been proven to inhibit AKT1 and other kinases, 
including the oncological target, FLT3. Chapter 3 deals with the design and synthesis of a 
new set of isoquinolinesulfonamide-based inhibitors for FLT3 (Figure 1). These compounds 
all contain the isoquinolinesulfonamide core and variations are at the phenyl moiety. 
Variations were introduced at the ortho, meta or para position by Suzuki coupling using 34 
different bulky (hetero)aromatic boronic acids (leading in total to a focused library of 102 
compounds).  
Figure 1. General structures (1 – 6) of the library containing 102 isoquinolinesulfonamide-based inhibitors for 
FLT3. 
 
The inhibitory potency towards PKA, AKT1, AKT2 and FLT3 of the 102 newly synthesized 
isoquinolinesulfonamides together with 137 isoquinolinesulfonamides previously 
prepared
1
 are discussed in Chapter 4. The effect of these 239 compounds on PKA, AKT1, 
AKT2 and FLT3 was evaluated using a TR-FRET kinase activity assay. The most active AKT1 
and AKT2 inhibitors contain a bulky heteroaromatic group at the ortho position (Figure 2). 
It is clearly that both the kinases AKT1 and AKT2 favor the same kind of compounds, which 
make it hard to find active and selective inhibitors towards AKT1. The most active PKA 
inhibitors of the series proved to be compounds 15 and 16. These compounds have the 
same conformation and contain an aromatic group at the para position, just like lead 
compound H-89. Apparently, electron-donating groups at this position are favourable for 




Figure 2. Ki values (µM) given for a selection of AKT1 (7 – 11), AKT2 (7, 8, 10, 12 - 14) and PKA (15 - 16) inhibitors, 
which are more active than lead compound H-89 based on their Ki values. 
 
Inhibition of both AKT1 and AKT2 has been shown to be lethal in mice, and the 
ability to inhibit one selectively over the other is therefor of medical importance. 
The most selective AKT1 over AKT2 inhibitors proved to be compounds 17 – 19 
(Figure 3). A methyl substituent at the linker alkene contributes to AKT1 selectivity 
over AKT2. Next to this, introduction of a para-halogen at the phenyl ring appears 
to improve the selectivity of AKT1 over AKT2. The configuration of the alkene 
moiety (E or Z) appears to play a role as well. Compounds 8, 10, and 20 – 22 (Figure 
3) are the most selective AKT1 over PKA inhibitors. These compounds contain 
aromatic groups having oxygen or nitrogen groups at the ortho position.  
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Figure 3. The most selective AKT1 over AKT2 (17 – 19) and AKT1 over PKA inhibitors (8, 10 and 20 – 22) based on 
their Ki value differences. 
 
To obtain a more selective and active AKT1 inhibitor, it may be of interest to study the 
effect of incorporation of a fluorine group at the para position, which is important for 
selectivity, and a bulky heteroaromatic group at the ortho position, which contributes to 
enhancement of activity. Suggested compounds featuring these properties are 23 and 24 
(Figure 4). Furthermore, a methyl group at the alkene site contributes to activity and 
selectivity as well, which suggests compounds 25 and 26 as future synthetic targets. 
Figure 4. Suggested isoquinolinesulfonamide inhibitors selective for FLT3. 
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Figure 5. IC50 values (nM) given for a selection of FLT3 inhibitors (15, 28 – 30), which are more active than lead 
compound 27 based on their Ki values. 
 
Another kinase studied in this Thesis is FLT3. The most active inhibitors for this kinase are 
compounds 15, 28 – 30 (Figure 5). They all have a heteroaromatic group at the para 
position and appeared to be at least 7 times more active as FLT3 inhibitors than the lead 
compound (27).  
Based on these SAR findings, a new set of FLT3 inhibitors (31 – 36) can be designed having 
an electron donating nitrogen-atom containing aromatic group at the para position. Some 
proposed structural analogues are depicted in Figure 6. 
 
Figure 6. Suggested isoquinolinesulfonamide inhibitors selective for FLT3. 
 
In the second part of this thesis, the synthesis and biological evaluation of chemical tools 
for profiling of kinases have been described. Three different methods for chemical
profiling have been highlighted: ABPP, photo-affinity labeling and AfBP.                                      
Chapter 5 describes the design and synthesis of two types of ABPs for labeling of Bruton’s 
tyrosine kinase (BTK), namely direct (37 and 38) and two-step bioorthogonal (39 – 41) BTK
activity-based probes (Figure 7).  
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 Figure 7. Structures of direct (37 and 38) and two-step bioorthogonal (39 – 41) BTK activity-based probes. 
The core of these probes is based on the covalent inhibitor ibrutinib, which forms a 
covalent bond by attack of a cysteine thiol in the BTK active site to the acrylamide moiety 
of ibrutinib. All five probes (37 – 41) contain an acryl amide group as does ibrutinib, and all 
probes were able to label BTK. The direct probes 37 and 38 label BTK in Ramos cell extract 
and in living Ramos cells. Two-step bioorthogonal labeling of BTK using the probes 39 – 40 
was also possible in in vitro and in situ experiments.               
It is not always favorable to perform BTK labeling under fluorescent conditions, for 
instance when background fluorescence is an issue. In addition, an important method to 
identify target proteins and to determine the exact site and mechanism of ABP binding is 
by analysis of labeled proteins using mass spectrometry. In this case, it is usual to label 
proteins with a biotin-tagged ABP and subsequently enrich them by affinity-purification 
using streptavidin-beads. To allow for identification of the targets of ibrutinib, ibrutinib-
biotin 44 has been synthesized by condensation (HATU, DiPEA) with biotin (43) (Scheme 
1). 




 Scheme 2.  Synthesis of immobilized dasatinib 3. Reagents and conditions: a) 45, DiPEA, DMF, 36% after 
RP-HPLC; b) 47, 1M CuSO4, 1M Na L-ascorbate, 23% after RP-HPLC.                                                                                                 
 
A disadvantage of ABPs featuring a biotin moiety is that the release of captured 
proteins from the beads requires harsh conditions and may result in contamination 
of the purified sample with endogenous biotinylated proteins. In such situations, an 
ABP containing a biotin in combination with a cleavable linker may form an 
attractive alternative. Therefore, ibrutinib-cleavable levulinoyl linker-biotin 48 was 
designed and synthesized (Scheme 2). This linker can be cleaved by treatment with 
an excess of hydrazine after protein enrichment.
2
  
The synthesis of ibrutinib-cleavable levulinoyl linker-biotin 48 commenced with 
reacting crude amine 42 with the ester-based levulinoyl linker succinimide 45 to 
obtain azide 46. A copper(I)-catalysed click ligation to alkyne-modified biotin 47 was 
then performed yielding the ibrutinib cleavable levulinoyl linker biotin 48 after 
HPLC purification. Both biotin probes (44 and 48) were able to select and visualize 
on SDS PAGE BTK from cell extracts. The utility of these probes in comparative and 




Not all kinases contain a nucleophilic moiety in the active site as BTK. To label these 
kinases covalently another type of chemical tool is required. Chapter 6 describes 
the synthesis and biological evaluation of two diazirine-functionalized 
photocrosslinking probes (49 and 50, Figure 8) for labeling of PKA and AKT1, which 
are kinases without a nucleophilic group in the active site. Both probes are based 
on the core of H-89, which is proven to inhibit PKA and AKT1, and contain a 
diazirine group. Diazirine will bind covalently to the kinase upon UV activation. As 
well, these probes feature an azide group, which serves as a bioorthogonal ligation 
handle. 
Figure 8. Structures of diazirine-functionalized photocrosslinking probes 49 and 50. 
According to a single point kinase active site-directed competition binding 
Kinomescan
TM
 assay, in which the capability of the probes to inhibit a panel of 111 
human kinases was examined, both probes 49 and 50 have a preference to inhibit 
Ser/Thr kinases including PKA and AKT1. Following this, both photocrosslinking 
probes were subjected to labeling experiments in which they showed to 
photocrosslink recombinant PKA and AKT1 efficiently and specifically upon UV 
activation. Other photocrosslinking groups that have been used in the past include 
benzophenone moieties. It would be of interest to investigate the benzophenone 
analogues 63 and 64 (Scheme 3) on their differences with respect to inhibitory 
potency and labeling efficiency. For the synthesis of both the probes, the 
benzophenone part can be obtained by protection of bromo-ketone 51 under 
Dean-Stark conditions giving compound 52. Compound 52 was in turn lithiated 
using n-BuLi before reaction with DMF to form aldehyde 53. Next, a Horner-
Wadsworth-Emmons (HWE) reaction between benzaldehyde 53 and phosphonate 
54 resulted in α-substituted cinnamonitrile 55 as a 1/1 mixture of E/Z isomers in 
95% yield. Since separation of the isomers in the nitrile-stage was partially 
successful, and the nitriles were observed to isomerise during the ensuing 
transimination, the mixture of nitriles was used in the ensuing reaction. 
Subsequently, E/Z cinnamonitrile mixture 55 was used in the four-step-one-pot 
trans-imination procedure according to Brussee et al.
3
, which has been described 
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Scheme 3. Synthesis of benzophenone-functionalized photocrosslinking probes 63 and 64. Reagents and 
conditions: a) ethylene glycol, p-toluenesulfonic acid monohydrate, benzene, Δ, 71%; b) n-BuLi, DMF, 
THF, -78 °C – RT, 80%; c) NaH, 53, 0 °C, THF, E/Z = 1/1, 95%; d) i) DiBAlH, -78 °C, Et2O; ii) MeOH, -100 °C; 
iii) 56, MeOH, RT; iv) NaBH4, -10 °C to RT; e) THF, HCl, H2O; f) Boc2O, TEA, DCM, 0 °C, 6.7% (59) and 18% 
(60) after RP-HPLC; g) i) TsCl, DCM, TEA, DMAP; ii) NaN3, DMF; h) DCM/TFA 1/1, v/v, RT, 44% (63) and 
38% (64) after RP-HPLC. 
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in detail in Chapter 6, and the crude E/Z mixture of trityl protected 
isoquinolineamide 57 was obtained. The Boc-groups and trityl-groups in 57 were 
deprotected under acidic conditions to obtain a crude mixture of 58, and 
installment of the Boc-group to yield isoquinolinesulfonamide 59 and 60 as crude 
E/Z mixture. HPLC purification allowed separation and isolation of both isomers. 
Both alcohols 59 and 60 were tosylated followed by substitution using NaN3 to 
obtain compounds 61 and 62. At last, deprotection of the Boc-group furnished the 
photo-affinity based probes 63 and 64 in 44% and 38% yield after HPLC purification. 
Probe 3 has the same double bond geometry as the parent inhibitor H-89 (1) and 
inhibits both PKA and AKT1 with a high potency. A change of the double bond 
configuration to (Z) does not have a significant influence on the inhibition of PKA 
but for AKT1 a partial loss of potency was observed. In this study, the recombinant 
kinases in pure form as well as in mixtures with control proteins could be labelled; 
additionally a variety of control experiments reveal that the probes act in an 
affinity-based manner on active enzymes and that UV activation is required for 
labeling have been performed. 
A third chemical profiling method for kinases has been described in Chapter 7. An affinity-
based probe (65, Figure 9) has been synthesized to investigate the drug targets of 
dasatinib in primary CLL. This affinity-based probe is obtained by coupling of the kinase 
inhibitor and clinical drug, dasatinib to NHS-activated sepharose beads. In this method, 
the targets are reversibly bound by the probe and are analyzed by SDS-PAGE and/or 
LC/MS after they are eluted from the immobilized dasatinib probe 65. 
Figure 9. Structure of affinity-based probe 65, which is based on the structure of dasatinib. 
 
In this study it was found that the important targets of dasatinib in primary CLL were c-Abl 
and BTK. Furthermore, other identified peptides corresponded to the kinases Lyn, Csk, 
Fyn, Yes, Src and Lck.  
An alternative strategy to identify the targets of dasatinib would be to use dasatinib-based 
probes containing a ligation handle. Two such two-step probes were designed and 
synthesized, one featuring a norbornene (69) and one containing an azide as ligation 
handles (71). The synthesis of both compounds is depicted in Scheme 4. Both probes were 
obtained by a reaction between the dasatinib-amine 67 with the corresponding OSu-
functionalized tag. In the future, the utility of these probes needs to be studied in detail.  
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Scheme 4. Synthesis of dasatinib-norbornene 69 and dasatinib-azide 71. Reagents and conditions: a) 68 
or 70, DiPEA, DMF, 69:  18%; 71: 28% after RP-HPLC. 
 
Affinity-based protein profiling can also be useful to study the targets and 
investigate the drug mechanism of H-89. Therefore, the Boc-protected H-89 72 was 
converted into the amine containing isoquinolineamide 73 by a Sonogashira cross-
coupling (Scheme 5). This probe can be in turn immobilized by coupling to a NHS-
Sepharose bead, which can then be used to isolate the targets of H-89. 
 
 
Scheme 5. Synthesis of affinity-based probe 73, based on H-89. Reagents and conditions: a) i) N-Boc-
propargylamine, pyrrolidine, CuI, Pd(PPh3)4, DMF; ii) TFA/DCM 1/1 v/v, RT, 34% after RP-HPLC. 
 
In this study, three chemical profiling methods to label kinases have been described 
including their advantages and disadvantages. To have a true comparison of these 
three methods, an affinity-based probe, a photoaffinity based probe and an 
activity-based probe have to be synthesized based on the same small molecule in 
the future. For example, next to the direct and two-step bioorthogonal ibrutinib 
probes (37-41), an affinity-based probe and a photoaffinity based probe, such as 
compounds 74 and 75, respectively should be developed (Figure 10). For affinity-
based profiling, the Michael-acceptor moiety has been displaced by an alkyl amine 
group, which in turn can be immobilized on a matrix. In the case of photoaffinity 
labeling, the acrylamide group has been displaced by the aryldiazirine, which serves 
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as the photoaffinity reactive group and by an azide group, which serves as the 
ligation handle.  
Figure 10. Designs of a ibrutinib-based affinity and photoaffinity probe 74 and 75, respectively. M = 
matrix.  
 
In this thesis, new powerful tools and assays have been developed that unite the 
fields of synthetic chemistry, protein biochemistry and cell biology for the global 
analysis of kinase expression and function. The value of chemical profiling as a 
method for functional proteome analysis has been further highlighted by its 
application as a screen to evaluate the potency and selectivity of kinase inhibitors. 
However, even though the numerous considerable advances  that has been made 
to date, chemical approaches for kinome analysis still face significant technical 
challenges. Currently, 1D or 2D electrophoresis is mostly used to analyze probe-
labeled proteins. A disadvantage of this method is the limited resolving power 
especially in cases where large number of proteins with similar molecular mass has 
to be analyzed. The use of LC-MS to analyze the large number of proteins overcome 
this problem due to its higher resolving power, but LC-MS has a much lower sample 
throughput. So the right strategy has to be chosen depending on the biological 
question being addressed. In addition, more selective probes are needed to explore 
the function of a particular kinase and also more general probes are needed that 
are able to label every single kinase in a cell, which are useful in studies of inhibitor 
selectivity. In either case, improvement of both the chemical and technical 
components of chemical profiling has to be made in the near future for a more in-
depth analysis of the kinome and the targets of kinase inhibitors. These chemical 
tools, as developed in this thesis, provide new handles to define the biology of 
kinases in cells. The exploration of the chemical space around the H-89 building 
block shows how new and more specific inhibitors can be developed for this 




General: Tetrahydrofuran (THF) was distilled over LiAlH4 before use. Acetonitrile (ACN), dichloromethane (DCM), 
N,N-dimethylformamide (DMF), methanol (MeOH) and trifluoroacetic acid (TFA) were of peptide synthesis grade, 
purchased at Biosolve, and used as received. All general chemicals (Fluka, Acros, Merck, Aldrich, Sigma) were 
used as received. Traces of water were removed from reagents used in reactions that require anhydrous 
conditions by coevaporation with toluene. Solvents that were used in reactions were stored over 4Å molecular 
sieves, except methanol and acetonitrile, which were stored over 3Å molecular sieves. Molecular sieves were 
flame dried before use. Unless noted otherwise all reactions were performed under an argon atmosphere. 
Column chromatography was performed on Silicycle Silia-P Flash Silica Gel, with a particle size of 40 – 63 µm. The 
eluents toluene and ethyl acetate were distilled prior to use. TLC analysis was conducted on Merck aluminium 
sheets (Silica gel 60 F254). Compounds were visualized by UV absorption (254 nm), by spraying with a solution of 
(NH4)6Mo7O24· 4H2O (25 g/L) and (NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% sulphuric acid, a solution of KMnO4 (20 g/L) 
and K2CO3 (10 g/L) in water, or ninhydrin (0.75 g/L) and acetic acid (12.5 mL/L) in ethanol, where appropriate, 
followed by charring at ca. 150°C. 1H- and 13C NMR spectra were recorded on a Bruker DMX-400 (400 MHz) or a 
Bruker DMX-600 (600 MHz) spectrometer. Chemical shifts are given in ppm (δ) relative to tetramethylsilane (1H 
NMR) or CDCl3 (
13C NMR) as internal standard. Mass spectra were recorded on a PE/Sciex API 165 instrument 
equipped with an Electrospray Interface (ESI) (Perkin-Elmer). High-resolution MS (HRMS) spectra were recorded 
with a Finnigan LTQ-FT (Thermo Electron). IR spectra were recorded on a Shimadzu FTIR-8300 and absorptions 
are given in cm-1. Optical rotations [α]D
23 were recorded on a Propol automatic polarimeter at room temperature. 
LC-MS analysis was performed on a Jasco HPLC system with a Phenomenex Gemini 3 µm C18 50 x 4.6 mm 
column (detection simultaneously at 214 and 254 nm), coupled to a PE Sciex API 165 mass spectrometer with ESI. 
HPLC gradients were 10 → 90%, 0 → 50% or 10 → 50% ACN in 0.1% TFA/H2O. Chiral HPLC analysis was 
performed on a Spectroflow 757 system (ABI Analytical Kratos Division, detection at 254 nm) equipped with a 
Chiralcel OD column (150 x 4.6 mm). The compounds were purified on a Gilson HPLC system coupled to a 
Phenomenex Gemini 5 µm 250 x 10 mm column and a GX281 fraction collector. The used gradients were either 0 
→ 30% or 10 → 40% ACN in 0.1% TFA/water, depending on the lipophilicity of the product. Appropriate fractions 




HATU (1.1 eq., 42 mg, 0.11 mmol) was added to a solution of biotin (2 eq., 50 mg, 0.20 mmol) and TEA (4 eq., 60 
µL, 0.4 mmol) in DMF (0.4 mL) and the reaction mixture was allowed to stir for 1 min. A solution of crude amine 
42 (42 mg, 0.1 mmol) in DMF (0.3 mL) was added and the resulting mixture was stirred overnight. EtOAc (10 mL) 
was added and the organic layer was washed with sat. aq. NaHCO3 and brine, dried over MgSO4, filtered and 
concentrated under reduced pressure. The title compound was obtained after RP-HPLC purification (linear 
gradient 40%  60% ACN in H2O, 0.1% TFA, 15 min) as a white solid (yield: 21.41 mg, 26.5 µmol, 26.5%). 
1H NMR 
(600 MHz, DMSO-d6): δ 8.33 (s, 1H), 8.13 (br s, 1H), 7.66 (s, 2H), 7.44 (t, J = 8.4 Hz, 2H), 7.20 (t, J = 7.2 Hz, 1H), 
7.17 (d, J = 8.4 Hz, 2H), 7.13 (d, J = 7.8 Hz, 2H), 6.82 (d, J = 11.4 Hz, 0.5H), 6.66 – 6.61 (m, 1H), 6.57 – 6.51 (m, 
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0.5H), 4.75 – 4.70 (m, 1H), 4.56 (d, J = 10.8 Hz, 1H), 4.32 (t, J = 6.6 Hz, 1H), 4.18 (d, J = 10.8 Hz, 1H), 4.13 (s, 1H), 
4.06 (d, J = 15 Hz, 1H), 3.38 – 3.30 (m, 2H), 3.28 – 3.18 (m, 1H), 3.10 (s, 1H), 3.00 – 2.90 (m, 3H), 2.81 – 2.80 (m, 
1H), 2.61 (s, 1H), 2.57 (s, 1H), 2.51 (s, 1H), 2.28 – 2.24 (m, 1H), 2.14 – 2.10 (m, 3H), 1.95 (d, J = 13.2 Hz, 1H), 1.61 – 
1.58 (m, 2H), 1.53 – 1.45 (m, 4H), 1.26 (br s, 3H), 1.23 (s, 1H), 1.22 (d, J = 13.2 Hz, 1H), 1.11 (s, 2H). 13C NMR (150 
MHz, DMSO-d6): δ 172.81, 163.85, 162.73, 157.34, 156.23, 153.57, 153.26, 144.18, 143.77, 130.18, 127.49, 
123.89, 119.02, 97.27, 62.66, 61.06, 59.22, 55.43, 55.13, 52.88, 52.24, 50.38, 49.48, 49.22, 46.32, 45.76, 45.21, 
44.77, 41.63, 40.43, 35.10, 31.31, 29.61, 29.44, 28.23, 28.07, 25.09, 24.91, 18.82. HRMS: calculated for 
C42H53N11O4S [M+H
+]: 808.40027; found: 808.40037. 
 
Ibrutinib Levulinoyl ester-based cleavable linker azide (46) 
DiPEA (3.5 eq., 0.12 mL, 0.70 mmol) and levulinoyl ester-based cleavable linker-OSu2 45 (2.2 eq., 0.22 g, 0.44 
mmol) were added to a solution of crude amine 42 (84 mg, 0.2 mmol) in DMF (0.5 mL). The reaction mixture was 
stirred overnight before being evaporated. The title compound was obtained after RP-HPLC purification (linear 
gradient 40%  60% ACN in H2O, 0.1% TFA, 15 min) as a white solid (yield: 69.7 mg, 71.0 µmol, 36%). 
1H NMR 
(600 MHz, DMSO-d6): δ 8.36 (s, 1H), 8.11 (br s, 1H), 7.66 (s, 2H), 7.44 (t, J = 7.8 Hz, 2H), 7.19 (t, J = 7.8 Hz, 1H), 
7.17 (d, J = 7.2 Hz, 2H), 7.13 (d, J = 9.0 Hz, 2H), 6.98 (s, 2H), 6.84 (d, J = 18.0 Hz, 0.5H), 6.69 (d, J = 15.0 Hz, 0.5H), 
6.65 – 6.59 (m, 0.5H), 6.58 – 6.51 (m, 0.5H), 4.79 – 4.30 (m, 1H), 4.58 (d, J = 18.0 Hz, 0.5H), 4.19 (d, J = 12.0 Hz, 
1H), 4.16 (d, J = 12.0 Hz, 0.5H), 3.54 (br s, 1H), 3.37 (br s, 4H), 3.30 (t, J = 7.2 Hz, 2H), 3.23 – 3.20 (m, 2H), 3.04 – 
2.95 (m, 4H), 2.89 – 2.80 (m, 10H), 2.56 (t, J = 7.2 Hz, 3H), 2.41 (s, 3H), 2.26 (t, J = 12.0 Hz, 1H), 2.15 – 2.13 (m, 
1H), 1.95 – 1.91 (m, 1H), 1.76 – 1.71 (m, 2H), 1.67 – 1.53 (m, 1H), 1.09 (s, 12H). 13C NMR (150 MHz, DMSO-d6): δ 
207.98, 172.27, 171.52, 163.82, 157.31, 157.02, 156.63, 156.20, 153.96, 153.36, 144.13, 143.58, 143.12, 139.93, 
138.75, 130.28, 127.36, 124.00, 123.22, 119.15, 97.00, 56.73, 55.12, 53.52, 51.87, 50.22, 50.00, 49.17, 38.60, 
36.84, 36.52, 30.67, 27.35, 26.51, 22.58. HRMS: calculated for C54H68N12O6 [M+H
+]: 981.53848; found: 981.53856. 
 
Ibrutinib Levulinoyl ester-based cleavable linker biotin (48) 
Aqueous CuSO4 (1.0 eq., 24.8 µL, 24.8 µmol, 1M) and aqueous sodium L-ascorbate (1.1 eq., 27.2 µL, 27.2 µmol, 
1M) were added to a solution of azide 46 (24 mg, 24 µmol) and biotin-Ahx-propargylamide 47 (1.5 eq., 14.2 mg, 
36 µmol) in DMF 0.8 mL. The reaction mixture was stirred at RT overnight and was concentrated in vacuo. The 
title compound was obtained after RP-HPLC purification (linear gradient 45%  65% ACN in H2O, 0.1% TFA, 15 
min) as a white solid (yield: 7.5 mg, 5.5 µmol, 23%). 1H NMR (600 MHz, DMSO-d6): δ 8.33 (s, 1H), 8.21 (t, J = 5.4 
Hz, 1H), 8.07 (br s, 1H), 7.87 (s, 1H), 7.7.0 (t, J = 5.4 Hz, 1H), 7.66 (s, 2H), 7.44 (t, J = 7.2 Hz, 2H), 7.19 (t, J = 7.2 Hz, 
1H), 7.18 (d, J = 6.6 Hz, 2H), 7.12 (d, J = 7.8 Hz, 2H), 6.98 (s, 2H), 6.82 (d, J = 15.0 Hz, 0.5H), 6.66 – 6.61 (m, 1H), 
6.58 – 6.51 (m, 0.5H), 6.39 (s, 1H), 6.33 (br s, 1H), 4.79 – 4.68 (m, 1H), 4.58 (d, J = 18.0 Hz, 1H), 4.31 – 4.28 (m, 
3H), 4.27 (d, J = 6.0 Hz, 2H), 4.18 (d, J = 6.0 Hz, 1H), 4.13 – 4.11 (m, 1H), 4.05 (t, J = 12.0 Hz, 1H), 3.25 – 3.22 (m, 
3H), 3.11 – 3.07 (m, 3H), 2.99 (q, J1 = 7.2 Hz, J2 = 13.2 Hz, 3H), 2.95 – 2.88 (m, 2H), 2.87 – 2.83 (m, 3H), 2.82 – 2.79 
(m, 6H), 2.62 – 2.58 (m, 2H), 2.39 (br s, 2H), 2.31 – 2.22 (m, 1H), 2.15 – 2.10 (m, 1H), 2.07 (s, 5H), 2.04 (t, J = 7.8 
Hz, 2H), 1.99 (t, J = 7.2 Hz, 2H), 1.98 – 1.93 (m, 1H), 1.61 – 1.59 (m, 2H), 1.52 – 1.46 (m, 5H), 1.37 – 1.34 (m, 2H), 
1.30 – 1.27 (m, 2H), 1.24 – 1.20 (m, 3H), 1.09 (s, 12H). 13C NMR (150 MHz, DMSO-d6): δ 207.79, 172.17, 172.00, 
171.82, 171.55, 163.86, 162.70, 157.31, 156.22, 145.03, 143.37, 139.79, 138.96, 130.14, 127.52, 126.16, 123.86, 
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123.64, 122.63, 119.00, 118.02, 117.32, 115.79, 115.36, 97.23, 63.29, 61.05, 59.20, 56.82, 55.39, 52.87, 52.22, 
49.52, 49.20, 48.50, 45.78, 45.21, 38.31, 36.87, 36.55, 35.21, 34.12, 30.69, 29.58, 29.37, 28.95, 28.19, 28.02, 





Ethylene glycol (1.1 eq., 6.13 mL, 110 mmol) and p-toluenesulfonic acid monohydrate (0.01 eq., 0.19 g, 1.0 
mmol) were added to a solution of (4-bromophenyl)(phenyl)methanone 51 (26.11 g, 100 mmol) in benzene (40 
mL) and the reaction mixture was refluxed with a Dean-Stark condenser for 48 hrs. The reaction mixture was 
poured into aqueous sodium bicarbonate and extracted with Et2O. The organic layer was washed with aqueous 
sodium bicarbonate, water and brine before being dried over MgSO4 and concentrated in vacuo. The residue was 
further purified by silica column chromatography (5%  20% DCM/pentane) to afford the title compound as a 
white powder (yield: 21.79 g, 71.3 mmol, 71%). 1H NMR (400 MHz, CDCl3, Me4Si) δ 7.49 – 7.46 (m, 2H), 7.43 – 
7.36 (m, 4H), 7.31 – 7.22 (m, 3H), 3.98 (s, 4H). 13C NMR (101 MHz, CDCl3) δ 141.53, 141.25, 131.14, 128.11, 
127.90, 125.90, 122.09, 108.85. 
 
4-(2-phenyl-1,3-dioxolan-2-yl)benzaldehyde (53) 
n-BuLi (1.2 eq., 10.4 mL, 16.60 mmol, 1.6 M in hexanes) was dropwise added to a solution of compound 52 (4.22 
g, 13.83 mmol) in THF at -78 °C. The resulting mixture was stirred at -78 °C for 30 min before dropwise addition 
of DMF (1.5 eq., 1.6 mL, 20.75 mmol). The reaction mixture was allowed to warm up to RT overnight. The 
mixture was poured into aqueous ammonium chloride (250 mL) and diluted with Et2O. The layers were separated 
and the organic layer was washed with brine and water, dried over MgSO4, filtered and evaporated. The 
obtained material was purified by column chromatography (2%  10% EtOAc/pentane) and the product was 
obtained as a white solid (yield: 2.81 g, 11.06 mmol, 80%). 1H NMR (400 MHz, CDCl3, Me4Si) δ 9.96 (s, 1H), 7.82 
(d, J = 8.4 Hz, 2H), 7.70 (d, J = 8.4 Hz, 2H), 7.51 (d, J = 7.2 Hz, 2H), 7.33 – 7.24 (m, 3H), 4.06 – 4.02 (m, 4H). 13C 
NMR (101 MHz, CDCl3) δ 191.74, 148.66, 141.28, 135.81, 129.55, 128.23, 126.59, 125.79, 108.75, 64.90. 
 
(E/Z)-2-(4-(2-phenyl-1,3-dioxolan-2-yl)benzylidene)-5-(trityloxy)pentanenitrile (55) 
To an ice-cold suspension of NaH (1 eq., 0.23 g, 5.77 mmol, 60% mineral oil) in THF (20 mL) a solution of 
phosphonate 54 (1.25 eq., 3.44 g, 7.21 mmol) in THF (5 mL) was added dropwise and stirred for 30 min. 
Next, a solution of aldehyde 53 (1.47 g, 5.77 mmol) in THF (5 mL) was added and the reaction mixture 
was allowed to warm to RT and stirred overnight. The solution was quenched by addition of freshly 
prepared sat. aq. Na2HSO3 (30 mL) and diluted with H2O (100 mL) and Et2O (50 mL). The layers were 
separated and the aqueous phase was extracted with Et2O (3 x 50 mL). The combined organic layers 
were washed with sat. aq. NaHCO3 and brine, dried over MgSO4, filtered and evaporated. The residue 
was further purified by column chromatography (80%  95% toluene/pentane) to afford the title 
compound as a white solid with an E/Z ratio of 1/1 (yield: 3.15 g, 5.46 mmol, 95%). 1H NMR (400 MHz, 
CDCl3, Me4Si) δ 7.59 – 7.50 (m, 10H), 7.43 – 7.37 (m, 12H), 7.29 – 7.09 (m, 26H), 7.08 (s, 1H), 6.78 (s, 1H), 
3.95 (s, 8H), 3.12 (d, J = 5.2 Hz, 4H), 2.57 (t, J = 7.2 Hz, 2H), 2.47 (t, J = 7.2 Hz, 2H), 1.91 (d, J = 6.0 Hz, 4H). 
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13C NMR (101 MHz, CDCl3) δ 143.87, 143.78, 143.47, 143.35, 143.00, 141.57, 133.47, 133.23, 128.97, 
128.38, 128.22, 128.06, 127.58, 126.77, 126.35, 125.83, 125.10, 120.08, 118.43, 115.36, 110.84, 108.82, 
86.43, 86.32, 64.76, 64.72, 62.16, 61.56, 32.96, 29.50, 28.43, 28.24, 26.64. HRMS: calculated for 
C40H35NO3 [M+H]
+ 578.26897; found 578.26883. 
 
Tert-butyl (E)-(2-(4-benzoylbenzylidene)-5-hydroxypentyl)(2-(isoquinoline-5-sulfonamido)ethyl)carbamate (59) 
A solution of nitrile 55 (8.37 g, 14.49 mmol) in anhydrous Et2O (75 mL) was cooled to -78 °C. DiBAl-H (2 
eq., 29 mL, 29 mmol, 1M solution in hexanes) was added dropwise and the reaction mixture was allowed 
to warm to 0 °C and stirred for 2h, after which TLC analysis showed complete consumption of starting 
material. Next, the mixture was cooled to -100 °C followed by rapid addition of MeOH (30 mL). After 5 
min a solution of isoquinoline amine 56 (2.5 eq., 13.24 g, 36.25 mmol) in MeOH (10 mL) was added 
dropwise and the reaction mixture was allowed to stir at RT overnight. Hereafter, the reaction was 
cooled to -10 °C and NaBH4 (2 eq., 1.10 g, 29.0 mmol) was added and the mixture was allowed to stir for 
3h at RT. The reaction mixture was diluted with 0.5 M aq. NaOH (100 mL) and the layers were separated. 
The aqueous layer was extracted with DCM (3 x 50 mL) and the combined organic phases were washed 
with H2O (3 x 50 mL) and brine, dried over MgSO4, filtered and evaporated. The crude product 57 was 
subjected to the next step without further purification. 
The crude product 57 was dissolved in THF (50 mL) and HCl (35 mL) was added. The reaction mixture was 
stirred for 1h at RT before addition of H2O (40 mL), the resulting mixture was stirred for 30 min at RT. 
The mixture was diluted with aqueous NaOH (10 M) to pH14 before addition of CHCl3 (100 mL). The 
layers were separated and the aqueous layer was extracted with CHCl3 (2x 100 mL). The combined 
organic layers were washed with brine, dried over MgSO4, filtered and concentrated. The crude product 
58 was subjected to the next step without further purification. 
The residue 58 was dissolved in DCM (75 mL) and was cooled to 0 °C. To this mixture Boc2O (1.5 eq., 4.74 
g, 21.75 mmol) and TEA (4 eq., 8.04 mL, 58.0 mmol) were added and the reaction was allowed to warm 
to RT and stirred overnight. The reaction mixture was concentrated under reduced pressure and re-
dissolved in H2O (150 mL) and DCM (150 mL). The organic layer was washed with sat. aq. NaHCO3 and 
brine, dried over MgSO4, filtered and concentrated in vacuo. The title compound was obtained after 
purification by RP-HPLC purification (linear gradient 40%  60% ACN in H2O, 0.1% TFA, 15 min) as yellow 
oil (yield: 0.61 g, 0.97 mmol, 6.7%). 
1H NMR (400 MHz, CDCl3, Me4Si) δ 9.31 (s, 1H), 8.56 (s, 1H), 8.48 (d, J = 6.0 Hz, 1H), 8.40 (d, J = 7.2 Hz, 
1H), 8.16 (d, J = 8.0 Hz, 1H), 7.65 (t, J = 8.0 Hz, 4H), 7.62 – 7.55 (m, 2H), 7.46 (t, J = 7.6 Hz, 2H), 7.30 (d, J = 
8.0 Hz, 2H), 7.02 (t, J = 6.8 Hz, 1H), 6.24 (s, 1H), 3.89 (s, 2H), 3.61 (t, J = 6.0 Hz, 2H), 3.39 (s, 2H), 3.16 (s, 
2H), 2.17 (s, 2H), 1.73 (s, 2H), 1.41 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 210.61, 196.08, 152.81, 144.31, 
141.27, 140.18, 137.22, 135.15, 134.35, 133.18, 132.77, 132.16, 130.94, 129.97, 129.61, 128.76, 128.17, 
128.02, 125.76, 117.31, 80.37, 69.36, 61.73, 53.71, 46.30, 41.78, 31.51, 27.40. HRMS: calculated for 
C35H39N3O6S [M+H]






This compound was prepared in the same reaction as 59. The title compound was obtained after purification by 
RP-HPLC purification (linear gradient 40%  60% ACN in H2O, 0.1% TFA, 15 min) as yellow oil (yield: 1.68 g, 2.67 
mmol, 18%). 1H NMR (400 MHz, CDCl3, Me4Si) δ 9.31 (s, 1H), 8.60 (s, 1H), 8.36 (d, J = 6.0 Hz, 1H), 8.26 (d, J = 7.2 
Hz, 1H), 8.15 (d, J = 8.0 Hz, 1H), 7.81 – 7.75 (m, 4H), 7.65 – 7.57 (m, 2H), 7.48 (t, J = 7.6 Hz, 2H), 7.19 (d, J = 8.0 Hz, 
1H), 6.56 (s, 1H), 4.07 (s, 2H), 3.67 (t, J = 6.0 Hz, 2H), 3.12 (t, J = 5.6 Hz, 2H), 2.81 (s, 2H), 2.12 (t, J = 7.2 Hz, 2H), 
1.80 – 1.77 (m, 2H), 1.43 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 196.16, 153.09, 144.89, 141.29, 140.38, 137.55, 
135.87, 134.37, 133.54, 133.18, 132.61, 131.25, 130.28, 130.07, 129.13, 128.87, 128.44, 126.01, 117.40, 81.15, 
62.69, 45.97, 30.34, 28.41, . HRMS: calculated for C35H39N3O6S [M+H]
+ 630.25596; found 630.25609. 
 
(E)-N-(2-((5-azido-2-(4-benzoylbenzylidene)pentyl)amino)ethyl)isoquinoline-5-sulfonamide (63) 
Alcohol 59 (0.16 g, 0.26 mmol) was dissolved in DCM (1 mL). After addition of TEA (1 eq., 36 µL, 0.26 
mmol) and DMAP (0.64 mg, 5 µmol), the resulting mixture was cooled to -20 °C. A solution of TsCl (1 eq., 
0.05 g, 0.26 mmol) in DCM (2 mL) was added dropwise and the reaction was stirred at -20 °C for 18h. 
Subsequently, 0.1 M aq. HCl (10 mL) was added and the layers were separated. The organic layer was 
washed with 0.1 M HCl (10 mL) and brine, dried over MgSO4, filtered and concentrated under reduced 
pressure. The crude product was subjected to the next step without further purification. 
The residue was dissolved in DMF (10 mL). To this was added NaN3 (20 eq., 0.34 g, 5.2 mmol) and the 
reaction was stirred at room temperature for 5h before being concentrated. The resulting residue 61 
was dissolved in DCM (2.5 mL) and TFA (2.5 mL) was added. The mixture was stirred for 1h at RT before 
it was co-evaporated with toluene (3x 10 mL). The resulting mixture was purified by RP-HPLC (linear 
gradient 40%  60% ACN in H2O, 0.1% TFA, 15 min) and the title compound was obtained as yellowish 
oil (yield: 0.06 g, 0.11 mmol, 44%). 1H NMR (600 MHz, MeOD) δ 9.58 (s, 1H), 8.73 – 8.70 (m, 2H), 8.62 (d, 
J = 7.2 Hz, 1H), 8.54 (d, J = 7.8 Hz, 1H), 7.95 (t, J = 7.8 Hz, 1H), 7.82 (d, J = 8.4 Hz, 2H), 7.79 (d, J = 6.6 Hz, 
2H), 7.66 (t, J = 7.8 Hz, 1H), 7.54 (t, J = 7.8 Hz, 2H), 7.49 (d, J = 8.4, 2H), 3.89 (s, 2H), 3.34 (t, J = 6.6 Hz, 
2H), 3.28 – 3.24 (m, 4H), 2.50 (t, J = 7.8 Hz, 2H), 1.83 – 1.78 (m, 2H). 13C NMR (151 MHz, MeOD) δ 197.92, 
153.18, 142.23, 141.73, 138.73, 137.81, 136.28, 135.91, 135.84, 135.75, 135.64, 133.97, 133.74, 133.49, 
131.37, 131.12, 130.60, 129.80, 129.51, 128.69, 127.54, 120.31, 53.20, 51.96, 48.26, 28.25, 27.62. HRMS: 
calculated for C30H30N6O3S [M+H]
+ 555.21001; found 555.21063. 
 
(Z)-N-(2-((5-azido-2-(4-benzoylbenzylidene)pentyl)amino)ethyl)isoquinoline-5-sulfonamide (64) 
This compound was prepared in the same reaction as 63. The title compound was obtained after 
purification by RP-HPLC purification (linear gradient 40%  60% ACN in H2O, 0.1% TFA, 15 min) as a 
yellow oil (yield: 0.08 g, 0.15 mmol, 38%). 1H NMR (600 MHz, MeOD) δ 9.49 (s, 1H), 8.63 – 8.61 (m, 2H), 
8.44 (t, J = 8.4 Hz, 2H), 7.85 (t, J = 7.8 Hz, 1H), 7.78 (t, J = 8.4 Hz, 2H), 7.75 (d, J = 7.2 Hz, 2H), 7.64 (t, J = 
3.6 Hz, 1H), 7.50 (t, J = 7.8 Hz, 2H), 7.38 (d, J = 7.8 Hz, 2H), 6.91 (s, 1H), 3.97 (s, 2H), 3.44 (t, J = 6.6 Hz, 
2H), 3.08 (t, J = 6.0 Hz, 2H), 3.03 (t, J = 5.4 Hz, 2H), 2.43 (t, J = 7.2 Hz, 2H), 1.93 – 1.88 (m, 2H). 13C NMR 
(151 MHz, MeOD) δ 197.77, 153.23, 142.51, 141.63, 138.56, 137.69, 136.01, 135.76, 135.62, 135.47, 
134.77, 134.29, 133.86, 133.31, 131.52, 131.32, 130.99, 130.48, 129.77, 129.51, 128.95, 128.54, 120.07, 
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51.92, 47.70, 46.83, 39.54, 32.38, 28.08. HRMS: calculated for C30H30N6O3S [M+H]




DiPEA (3 eq., 12 µL, 69 µmol) and 2,5-dioxopyrrolidin-1-yl bicyclo[2.2.1]hept-5-ene-2-carboxylate (68) (2 eq., 11 
mg, 45 µmol) were added to a solution of Dasatinib-amine 67 (11 mg, 23 µmol) in DMF (2 mL). The reaction 
mixture was stirred at RT overnight. The title compound was obtained after purification by RP-HPLC purification 
(linear gradient 20%  40% ACN in H2O, 0.1% TFA, 15 min) as a white solid (yield: 2.67 mg, 4.4 µmol, 18%). 
1H 
NMR (400 MHz, DMSO-d6) δ 11.76 (s, 1H), 10.04 (s, 1H), 8.36 (s, 1H), 7.52 (d, J = 7.2 Hz, 1H), 7.39 (d, J = 9.6 Hz, 
2H), 6.28 (s, 1H), 5.32 – 3.87 (m, 10H), 3.35 – 3.21 (m, 2H), 2.66 (s, 6H), 2.56 (s, 3H), 2.35 (s, 3H), 2.03 (s, 3H). 13C 
NMR (101 MHz, DMSO-d6) δ 165.38, 162.45, 162.05, 159.91, 158.93, 157.19, 140.81, 138.84, 133.51, 132.45, 
129.07, 128.23, 127.05, 125.94, 83.28, 53.15, 51.26, 41.70, 25.57, 21.09, 18.32. HRMS: calculated for 
C30H35ClN8O2S [M+H]
+ 607.22922; found 607.22963. 
 
Dasatinib-azide (71) 
This compound was prepared in the same reaction as 69. However, 2,5-dioxopyrrolidin-1-yl 6-azidohexanoate 
(70) was used instead of the norbornene-succinimide 68. The title compound was obtained after purification by 
RP-HPLC purification (linear gradient 20%  40% ACN in H2O, 0.1% TFA, 15 min) as a white solid (yield: 4.03 mg, 
6.4 µmol, 28%). 1H NMR (400 MHz, DMSO-d6) δ 11.71 (s, 1H), 9.89 (s, 1H), 8.21 (s, 1H), 7.37 (d, J = 7.2 Hz, 1H), 
7.23 (d, J = 10.0 Hz, 2H), 6.10 (s, 1H), 4.44 – 3.51 (m, 6H), 3.31 – 2.83 (m, 4H), 2.51 (s, 2H), 2.40 (s, 3H), 2.20 (s, 
3H), 2.07 (t, J = 6.4 Hz, 2H), 1.88 (s, 2H), 1.54 – 1.43 (m, 4H), 1.33 – 1.24 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 
165.37, 162.05, 159.89, 157.16, 140.81, 138.82, 133.49, 132.43, 129.06, 128.22, 127.03, 50.54, 35.15, 28.03, 
25.82, 24.63, 22.32, 21.09, 18.32. HRMS: calculated for C28H36ClN11O2S [M+H]
+ 626.24627; found 626.24685. 
 
(E)-N-(2-((3-(4-(3-aminoprop-1-yn-1-yl)phenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide (73) 
In separate flasks, a solution of the N-Boc-propargylamine (1.5 eq., 93 mg, 0.6 mmol), isoquinolinephenyl 
bromide 72 (220 mg, 0.4 mmol) and pyrrolidine (3 eq., 0.10 mL, 1.2 mmol) in DMF (0.5 mL), a solution of 
CuI (0.1 eq., 8 mg, 40 µmol) in DMF (100 µL) and a solution of Pd(PPh3)4 (0.05 eq., 23 mg, 20 µmol) in 
DMF (100 µL) were flushed with argon for 1 hr in an ultrasonic bath. To the alkyne mixture were added 
subsequently the CuI and the Pd(PPh3)4 solutions and the resulting mixture was stirred at 80 °C 
overnight. The reaction mixture was filtered over a short silica column and was flushed with DCM/MeOH 
(1/1 v/v; 10x column volume). The eluate was concentrated and the crude product was subjected to the 
next step without further purification. 
The residue was dissolved in DCM (2 mL) and TFA (2 mL) was added and the reaction mixture was stirred for 2h 
at RT. The mixture was then co-evaporated with toluene (5x). The title compound was obtained after purification 
by RP-HPLC purification (linear gradient 25%  45% ACN in H2O, 0.1% TFA, 15 min) as a yellow oil (yield: 56,6 
mg, 0.13 mmol, 34%). 1H NMR (600 MHz, DMSO-d6) δ 9.60 (s, 1H), 8.75 (s, 1H), 8.70 (s, 1H), 8.61 (d, J = 7.2 Hz, 
1H), 8.53 (d, J = 8.4 Hz, 1H), 7.94 (t, J = 7.8 Hz, 1H), 7.47 (s, 4H), 6.85 (d, J = 15.6 Hz, 1H), 6.36 – 6.33 (m, 1H), 4.05 
(s, 2H), 3.86 (d, J = 7.2 Hz, 2H), 3.19 (s, 4H). 13C NMR (151 MHz, DMSO-d6) δ 152.86, 138.88, 137.77, 136.46, 
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136.04, 135.75, 133.56, 133.22, 133.08, 130.10, 128.81, 128.07, 123.01, 122.83, 122.45, 120.91, 87.36, 82.58, 
50.33, 47.62, 40.11, 30.70. HRMS: calculated for C23H24N4O2S [M+H]
+ 421.16200; found 421.16256. 
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Kinasen spelen een belangrijke rol in vele ziekten, zoals kanker, diabetes en 
infectieziekten. Daarom zijn kinasen een interessante doelgroep voor geneesmiddelen 
ontwikkeling. Er zijn remmers voor verscheidene kinasen op de markt, maar wegens 
resistentie, bijwerkingen of gebrek aan remmers voor bepaalde kinase families is het 
noodzakelijk om onderzoek te doen naar nieuwe klassen van verbindingen gericht op 
kinasen. Om dit te bereiken moeten er niet alleen nieuwe remmers ontwikkeld worden, 
maar ook moleculair gereedschappen (“probes”). Deze probes kunnen gebruikt worden 
om de activiteit en aanwezigheid van kinasen in hun biologische omgeving vast te stellen, 
te kwantificeren en de selectiviteit van remmers te bepalen. Het in dit proefschrift 
beschreven onderzoek richt zich op de ontwikkeling van potentere AKT1 en FLT3 kinase 
remmers. Tevens heeft dit onderzoek als doel de synthese en toepassing van nieuwe 
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probes om de kinasen, die betrokken zijn bij de diverse kankersoorten en andere ziekten, 
in kaart te brengen. Een korte beschrijving over de functies en de rollen van de kinasen die 
een onderwerp zijn in dit proefschrift is gegeven in Hoofdstuk 1.                                   
In de afgelopen decennia zijn er vele chemische benaderingen ontwikkeld voor het 
bestuderen van de biologische functionele rol van kinasen, en om de selectiviteit en de 
doeleiwitten van kinase remmers in kaart te brengen. Hoofdstuk 2 beschrijft en vergelijkt 
de principes van drie chemische methodes toegepast op kinase onderzoek: “activity-based 
protein profiling” (ABPP), “photoaffinity labeling”en “affinity-based profiling (AfBP). Deze 
drie methodes vormen de rode lijn van dit proefschrift.                      
H-89, een isoquinolinesulfonamide gebaseerde verbinding, is een welbekende potente 
PKA remmer. Analogen van deze verbinding remmen tevens AKT1 en andere kinasen, 
waaronder het oncologische doelwit, FLT3. Hoofdstuk 3 behandelt het ontwerp en de 
synthese van een nieuwe set van isoquinolinesulfonamide gebaseerde remmers voor 
FLT3. Deze verbindingen bevatten allemaal de isoquinolinesulfonamide kern, waarbij 
variatie is geïntroduceerd op de fenyl groep door gebruik te maken van Suzuki koppeling 
reacties op de ortho, meta of para positie. Er zijn 34 verschillende omvangrijke 
(hetero)aromatische boorzuren gebruikt, waardoor er 102 nieuwe 
isoquinolinesulfonamide analogen zijn ontstaan.                        
Het biologisch effect van de 102 nieuwe isoquinolinesulfonamides samen met 137 andere 
isoquinolinesulfonamide analogen, welke in voorafgaande onderzoek zijn gesynthetiseerd, 
wordt besproken in Hoofdstuk 4. De remmingspotentie van deze 239 verbindingen op 
PKA, AKT1, AKT2 en FLT3 is bepaald aan de hand van een TR-FRET kinase assay. De 
resultaten uit dit hoofdstuk tonen aan dat zowel AKT1 als AKT2 een voorkeur hebben voor 
remmers met een omvangrijke heteroaromatische groep op de ortho positie. Dit gegeven 
maakt het lastig om actieve en selectieve remmers te ontwikkelen voor AKT1. Het is 
belangrijk om selectieve AKT1 remmers te vinden, gezien eerder onderzoek heeft 
aangetoond dat remming van zowel AKT1 als AKT2 leidt tot de dood van muizen. In dit 
onderzoek is aangetoond dat de meest selectieve AKT1 remmers een methyl 
gesubstitueerde alkeen groep bevatten en de introductie van een halogeen groep op de 
fenyl ring op de para positie is ook bevorderlijk voor de AKT1 over AKT2 selectiviteit. Een 
ander kinase dat bestudeerd is in dit proefschrift is FLT3. De meest actieve remmers voor 
FLT3 bevatten een heterearomatische groep op de para positie van de fenylring.  
In het tweede deel van dit proefschrift worden de syntheses en biologische evaluaties van 
de chemische probes beschreven. Drie verschillende chemische benaderingen worden 
uitgelicht namelijk: ABPP, AfBP en “photoaffinity labeling”.  
Hoofdstuk 5 beschrijft het ontwerp en de synthese van twee typen “activity-based 
probes” (ABPs)  om Bruton’s tyrosine kinase (BTK) te labelen, namelijk directe en 
tweestaps bioorthogonale ABPs. Directe ABPs bevatten een label, waarmee het doeleiwit 
direct kan worden gevisualiseerd of geïsoleerd. Tweestaps ABPs daarentegen bevatten 
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een kleine reactieve groep die kan worden gebruikt om het label in een later stadium te 
introduceren, nadat de ABP aan zijn doeleiwit heeft gebonden.  De ABPs voor BTK zijn 
gebaseerd op de covalente remmer ibrutinib. Een covalente band wordt gevormd tussen 
BTK en ibrutinib door een nucleofiele aanval van de cysteine in de actieve holte van BTK 
op het acrylamide gedeelte van ibrutinib. Resultaten uit dit onderzoek tonen aan de 
directe probe BTK kan labelen in zowel Ramos cell extract als in levende Ramos cellen. 
Ook de tweestaps bioorthogonale probes waren in staat om BTK te labelen in in vitro en in 
situ experimenten. Labeling met behulp van de directe probes resulteerde in minder 
achtergrond labeling dan de tweestaps probes.  
Niet alle kinasen zoals BTK bevatten een nucleofiele groep in de actieve holte. Om deze 
kinasen covalent te labelen zijn er andere type chemische gereedschappen vereist. 
Hoofdstuk 6 behandelt de synthese en biologische toepassing van twee diazerine-
gefunctionaliseerde fotoreactieve probes. Deze probes werden vervolgens gebruikt om 
PKA en AKT1 te labelen. Beide probes zijn gebaseerd op het chemische structuur van H-89, 
welke zowel PKA als AKT1 remt, en bevatten een aryl trifluoromethyl diazerine groep als 
de fotoreactieve groep. De diazerine ring gaat een covalente binding aan met zijn 
doeleiwit na UV belichting. Daarnaast bevatten deze verbindingen een azide groep, welke 
gebruikt wordt als de bioorthogonale ligatie handvat. Beide probes waren in staat 
recombinante PKA en AKT1 te labelen. De probe met een E-configuratie was potenter dan 
de probe met een Z-configuratie.  
Een derde chemische methode om kinasen te labelen is beschreven in Hoofdstuk 7. Een 
affiniteits-gebaseerde probe werd gesynthetiseerd om doeleiwitten van dasatinib in 
primaire chronische lymfatische leukemie (CLL) te onderzoeken. Deze affiniteits-
gebaseerde probe werd verkregen door een koppeling van de kinase remmer dasatinib 
aan de NHS-geactiveerde sepharose bollen. In deze methode werden de doeleiwitten 
reversibel gebonden door de probe en geanalyseerd door middel van SDS-PAGE en/of LC-
MS nadat ze geëlueerd werden van de geimmobiliseerde dasatinib probe. Uit deze studie 
is gebleken dat c-Abl en BTK de hoofddoeleiwitten van dasatinib in primaire CLL waren. 
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